ASD Acronym,Designation,Title of Standard,Abstract,Link,Published Status
FDA,FDA-2022-D-0084,Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-guidance
FDA,FDA-2024-D-4643,Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-ovarian-toxicity-premenopausal-adults-during-drug-development-oncologic-products,
FDA,FDA-2024-D-4540,Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-followup-testing-ames-positive-drug-active-ingredient-or-metabolite-support-first-human,
FDA,FDA-2024-D-2274,Transitional Enforcement Policy for Ethylene Oxide Sterilization Facility Changes for Class III Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transitional-enforcement-policy-ethylene-oxide-sterilization-facility-changes-class-iii-devices,
FDA,FDA-2023-D-0488,Orthopedic Non-Spinal Metallic Bone Screws and Washers - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orthopedic-non-spinal-metallic-bone-screws-and-washers-performance-criteria-safety-and-performance,
FDA,FDA-2019-D-1652,"Orthopedic Non-Spinal Bone Plates, Screws, and Washers - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orthopedic-non-spinal-bone-plates-screws-and-washers-premarket-notification-510k-submissions,
FDA,FDA-2016-D-2565,"510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review:  Guidance for Industry, Food and Drug Administration Staff, and Third Party Review Organizations",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-third-party-review-program-and-third-party-emergency-use-authorization-eua-review,
FDA,FDA-2024-D-4311,Frequently Asked Questions â€” Developing Potential Cellular and Gene Therapy Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-developing-potential-cellular-and-gene-therapy-products,
FDA,FDA-2024-D-4624,Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-assessment-oligonucleotide-based-therapeutics,
FDA,FDA-2011-N-0144,Guidance for Industry: FDA's Voluntary Qualified Importer Program,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fdas-voluntary-qualified-importer-program,
FDA,FDA-2021-D-0367,CPG Sec 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products â€“ Decomposition and Histamine (CPG 7108.24),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540525-scombrotoxin-histamine-forming-fish-and-fishery-products-decomposition-and-histamine,
FDA,FDA-2014-D-0092,Study Data Technical Conformance Guide - Technical Specifications Document,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/study-data-technical-conformance-guide-technical-specifications-document,
FDA,FDA-2023-D-0093,M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m13a-bioequivalence-immediate-release-solid-oral-dosage-forms,
FDA,FDA-2024-D-2977,CVM GFI #293 - FDA Enforcement Policy for AAFCO-Defined Animal Feed Ingredients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-293-fda-enforcement-policy-aafco-defined-animal-feed-ingredients,
FDA,FDA-2023-D-1083,"Guidance for Industry: Insanitary Conditions in the Preparation, Packing, and Holding of Tattoo Inks and the Risk of Microbial Contamination",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-insanitary-conditions-preparation-packing-and-holding-tattoo-inks-and-risk,
FDA,FDA-2024-D-3903,Drug Interaction Information in Human Prescription Drug and Biological Product Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-interaction-information-human-prescription-drug-and-biological-product-labeling,
FDA,FDA-2022-D-2061,Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-drug-master-files-advance-certain-anda-submissions-under-gdufa,
FDA,FDA-2024-D-3993,"Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-development-blood-collection-processing-and-storage-systems-manufacture-blood,
FDA,FDA-2024-D-2732,Postoperative Nausea and Vomiting: Developing Drugs for Prevention,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postoperative-nausea-and-vomiting-developing-drugs-prevention,
FDA,FDA-2022-D-0112,Core Patient-Reported Outcomes in Cancer Clinical Trials:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/core-patient-reported-outcomes-cancer-clinical-trials,
FDA,FDA-2020-D-2303,Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-long-term-clinical-neurodevelopmental-safety-studies-neonatal-product-development,
FDA,FDA-2017-D-5868,Requests for Reconsideration at the Division Level Under GDUFA,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-reconsideration-division-level-under-gdufa,
FDA,FDA-2023-D-4095,Endosseous Dental Implants and Endosseous Dental Implant Abutments - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/endosseous-dental-implants-and-endosseous-dental-implant-abutments-performance-criteria-safety-and,
FDA,FDA-2024-D-4409,CVM GFI #284 Using Relative Supersaturation to Support â€œUrinary Tract Healthâ€ Claims for Adult Maintenance Cat Food,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-284-using-relative-supersaturation-support-urinary-tract-health-claims-adult-maintenance-cat,
FDA,FDA-2024-D-4774,Temporary Policies for Compounding Certain Parenteral Drug Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/temporary-policies-compounding-certain-parenteral-drug-products,
FDA,FDA-2017-D-1105,"Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations:  Questions and Answers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions,
FDA,FDA-2000-D-0598,Dental Impression Materials - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-impression-materials-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2024-D-4168,Dental Ceramics - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-ceramics-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2024-D-4171,Dental Cements - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-cements-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2024-D-4169,CVM GFI #116 (VICH GL23 (R2)) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing (Revision 2),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-116-vich-gl23-r2-studies-evaluate-safety-residues-veterinary-drugs-human-food-genotoxicity,
FDA,FDA-2024-D-4170,Air Powered Dental Handpieces and Air Motors - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/air-powered-dental-handpieces-and-air-motors-performance-criteria-safety-and-performance-based,
FDA,FDA-2018-D-4115,Clarification of Radiation Control Regulations For Manufacturers of Diagnostic X-Ray Equipment:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-radiation-control-regulations-manufacturers-diagnostic-x-ray-equipment,
FDA,FDA-2022-D-0113,Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-human-radiolabeled-mass-balance-studies,
FDA,FDA-2011-N-0921,"Small Entity Compliance Guide: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-standards-growing-harvesting-packing-and-holding-produce-human,
FDA,FDA-2002-D-0223,An Acceptable Circular of Information for the Use of Human Blood and Blood Components:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptable-circular-information-use-human-blood-and-blood-components,
FDA,FDA-2019-D-3805,"The Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/accreditation-scheme-conformity-assessment-asca-program,
FDA,FDA-2019-D-3805,"Biocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program : Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biocompatibility-testing-medical-devices-standards-specific-information-accreditation-scheme-0,
FDA,FDA-2019-D-3805,"Basic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/basic-safety-and-essential-performance-medical-electrical-equipment-medical-electrical-systems-and-0,
FDA,FDA-2024-D-4165,Chemical Analysis for Biocompatibility Assessment of Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemical-analysis-biocompatibility-assessment-medical-devices,
FDA,FDA-2022-D-2870,Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/integrating-randomized-controlled-trials-drug-and-biological-products-routine-clinical-practice,
FDA,FDA-2024-D-2052,Conducting Clinical Trials With Decentralized Elements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conducting-clinical-trials-decentralized-elements,
FDA,FDA-2014-D-1492,"CVM GFI #227 Chemistry, Manufacturing, and Controls (CMC) Technical Section Filing Strategies",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-227-chemistry-manufacturing-and-controls-cmc-technical-section-filing-strategies,
FDA,,Data Standards Catalog,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-catalog,
FDA,FDA-2024-D-3163,Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-generating-clinical-evidence-oncology-multiregional-clinical-development-programs,
FDA,FDA-2024-D-3742,Providing Regulatory Submissions in Electronic Format â€” Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications,
FDA,FDA-2014-N-1006,Enforcement Policy for Required Warnings for Cigarette Packages and Advertisements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-required-warnings-cigarette-packages-and-advertisements,
FDA,FDA-2019-D-5364,Submission of Plans for Cigarette Packages and Cigarette Advertisements (Revised),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-plans-cigarette-packages-and-cigarette-advertisements-revised,
FDA,FDA-2020-D-0988,Required Warnings for Cigarette Packages and Advertisements: Small Entity Compliance Guide (Revised):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/required-warnings-cigarette-packages-and-advertisements-small-entity-compliance-guide-revised,
FDA,FDA-2017-D-5670,ANDA Submissions | Amendments to Abbreviated New Drug Applications Under GDUFA:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-amendments-abbreviated-new-drug-applications-under-gdufa,
FDA,FDA-2020-D-1317,"Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension/Revocation of Certificates, or Patient and Referring Provider Notification Orders:  Guidance for Mammography Facilities and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appeal-options-available-mammography-facilities-concerning-adverse-accreditation-decisions,
FDA,,Withdrawn Guidances (Biologics),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/withdrawn-guidances-biologics,
FDA,FDA-2015-D-1580,"Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle: Draft Guidance for Industry, Food and Drug Administration Staff, and Other Interested Parties",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/incorporating-voluntary-patient-preference-information-over-total-product-life-cycle,
FDA,FDA-2020-D-1530,Control of Nitrosamine Impurities in Human Drugs:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs,
FDA,FDA-2018-D-1216,Bioresearch Monitoring Technical Conformance Guide,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioresearch-monitoring-technical-conformance-guide,
FDA,FDA-2022-D-2873,Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/voluntary-malfunction-summary-reporting-vmsr-program-manufacturers,
FDA,FDA-2021-D-0614,CVM GFI #64 (VICH  GL2) Validation of Analytical Procedures: Methodology,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-64-vich-gl2-validation-analytical-procedures-methodology,
FDA,FDA-2021-D-0616,CVM GFI #63 (VICH GL1) Validation of Analytical Procedures: Definition and Terminology,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-63-vich-gl1-validation-analytical-procedures-definition-and-terminology,
FDA,FDA-2013-N-0134,Mammography Quality Standards Act and Regulation Amendments: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mammography-quality-standards-act-and-regulation-amendments-small-entity-compliance-guide,
FDA,FDA-2023-D-3788,"FDA and Industry Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-and-industry-procedures-section-513g-requests-information-under-federal-food-drug-and-cosmetic,
FDA,FDA-2010-D-0153,Electronic Submission Template for Medical Device De Novo Requests:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-medical-device-de-novo-requests,
FDA,FDA-2024-D-2338,Predetermined Change Control Plans for Medical Devices: Draft Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/predetermined-change-control-plans-medical-devices,
FDA,FDA-2023-D-0044,Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-specific-guidance-meetings-between-fda-and-anda-applicants-under-gdufa,
FDA,FDA-2020-D-0957,Acceptable Media for Electronic Product User Manuals:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptable-media-electronic-product-user-manuals,
FDA,FDA-2014-D-0055,Draft Guidance for Industry: Voluntary Sodium Reduction Goals (Edition 2),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-voluntary-sodium-reduction-goals-edition-2,
FDA,FDA-2024-D-2978,CVM GFI #294 - Animal Food Ingredient Consultation (AFIC),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-294-animal-food-ingredient-consultation-afic,
FDA,FDA-2018-D-0342,Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases:  Guidance for Industry; Availability,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases,
FDA,FDA-2022-D-2827,Bacillus Calmette-GuÃ©rin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment : Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and,
FDA,FDA-2022-D-1527,M12 Drug Interaction Studies: Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m12-drug-interaction-studies-questions-and-answers,
FDA,FDA-2022-D-1527,M12 Drug Interaction Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m12-drug-interaction-studies,
FDA,FDA-2016-D-1280,FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-regional-implementation-guide-e2br3-electronic-transmission-individual-case-safety-reports-drug,
FDA,FDA-1999-D-2955,Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory,
FDA,FDA-2022-D-2059,Providing Over-the-Counter Monograph Submissions in Electronic Format,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-over-counter-monograph-submissions-electronic-format,
FDA,FDA-2020-D-2307,"CVM GFI #100 (VICH GL18 (R2)) Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision 2)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-100-vich-gl18-r2-impurities-residual-solvents-new-veterinary-medicinal-products-active,
FDA,FDA-2017-D-6821,Container Closure System and Component Changes: Glass Vials and Stoppers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-system-and-component-changes-glass-vials-and-stoppers,
FDA,FDA-2024-D-2581,Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-manufacturing-changes-biosimilar-and-interchangeable-biosimilar-products-questions-and,
FDA,FDA-2024-D-2682,Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-investigational-and-licensed-covid-19-convalescent-plasma,
FDA,FDA-2024-D-2442,Pediatric Inflammatory Bowel Disease:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-inflammatory-bowel-disease-developing-drugs-treatment,
FDA,FDA-2022-D-0362,Blood Pressure and Pulse Donor Eligibility Requirements â€“ Compliance Policy:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/blood-pressure-and-pulse-donor-eligibility-requirements-compliance-policy,
FDA,FDA-2004-D-0371,Application User Fees for Combination Products:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/application-user-fees-combination-products,
FDA,FDA-2018-D-0178,Drugs for the Treatment of Partial Onset Seizures: Extrapolation of Efficacy from Adults to Pediatric Patients  1 Month of Age and Older,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drugs-treatment-partial-onset-seizures-extrapolation-efficacy-adults-pediatric-patients-1-month-age,
FDA,FDA-2024-D-2511,Dental Curing Lights - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-curing-lights-premarket-notification-510k-submissions,
FDA,FDA-2024-D-2512,Dental Composite Resin Devices - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-composite-resin-devices-premarket-notification-510k-submissions,
FDA,FDA-2023-D-0466,Clinical Considerations for Studies of Devices Intended to Treat Opioid Use Disorder:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-considerations-studies-devices-intended-treat-opioid-use-disorder,
FDA,FDA-2014-D-0447,"Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/purpose-and-content-use-related-risk-analyses-drugs-biological-products-and-combination-products,
FDA,FDA-2024-D-2484,Addressing Misinformation About Medical Devices and Prescription Drugs:  Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/addressing-misinformation-about-medical-devices-and-prescription-drugs-questions-and-answers,
FDA,FDA-2024-D-2754,"M14 General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies That Utilize Real-World Data for Safety Assessment of Medicines",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m14-general-principles-plan-design-and-analysis-pharmacoepidemiological-studies-utilize-real-world,
FDA,FDA-2024-D-2560,Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/essential-drug-delivery-outputs-devices-intended-deliver-drugs-and-biological-products,
FDA,FDA-2022-D-2899,Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies,
FDA,FDA-2023-D-3740,CVM GFI #283 Priority Zoonotic Animal Drug Designation and Review Process,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-283-priority-zoonotic-animal-drug-designation-and-review-process,
FDA,FDA-2021-D-0789,CVM GFI #276 Effectiveness of Anthelmintics:  Specific Recommendations for Products Proposed for the Prevention of Heartworm Disease in Dogs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-276-effectiveness-anthelmintics-specific-recommendations-products-proposed-prevention,
FDA,FDA-2023-N-2177,Laboratory Developed Tests: Small Entity Compliance Guide:  Guidance for Laboratory Manufacturers and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laboratory-developed-tests-small-entity-compliance-guide,
FDA,FDA-2024-D-1668,"CVM GFI #292 Chemistry, Manufacturing, and Controls Considerations for Type A Medicated Articles",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-292-chemistry-manufacturing-and-controls-considerations-type-medicated-articles,
FDA,FDA-2024-D-1202,"CVM GFI #288 Chemistry, Manufacturing, and Controls in Support of Recombinant Protein Products for Veterinary Medicinal Use",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-288-chemistry-manufacturing-and-controls-support-recombinant-protein-products-veterinary,
FDA,FDA-2023-D-0592,"CVM GFI #279 Demonstrating Bioequivalence for Type A Medicated Articles Containing Active Pharmaceutical Ingredient(s) Considered to be Poorly Soluble in Aqueous Media, That Exhibit Little to No Systemic Bioavailability, and Are Locally Acting",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-279-demonstrating-bioequivalence-type-medicated-articles-containing-active-pharmaceutical,
FDA,FDA-2023-D-1275,CVM GFI #278 Human User Safety in New and Abbreviated New Animal Drug Applications,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-278-human-user-safety-new-and-abbreviated-new-animal-drug-applications,
FDA,FDA-2017-D-0154,Considerations in Demonstrating Interchangeability With a Reference Product: Update,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-demonstrating-interchangeability-reference-product-update,
FDA,FDA-2013-D-0710,"Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/circumstances-constitute-delaying-denying-limiting-or-refusing-drug-or-device-inspection,
FDA,FDA-2022-D-1981,Facility Readiness:  Goal Date Decisions Under GDUFA,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/facility-readiness-goal-date-decisions-under-gdufa,
FDA,FDA-2023-D-4067,Diabetic Foot Infections: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diabetic-foot-infections-developing-drugs-treatment,
FDA,FDA-2022-D-0235,Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-development-oligonucleotide-therapeutics,
FDA,FDA-2024-D-2221,Standardized Format for Electronic Submission for Marketing Applications Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for Center of Biologics Evaluation and Research Submissions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standardized-format-electronic-submission-marketing-applications-content-planning-bioresearch,
FDA,FDA-2023-D-5021,Processes and Practices Applicable to Bioresearch Monitoring Inspections: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/processes-and-practices-applicable-bioresearch-monitoring-inspections,
FDA,FDA-2024-D-1829,Platform Technology Designation Program for Drug Development,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/platform-technology-designation-program-drug-development,
FDA,FDA-2000-D-0784,CVM GFI #115 (VICH GL22) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Toxicity Testing (Revision 1),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-115-vich-gl22-studies-evaluate-safety-residues-veterinary-drugs-human-food-reproduction,
FDA,FDA-2018-N-3741,"Remanufacturing of Medical Devices:  Guidance for Industry, Entities That Perform Servicing or Remanufacturing, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/remanufacturing-medical-devices,
FDA,FDA-2024-D-1032,REMS Logic Model: A Framework to Link Program Design With Assessment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-logic-model-framework-link-program-design-assessment,
FDA,FDA-2024-D-1133,Enforcement Policy for Certain In Vitro Diagnostic Devices for Immediate Public Health Response in the Absence of a Declaration under Section 564: Draft Guidance for Laboratory Manufacturers and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-certain-in-vitro-diagnostic-devices-immediate-public-health-response-absence,
FDA,FDA-2023-D-5365,CVM GFI #290 (VICH GL61) â€“ Pharmaceutical Development,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-290-vich-gl61-pharmaceutical-development,
FDA,FDA-2024-D-0083,Consideration of Enforcement Policies for Tests During a Section 564 Declared Emergency: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/consideration-enforcement-policies-tests-during-section-564-declared-emergency,
FDA,FDA-2008-D-0394,CVM GFI #187B Heritable Intentional Genomic Alterations in Animals: The Approval Process,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-187b-heritable-intentional-genomic-alterations-animals-approval-process,
FDA,FDA-2019-D-2648,CVM GFI #187A Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-187a-heritable-intentional-genomic-alterations-animals-risk-based-approach,
FDA,FDA-1998-D-0067,Recognition and Use of a Standard for Uniform Blood and Blood Component Container Labels:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recognition-and-use-standard-uniform-blood-and-blood-component-container-labels,
FDA,FDA-2010-N-0155,Small Entity Compliance Guide: Revocation of Uses of Partially Hydrogenated Oils in Foods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-revocation-uses-partially-hydrogenated-oils-foods,
FDA,FDA-2024-D-1669,Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-human-allogeneic-cells-expanded-use-cell-based-medical-products,
FDA,FDA-2024-D-1244,CVM GFI #287 - Raw Data for Safety and Effectiveness Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-287-raw-data-safety-and-effectiveness-studies,
FDA,FDA-2024-D-1461,CVM GFI #120 Veterinary Feed Directive Regulation Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-120-veterinary-feed-directive-regulation-questions-and-answers,
FDA,FDA-2024-D-1613,Content and Format of Composition Statement and Corresponding Statement of Ingredients in Labeling in NDAs and ANDAs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-composition-statement-and-corresponding-statement-ingredients-labeling-ndas-and,
FDA,FDA-2024-D-1243,Considerations for the Use of Human-and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-human-and-animal-derived-materials-manufacture-cell-and-gene-therapy-and-tissue,
FDA,FDA-2024-D-1402,"Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications: Draft Guidance for Industry, IRBs, and Clinical Investigators",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-washout-periods-and-concomitant-medications,
FDA,FDA-2024-D-1377,"Cancer Clinical Trial Eligibility Criteria: Performance Status: Draft Guidance for Industry, IRBs, and Clinical Investigators",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-performance-status,
FDA,FDA-2024-D-1376,"Cancer Clinical Trial Eligibility Criteria: Laboratory Values: Draft Guidance for Industry, IRBs, and Clinical Investigators",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-laboratory-values,
FDA,FDA-2019-D-5473,Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/promotional-labeling-and-advertising-considerations-prescription-biological-reference-and-biosimilar,
FDA,FDA-2024-D-1245,Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-new-dietary-ingredient-notifications-and-related-issues,
FDA,FDA-2024-D-0706,Draft Guidance for Industry: New Dietary Ingredient Notification Master Files for Dietary Supplements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-new-dietary-ingredient-notification-master-files-dietary-supplements,
FDA,FDA-2011-D-0376,Data Integrity for In Vivo Bioavailability and Bioequivalence Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-in-vivo-bioavailability-and-bioequivalence-studies,
FDA,FDA-2022-D-1173,Providing Regulatory Submissions in Electronic Format: IND Safety Reports Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-ind-safety-reports-guidance-industry,
FDA,FDA-2019-D-3953,Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-expedited-safety-reports-ind-exempt-babe-studies-guidance-industry,
FDA,FDA-2024-D-1242,Animal Studies for Dental Bone Grafting Material Devices - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/animal-studies-dental-bone-grafting-material-devices-premarket-notification-510k-submissions,
FDA,FDA-2002-D-0176,Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/handling-and-retention-bioavailability-ba-and-bioequivalence-be-testing-samples,
FDA,FDA-2023-D-5470,Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-evidence-considerations-regarding-non-interventional-studies-drug-and-biological-products,
FDA,FDA-2014-D-1167,"CVM GFI #285 - Manufacture of Batches in Support of Original NADAs, ANADAs, and CNADAs",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-285-manufacture-batches-support-original-nadas-anadas-and-cnadas,
FDA,FDA-2024-D-1054,Controlled Correspondence Related to Generic Drug Development,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/controlled-correspondence-related-generic-drug-development,
FDA,FDA-2010-D-0133,Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program - Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program-draft-guidance,
FDA,FDA-2018-D-1774,"Pharmacokinetics in Patients with Impaired Renal Function â€” Study Design, Data Analysis, and Impact on Dosing",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-renal-function-study-design-data-analysis-and-impact-dosing,
FDA,FDA-2024-D-0664,Evaluation of Thermal Effects of Medical Devices that Produce Tissue Heating and/or Cooling: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-thermal-effects-medical-devices-produce-tissue-heating-andor-cooling,
FDA,FDA-2023-D-5616,Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the FD&C Act: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/select-updates-premarket-cybersecurity-guidance-section-524b-fdc-act,
FDA,FDA-2024-D-0803,E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2dr1-post-approval-safety-data-definitions-and-standards-management-and-reporting-individual-case,
FDA,FDA-2021-D-1158,Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/annual-reportable-labeling-changes-new-drug-applications-and-abbreviated-new-drug-applications,
FDA,FDA-2013-D-0077,Early Alzheimerâ€™s Disease: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-alzheimers-disease-developing-drugs-treatment,
FDA,FDA-2022-D-1503,Q14 Analytical Procedure Development,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q14-analytical-procedure-development,
FDA,FDA-2022-D-1503,Q2(R2) Validation of Analytical Procedures,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2r2-validation-analytical-procedures,
FDA,FDA-2023-D-5280,Guidance for Industry: New Dietary Ingredient Notification Procedures and Timeframes - Dietary Supplements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-new-dietary-ingredient-notification-procedures-and-timeframes-dietary-supplements,
FDA,FDA-2022-D-2997,"Key Information and Facilitating Understanding in Informed Consent Guidance for Sponsors, Investigators, and Institutional Review Boards",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/key-information-and-facilitating-understanding-informed-consent-guidance-sponsors-investigators-and,
FDA,FDA-2021-D-1051,Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-antibody-drug-conjugates-guidance-industry,
FDA,FDA-2021-D-1031,Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-amount-listed-drugs-and-biological-products-technical-conformance-guide,
FDA,FDA-2020-D-1824,Select Updates for the Medical Device User Fee Small Business Qualification and Certification Guidance: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/select-updates-medical-device-user-fee-small-business-qualification-and-certification-guidance,
FDA,FDA-2018-D-1873,Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs,
FDA,FDA-2019-D-4658,Guidance for Industry: Foods Derived from Plants Produced Using Genome Editing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-foods-derived-plants-produced-using-genome-editing,
FDA,FDA-2013-D-0447,Charging for Investigational Drugs Under an IND: Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/charging-investigational-drugs-under-ind-questions-and-answers,
FDA,FDA-2001-D-0219,Use of Data Monitoring Committees in Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-data-monitoring-committees-clinical-trials,
FDA,FDA-2023-D-4974,Advanced Manufacturing Technologies Designation Program,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/advanced-manufacturing-technologies-designation-program,
FDA,FDA-2020-D-1057,Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/notifying-fda-discontinuance-or-interruption-manufacturing-finished-products-or-active,
FDA,FDA-2021-D-1031,Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-amount-listed-drugs-and-biological-products-under-section-510j3-fdc-act,
FDA,FDA-2023-D-5303,Draft Guidance for Industry: Recommendations for Collecting Representative Samples for Food Testing Used as Evidence for Release of Certain Fish and Fishery Products Subject to Detention Without Physical Examination (DWPE) and Removal of a Foreign Manufacturerâ€™s Goods from DWPE,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-recommendations-collecting-representative-samples-food-testing-used-evidence,
FDA,FDA-2022-D-0810,Conducting Remote Regulatory Assessments Questions and Answers: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conducting-remote-regulatory-assessments-questions-and-answers,
FDA,FDA-2021-D-0404,CVM GFI #214 (VICH GL35) Pharmacovigilance of Veterinary Medicinal Products Electronic Standards for Transfer of Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-214-vich-gl35-pharmacovigilance-veterinary-medicinal-products-electronic-standards-transfer,
FDA,FDA-2010-D-0241,CVM GFI #188 Data Elements for Submission of Veterinary Adverse Event Reports to the Center for Veterinary Medicine,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-188-data-elements-submission-veterinary-adverse-event-reports-center-veterinary-medicine,
FDA,FDA-2011-D-0588,Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products,
FDA,FDA-2016-D-3561,Draft Guidance for Industry: Hazard Analysis and Risk-Based Preventive Controls for Human Food,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-hazard-analysis-and-risk-based-preventive-controls-human-food,
FDA,FDA-2016-D-2343,Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical,
FDA,FDA-2021-D-0398,Human Gene Therapy Products Incorporating Human Genome Editing:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-editing,
FDA,FDA-2023-D-4761,CVM GFI #286 (VICH GL60) - Good Manufacturing Practice for Active Pharmaceutical Ingredients Used in Veterinary Medicinal Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-286-vich-gl60-good-manufacturing-practice-active-pharmaceutical-ingredients-used-veterinary,
FDA,FDA-2018-D-4726,Revising ANDA  Labeling Following  Revision of the RLD  Labeling Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revising-anda-labeling-following-revision-rld-labeling-guidance-industry,
FDA,FDA-2022-D-0092,ANDA Submissions â€“ Amendments and Requests for Final Approval to Tentatively Approved ANDAs:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-amendments-and-requests-final-approval-tentatively-approved-andas,
FDA,FDA-2023-D-5430,Characterization of Metallic Coatings and/or Calcium Phosphate Coatings on Orthopedic Devices: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/characterization-metallic-coatings-andor-calcium-phosphate-coatings-orthopedic-devices,
FDA,FDA-2022-D-2512,Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5ar2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin,
FDA,FDA-2008-D-0611,Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-and-review-sterility-information-premarket-notification-510k-submissions-devices-labeled,
FDA,FDA-2023-D-5408,Reformulating Drug Products That Contain Carbomers Manufactured With Benzene,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reformulating-drug-products-contain-carbomers-manufactured-benzene,
FDA,FDA-2023-D-4299,Quality Considerations for Topical Ophthalmic Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-considerations-topical-ophthalmic-drug-products,
FDA,FDA-2023-D-4177,Potency Assurance for Cellular and Gene Therapy Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-assurance-cellular-and-gene-therapy-products,
FDA,FDA-2009-N-0582,Rare Diseases: Considerations for the Development of Drugs and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-considerations-development-drugs-and-biological-products,
FDA,FDA-2015-D-2818,"Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule Questions and Answers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/direct-consumer-prescription-drug-advertisements-presentation-major-statement-clear-conspicuous-and,
FDA,FDA-1997-D-0444,Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-registries-support-regulatory-decision-making-drug-and-biological-products,
FDA,FDA-2021-D-1128,Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations,
FDA,FDA-2021-D-1146,"CVM GFI #61 Special Considerations, Incentives, and Programs to Support the Approval of New Animal Drugs for Minor Uses and for Minor Species",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-61-special-considerations-incentives-and-programs-support-approval-new-animal-drugs-minor,
FDA,FDA-2020-D-1136,Master Protocols for Drug and Biological Product Development,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development,
FDA,FDA-2023-D-5259,Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-monoclonal-antibody-products-targeting-sars-cov-2-emergency-use-authorization,
FDA,FDA-2021-D-0548,Data Standards for Drug and Biological Product Submissions Containing Real-World Data:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-drug-and-biological-product-submissions-containing-real-world-data,
FDA,FDA-2023-D-1716,Guidance for Industry:  Registration and Listing of Cosmetic Product Facilities and Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-registration-and-listing-cosmetic-product-facilities-and-products,
FDA,FDA-2023-D-3391,Draft: Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-use-real-world-evidence-support-regulatory-decision-making-medical-devices,
FDA,FDA-2023-D-4395,Clinical Pharmacology Considerations for Peptide Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-peptide-drug-products,
FDA,FDA-2011-F-0172,Draft Guidance for Industry: Menu Labeling Supplemental Guidance (Edition 2),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-menu-labeling-supplemental-guidance-edition-2,
FDA,FDA-2018-D-2613,Presenting Quantitative Efficacy and Risk Information in  Direct-to-Consumer (DTC) Promotional Labeling and Advertisements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/presenting-quantitative-efficacy-and-risk-information-direct-consumer-dtc-promotional-labeling-and,
FDA,FDA-2015-D-3517,Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/verification-systems-under-drug-supply-chain-security-act-certain-prescription-drugs,
FDA,FDA-2015-D-3539,"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act - Revision 2",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503b-federal-food-drug-and-0,
FDA,FDA-2018-D-3462,"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and-0,
FDA,FDA-2009-D-0189,CVM GFI #199 Animal Generic Drug User Fees and Fee Waivers and Reductions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-199-animal-generic-drug-user-fees-and-fee-waivers-and-reductions,
FDA,FDA-2023-D-4722,Small Entity Compliance Guide: Milk and Cream Products and Yogurt Products; Final Rule to Revoke the Standards for Lowfat Yogurt and Nonfat Yogurt and To Amend the Standard for Yogurt,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-milk-and-cream-products-and-yogurt-products-final-rule-revoke,
FDA,FDA-2020-D-1370,COVID-19: Developing Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention,
FDA,FDA-2023-D-4719,Translation of Good Laboratory Practice Study Reports: Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/translation-good-laboratory-practice-study-reports-questions-and-answers,
FDA,FDA-2021-D-0980,Select Updates for the 506J Guidance: 506J Device List and Additional Notifications: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/select-updates-506j-guidance-506j-device-list-and-additional-notifications,
FDA,FDA-2022-D-0053,Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/notifying-fda-permanent-discontinuance-or-interruption-manufacturing-device-under-section-506j-fdc,
FDA,FDA-2022-D-0053,Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-credibility-computational-modeling-and-simulation-medical-device-submissions,
FDA,FDA-2023-D-1716,Guidance for Industry: Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Listing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-compliance-policy-cosmetic-product-facility-registration-and-cosmetic-product,
FDA,FDA-2022-D-0823,Real-Time Oncology Review (RTOR) :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-time-oncology-review-rtor,
FDA,FDA-2018-D-1216,Submitting Patient-Reported Outcome Data in Cancer Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-patient-reported-outcome-data-cancer-clinical-trials,
FDA,FDA-2018-D-1216,Submitting Clinical Trial Datasets and Documentation for Clinical Outcome Assessments Using Item Response Theory,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-clinical-trial-datasets-and-documentation-clinical-outcome-assessments-using-item,
FDA,FDA-2023-N-4372,Process to Request a Review of FDA's Decision Not to Issue Certain Export Certificates for Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-request-review-fdas-decision-not-issue-certain-export-certificates-devices,
FDA,FDA-2018-D-2310,Enforcement Policy for Clinical Electronic Thermometers:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-clinical-electronic-thermometers,
FDA,FDA-2023-D-4595,Enforcement Policy for Certain Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-certain-supplements-approved-premarket-approval-pma-or-humanitarian-device,
FDA,FDA-2023-D-4416,Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/remote-interactive-evaluations-drug-manufacturing-and-bioresearch-monitoring-facilities,
FDA,FDA-2008-D-0053,Topical Dermatologic Corticosteroids:  In Vivo Bioequivalence,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/topical-dermatologic-corticosteroids-in-vivo-bioequivalence-0,
FDA,FDA-2022-D-2170,Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/communications-firms-health-care-providers-regarding-scientific-information-unapproved-uses,
FDA,FDA-2020-D-1137,Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/voluntary-consensus-standards-recognition-program-regenerative-medicine-therapies,
FDA,FDA-2022-D-0745,Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-non-invasive-remote-monitoring-devices-used-support-patient-monitoring,
FDA,FDA-2023-D-4356,Development and Licensure of Vaccines to Prevent COVID-19:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19,
FDA,FDA-2011-D-0147,"Establishing That a Tobacco Product Was Commercially Marketed in the United States as of February 15, 2007 (Revised):  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-tobacco-product-was-commercially-marketed-united-states-february-15-2007-revised,
FDA,FDA-2011-D-0125,Demonstrating the Substantial Equivalence of a New Tobacco Product: Responses to Frequently Asked Questions (Revised):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-equivalence-new-tobacco-product-responses-frequently-asked-questions,
FDA,FDA-2020-D-2316,Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol,
FDA,FDA-2022-D-0588,"Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-regarding-blood-and-blood-component-donation-suitability-donor-eligibility-and,
FDA,FDA-2020-D-2016,Benefit-Risk Assessment for New Drug and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-assessment-new-drug-and-biological-products,
FDA,FDA-2011-N-0179,Investigational COVID-19 Convalescent Plasma:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-covid-19-convalescent-plasma,
FDA,FDA-2020-D-1825,Guidance for Industry: Prior Notice of Imported Food Questions and Answers (Edition 4),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-prior-notice-imported-food-questions-and-answers-edition-4,
FDA,FDA-2015-D-2148,Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-and-labeling-medical-devices-safety-magnetic-resonance-mr-environment,
FDA,FDA-2019-D-2837,Submission of Premarket Notifications for Magnetic Resonance Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-premarket-notifications-magnetic-resonance-diagnostic-devices,
FDA,FDA-2023-D-1848,Stimulant Use Disorders: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/stimulant-use-disorders-developing-drugs-treatment,
FDA,FDA-2022-D-0219,Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--â€œDose Bandingâ€,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-prescription-drug-and-biological-products-labeling-dosing-based-weight-or-body-surface-area,
FDA,FDA-2021-D-0872,Electronic Submission Template for Medical Device 510(k) Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-medical-device-510k-submissions,
FDA,FDA-2023-D-4045,Technical Considerations for Medical Devices with Physiologic Closed-Loop Control Technology:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-medical-devices-physiologic-closed-loop-control-technology,
FDA,FDA-2021-D-0996,Antimicrobial Susceptibility Test (AST) System Devices â€“ Updating Breakpoints in Device Labeling:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antimicrobial-susceptibility-test-ast-system-devices-updating-breakpoints-device-labeling,
FDA,FDA-2017-D-0175,"Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-standards-growing-harvesting-packing-and-holding-sprouts-human-consumption,
FDA,FDA-2017-D-0175,"Graft-versus-Host Diseases: Developing Drugs, Biological Products, and Certain Devices for Prevention or Treatment",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/graft-versus-host-diseases-developing-drugs-biological-products-and-certain-devices-prevention-or,
FDA,FDA-2023-D-3900,"Draft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-standards-growing-harvesting-packing-and-holding-sprouts-human-consumption,
FDA,FDA-2021-D-1158,Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions,
FDA,FDA-2023-D-2925,CVM GFI #273 Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-273-defining-durations-use-approved-medically-important-antimicrobial-drugs-fed-food,
FDA,FDA-2023-D-3031,Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-sponsors-or-applicants-pdufa-products,
FDA,FDA-2017-D-6530,Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alternative-tools-assessing-drug-manufacturing-facilities-identified-pending-applications,
FDA,FDA-2023-D-3550,Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-conduct-clinical-trials-medical-products-during-major-disruptions-due-disasters-and,
FDA,FDA-2020-D-1139,Guidance for Industry: Returning Refrigerated Transport Vehicles and Refrigerated Storage Units to Food Uses After Using Them to  Preserve Human Remains,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-returning-refrigerated-transport-vehicles-and-refrigerated-storage-units-food-uses,
FDA,FDA-2023-D-2318,Regulatory Considerations for Prescription Drug Use-Related Software,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-prescription-drug-use-related-software,
FDA,FDA-2023-D-2482,Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-one-adequate-and-well-controlled-clinical,
FDA,FDA-2016-D-0643,Labeling for Biosimilar and Interchangeable Biosimilar Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-biosimilar-and-interchangeable-biosimilar-products,
FDA,FDA-2011-D-0611,Biosimilarity and Interchangeability:  Additional Draft Q&As on Biosimilar Development and the BPCI Act (Revision 1): Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biosimilarity-and-interchangeability-additional-draft-qas-biosimilar-development-and-bpci-act,
FDA,FDA-2023-D-2654,Medical Devices with Indications Associated with Weight Loss - Non-Clinical Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-devices-indications-associated-weight-loss-non-clinical-recommendations,
FDA,FDA-2018-N-3771,Medical Devices with Indications Associated with Weight Loss - Clinical Study and Benefit-Risk Considerations: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-devices-indications-associated-weight-loss-clinical-study-and-benefit-risk-considerations,
FDA,FDA-2022-D-0109,Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fostering-medical-device-improvement-fda-activities-and-engagement-voluntary-improvement-program,
FDA,FDA-2019-N-4060,CVM GFI #282 Informed Consent Forms for Studies that Enroll Client-Owned Companion Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-282-informed-consent-forms-studies-enroll-client-owned-companion-animals,
FDA,FDA-2019-N-4060,Annual Status Report Information and Other Submissions for Postmarketing Requirements and Commitments: Using Forms FDA 3988 and FDA 3989 Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/annual-status-report-information-and-other-submissions-postmarketing-requirements-and-commitments,
FDA,FDA-2017-D-5966,Breakthrough Devices Program:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/breakthrough-devices-program,
FDA,FDA-2023-D-3452,Institutional Review Board (IRB) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products:   Guidance for IRBs and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-board-irb-review-individual-patient-expanded-access-submissions-investigational,
FDA,FDA-2023-D-3518,"Use of International Standard ISO 10993-1, ""Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"" :  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-international-standard-iso-10993-1-biological-evaluation-medical-devices-part-1-evaluation-and,
FDA,FDA-2013-D-0350,Endogenous Cushingâ€™s Syndrome: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/endogenous-cushings-syndrome-developing-drugs-treatment,
FDA,FDA-2015-D-4848,Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-use-clinical-data-premarket-notification-510k-submissions,
FDA,FDA-2023-D-3134,Evidentiary Expectations for 510(k) Implant Devices: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evidentiary-expectations-510k-implant-devices,
FDA,FDA-2023-D-3132,Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-selecting-predicate-device-support-premarket-notification-510k-submission,
FDA,FDA-2023-D-3133,Application of Human Factors Engineering Principles for Combination Products: Questions and Answers:  Guidance for Industry and  FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/application-human-factors-engineering-principles-combination-products-questions-and-answers,
FDA,FDA-2014-D-1981,"DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dscsa-standards-interoperable-exchange-information-tracing-certain-human-finished-prescription-drugs,
FDA,FDA-2023-D-3370,Post-Warning Letter Meetings Under GDUFA,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/post-warning-letter-meetings-under-gdufa,
FDA,FDA-2021-D-0544,Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex:  Developing Drugs for Treatment :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nontuberculous-mycobacterial-pulmonary-disease-caused-mycobacterium-avium-complex-developing-drugs,
FDA,FDA-2020-D-1138,Enforcement Policy for Face Masks and Barrier Face Coverings During the Coronavirus Disease (COVID-19) Public Health Emergency :  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-face-masks-and-barrier-face-coverings-during-coronavirus-disease-covid-19-public,
FDA,FDA-2019-D-4212,Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Productâ€”Compliance Policies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/wholesale-distributor-verification-requirement-saleable-returned-drug-product-and-dispenser-0,
FDA,FDA-2010-D-0431,Civil Money Penalties and No-Tobacco-Sale Orders For Tobacco Retailers (*Revised):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/civil-money-penalties-and-no-tobacco-sale-orders-tobacco-retailers-revised,
FDA,FDA-2021-D-1214,Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhanced-drug-distribution-security-package-level-under-drug-supply-chain-security-act,
FDA,FDA-2020-D-2024,Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug,
FDA,FDA-2023-D-1909,"Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act--Compliance Policies",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhanced-drug-distribution-security-requirements-under-section-582g1-federal-food-drug-and-cosmetic,
FDA,FDA-1994-D-0221,Guidance for Industry: The Seafood List FDAâ€™s Guide to Determine Acceptable Seafood Names,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-seafood-list-fdas-guide-determine-acceptable-seafood-names,
FDA,FDA-2006-D-0031,"Informed Consent:  Guidance for IRBs, Clinical Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent,
FDA,FDA-2023-D-1954,Off-The-Shelf Software Use in Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/shelf-software-use-medical-devices,
FDA,FDA-2018-D-1922,Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-sponsors-or-applicants-bsufa-products-guidance-industry,
FDA,FDA-2019-D-3598,Classification Categories for Certain Supplements Under BsUFA III,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/classification-categories-certain-supplements-under-bsufa-iii,
FDA,FDA-2022-D-2629,Postmarketing Approaches to Obtain Data on Populations Underrepresented in Clinical Trials for Drugs and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-approaches-obtain-data-populations-underrepresented-clinical-trials-drugs-and,
FDA,FDA-2023-D-2439,QTc Information in Human Prescription Drug and Biological Product Labeling: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qtc-information-human-prescription-drug-and-biological-product-labeling,
FDA,FDA-2020-D-1530,Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-acceptable-intake-limits-nitrosamine-drug-substance-related-impurities,
FDA,FDA-2018-D-1434,"Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/waivers-exceptions-and-exemptions-requirements-section-582-federal-food-drug-and-cosmetic-act,
FDA,FDA-2018-D-1635,"PDUFA Waivers, Reductions, and Refunds for Fixed- Combinations and Single-Entity Versions of Previously Approved Antiretrovirals under PEPFAR",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pdufa-waivers-reductions-and-refunds-fixed-combinations-and-single-entity-versions-previously,
FDA,FDA-2004-D-0301,Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of Human Immunodeficiency Virus-One Under the Presidentâ€™s Emergency Plan for Acquired Immunodeficiency Syndrome Relief,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fixed-combinations-and-single-entity-versions-previously-approved-antiretrovirals-treatment-or,
FDA,FDA-2017-D-6209,Assessing User Fees Under the Biosimilar User Fee Amendments of 2022:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-biosimilar-user-fee-amendments-2022,
FDA,FDA-2022-D-0986,Hydrogen Peroxide-Based Contact Lens Care Products: Consumer Labeling Recommendations - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hydrogen-peroxide-based-contact-lens-care-products-consumer-labeling-recommendations-premarket,
FDA,FDA-2018-D-4417,CDERâ€™s Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cders-program-recognition-voluntary-consensus-standards-related-pharmaceutical-quality,
FDA,FDA-2022-D-0055,Questions and Answers | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-m7r2-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals,
FDA,FDA-2022-D-0055,M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m7r2-addendum-application-principles-ich-m7-guideline-calculation-compound-specific-acceptable,
FDA,FDA-2020-N-1790,Guidance for Industry | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-m7r2-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals,
FDA,FDA-2013-D-1279,"Qualification of Medical Device Development Tools:  Guidance for Industry, Tool Developers, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-medical-device-development-tools,
FDA,FDA-2023-D-0559,"Postmarketing Studies and Clinical Trials:  Determining Good Cause for Noncompliance with Section 505(o)(3)(E)(ii) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-studies-and-clinical-trials-determining-good-cause-noncompliance-section-505o3eii,
FDA,FDA-2023-D-2436,Temporary Policy Regarding Preventive Controls and FSVP Food Supplier Verification Onsite Audit Requirements Due to COVID-19:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/temporary-policy-regarding-preventive-controls-and-fsvp-food-supplier-verification-onsite-audit,
FDA,FDA-2023-D-2827,Temporary Policy Regarding Accredited Third-Party Certification Program Onsite Observation and Certificate Duration Requirements Due to COVID-19 :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/temporary-policy-regarding-accredited-third-party-certification-program-onsite-observation-and,
FDA,FDA-2023-D-2828,Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-changes-and-comparability-human-cellular-and-gene-therapy-products,
FDA,FDA-2018-D-2647,Inborn Errors of Metabolism That Use Dietary Management: Considerations for Optimizing and Standardizing Diet in Clinical Trials for Drug Product Development: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inborn-errors-metabolism-use-dietary-management-considerations-optimizing-and-standardizing-diet,
FDA,FDA-2021-D-1096,Patient-Matched Guides to Orthopedic Implants: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-matched-guides-orthopedic-implants,
FDA,FDA-2023-D-2370,Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-rhinosinusitis-nasal-polyps-developing-drugs-treatment,
FDA,FDA-2023-D-0939,"Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prohibition-wholesaling-under-section-503b-federal-food-drug-and-cosmetic-act,
FDA,FDA-2023-D-2204,Psychedelic Drugs: Considerations for Clinical Investigations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations,
FDA,FDA-2023-D-1987,"Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-dispute-resolution-and-administrative-hearings-final-administrative-orders-under-section-505g,
FDA,FDA-2023-D-2034,Alternative Procedures for the Manufacture of Cold-Stored Platelets Intended for the Treatment of Active Bleeding when Conventional Platelets Are Not Available or Their Use Is Not Practical:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alternative-procedures-manufacture-cold-stored-platelets-intended-treatment-active-bleeding-when,
FDA,FDA-2020-D-1480,Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-drug-interaction-assessment-therapeutic-proteins-guidance-industry,
FDA,FDA-2022-D-2275,"Oncology Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot Program:  Guidance for Industry, Clinical Laboratories, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oncology-drug-products-used-certain-in-vitro-diagnostic-tests-pilot-program,
FDA,FDA-2019-D-3764,CVM GFI #171 - Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A Medicated Articles Containing Active Pharmaceutical Ingredients Considered to Be Soluble in Aqueous Media,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-171-demonstrating-bioequivalence-soluble-powder-oral-dosage-form-products-and-type-medicated,
FDA,FDA-2016-D-1342,Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implementation-acceptable-full-length-and-abbreviated-donor-history-questionnaires-and-accompanying-0,
FDA,FDA-2021-D-0775,Content of Premarket Submissions for Device Software Functions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-premarket-submissions-device-software-functions,
FDA,FDA-2012-D-0880,Assessing User Fees Under the Generic Drug User Fee Amendments of 2022,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-generic-drug-user-fee-amendments-2022,
FDA,FDA-2020-D-1848,Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-combined-oral-contraceptives-guidance-industry,
FDA,FDA-2023-D-1955,E6(R3) GOOD CLINICAL PRACTICE (GCP),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp,
FDA,FDA-2019-D-5607,Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-evaluation-immunotoxic-potential-pharmaceuticals,
FDA,FDA-2021-D-0861,Cover Letter Attachments for Controlled Correspondences and ANDA Submissions:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cover-letter-attachments-controlled-correspondences-and-anda-submissions,
FDA,FDA-2019-D-4656,Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program,
FDA,FDA-2018-D-1774,Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interstitial-cystitisbladder-pain-syndrome-establishing-drug-development-programs-treatment,
FDA,FDA-2012-D-0322,Migraine:  Developing Drugs for Preventive Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/migraine-developing-drugs-preventive-treatment,
FDA,FDA-2022-D-1729,Guidance for Industry: Action Level for Inorganic Arsenic in Apple Juice,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-action-level-inorganic-arsenic-apple-juice,
FDA,FDA-2019-D-0934,Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-clinical-performance-assessment-tissue-containment-systems-used-during-power-morcellation,
FDA,FDA-2022-D-0737,Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adjusting-covariates-randomized-clinical-trials-drugs-and-biological-products,
FDA,FDA-2023-D-0625,Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diabetes-mellitus-efficacy-endpoints-clinical-trials-investigating-antidiabetic-drugs-and-biological,
FDA,FDA-2023-D-1618,Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-whole-slide-imaging-nonclinical-toxicology-studies-questions-and-answers,
FDA,FDA-2021-D-1268,Generally Accepted Scientific Knowledge in Applications for Drug and Biological Products:  Nonclinical Information,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/generally-accepted-scientific-knowledge-applications-drug-and-biological-products-nonclinical,
FDA,FDA-2023-D-1336,Small Entity Compliance Guide: Requirements for Additional Traceability Records for Certain Foods: What You Need to Know About the FDA Regulation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-requirements-additional-traceability-records-certain-foods-what-you,
FDA,FDA-2005-D-0460,Pediatric Drug Development:  Regulatory Considerations â€” Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-drug-development-regulatory-considerations-complying-pediatric-research-equity-act-and,
FDA,FDA-2005-D-0460,Pediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act:  Scientific Considerations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-drug-development-under-pediatric-research-equity-act-and-best-pharmaceuticals-children-act,
FDA,FDA-2020-D-1140,CVM GFI #271 Reporting and Mitigating Animal Drug Shortages,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-271-reporting-and-mitigating-animal-drug-shortages,
FDA,FDA-2016-D-1342,Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-evaluating-donor-eligibility-using-individual-risk-based-questions-reduce-risk-human,
FDA,FDA-2015-D-1211,Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Blood and Blood Components:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implementation-acceptable-full-length-and-abbreviated-donor-history-questionnaires-and-accompanying,
FDA,FDA-2023-D-1103,CPG Sec 555.250 DRAFT: Major Food Allergen Labeling and Cross-contact,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555250-draft-major-food-allergen-labeling-and-cross-contact,
FDA,FDA-2023-D-1573,"Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-glycerin-propylene-glycol-maltitol-solution-hydrogenated-starch-hydrolysate-sorbitol,
FDA,FDA-2022-D-0705,Q9(R1) Quality Risk Management,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q9r1-quality-risk-management,
FDA,FDA-2017-D-6821,Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/smoking-cessation-and-related-indications-developing-nicotine-replacement-therapy-drug-products,
FDA,FDA-2019-D-0297,S12 NONCLINICAL BIODISTRIBUTION CONSIDERATIONS FOR GENE THERAPY PRODUCTS:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s12-nonclinical-biodistribution-considerations-gene-therapy-products,
FDA,FDA-2021-D-0875,Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-prescription-drug-user-fee-amendments-2022,
FDA,FDA-1992-S-0039,CVM GFI #108 Registering with CVMâ€™s Electronic Submission System,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-108-registering-cvms-electronic-submission-system,
FDA,FDA-2023-D-1146,Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-radiation-syndrome-developing-drugs-prevention-and-treatment,
FDA,FDA-2023-D-1031,Peripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/peripheral-percutaneous-transluminal-angioplasty-pta-and-specialty-catheters-premarket-notification,
FDA,FDA-2019-D-5422,"Guidance for Industry: Transition from Temporary Policy During the COVID-19 Public Health Emergency Regarding the Qualified Exemption from the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-transition-temporary-policy-during-covid-19-public-health-emergency-regarding,
FDA,FDA-2004-D-0369,Over-the-Counter Monograph Order Requests: Format and Content,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/over-counter-monograph-order-requests-format-and-content,
FDA,FDA-2023-D-1188,CVM GFI #170 Animal Drug User Fees and Fee Waivers and Reductions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-170-animal-drug-user-fees-and-fee-waivers-and-reductions,
FDA,FDA-2018-D-3546,Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas,
FDA,FDA-2016-D-1254,Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-adhesion-transdermal-and-topical-delivery-systems-andas-draft-guidance-industry,
FDA,FDA-2019-D-0362,A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/risk-based-approach-monitoring-clinical-investigations-questions-and-answers,
FDA,FDA-2023-D-0026,Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory,
FDA,FDA-2009-D-0268,Guidance for Industry: Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-labeling-certain-beers-subject-labeling-jurisdiction-food-and-drug-administration,
FDA,FDA-2022-D-2628,Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial,
FDA,FDA-2023-D-0606,Tobacco Health Document Submission (Revised):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tobacco-health-document-submission-revised,
FDA,FDA-2009-D-0508,Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/registration-and-product-listing-owners-and-operators-domestic-tobacco-product-establishments,
FDA,FDA-2009-D-0600,CVM GFI #281 Infectious Otitis Externa Drugs for Topical Use in Dogs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-281-infectious-otitis-externa-drugs-topical-use-dogs,
FDA,FDA-2023-D-0266,"Research Involving Children as Subjects and Not Otherwise Approvable by an Institutional Review Board: Process for Referrals to Food and Drug Administration and Office for Human Research Protections: Draft Guidance for Institutional Review Boards, Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/research-involving-children-subjects-and-not-otherwise-approvable-institutional-review-board-process,
FDA,FDA-2022-D-0142,Identification of Medicinal Products â€”  Implementation and Use,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/identification-medicinal-products-implementation-and-use,
FDA,FDA-2015-D-3419,Soft (Hydrophilic) Daily Wear Contact Lenses - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/soft-hydrophilic-daily-wear-contact-lenses-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2019-D-4843,General Considerations for Animal Studies Intended to Evaluate Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-considerations-animal-studies-intended-evaluate-medical-devices,
FDA,FDA-2021-D-1149,"Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency:  Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transition-plan-medical-devices-fall-within-enforcement-policies-issued-during-coronavirus-disease,
FDA,FDA-2021-D-1118,"Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19):  Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transition-plan-medical-devices-issued-emergency-use-authorizations-euas-related-coronavirus-disease,
FDA,FDA-2023-D-0110,Draft Guidance for Industry: Questions and Answers About Dietary Guidance Statements in Food Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-questions-and-answers-about-dietary-guidance-statements-food-labeling,
FDA,FDA-2023-D-1027,Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics,
FDA,FDA-2022-D-2856,Prohibition of Distributing Free Samples of Tobacco Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prohibition-distributing-free-samples-tobacco-products,
FDA,FDA-2014-N-0189,Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-tobacco-product-applications-electronic-nicotine-delivery-systems-ends,
FDA,FDA-2011-N-0121,Pharmacogenomic Data Submissions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenomic-data-submissions-0,
FDA,FDA-2017-D-0120,Listing of Ingredients in Tobacco Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/listing-ingredients-tobacco-products,
FDA,FDA-2009-D-0524,"Interpretation of and Compliance Policy for Certain Label Requirement; Applicability of Certain Federal Food, Drug, and Cosmetic Act Requirements to Vape Shops:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interpretation-and-compliance-policy-certain-label-requirement-applicability-certain-federal-food,
FDA,FDA-2015-D-2496,Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products - Small Entity Compliance Guide:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/further-amendments-general-regulations-food-and-drug-administration-incorporate-tobacco-products,
FDA,FDA-2017-D-0113,"FDA Deems Certain Tobacco Products Subject to FDA Authority, Sales and Distribution Restrictions, and Health Warning Requirements for Packages and Advertisements:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-deems-certain-tobacco-products-subject-fda-authority-sales-and-distribution-restrictions-and,
FDA,FDA-2015-D-0404,Determination of the Period Covered by a No-Tobacco-Sale Order and Compliance With an Order:  Guidance for Tobacco Retailers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determination-period-covered-no-tobacco-sale-order-and-compliance-order,
FDA,FDA-2021-D-1155,Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/definitions-suspect-product-and-illegitimate-product-verification-obligations-under-drug-supply,
FDA,FDA-2018-D-0338,CVM GFI #106 The Use of Published Literature in Support of New Animal Drug Approvals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-106-use-published-literature-support-new-animal-drug-approvals,
FDA,FDA-2013-D-0880,Guidance for Industry: Frequently Asked Questions About Medical Foods - Third Edition,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-frequently-asked-questions-about-medical-foods-third-edition,
FDA,FDA-2023-D-0608,Development of Local Anesthetic Drug Products With Prolonged Duration of Effect,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-local-anesthetic-drug-products-prolonged-duration-effect,
FDA,FDA-2020-D-1794,"Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications  Guidance for Industry:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-gastric-ph-dependent-drug-interactions-acid-reducing-agents-study-design-data-analysis,
FDA,FDA-2013-S-0610,Guidance for Industry: Labeling of Infant Formula,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-labeling-infant-formula,
FDA,FDA-2023-D-0202,Q13 Continuous Manufacturing of Drug Substances and Drug Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q13-continuous-manufacturing-drug-substances-and-drug-products,
FDA,FDA-2021-D-1047,Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-assay-considerations-monoclonal-antibodies-and-other-therapeutic-proteins-targeting-viral,
FDA,FDA-2022-D-0073,Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/neovascular-age-related-macular-degeneration-developing-drugs-treatment,
FDA,FDA-2018-D-4115,Policy Clarification and Premarket Notification [510(k)] Submissions for Ultrasonic Diathermy Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-clarification-and-premarket-notification-510k-submissions-ultrasonic-diathermy-devices,
FDA,FDA-2001-N-0178,"Performance Standard for Diagnostic X-Ray Systems and Their Major Components (21CFR 1020.30, 1020.31, 1020.32, 1020.33); Small Entity Compliance Guide",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/performance-standard-diagnostic-x-ray-systems-and-their-major-components-21cfr-102030-102031-102032,
FDA,FDA-2017-D-7011,Medical X-Ray Imaging Devices Conformance with IEC Standards:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-x-ray-imaging-devices-conformance-iec-standards,
FDA,FDA-2017-D-5372,Marketing Clearance of Diagnostic Ultrasound Systems and Transducers :  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-clearance-diagnostic-ultrasound-systems-and-transducers,
FDA,FDA-2016-D-2049,Laser Products - Conformance with IEC 60825-1 Ed. 3 and IEC 60601-2-22 Ed. 3.1 (Laser Notice No. 56):  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laser-products-conformance-iec-60825-1-ed-3-and-iec-60601-2-22-ed-31-laser-notice-no-56,
FDA,FDA-2017-D-4764,Guidance for Industry and Food and Drug Administration Staff - Assembler's Guide to Diagnostic X-Ray Equipment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-food-and-drug-administration-staff-assemblers-guide-diagnostic-x-ray-equipment,
FDA,FDA-2023-D-0451,Draft Guidance for Industry: Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-labeling-plant-based-milk-alternatives-and-voluntary-nutrient-statements,
FDA,FDA-2023-D-0169,Draft Guidance for Industry:  Protein Efficiency Ratio (PER) Rat Bioassay Studies to Demonstrate that a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-protein-efficiency-ratio-rat-bioassay-studies-demonstrate-new-infant-formula,
FDA,FDA-2022-D-2424,"Compounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-certain-ibuprofen-oral-suspension-products-under-section-503b-federal-food-drug-and,
FDA,FDA-2022-D-2983,Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products,
FDA,FDA-2022-D-2315,"Surveying, Leveling, and Alignment Laser Products:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surveying-leveling-and-alignment-laser-products,
FDA,FDA-2014-D-0435,Early Lyme Disease as Manifested by Erythema Migrans:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-lyme-disease-manifested-erythema-migrans-developing-drugs-treatment,
FDA,FDA-2022-D-0173,CVM GFI #272 Practices to Prevent Unsafe Contamination of Animal Feed from Drug Carryover,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-272-practices-prevent-unsafe-contamination-animal-feed-drug-carryover,
FDA,FDA-2022-D-2658,Acromegaly:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acromegaly-developing-drugs-treatment,
FDA,FDA-1998-D-0038,CVM GFI #152 Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-152-evaluating-safety-antimicrobial-new-animal-drugs-regard-their-microbiological-effects,
FDA,FDA-2022-D-0278,Draft Guidance for Industry: Action Levels for Lead in Food Intended for Babies and Young Children,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-action-levels-lead-food-intended-babies-and-young-children,
FDA,FDA-2020-D-1079,Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cannabis-and-cannabis-derived-compounds-quality-considerations-clinical-research-guidance-industry,
FDA,FDA-2022-D-2395,Mpox: Development of Drugs and Biological Products; Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mpox-development-drugs-and-biological-products-guidance-industry,
FDA,FDA-2007-D-0201,Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests (Revised):  Guidance for Test Developers and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-evaluating-impact-viral-mutations-covid-19-tests-revised,
FDA,FDA-2020-D-0987,Policy for Coronavirus Disease-2019 Tests (Revised):  Guidance for Developers and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-revised,
FDA,FDA-2022-D-3116,Photobiomodulation (PBM) Devices - Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/photobiomodulation-pbm-devices-premarket-notification-510k-submissions,
FDA,FDA-2020-D-0987,Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products â€” Content and Format,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dosage-and-administration-section-labeling-human-prescription-drug-and-biological-products-content,
FDA,FDA-2017-D-5225,Guidance for Industry: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-foreign-supplier-verification-programs-importers-food-humans-and-animals,
FDA,FDA-2009-D-0461,REMS Document Technical Conformance Guide,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-document-technical-conformance-guide,
FDA,,Format and Content of a REMS Document Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-rems-document-guidance-industry,
FDA,FDA-2022-D-3054,M11 Template: Clinical Electronic Structured Harmonised Protocol,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m11-template-clinical-electronic-structured-harmonised-protocol,
FDA,FDA-2022-D-3054,M11 Technical Specification: Clinical Electronic Structured Harmonised Protocol,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m11-technical-specification-clinical-electronic-structured-harmonised-protocol,
FDA,FDA-2022-D-3054,M11 Clinical Electronic Structured Harmonised Protocol,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m11-clinical-electronic-structured-harmonised-protocol,
FDA,FDA-2017-D-0085,Guidance for Industry: Best Practices for Convening a GRAS Panel,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-best-practices-convening-gras-panel,
FDA,FDA-2013-D-1319,Pulmonary Tuberculosis: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pulmonary-tuberculosis-developing-drugs-treatment,
FDA,FDA-2020-D-1548,Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/failure-respond-anda-complete-response-letter-within-regulatory-timeframe-guidance-industry,
FDA,FDA-2015-D-4599,Content of Human Factors Information in Medical Device Marketing Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-human-factors-information-medical-device-marketing-submissions,
FDA,FDA-2017-D-6580,Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-reduce-risk-transfusion-transmitted-malaria,
FDA,FDA-2000-D-0187,Homeopathic Drug Products Guidance for FDA Staff and Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/homeopathic-drug-products-guidance-fda-staff-and-industry,
FDA,FDA-2022-D-2301,Small Volume Parenteral Drug Products and Pharmacy Bulk Packages for Parenteral Nutrition: Aluminum Content and Labeling Recommendations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-volume-parenteral-drug-products-and-pharmacy-bulk-packages-parenteral-nutrition-aluminum,
FDA,FDA-2021-D-0691,Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetic-based-criteria-supporting-alternative-dosing-regimens-programmed-cell-death-receptor,
FDA,FDA-2019-D-1828,E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e19-selective-approach-safety-data-collection-specific-late-stage-pre-approval-or-post-approval,
FDA,FDA-2017-D-3101,Statistical Approaches to Establishing Bioequivalence,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence-0,
FDA,FDA-2001-D-0197,ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-pre-submission-facility-correspondence-related-prioritized-generic-drug-submissions,
FDA,FDA-2010-D-0265,"Clinical Investigator Administrative Actions - Disqualification:  Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-investigator-administrative-actions-disqualification,
FDA,FDA-2022-D-0099,Guidance for Industry: Questions and Answers Regarding Food Allergen Labeling (Edition 5),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-food-allergen-labeling-edition-5,
FDA,FDA-2022-D-0099,Draft Guidance for Industry: Questions and Answers Regarding Food Allergen Labeling (Edition 5),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-questions-and-answers-regarding-food-allergen-labeling-edition-5,
FDA,FDA-2013-D-0811,Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota,
FDA,FDA-2022-D-2922,Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-certain-beta-lactam-products-shortage-under-section-503a-federal-food-drug-and-cosmetic,
FDA,FDA-2021-D-0997,"Referencing the Definition of ""Device"" in the Federal Food, Drug, and Cosmetic Act in Guidance, Regulatory Documents, Communications, and Other Public Documents:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/referencing-definition-device-federal-food-drug-and-cosmetic-act-guidance-regulatory-documents,
FDA,FDA-2022-D-0697,Sameness Evaluations in an ANDA â€” Active Ingredients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sameness-evaluations-anda-active-ingredients,
FDA,FDA-2019-D-1469,Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/studying-multiple-versions-cellular-or-gene-therapy-product-early-phase-clinical-trial,
FDA,FDA-2021-D-0776,M10 Bioanalytical Method Validation and Study Sample Analysis,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m10-bioanalytical-method-validation-and-study-sample-analysis,
FDA,FDA-2020-D-2107,S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s1br1-addendum-s1b-testing-carcinogenicity-pharmaceuticals,
FDA,FDA-2021-D-0669,Cross Labeling Oncology Drugs in Combination Regimens,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cross-labeling-oncology-drugs-combination-regimens,
FDA,2021-709,"Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Small Entity Compliance Guide:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulation-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-small-entity-compliance,
FDA,FDA-2013-D-0446,Expanded Access to Investigational Drugs for Treatment Use:  Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expanded-access-investigational-drugs-treatment-use-questions-and-answers-0,
FDA,FDA-2022-D-0563,Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-over-counter-monograph-drug-user-fee-program,
FDA,FDA-2022-D-0760,Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/measuring-growth-and-evaluating-pubertal-development-pediatric-clinical-trials-draft-guidance,
FDA,FDA-2022-D-1261,"Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clostridioides-difficile-infection-developing-drugs-treatment-reduction-recurrence-and-prevention,
FDA,FDA-2017-D-5711,Developing and Responding to Deficiencies in Accordance with the Least Burdensome Provisions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-and-responding-deficiencies-accordance-least-burdensome-provisions,
FDA,FDA-2022-D-1862,Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/physicochemical-and-structural-q3-characterization-topical-drug-products-submitted-andas,
FDA,FDA-2022-D-1859,Multiple Endpoints in Clinical Trials:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-endpoints-clinical-trials,
FDA,FDA-2022-D-1864,In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-release-test-studies-topical-drug-products-submitted-andas,
FDA,FDA-2020-D-2101,In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-permeation-test-studies-topical-drug-products-submitted-andas,
FDA,FDA-2016-D-4460,Human Gene Therapy for Neurodegenerative Diseases:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-neurodegenerative-diseases,
FDA,FDA-2021-D-0399,Guidance for Industry: Refusal of Inspection by a Foreign Food Establishment or Foreign Government,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-refusal-inspection-foreign-food-establishment-or-foreign-government,
FDA,FDA-2021-D-0401,"CVM GFI #254 Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-254-donor-eligibility-animal-cells-tissues-and-cell-and-tissue-based-products,
FDA,FDA-2017-D-6528,"CVM GFI #253 Current Good Manufacturing Practice for Animal Cells, Tissues, and Cell- and Tissue-Based Products",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-253-current-good-manufacturing-practice-animal-cells-tissues-and-cell-and-tissue-based,
FDA,FDA-2021-D-1246,Small Entity Compliance Guide: Laboratory Accreditation for Analyses of Foods - What You Need to Know,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-laboratory-accreditation-analyses-foods-what-you-need-know,
FDA,FDA-2022-D-1126,"CVM GFI #258 Use of Tracers in Animal Food, Type A Medicated Articles, and Medicated Feeds",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-258-use-tracers-animal-food-type-medicated-articles-and-medicated-feeds,
FDA,FDA-2022-D-0286,Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tissue-agnostic-drug-development-oncology,
FDA,FDA-2020-D-1298,"Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials: Draft Guidance for Industry; Availability",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/characterizing-collecting-and-reporting-immune-mediated-adverse-reactions-cancer-immunotherapeutic,
FDA,FDA-2022-D-1744,Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment:  Guidance for Industry; Availability,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-myeloid-leukemia-developing-drugs-and-biological-products-treatment-0,
FDA,FDA-2014-D-0901,ANDA Submissions â€“ Prior Approval Supplements Under GDUFA:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-prior-approval-supplements-under-gdufa,
FDA,FDA-2016-D-0973,"Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/comparability-protocols-postapproval-changes-chemistry-manufacturing-and-controls-information-nda,
FDA,FDA-2011-D-0514,Procedures for Handling Post-Approval Studies Imposed by PMA Order:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-handling-post-approval-studies-imposed-pma-order,
FDA,FDA-2005-D-0027,"Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-surveillance-under-section-522-federal-food-drug-and-cosmetic-act,
FDA,FDA-2019-D-0065,User Fees for 513(g) Requests for Information:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fees-513g-requests-information,
FDA,FDA-2017-D-5739,User Fees and Refunds for Premarket Notification Submissions (510(k)s):  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fees-and-refunds-premarket-notification-submissions-510ks,
FDA,FDA-2017-D-5928,User Fees and Refunds for Premarket Approval Applications and Device Biologics License Applications:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fees-and-refunds-premarket-approval-applications-and-device-biologics-license-applications,
FDA,FDA-2017-D-6752,User Fees and Refunds for De Novo Classification Requests :  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fees-and-refunds-de-novo-classification-requests,
FDA,FDA-2017-D-5713,Post-Complete Response Letter Clarification Teleconferences Between FDA and ANDA Applicants Under GDUFA Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/post-complete-response-letter-clarification-teleconferences-between-fda-and-anda-applicants-under,
FDA,FDA-2009-D-0051,Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/information-requests-and-discipline-review-letters-under-generic-drug-user-fee-amendments,
FDA,FDA-2003-D-0198,Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-anda-applicants-complex-products-under-gdufa-guidance-industry,
FDA,FDA-2010-D-0144,Competitive Generic Therapies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/competitive-generic-therapies,
FDA,FDA-2013-N-1434,"Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/size-shape-and-other-physical-attributes-generic-tablets-and-capsules,
FDA,FDA-2017-D-5712,FDA and Industry Actions on Premarket Notification (510(k)) Submissions: Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-and-industry-actions-premarket-notification-510k-submissions-effect-fda-review-clock-and-goals,
FDA,FDA-2003-D-0378,FDA and Industry Actions on Premarket Approval Applications (PMAs): Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-and-industry-actions-premarket-approval-applications-pmas-effect-fda-review-clock-and-goals,
FDA,FDA-2003-D-0033,FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-and-industry-actions-de-novo-classification-requests-effect-fda-review-clock-and-goals,
FDA,FDA-2022-D-0814,Guidance for Industry: Infant Formula Transition Plan for Exercise of Enforcement Discretion,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-infant-formula-transition-plan-exercise-enforcement-discretion,
FDA,FDA-2009-D-0503,Policy for Device Software Functions and Mobile Medical Applications:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications,
FDA,FDA-2017-D-6569,"Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-data-systems-medical-image-storage-devices-and-medical-image-communications-devices,
FDA,FDA-2009-D-0503,Display Devices for Diagnostic Radiology:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/display-devices-diagnostic-radiology,
FDA,FDA-2016-D-0270,Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data - Premarket Notification [510(k)] Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-assisted-detection-devices-applied-radiology-images-and-radiology-device-data-premarket,
FDA,FDA-2014-D-0798,Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in Premarket Notification (510(k)) Submissions:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-performance-assessment-considerations-computer-assisted-detection-devices-applied-radiology,
FDA,FDA-2011-D-0530,Clinical Decision Support Software:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software,
FDA,FDA-2022-D-0738,"Ethical Considerations for Clinical Investigations of Medical Products Involving Children: Draft Guidance for Industry, Sponsors, and IRBs",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ethical-considerations-clinical-investigations-medical-products-involving-children,
FDA,FDA-2022-D-1847,Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exemption-and-exclusion-certain-requirements-drug-supply-chain-security-act-distribution-fda,
FDA,FDA-2022-D-1358,How To Obtain a Covered Product Authorization,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-obtain-covered-product-authorization,
FDA,FDA-2013-D-1156,Q3D(R2) â€“ Guideline for Elemental Impurities:  International Council for Harmonisation; Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3dr2-guideline-elemental-impurities,
FDA,FDA-2022-D-0795,Computer Software Assurance for Production and Quality System Software: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-software-assurance-production-and-quality-system-software,
FDA,FDA-2019-D-1263,Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drug-and-biological-products,
FDA,FDA-2021-D-0528,Statement of Identity and Strength â€” Content and Format of Labeling for Human Nonprescription Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statement-identity-and-strength-content-and-format-labeling-human-nonprescription-drug-products,
FDA,FDA-2022-D-1837,"Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug,
FDA,FDA-2013-D-1275,"Policy for Monkeypox Tests to Address the Public Health Emergency:  Guidance for Laboratories, Commercial Manufacturers and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-monkeypox-tests-address-public-health-emergency,
FDA,FDA-2012-D-0429,Meetings with Industry and Investigators on the Research and Development of Tobacco Products (Revised):  Guidance for Industry and Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/meetings-industry-and-investigators-research-and-development-tobacco-products-revised,
FDA,FDA-2022-D-1908,"General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-clinical-pharmacology-considerations-pediatric-studies-drugs-including-biological-products,
FDA,FDA-2022-D-1562,E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e14-and-s7b-clinical-and-nonclinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic,
FDA,FDA-2020-D-1791,E11A Pediatric Extrapolation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e11a-pediatric-extrapolation,
FDA,FDA-2019-D-4188,Tobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tobacco-products-principles-designing-and-conducting-tobacco-product-perception-and-intention,
FDA,FDA-2017-D-6765,Replacement Reagent and Instrument Family Policy for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/replacement-reagent-and-instrument-family-policy-in-vitro-diagnostic-devices,
FDA,FDA-2020-D-1380,Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-requirements-hearing-aid-devices-and-personal-sound-amplification-products,
FDA,FDA-2022-D-1494,CVM GFI #97 (VICH GL14) Effectiveness of Anthelmintics:  Specific Recommendations for Caprines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-97-vich-gl14-effectiveness-anthelmintics-specific-recommendations-caprines,
FDA,FDA-2022-D-1494,CVM GFI #96 (VICH GL13) Effectiveness of Anthelmintics:  Specific Recommendations for Ovines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-96-vich-gl13-effectiveness-anthelmintics-specific-recommendations-ovines,
FDA,FDA-2022-D-1494,CVM GFI #95 (VICH GL12) Effectiveness of Anthelmintics:  Specific Recommendations for Bovines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-95-vich-gl12-effectiveness-anthelmintics-specific-recommendations-bovines,
FDA,FDA-2022-D-1494,CVM GFI #90 (VICH GL7) Effectiveness of Anthelmintics: General Recommendations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-90-vich-gl7-effectiveness-anthelmintics-general-recommendations,
FDA,FDA-2022-D-1494,CVM GFI #114 (VICH GL21) Effectiveness of Anthelmintics: Specific Recommendations for Chickens Gallus gallus,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-114-vich-gl21-effectiveness-anthelmintics-specific-recommendations-chickens-gallus-gallus,
FDA,FDA-2022-D-1494,CVM GFI #113 (VICH GL20) Effectiveness of Anthelmintics: Specific Recommendations for Felines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-113-vich-gl20-effectiveness-anthelmintics-specific-recommendations-felines,
FDA,FDA-2022-D-1494,CVM GFI #111 (VICH GL19) Effectiveness of Anthelmintics: Specific Recommendations for Canines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-111-vich-gl19-effectiveness-anthelmintics-specific-recommendations-canines,
FDA,FDA-2022-D-1494,CVM GFI #110 (VICH GL16) Effectiveness of Anthelmintics: Specific Recommendations for Porcines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-110-vich-gl16-effectiveness-anthelmintics-specific-recommendations-porcines,
FDA,FDA-2022-D-1494,CVM GFI #109 (VICH GL15) Effectiveness of Anthelmintics: Specific Recommendations for Equines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-109-vich-gl15-effectiveness-anthelmintics-specific-recommendations-equines,
FDA,FDA-2018-D-4533,"Guidance for Industry: Questions and Answers Regarding the Final Rule on Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-final-rule-prevention-salmonella-enteritidis-shell-0,
FDA,FDA-2000-N-0190,CVM GFI #256 - Compounding Animal Drugs from Bulk Drug Substances,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-256-compounding-animal-drugs-bulk-drug-substances,
FDA,FDA-2022-D-0490,Guidance for Industry: Policy Regarding N-acetyl-L-cysteine,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-policy-regarding-n-acetyl-l-cysteine,
FDA,FDA-2017-D-6821,Changes to Disposable Manufacturing Materials:  Questions and Answers Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-disposable-manufacturing-materials-questions-and-answers-guidance-industry,
FDA,FDA-2022-D-1253,Laser-Assisted In Situ Keratomileusis (LASIK) Lasers - Patient Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laser-assisted-situ-keratomileusis-lasik-lasers-patient-labeling-recommendations,
FDA,FDA-2019-D-3132,General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-clinical-pharmacology-considerations-neonatal-studies-drugs-and-biological-products-guidance,
FDA,FDA-2020-D-1802,Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-available-therapy-non-curative-settings,
FDA,FDA-2017-D-6841,"Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices, Direct Marking, and Global Unique Device Identification Database Requirements for Certain Devices:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identification-policy-regarding-compliance-dates-class-i-and-unclassified-devices,
FDA,FDA-2020-D-1068,Orange Book Questions and Answers Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orange-book-questions-and-answers-guidance-industry,
FDA,FDA-2022-D-0528,Evaluation of Therapeutic Equivalence,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-therapeutic-equivalence,
FDA,FDA-2019-D-1615,Instructions for Use â€” Patient Labeling for Human Prescription Drug and Biological Products â€” Content and Format,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/instructions-use-patient-labeling-human-prescription-drug-and-biological-products-content-and-format,
FDA,FDA-2018-D-0388,CVM GFI #245 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-245-hazard-analysis-and-risk-based-preventive-controls-food-animals,
FDA,FDA-2017-D-1956,Identifying Trading Partners Under the Drug Supply Chain Security Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/identifying-trading-partners-under-drug-supply-chain-security-act,
FDA,FDA-2022-D-1385,"Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome,
FDA,FDA-2020-D-1497,Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bladder-cancer-developing-drugs-and-biologics-adjuvant-treatment,
FDA,FDA-2020-D-1496,Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/renal-cell-carcinoma-developing-drugs-and-biologics-adjuvant-treatment,
FDA,FDA-2021-D-1152,Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-alternate-electronic-format-guidance-industry,
FDA,FDA-2020-D-0420,Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-penicillin-beta-lactam-drugs-cgmp-framework-preventing-cross-contamination-0,
FDA,FDA-2011-D-0104,Considerations for Rescinding Breakthrough Therapy Designation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-rescinding-breakthrough-therapy-designation,
FDA,FDA-2018-D-4368,Assessing the Effects of Food on Drugs in INDs and NDAs â€“ Clinical Pharmacology Considerations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-effects-food-drugs-inds-and-ndas-clinical-pharmacology-considerations,
FDA,FDA-2019-D-1997,FDA Oversight of Food Covered by Systems Recognition Arrangements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-oversight-food-covered-systems-recognition-arrangements,
FDA,FDA-2019-D-1470,Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-performance-assessment-quantitative-imaging-radiological-device-premarket-submissions,
FDA,FDA-2015-D-3787,Electromagnetic Compatibility (EMC) of Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electromagnetic-compatibility-emc-medical-devices,
FDA,FDA-2011-D-0287,Guidance for Industry: Fish and Fishery Products Hazards and Controls,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fish-and-fishery-products-hazards-and-controls,
FDA,FDA-2019-D-2808,Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry:  Clinical/Medical,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/advanced-prostate-cancer-developing-gonadotropin-releasing-hormone-analogues-guidance-industry,
FDA,FDA-2021-D-0958,Importation of Prescription Drugs Final Rule Questions and Answers; Small Entity Compliance Guide,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/importation-prescription-drugs-final-rule-questions-and-answers-small-entity-compliance-guide,
FDA,FDA-2013-D-0744,Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases â€“ Questions and Answers (Revision 1),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases-questions,
FDA,FDA-2012-D-0307,Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-reduce-possible-risk-transmission-creutzfeldt-jakob-disease-and-variant-creutzfeldt,
FDA,FDA-2022-D-0281,Risk Management Plans to Mitigate the Potential for Drug Shortages,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/risk-management-plans-mitigate-potential-drug-shortages,
FDA,FDA-2022-D-0277,Draft Guidance for Industry: Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-market Notification,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-policy-regarding-certain-new-dietary-ingredients-and-dietary-supplements,
FDA,FDA-2013-D-0401,Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-container-labels-and-carton-labeling-design-minimize-medication-errors,
FDA,FDA-1998-D-0019,Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production - Level 2 revision:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision,
FDA,FDA-2018-D-4534,Guidance for Industry: Reducing Microbial Food Safety Hazards in the Production of Seed for Sprouting,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-reducing-microbial-food-safety-hazards-production-seed-sprouting,
FDA,FDA-2005-D-0155,CVM GFI #3 General Principles for Evaluating the Human Food Safety of New Animal Drugs Used In Food-Producing Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-3-general-principles-evaluating-human-food-safety-new-animal-drugs-used-food-producing,
FDA,FDA-2022-D-0168,Benefit-Risk Considerations for Product Quality Assessments,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-considerations-product-quality-assessments,
FDA,FDA-2021-D-0131,Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/feasibility-and-early-feasibility-clinical-studies-certain-medical-devices-intended-therapeutically,
FDA,Docket No. FDA-2022-D-0084,Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Draft Guidance for Industry; Availability,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-draft-guidance,
FDA,FDA-2022-D-0814,Guidance for Industry: Infant Formula Enforcement Discretion Policy,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-infant-formula-enforcement-discretion-policy,
FDA,FDA-2011-D-0720,Electronic Submission of IND Safety Reports Technical Conformance Guide :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-ind-safety-reports-technical-conformance-guide,
FDA,FDA-2011-D-0720,E2B(R3) The Electronic Transmission of Individual Case Safety Reports Implementation Guide â€”Appendix to the Implementation Guide â€” Backwards and Forwards Compatibility,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2br3-electronic-transmission-individual-case-safety-reports-implementation-guide-appendix,
FDA,FDA-2018-D-1216,E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide â€” Data Elements and Message Specification; and Appendix to the Implementation Guide â€” Backwards and Forwards Compatibility,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2br3-electronic-transmission-individual-case-safety-reports-implementation-guide-data-elements-and,
FDA,FDA-2022-D-0091,Ulcerative Colitis:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ulcerative-colitis-developing-drugs-treatment,
FDA,FDA-2022-D-0370,Draft Guidance for Industry: Questions and Answers on the Accredited Third-Party Certification Program,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-questions-and-answers-accredited-third-party-certification-program,
FDA,FDA-2022-D-0140,Crohnâ€™s Disease:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/crohns-disease-developing-drugs-treatment,
FDA,FDA-2011-N-0143,Providing Submissions in Electronic Format â€” Postmarketing Safety Reports,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-submissions-electronic-format-postmarketing-safety-reports,
FDA,FDA-2001-D-0067,Guidance for Industry: Compliance with Providing an Acceptable Unique Facility Identifier for the Foreign Supplier Verification Programs for Food Importers Regulation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-compliance-providing-acceptable-unique-facility-identifier-foreign-supplier,
FDA,FDA-2019-D-5609,Draft Guidance for Industry: Action Levels for Lead in Juice,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-action-levels-lead-juice,
FDA,FDA-2017-D-0759,Refuse to Accept Policy for 510(k)s:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/refuse-accept-policy-510ks,
FDA,FDA-2012-D-0523,"Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry,
FDA,FDA-2021-N-0553,"Draft Guidance for FDA Staff and Stakeholders: Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-fda-staff-and-stakeholders-evaluating-public-health-importance-food-allergens-other,
FDA,FDA-2018-D-4367,Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/celiac-disease-developing-drugs-adjunctive-treatment-gluten-free-diet,
FDA,FDA-2021-D-1238,Bioavailability Studies Submitted in NDAs or INDs â€“ General Considerations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-studies-submitted-ndas-or-inds-general-considerations,
FDA,FDA-2022-D-0108,"Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use: Draft Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-waiver-requests-ph-adjusters-generic-drug-products-intended-parenteral-ophthalmic-or,
FDA,FDA-2019-D-3324,Guidance for Industry: Reconditioning of Fish and Fishery Products by Segregation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-reconditioning-fish-and-fishery-products-segregation,
FDA,FDA-2021-D-0603,Facet Screw Systems - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/facet-screw-systems-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2021-D-0604,Denture Base Resins - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/denture-base-resins-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2015-D-1163,Surgical Sutures - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surgical-sutures-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2022-D-0552,Providing Regulatory Submissions in Electronic and Non-Electronic Formatâ€”Promotional Labeling and Advertising Materials for Human Prescription Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-and-non-electronic-format-promotional-labeling-and,
FDA,FDA-2022-D-0552,Orthopedic Fracture Fixation Plates - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orthopedic-fracture-fixation-plates-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2019-D-3049,E8(R1) General Considerations for Clinical Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e8r1-general-considerations-clinical-studies,
FDA,FDA-2018-D-3903,Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-hepatitis-b-virus-infection-developing-drugs-treatment,
FDA,FDA-2022-D-0192,Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4  Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/certain-ophthalmic-products-policy-regarding-compliance-21-cfr-part-4-guidance-industry,
FDA,FDA-2021-D-0563,"Guidance for Industry: Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier Verification Programs, Intentional Adulteration, and Produce Safety Regulations: Enforcement Policy Regarding Certain Provisions",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-current-good-manufacturing-practice-and-preventive-controls-foreign-supplier,
FDA,FDA-2018-D-2074,"Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C:  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/initiation-voluntary-recalls-under-21-cfr-part-7-subpart-c,
FDA,FDA-2019-D-5572,Inclusion of Older Adults in Cancer Clinical Trials:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inclusion-older-adults-cancer-clinical-trials,
FDA,FDA-2011-D-0893,Center for Devices and Radiological Health (CDRH) Appeals Processes:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/center-devices-and-radiological-health-cdrh-appeals-processes,
FDA,FDA-2018-D-2777,Pre-Launch Activities Importation Requests (PLAIR):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pre-launch-activities-importation-requests-plair,
FDA,FDA-2018-D-3292,Master Protocols:  Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and,
FDA,FDA-2013-D-0836,Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expansion-cohorts-use-first-human-clinical-trials-expedite-development-oncology-drugs-and-biologics,
FDA,FDA-2019-D-4247,"Patient-Focused Drug Development: Methods to Identify What Is Important to Patients:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-methods-identify-what-important-patients,
FDA,FDA-2011-N-0146,Guidance for Industry and FDA Staff: Model Accreditation Standards for Third-Party Certification Body Accreditation for Food Safety Audits,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-staff-model-accreditation-standards-third-party-certification-body,
FDA,FDA-2021-N-0556,Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-non-opioid-analgesics-acute-pain-draft-guidance-industry,
FDA,FDA-2014-D-1411,Population Pharmacokinetics:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/population-pharmacokinetics,
FDA,FDA-2019-D-2398,Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling--Content and Format: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-information-human-prescription-therapeutic-protein-and-select-drug-product-labeling,
FDA,FDA-2018-D-1636,Drug Product Tracing: The Effect of Section 585 of the FD&C Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-product-tracing-effect-section-585-fdc-act,
FDA,FDA-2021-D-1041,Assessment of Pressor Effects of Drugs Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-pressor-effects-drugs-guidance-industry,
FDA,FDA-2022-D-0080,Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-food-and-drug-administration-and-sponsors-or-requestors-over-counter,
FDA,FDA-2017-D-6854,Principles of Premarket Pathways for Combination Products:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/principles-premarket-pathways-combination-products,
FDA,FDA-2019-D-0078,"Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation:  Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/principles-selecting-developing-modifying-and-adapting-patient-reported-outcome-instruments-use,
FDA,FDA-2020-D-1564,"Patient Engagement in the Design and Conduct of Medical Device Clinical Studies:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-engagement-design-and-conduct-medical-device-clinical-studies,
FDA,FDA-2019-D-3846,Good ANDA Submission Practices Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-anda-submission-practices-guidance-industry,
FDA,FDA-2003-D-0433,Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH):  Guidance for Industry Technical Specifications Document,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-specifications-submitting-clinical-trial-data-sets-treatment-noncirrhotic-nonalcoholic,
FDA,FDA-2018-D-1216,CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-159-vich-gl36-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach,
FDA,FDA-2021-D-0593,Collecting and Providing 702(b) Portions of FDA Official Samples: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collecting-and-providing-702b-portions-fda-official-samples,
FDA,FDA-2019-D-2330,Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pathology-peer-review-nonclinical-toxicology-studies-questions-and-answers,
FDA,FDA-2020-D-1118,Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH):  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-clinical-and-clinical-investigation-devices-used-treatment-benign-prostatic-hyperplasia-bph,
FDA,FDA-2019-D-5606,Arthroscopy Pump Tubing Sets Intended for Multiple Patient Use - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/arthroscopy-pump-tubing-sets-intended-multiple-patient-use-premarket-notification-510k-submissions,
FDA,FDA-2017-D-3716,Validation and Verification of Analytical Testing Methods Used for Tobacco Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/validation-and-verification-analytical-testing-methods-used-tobacco-products,
FDA,FDA-2017-D-3716,Guidance for Industry: Seafood HACCP and the FDA Food Safety Modernization Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-seafood-haccp-and-fda-food-safety-modernization-act,
FDA,FDA-2017-D-3716,Guidance for Industry: Low-Acid Foods Packaged in Hermetically Sealed Containers (LACF) Regulation and the FDA Food Safety Modernization Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-low-acid-foods-packaged-hermetically-sealed-containers-lacf-regulation-and-fda,
FDA,FDA-2021-D-0756,Guidance for Industry: Juice HACCP and the FDA Food Safety Modernization Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-juice-haccp-and-fda-food-safety-modernization-act,
FDA,FDA-2021-D-0241,Inspection of Injectable Products for Visible Particulates: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inspection-injectable-products-visible-particulates,
FDA,FDA-2020-D-1301,Q3C(R8) Impurities: Guidance for Residual Solvents   Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3cr8-impurities-guidance-residual-solvents-guidance-industry,
FDA,FDA-2021-D-0406,Bowel Cleansing for Colonoscopy:  Efficacy and Safety Considerations for Developing New Products : Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bowel-cleansing-colonoscopy-efficacy-and-safety-considerations-developing-new-products,
FDA,FDA-2017-D-2802,Development of Anti-Infective Drug Products for the Pediatric Population :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-anti-infective-drug-products-pediatric-population,
FDA,FDA-2020-D-1518,CMC Postapproval Manufacturing Changes for Specified Biological Products To Be Documented in Annual Reports,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cmc-postapproval-manufacturing-changes-specified-biological-products-be-documented-annual-reports,
FDA,FDA-2021-D-0373,Tobacco Product User Fees: Responses to Frequently Asked Questions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tobacco-product-user-fees-responses-frequently-asked-questions,
FDA,FDA-2021-D-1140,IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-life,
FDA,FDA-2021-D-1139,"Investigational New Drug Application Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases:  Chemistry, Manufacturing, and Controls Recommendations, Guidance for Sponsor-Investigators : Draft Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drug,
FDA,FDA-2017-D-6784,Manufacture of Blood Components Using a Pathogen Reduction Device in Blood Establishments: Questions and Answers:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacture-blood-components-using-pathogen-reduction-device-blood-establishments-questions-and,
FDA,FDA-2016-D-4484,Guidance for Industry: Temporary Permits for Interstate Shipment of Experimental Packs of Food Varying from the Requirements of Definitions and Standards of Identity,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-temporary-permits-interstate-shipment-experimental-packs-food-varying-requirements,
FDA,FDA-1999-D-0062,Guidance for Industry: Preparation of Food Contact Substance Notifications (Toxicology Recommendations),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparation-food-contact-substance-notifications-toxicology-recommendations,
FDA,FDA-2000-D-0138,Guidance for Industry:  Preparation of Food Contact  Substance Notifications (Administrative),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparation-food-contact-substance-notifications-administrative,
FDA,FDA-2014-D-0055,"Guidance for Industry: Voluntary Sodium Reduction Goals:  Target Mean and Upper Bound Concentrations for Sodium in Commercially Processed, Packaged, and Prepared Foods",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-voluntary-sodium-reduction-goals,
FDA,FDA-2019-D-1262,Surgical Staplers and Staples for Internal Use - Labeling Recommendations:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surgical-staplers-and-staples-internal-use-labeling-recommendations,
FDA,FDA-2020-D-1396,"Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hospital-and-health-system-compounding-under-section-503a-federal-food-drug-and-cosmetic-act,
FDA,FDA-2020-D-1400,CVM GFI #268 Adaptive and Other Innovative Designs for Effectiveness Studies of New Animal Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-268-adaptive-and-other-innovative-designs-effectiveness-studies-new-animal-drugs,
FDA,FDA-2020-D-1402,CVM GFI #267 Biomarkers and Surrogate Endpoints in Clinical Studies to Support Effectiveness of New Animal Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-267-biomarkers-and-surrogate-endpoints-clinical-studies-support-effectiveness-new-animal,
FDA,FDA-2020-D-1401,CVM GFI #266 Use of Real-World Data and Real-World Evidence to Support Effectiveness of New Animal Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-266-use-real-world-data-and-real-world-evidence-support-effectiveness-new-animal-drugs,
FDA,FDA-2016-D-0271,CVM GFI #265 Use of Data from Foreign Investigational Studies to Support Effectiveness of New Animal Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-265-use-data-foreign-investigational-studies-support-effectiveness-new-animal-drugs,
FDA,FDA-2017-D-6069,De Novo Classification Process (Evaluation of Automatic Class III Designation):  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/de-novo-classification-process-evaluation-automatic-class-iii-designation,
FDA,FDA-2011-D-0689,Acceptance Review for De Novo Classification Requests:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptance-review-de-novo-classification-requests,
FDA,FDA-2019-D-5392,Microbiological Quality Considerations in Non-Sterile Drug Manufacturing: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/microbiological-quality-considerations-non-sterile-drug-manufacturing,
FDA,FDA-2021-D-0368,Investigator Responsibilities â€“ Safety Reporting for Investigational Drugs and Devices: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigator-responsibilities-safety-reporting-investigational-drugs-and-devices,
FDA,FDA-2021-D-0432,Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interpreting-sameness-gene-therapy-products-under-orphan-drug-regulations,
FDA,FDA-2017-D-6821,Questions and Answers on Quality Related Controlled Correspondence Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-quality-related-controlled-correspondence-guidance-industry,
FDA,FDA-2011-D-0611,Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-biosimilar-development-and-bpci-act-guidance-industry,
FDA,FDA-2011-D-0611,New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3): Draft New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3).â€,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/new-and-revised-draft-qas-biosimilar-development-and-bpci-act-revision-3,
FDA,FDA-2017-D-6821,Q2(R1) Validation of Analytical Procedures: Text and Methodology  Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2r1-validation-analytical-procedures-text-and-methodology-guidance-industry,
FDA,FDA-2007-D-0369,Withdrawn CDER Product Specific Guidances,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/withdrawn-cder-product-specific-guidances,
FDA,FDA-2007-D-0207,Guidance for Industry: Microbiological Considerations for Antimicrobial Agents Used in Food Applications,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-microbiological-considerations-antimicrobial-agents-used-food-applications,
FDA,FDA-2013-D-1464,Notifying FDA of Fatalities Related to Blood Collection or Transfusion:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/notifying-fda-fatalities-related-blood-collection-or-transfusion,
FDA,,FDA Export Certification:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-export-certification,
FDA,FDA-2002-D-0010,Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug,
FDA,FDA-2015-D-0868,Nonmetastatic Castration-Resistant Prostate Cancer: Considerations for Metastasis-Free Survival Endpoint in Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonmetastatic-castration-resistant-prostate-cancer-considerations-metastasis-free-survival-endpoint,
FDA,FDA-2018-D-3931,Development and Submission of Near Infrared Analytical Procedures,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-submission-near-infrared-analytical-procedures,
FDA,FDA-2021-D-0519,Rabies:  Developing Monoclonal Antibody Cocktails for the Passive Immunization Component of Post-Exposure Prophylaxis Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rabies-developing-monoclonal-antibody-cocktails-passive-immunization-component-post-exposure,
FDA,FDA-2018-D-2326,Field Alert Report Submission: Questions and Answers Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/field-alert-report-submission-questions-and-answers-guidance-industry,
FDA,FDA-2020-D-1456,Guidance for Industry: Use of Recycled Plastics in Food Packaging (Chemistry Considerations),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-use-recycled-plastics-food-packaging-chemistry-considerations,
FDA,FDA-2019-D-3361,CVM GFI #261 - Eligibility Criteria for Expanded Conditional Approval of New Animal Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-261-eligibility-criteria-expanded-conditional-approval-new-animal-drugs,
FDA,FDA-2019-D-1261,Technical Considerations for Non-Clinical Assessment of Medical Devices Containing Nitinol:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-non-clinical-assessment-medical-devices-containing-nitinol,
FDA,FDA-2016-D-1853,Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI):  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identification-system-form-and-content-unique-device-identifier-udi,
FDA,FDA-2020-D-0938,Evaluating Cancer Drugs in Patients with Central Nervous System Metastases:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluating-cancer-drugs-patients-central-nervous-system-metastases,
FDA,FDA-2020-D-2323,Assessment of Adhesion for Topical and Transdermal Systems Submitted in New Drug Applications : Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-adhesion-topical-and-transdermal-systems-submitted-new-drug-applications,
FDA,FDA-2020-D-2099,Sponsor Responsibilities - Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sponsor-responsibilities-safety-reporting-requirements-and-safety-assessment-ind-and,
FDA,FDA-2012-D-0097,Providing Regulatory Submissions in Electronic Format -- Standardized Study Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-standardized-study-data,
FDA,FDA-1995-D-0288,"Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-controls-changes-approved-application-certain-biological-products,
FDA,FDA-2020-D-1553,Premenopausal Women with Breast Cancer: Developing Drugs for Treatment:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premenopausal-women-breast-cancer-developing-drugs-treatment,
FDA,FDA-2019-D-3614,CVM GFI #263 Recommendations for Sponsors of Medically Important Antimicrobial Drugs Approved for Use in Animals to Voluntarily Bring Under Veterinary Oversight All Products That Continue to be Available Over-the-Counter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-263-recommendations-sponsors-medically-important-antimicrobial-drugs-approved-use-animals,
FDA,FDA-2014-D-0609,Product Identifiers under the Drug Supply Chain Security Act - Questions and Answers:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-identifiers-under-drug-supply-chain-security-act-questions-and-answers,
FDA,FDA-2018-D-3175,Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-supply-chain-security-act-implementation-identification-suspect-product-and-notification,
FDA,FDA-2021-D-0391,Oral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oral-drug-products-administered-enteral-feeding-tube-in-vitro-testing-and-labeling-recommendations,
FDA,FDA-2021-D-0242,CPG Sec 570.500 Aflatoxins in Pistachio Nuts,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570500-aflatoxins-pistachio-nuts,
FDA,FDA-2021-D-0243,CPG Sec 570.375 Aflatoxins in Peanuts and Peanut Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570375-aflatoxins-peanuts-and-peanut-products,
FDA,FDA-2021-D-0244,CPG Sec 570.200 Aflatoxins in Brazil Nuts,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570200-aflatoxins-brazil-nuts,
FDA,FDA-2021-D-0245,CPG Sec 555.400 Aflatoxins in Human Food,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555400-aflatoxins-human-food,
FDA,FDA-2019-D-0621,FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fdara-implementation-guidance-pediatric-studies-molecularly-targeted-oncology-drugs-amendments-sec,
FDA,FDA-2019-D-4751,Bispecific Antibody Development Programs Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bispecific-antibody-development-programs-guidance-industry,
FDA,FDA-2021-D-0166,Peripheral Vascular Atherectomy Devices - Premarket Notification [510(k)] Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/peripheral-vascular-atherectomy-devices-premarket-notification-510k-submissions,
FDA,FDA-2014-N-1130,Implanted Brain-Computer Interface (BCI) Devices for Patients with Paralysis or Amputation - Non-clinical Testing and Clinical Considerations:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implanted-brain-computer-interface-bci-devices-patients-paralysis-or-amputation-non-clinical-testing,
FDA,FDA-2018-D-2494,ICH Q12: Implementation Considerations for FDA-Regulated Products: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ich-q12-implementation-considerations-fda-regulated-products,
FDA,FDA-2017-D-5767,"Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs  Frequently Asked Questions  Statement of Investigator  (Form FDA 1572) (Revision 1): Draft Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs  Frequently Asked Questions  Statement of Investigator  (Form FDA 1572) (Revision 1)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/information-sheet-guidance-sponsors-clinical-investigators-and-irbs-frequently-asked-questions,
FDA,FDA-2021-D-0351,Chemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemotherapy-induced-nausea-and-vomiting-developing-drugs-prevention-guidance-industry,
FDA,FDA-2008-D-0406,ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-certain-highly-purified-synthetic-peptide-drug-products-refer-listed-drugs-rdna-origin,
FDA,FDA-2021-D-0409,COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-master-protocols-evaluating-drugs-and-biological-products-treatment-or-prevention,
FDA,FDA-2018-D-3614,S5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s5r3-detection-reproductive-and-developmental-toxicity-human-pharmaceuticals,
FDA,FDA-2018-D-1609,S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals :  International Council for Harmonisation; Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s11-nonclinical-safety-testing-support-development-pediatric-pharmaceuticals,
FDA,FDA-2017-D-6113,Qualified Infectious Disease Product Designation Questions and Answers:  Guidance for Industy,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualified-infectious-disease-product-designation-questions-and-answers,
FDA,FDA-2018-D-1609,Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management-guidance,
FDA,FDA-2017-D-5138,Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Annex,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management-annex,
FDA,FDA-2017-D-7001,M9 Biopharmaceutics Classification System-Based Biowaivers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m9-biopharmaceutics-classification-system-based-biowaivers,
FDA,FDA-2018-D-4524,E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e9r1-statistical-principles-clinical-trials-addendum-estimands-and-sensitivity-analysis-clinical,
FDA,,Submitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies of Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-nonclinical-datasets-evaluation-rodent-carcinogenicity-studies-pharmaceuticals,
FDA,FDA-2021-D-0320,Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or,
FDA,FDA-2012-D-1002,Guidance for Industry: Enforcement Policy for Providing an Acceptable Unique Facility Identifier (UFI) for the 2020 Food Facility Registration Biennial Renewal Period,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-enforcement-policy-providing-acceptable-unique-facility-identifier-ufi-2020-food,
FDA,FDA-2020-D-1137,Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-considerations-licensed-and-investigational-cellular-and-gene-therapy-products-during,
FDA,FDA-2019-D-4048,Safer Technologies Program for Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safer-technologies-program-medical-devices,
FDA,FDA-2019-D-2105,Mouse Embryo Assay for Assisted Reproduction Technology Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mouse-embryo-assay-assisted-reproduction-technology-devices,
FDA,FDA-2020-D-2199,IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-procedural,
FDA,FDA-2016-N-0124,Product Labeling for Laparoscopic Power Morcellators:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-labeling-laparoscopic-power-morcellators,
FDA,FDA-2014-D-1804,Consumer Antiseptic  Rub Final Rule Questions and Answers Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/consumer-antiseptic-rub-final-rule-questions-and-answers-guidance-industry,
FDA,FDA-2017-D-4303,Providing Regulatory Submissions in Electronic Format --Content of the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-content-risk-evaluation-and-mitigation-strategies,
FDA,FDA-2019-D-0892,Guidance for Industry: The Use of an Alternate Name for Potassium Chloride in Food Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-use-alternate-name-potassium-chloride-food-labeling,
FDA,FDA-2014-D-1814,Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacterial-risk-control-strategies-blood-collection-establishments-and-transfusion-services-enhance,
FDA,FDA-2020-D-2214,Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interacting-fda-complex-innovative-trial-designs-drugs-and-biological-products,
FDA,FDA-2019-D-3679,Dry Eye: Developing Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dry-eye-developing-drugs-treatment-guidance-industry,
FDA,FDA-2020-D-0064,Spinal Plating Systems - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/spinal-plating-systems-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2019-D-1650,Magnetic Resonance (MR) Receive-only Coil - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/magnetic-resonance-mr-receive-only-coil-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2019-D-1647,CVM GFI #262 Pre-Submission Consultation Process for Animal Food Additive Petitions or Generally Recognized as Safe (GRAS) Notices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-262-pre-submission-consultation-process-animal-food-additive-petitions-or-generally,
FDA,FDA-2014-D-0622,Best Practices in Developing Proprietary Names for Human Prescription Drug Products; Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-developing-proprietary-names-human-prescription-drug-products-guidance-industry,
FDA,FDA-2020-D-0770,Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-developing-proprietary-names-human-nonprescription-drug-products-draft-guidance,
FDA,FDA-2019-D-4739,Requesting FDA Feedback on Combination Products :  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requesting-fda-feedback-combination-products,
FDA,FDA-2003-D-0128,"Recommendations for Screening, Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-screening-testing-and-management-blood-donors-and-blood-and-blood-components-based,
FDA,FDA-2019-D-3904,Compliance Policy Guide CPG Sec. 110.650 Weekly Entry Filing Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-guide-cpg-sec-110650-weekly-entry-filing-guidance-industry-and-fda-staff,
FDA,FDA-2016-D-4437,CVM GFI #242 In-Use Stability Studies and Associated Labeling Statements for Multiple-Dose Injectable Animal Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-242-use-stability-studies-and-associated-labeling-statements-multiple-dose-injectable-animal,
FDA,FDA-2010-D-0529,Qualification Process for Drug Development Tools Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-process-drug-development-tools-guidance-industry-and-fda-staff,
FDA,FDA-2018-D-0943,CVM GFI #255 Elemental Impurities in Animal Drug Products Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-255-elemental-impurities-animal-drug-products-questions-and-answers,
FDA,FDA-2018-D-1752,Public Availability of Lists of Retail Consignees to Effectuate Certain Human and Animal Food Recalls:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/public-availability-lists-retail-consignees-effectuate-certain-human-and-animal-food-recalls,
FDA,FDA-2009-D-0052,CVM GFI #197 Documenting Electronic Data Files and Statistical Analysis Programs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-197-documenting-electronic-data-files-and-statistical-analysis-programs,
FDA,FDA-2019-D-3592,"Certificates of Confidentiality:  Guidance for Sponsors, Sponsor-Investigators, Researchers, Industry, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/certificates-confidentiality,
FDA,FDA-2020-D-0530,Regulatory Considerations for Microneedling Products:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-microneedling-products,
FDA,FDA-2017-D-4792,Draft Guidance for Industry: Voluntary Disclosure of Sesame as an Allergen,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-voluntary-disclosure-sesame-allergen,
FDA,FDA-2019-D-1264,"Enhancing the Diversity of Clinical Trial Populations â€” Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial,
FDA,FDA-2017-D-5913,Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-prescription-drug-user-fee-amendments-2017-guidance-industry,
FDA,FDA-2016-D-2268,Insanitary Conditions at Compounding Facilities Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/insanitary-conditions-compounding-facilities-guidance-industry,
FDA,FDA-2004-D-0042,Guidance for Industry: Prior Notice of Imported Food Contingency Plan for System Outages,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-prior-notice-imported-food-contingency-plan-system-outages,
FDA,FDA-2018-D-2583,Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-orally-inhaled-nicotine-containing-drug-products-guidance-industry,
FDA,FDA-2017-D-0114,Referencing Approved Drug Products in ANDA Submissions Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/referencing-approved-drug-products-anda-submissions-guidance-industry,
FDA,FDA-2019-D-4212.,Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Productâ€”Compliance Policies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/wholesale-distributor-verification-requirement-saleable-returned-drug-product-and-dispenser,
FDA,FDA-2019-D-0725,Testing for Biotin Interference in In Vitro Diagnostic Devices:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-biotin-interference-in-vitro-diagnostic-devices,
FDA,FDA-2012-D-1002,Guidance for Industry: U.S. Agent Voluntary Identification System (VIS) for Food Facility Registration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-us-agent-voluntary-identification-system-vis-food-facility-registration,
FDA,FDA-2019-D-1876,Guidance for Industry: The Declaration of Allulose and Calories from Allulose on Nutrition and Supplement Facts Labels,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-declaration-allulose-and-calories-allulose-nutrition-and-supplement-facts-labels,
FDA,FDA-2018-D-2382,Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/opioid-use-disorder-endpoints-demonstrating-effectiveness-drugs-treatment-guidance-industry,
FDA,FDA-2019-D-5743,"Importation of Certain FDA- Approved Human Prescription Drugs, Including Biological Products, and Combination Products under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/importation-certain-fda-approved-human-prescription-drugs-including-biological-products-and,
FDA,FDA-2020-D-1517,"The Use of Physiologically Based Pharmacokinetic Analyses â€” Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls : Draft Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-physiologically-based-pharmacokinetic-analyses-biopharmaceutics-applications-oral-drug-product,
FDA,FDA-2004-D-0124,Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/self-monitoring-blood-glucose-test-systems-over-counter-use,
FDA,FDA-2013-D-1445,"Saline, Silicone Gel, and Alternative Breast Implants:  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/saline-silicone-gel-and-alternative-breast-implants,
FDA,FDA-2019-D-4467,Breast Implants - Certain Labeling Recommendations to Improve Patient Communication:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/breast-implants-certain-labeling-recommendations-improve-patient-communication,
FDA,FDA-2013-D-1446,Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/blood-glucose-monitoring-test-systems-prescription-point-care-use,
FDA,FDA-2019-D-3805,"The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/accreditation-scheme-conformity-assessment-asca-pilot-program,
FDA,FDA-2019-D-3805,"Biocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biocompatibility-testing-medical-devices-standards-specific-information-accreditation-scheme,
FDA,FDA-2019-D-3805,"Basic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/basic-safety-and-essential-performance-medical-electrical-equipment-medical-electrical-systems-and,
FDA,FDA-2019-D-0177,Recognition and Withdrawal of Voluntary Consensus Standards:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recognition-and-withdrawal-voluntary-consensus-standards,
FDA,FDA-2020-D-1621,Geriatric Information in Human Prescription Drug and Biological Product Labeling Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/geriatric-information-human-prescription-drug-and-biological-product-labeling-guidance-industry,
FDA,FDA-2018-D-2936,Eosinophilic Esophagitis: Developing Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/eosinophilic-esophagitis-developing-drugs-treatment-guidance-industry,
FDA,FDA-2008-D-0614,CVM GFI #191 Changes to Approved NADAs - New NADAs vs. Category II Supplemental NADAs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-191-changes-approved-nadas-new-nadas-vs-category-ii-supplemental-nadas,
FDA,FDA-2020-D-1298,Acute Myeloid Leukemia:  Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-myeloid-leukemia-developing-drugs-and-biological-products-treatment,
FDA,FDA-2019-D-1651,Cutaneous Electrodes for Recording Purposes - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cutaneous-electrodes-recording-purposes-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2019-D-1649,Conventional Foley Catheters - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conventional-foley-catheters-performance-criteria-safety-and-performance-based-pathway,
FDA,FDA-2018-D-0787,"Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank:  Guidance for Responsible Parties, Submitters of Certain Applications and Submissions to FDA, and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/civil-money-penalties-relating-clinicaltrialsgov-data-bank,
FDA,FDA-2019-D-2966,Male Breast Cancer: Developing Drugs for Treatment:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/male-breast-cancer-developing-drugs-treatment,
FDA,FDA-2018-D-4615,"Marketing Status Notifications Under Section 506I of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-status-notifications-under-section-506i-federal-food-drug-and-cosmetic-act,
FDA,FDA-2018-D-2032,Limited Population Pathway for Antibacterial and Antifungal Drugs Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/limited-population-pathway-antibacterial-and-antifungal-drugs-guidance-industry,
FDA,FDA-2016-D-1099,Guidance for Industry: Action Level for Inorganic Arsenic in Rice Cereals for Infants,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-action-level-inorganic-arsenic-rice-cereals-infants,
FDA,,Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-study-plans-content-and-process-submitting-initial-pediatric-study-plans-and-amended,
FDA,,CPG Sec. 280.110-  Microbiological Control Requirements-Licensed Anti-Human Globulin and Blood Grouping Reagents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-280110-microbiological-control-requirements-licensed-anti-human-globulin-and-blood-grouping,
FDA,FDA-2013-D-0814,CPG Sec. 280.100 -  Stability Requirements -  Licensed In Vitro Diagnostic Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-280100-stability-requirements-licensed-in-vitro-diagnostic-products,
FDA,FDA-2012-D-0432,"Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products-Content and Format: Draft Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pregnancy-lactation-and-reproductive-potential-labeling-human-prescription-drug-and-biological,
FDA,FDA-2017-D-0829,Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pathological-complete-response-neoadjuvant-treatment-high-risk-early-stage-breast-cancer-use,
FDA,FDA-2014-D-1551,Multiple Function Device Products: Policy and Considerations:  Guidance for Industry and Food and Drug Administration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-function-device-products-policy-and-considerations,
FDA,FDA-2018-D-1339,Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expiration-dating-unit-dose-repackaged-solid-oral-dosage-form-drug-products,
FDA,FDA-2020-D-1294,Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/setting-endotoxin-limits-during-development-investigational-oncology-drugs-and-biological-products,
FDA,FDA-2017-D-6146,"Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal,
FDA,FDA-2019-D-2223,"Providing Regulatory Submissions for Medical Devices in Electronic Format - Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-medical-devices-electronic-format-submissions-under-section-745ab,
FDA,FDA-2019-D-3769,Clinical Investigations for Prostate Tissue Ablation Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-investigations-prostate-tissue-ablation-devices,
FDA,FDA-2016-D-3004,CPG Sec 540.750 - Use of The Seafood List to Determine Acceptable Seafood Names,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540750-use-seafood-list-determine-acceptable-seafood-names,
FDA,FDA-2019-D-0357,Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-patients-organ-dysfunction-or-prior-or-concurrent,
FDA,FDA-2019-D-0358,"Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-patients-hiv-hepatitis-b-virus-or-hepatitis-c-virus,
FDA,FDA-2019-D-0363,Cancer Clinical Trial Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-minimum-age-considerations-inclusion-pediatric-patients,
FDA,FDA-2019-D-0359,Cancer Clinical Trial Eligibility Criteria: Brain Metastases,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-brain-metastases,
FDA,FDA-2019-D-0914,Review and Update of Device Establishment Inspection Processes and Standards:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-and-update-device-establishment-inspection-processes-and-standards,
FDA,FDA-2018-D-0626,CVM GFI #240 Proprietary Names for New Animal Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-240-proprietary-names-new-animal-drugs,
FDA,FDA-2008-D-0610,Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-adverse-event-reporting-medical-products-and-dietary-supplements-during-pandemic,
FDA,FDA-2015-N-3785,Classification of Posterior Cervical Screw Systems: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/classification-posterior-cervical-screw-systems-small-entity-compliance-guide,
FDA,FDA-2019-D-0661,Enforcement Priorities for Electronic Nicotine Delivery System (ENDS) and Other Deemed Products on the Market Without Premarket Authorization:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market,
FDA,FDA-2018-N-0628,eCopy Program for Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ecopy-program-medical-device-submissions,
FDA,FDA-2018-D-4711,Nonbinding Feedback After Certain FDA Inspections of Device Establishments:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonbinding-feedback-after-certain-fda-inspections-device-establishments,
FDA,FDA-2019-D-5573,"Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA: Draft Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-demonstrating-reliability-emergency-use-injectors-submitted-under-bla-nda,
FDA,FDA-2018-D-4662,CVM GFI #259 (VICH GL58) Stability Testing of New Veterinary Drug Substances and Medicinal Products in Climatic Zones III and IV,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-259-vich-gl58-stability-testing-new-veterinary-drug-substances-and-medicinal-products,
FDA,FDA-2018-D-3380,Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-and-labeling-in-vitro-companion-diagnostic-devices-specific-group-oncology-therapeutic,
FDA,FDA-2014-D-0329,Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fees-human-drug-compounding-outsourcing-facilities-under-sections-503b-and-744k-fdc-act,
FDA,FDA-2013-D-0501,Center for Devices and Radiological Health (CDRH) Appeals Processes: Questions and Answers About 517A:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/center-devices-and-radiological-health-cdrh-appeals-processes-questions-and-answers-about-517a,
FDA,,CPG Section 110.800 Post Detention Sampling Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-section-110800-post-detention-sampling-guidance-industry,
FDA,FDA-2020-D-0567,Restricted Delivery Systems: Flow Restrictors for Oral Liquid Drug Products Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/restricted-delivery-systems-flow-restrictors-oral-liquid-drug-products-guidance-industry,
FDA,FDA-2001-D-0007,Biological Product Deviation Reporting for Blood and Plasma Establishments:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biological-product-deviation-reporting-blood-and-plasma-establishments,
FDA,FDA-2019-N-6084,Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/type-2-diabetes-mellitus-evaluating-safety-new-drugs-improving-glycemic-control-guidance-industry,
FDA,FDA-2014-D-0217,Premarket Notification (510(k)) Submissions for Electrosurgical Devices for General Surgery:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-510k-submissions-electrosurgical-devices-general-surgery,
FDA,FDA-2020-D-0043,Contact Dermatitis From Topical Drug Products for Cutaneous Application: Human Safety Assessment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contact-dermatitis-topical-drug-products-cutaneous-application-human-safety-assessment-guidance,
FDA,FDA-2015-D-4750.,The â€œDeemed to be a Licenseâ€ Provision of the BPCI Act: Questions and Answers :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deemed-be-license-provision-bpci-act-questions-and-answers,
FDA,FDA-2016-D-4436,Bone Anchors - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bone-anchors-premarket-notification-510k-submissions,
FDA,,"Product Recalls, Including Removals and Corrections:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-recalls-including-removals-and-corrections,
FDA,FDA-2019-D-5664,CVM GFI #264 Standardized Medicated Feed Assay Limits,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-264-standardized-medicated-feed-assay-limits,
FDA,FDA-2017-D-5570,Recommendations for Dual 510(k) and CLIA Waiver by Application Studies:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-dual-510k-and-clia-waiver-application-studies,
FDA,FDA-2017-D-5625,Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-clinical-laboratory-improvement-amendments-1988-clia-waiver-applications,
FDA,None found,Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/specifications-preparing-and-submitting-electronic-icsrs-and-icsr-attachments,
FDA,FDA-2018-D-1398,Supplemental Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supplemental-draft-guidance-industry-mitigation-strategies-protect-food-against-intentional,
FDA,FDA-2019-D-5270,Biosimilars and Interchangeable Biosimilars:  Licensure for Fewer Than All Conditions of Use for Which the Reference Product Has Been Licensed Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biosimilars-and-interchangeable-biosimilars-licensure-fewer-all-conditions-use-which-reference,
FDA,FDA-2018-D-3324,Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I/II):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-serological-tests-reduce-risk-transfusion-transmitted-human-t-lymphotropic-virus-types-i-and-ii,
FDA,FDA-2019-D-5404,Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment Guidance for Industry: Draft Guidance for Industy,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mucopolysaccharidosis-type-iii-sanfilippo-syndrome-developing-drugs-treatment-guidance-industry,
FDA,FDA-2012-N-1210,Small Entity Compliance Guide: Revision of the Nutrition and Supplement Facts Labels,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-revision-nutrition-and-supplement-facts-labels,
FDA,FDA-2018-D-2173,Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-retroviral-vector-based-human-gene-therapy-products-replication-competent-retrovirus-during,
FDA,2008-D-0205,Long Term Follow-up After Administration of Human Gene Therapy Products:   Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products,
FDA,FDA 2018-D-2238,Human Gene Therapy for Retinal Disorders:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-retinal-disorders,
FDA,FDA-2018-D-2258,Human Gene Therapy for Rare Diseases:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-rare-diseases,
FDA,FDA-2018-D-2236,Human Gene Therapy for Hemophilia:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-hemophilia,
FDA,FDA-1999-D-0081,"Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs):  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug,
FDA,FDA-2018-D-3090,Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and,
FDA,FDA-2014-D-0779,Current Good Manufacturing Practiceâ€”Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-guidance-human-drug-compounding-outsourcing-facilities-under,
FDA,FDA-2018-D-1459,"Guidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-serving-sizes-foods-can-reasonably-be-consumed-one-eating-occasion-reference,
FDA,FDA-2019-D-4964,Submitting Study Datasets for Vaccines to the Office of Vaccines Research and Review:  Guidance for Industry; Technical Specifications Document,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-study-datasets-vaccines-office-vaccines-research-and-review,
FDA,FDA-2018-D-1329,Recommended Content and Format of Non-Clinical Bench Performance Testing Information in Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-content-and-format-non-clinical-bench-performance-testing-information-premarket,
FDA,FDA-2018-D-1216,Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products,
FDA,FDA-2018-D-3759,Considerations for the Development of Dried Plasma Products Intended for Transfusion:   Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-dried-plasma-products-intended-transfusion,
FDA,FDA-2019-D-5585,Bridging for Drug-Device and Biologic-Device Combination Products: Draft  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bridging-drug-device-and-biologic-device-combination-products,
FDA,FDA-2016-D-4414,Real-Time Premarket Approval Application (PMA) Supplements:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-time-premarket-approval-application-pma-supplements,
FDA,FDA-1998-D-0281,"Guidance for Industry: Nutrition and Supplement Facts Labels Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-nutrition-and-supplement-facts-labels-questions-and-answers-related-compliance,
FDA,FDA-2017-D-5971,Annual Reports for Approved Premarket Approval Applications (PMA) :  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/annual-reports-approved-premarket-approval-applications-pma,
FDA,FDA-2012-D-0524,Acceptance and Filing Reviews for Premarket Approval Applications (PMAs):  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptance-and-filing-reviews-premarket-approval-applications-pmas,
FDA,FDA-2006-D-0039,"30-Day Notices, 135-Day Premarket Approval (PMA) Supplements and 75-Day Humanitarian Device Exemption (HDE) Supplements for Manufacturing Method or Process Changes:  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/30-day-notices-135-day-premarket-approval-pma-supplements-and-75-day-humanitarian-device-exemption,
FDA,,Chapter 2 - Biologics,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-2-biologics,
FDA,FDA-2019-D-4433,Development of Locally Applied Corticosteroid Products for the Short-Term Treatment of Symptoms Associated with Internal or External Hemorrhoids Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-locally-applied-corticosteroid-products-short-term-treatment-symptoms-associated,
FDA,FDA-2018-D-3124,Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry,
FDA,,"CPG Sec. 230.150 Blood Donor Classification Statement, Paid or Volunteer Donor",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-230150-blood-donor-classification-statement-paid-or-volunteer-donor,
FDA,FDA-2019-D-5324,Compliance Policy for Limited Modifications to Certain Marketed Tobacco Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-limited-modifications-certain-marketed-tobacco-products,
FDA,FDA-2019-D-5255,Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-immunogenicity-considerations-biosimilar-and-interchangeable-insulin-products,
FDA,FDA-2019-D-4447,Transdermal and Topical Delivery Systems - Product Development and Quality Considerations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transdermal-and-topical-delivery-systems-product-development-and-quality-considerations,
FDA,FDA-2018-D-1835,Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/smallpox-variola-virus-infection-developing-drugs-treatment-or-prevention-guidance-industry,
FDA,FDA-2019-D-3989,Drug Master Files Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-master-files-guidance-industry,
FDA,FDA-2019-D-4042,Chronic Hepatitis D Virus Infection: Developing Drugs for Treatment  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-hepatitis-d-virus-infection-developing-drugs-treatment-guidance-industry,
FDA,FDA-2019-D-4258,Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts With Electronics or Software Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/type-v-dmfs-cder-led-combination-products-using-device-constituent-parts-electronics-or-software,
FDA,FDA-2009-D-0283,"Postmarketing Studies and Clinical Trialsâ€”Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry: Draft Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-studies-and-clinical-trials-implementation-section-505o3-federal-food-drug-and-0,
FDA,FDA-2017-D-6821,Identification of Manufacturing Establishments in Applications Submitted to CBER and CDER Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/identification-manufacturing-establishments-applications-submitted-cber-and-cder-questions-and,
FDA,2019-22690,"Prescription Drug User Fee Act Waivers, Reductions, and Refunds for Drug and Biological Products Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-drug-user-fee-act-waivers-reductions-and-refunds-drug-and-biological-products-guidance,
FDA,FDA-2018-D-0944,Investigational In Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-in-vitro-diagnostics-oncology-trials-streamlined-submission-process-study-risk,
FDA,FDA-2018-D-1775,"Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings - Labeling Considerations:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/intravascular-catheters-wires-and-delivery-systems-lubricious-coatings-labeling-considerations,
FDA,FDA-2018-D-1788,"Coronary, Peripheral, and Neurovascular Guidewires - Performance Tests and Recommended Labeling:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/coronary-peripheral-and-neurovascular-guidewires-performance-tests-and-recommended-labeling,
FDA,FDA-2015-D-1246,Investigational Enzyme Replacement Therapy Products:  Nonclinical Assessment:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-enzyme-replacement-therapy-products-nonclinical-assessment,
FDA,FDA-2018-D-3197,Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/further-testing-donations-are-reactive-licensed-donor-screening-test-antibodies-hepatitis-c-virus,
FDA,FDA-2017-D-6294,General Wellness: Policy for Low Risk Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-wellness-policy-low-risk-devices,
FDA,FDA-2014-N-1039,Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-existing-medical-software-policies-resulting-section-3060-21st-century-cures-act,
FDA,FDA-2013-N-0035,Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry,
FDA,FDA-2019-D-4212,Wholesale Distributor Verification Requirement for Saleable Returned Drug Productâ€”Compliance Policy Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/wholesale-distributor-verification-requirement-saleable-returned-drug-product-compliance-policy,
FDA,FDA-2018-D-1387,Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-and-performance-based-pathway,
FDA,FDA-2009-D-0008,"Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/citizen-petitions-and-petitions-stay-action-subject-section-505q-federal-food-drug-and-cosmetic-act,
FDA,FDA-2019-D-4015,The Special 510(k) Program:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/special-510k-program,
FDA,FDA-2018-D-3304,The Abbreviated 510(k) Program:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/abbreviated-510k-program,
FDA,FDA-2014-D-0223,Humanitarian Device Exemption (HDE) Program:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/humanitarian-device-exemption-hde-program,
FDA,FDA-2014-D-0223,Humanitarian Use Device (HUD) Designations :  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/humanitarian-use-device-hud-designations,
FDA,FDA-2009-D-0008,Evaluation of Internal Standard Responses During Chromatographic Bioanalysis: Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-internal-standard-responses-during-chromatographic-bioanalysis-questions-and-answers,
FDA,FDA-2018-D-0075,Guidance for Industry: Policy Related to Cranberry Products with Added Flavorings,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-policy-related-cranberry-products-added-flavorings,
FDA,FDA-2018-D-3130,Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/factors-consider-when-making-benefit-risk-determinations-medical-device-premarket-approval-and-de,
FDA,FDA-2011-D-0577,"Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/consideration-uncertainty-making-benefit-risk-determinations-medical-device-premarket-approvals-de,
FDA,FDA-2018-D-3092,Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/placebos-and-blinding-randomized-controlled-cancer-clinical-trials-drug-and-biological-products,
FDA,FDA-2018-D-2354,CVM GFI #257 (VICH GL57) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Marker Residue Depletion Studies to Establish Product Withdrawal Periods in Aquatic Species,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-257-vich-gl57-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,
FDA,FDA-2016-D-4484,Osteoporosis:  Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/osteoporosis-nonclinical-evaluation-drugs-intended-treatment-guidance-industry,
FDA,FDA-2016-D-1273,"Guidance for Industry: Converting Units of Measure for Folate, Niacin, and Vitamins A, D, and E on the Nutrition and Supplement Facts Labels",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-converting-units-measure-folate-niacin-and-vitamins-d-and-e-nutrition-and,
FDA,FDA-2017-D-2163,Gastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/gastroparesis-clinical-evaluation-drugs-treatment-guidance-industry,
FDA,FDA-2015-D-2479,Child-Resistant Packaging Statements in Drug Product Labeling Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/child-resistant-packaging-statements-drug-product-labeling-guidance-industry,
FDA,FDA-2019-D-2973,Fabry Disease: Developing Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fabry-disease-developing-drugs-treatment-guidance-industry,
FDA,FDA-2018-D-1772,Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oncology-therapeutic-radiopharmaceuticals-nonclinical-studies-and-labeling-recommendations-guidance,
FDA,FDA-2016-D-1659,Vulvovaginal Candidiasis:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vulvovaginal-candidiasis-developing-drugs-treatment,
FDA,FDA-2018-D-1562,Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/uncomplicated-urinary-tract-infections-developing-drugs-treatment-guidance-industry,
FDA,FDA-2016-D-1662,Bacterial Vaginosis: Developing Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacterial-vaginosis-developing-drugs-treatment-guidance-industry,
FDA,FDA-2014-D-1461,Rare Pediatric Disease Priority Review Vouchers: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-pediatric-disease-priority-review-vouchers,
FDA,FDA-2017-D-0198,Delayed Graft Function in Kidney Transplantation: Developing Drugs for Prevention Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/delayed-graft-function-kidney-transplantation-developing-drugs-prevention-guidance-industry,
FDA,FDA-2018-D-1771,Metal Expandable Biliary Stents - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/metal-expandable-biliary-stents-premarket-notification-510k-submissions,
FDA,,Providing Regulatory Submissions in Electronic Format--Submission of Manufacturing Establishment Information Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-submission-manufacturing-establishment,
FDA,FDA-2008-D-0165,CVM GFI #181 Blue Bird Medicated Feed Labels,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-181-blue-bird-medicated-feed-labels,
FDA,FDA-2008-N-0424,Postmarketing Safety Reporting for Combination Products:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-safety-reporting-combination-products,
FDA,FDA-2017-D-6821,Submitting Next Generation Sequencing Data to the Division of Antiviral Products Guidance for Industry Technical Specifications Document,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-next-generation-sequencing-data-division-antiviral-products-guidance-industry-technical,
FDA,FDA-2019-D-2153,Establishing Effectiveness and Safety for Hormonal Drug Products Intended to Prevent Pregnancy Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-effectiveness-and-safety-hormonal-drug-products-intended-prevent-pregnancy-guidance,
FDA,FDA-2019-D-2397,Using the Inactive Ingredient Database Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-inactive-ingredient-database-guidance-industry,
FDA,FDA-2014-D-0331,"Live Case Presentations During Investigational Device Exemption (IDE) Clinical Trials:  Guidance for Institutional Review Boards, Industry, Clinical Investigators, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/live-case-presentations-during-investigational-device-exemption-ide-clinical-trials,
FDA,FDA-2019-D-1768,Harmonizing Compendial Standards With Drug Application Approval Using the USP Pending Monograph Process Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/harmonizing-compendial-standards-drug-application-approval-using-usp-pending-monograph-process,
FDA,FDA-2014-D-1747,Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/risk-evaluation-and-mitigation-strategies-modifications-and-revisions-guidance-industry,
FDA,FDA-2019-D-2733,Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency Immediately in Effect Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-certain-compounding-oral-oxitriptan-5-htp-drug-products-patients,
FDA,FDA-2019-D-1917,Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products â€”  Content and Format   Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-abuse-and-dependence-section-labeling-human-prescription-drug-and-biological-products-content,
FDA,FDA-2018-D-2016,Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/treatment-heart-failure-endpoints-drug-development-guidance-industry,
FDA,FDA-2019-D-2314,Epidermolysis Bullosa:  Developing Drugs for Treatment of Cutaneous Manifestations; Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/epidermolysis-bullosa-developing-drugs-treatment-cutaneous-manifestations-guidance-industry,
FDA,FDA-2019-D-1828,E19 OPTIMISATION OF SAFETY DATA COLLECTION,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e19-optimisation-safety-data-collection,
FDA,FDA-2019-D-1469,M10 BIOANALYTICAL METHOD VALIDATION,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m10-bioanalytical-method-validation,
FDA,FDA-2019-D-1536,Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/opioid-analgesic-drugs-considerations-benefit-risk-assessment-framework-guidance-industry,
FDA,FDA-2014-D-0725,ANDA Submissions â€” Content and Format of Abbreviated New Drug Applications:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-content-and-format-abbreviated-new-drug-applications,
FDA,FDA-2018-D-0671,Guidance for Industry: Determining the Number of Employees for Purposes of the â€œSmall Businessâ€ Definition in Parts 117 and 507,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-determining-number-employees-purposes-small-business-definition-parts-117-and-507,
FDA,FDA-2018-D-0075,"Guidance for Industry: Declaration of Added Sugars on Honey, Maple Syrup, Other Single-Ingredient Sugars and Syrups, and Certain Cranberry Products",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-declaration-added-sugars-honey-maple-syrup-other-single-ingredient-sugars-and,
FDA,FDA-2019-D-1516,Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonalcoholic-steatohepatitis-compensated-cirrhosis-developing-drugs-treatment-guidance-industry,
FDA,FDA-2019-D-2131,"Draft Guidance for Industry: Evaluating Alternate Curricula for the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-evaluating-alternate-curricula-standards-growing-harvesting-packing-and,
FDA,FDA-2021-D-0628,CPG Sec. 651.100  Ethylenediamine Dihydroiodide (EDDI),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-651100-ethylenediamine-dihydroiodide-eddi,
FDA,FDA-2013-D-0221,Formal Dispute Resolution: Sponsor Appeals Above the Division Level Guidance for Industry and Review Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-dispute-resolution-sponsor-appeals-above-division-level-guidance-industry-and-review-staff,
FDA,FDA-2019-D-2011,Section 503A Bulks List Final Rule Questions and Answers; Small Entity Compliance Guide;:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/section-503a-bulks-list-final-rule-questions-and-answers-small-entity-compliance-guide,
FDA,FDA-2019-D-2102,Development of Therapeutic Protein Biosimilars:  Comparative Analytical Assessment and Other Quality-Related Considerations   Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other-quality,
FDA,FDA-2017-D-0154,Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-demonstrating-interchangeability-reference-product-guidance-industry,
FDA,FDA-2017-D-5974,Oncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oncology-pharmaceuticals-reproductive-toxicity-testing-and-labeling-recommendations-guidance,
FDA,FDA-2018-D-1456,Maximal Usage Trials for Topically Applied Active Ingredients Being Considered for Inclusion in an Over-The-Counter Monograph: Study Elements and Considerations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/maximal-usage-trials-topically-applied-active-ingredients-being-considered-inclusion-over-counter,
FDA,FDA-2017-D-2165,Determining Whether to Submit an ANDA or a 505(b)(2) Application,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-whether-submit-anda-or-505b2-application,
FDA,FDA-2018-D-4525.,Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-reducing-risk-transfusion-transmitted-babesiosis,
FDA,FDA-2018-D-4693,Postapproval Pregnancy Safety Studies Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-pregnancy-safety-studies-guidance-industry,
FDA,FDA-2018-D-2478,Clinical Lactation Studies: Considerations for Study Design,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-lactation-studies-considerations-study-design,
FDA,FDA-2016-D-1814,Utilizing Animal Studies to Evaluate Organ Preservation Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/utilizing-animal-studies-evaluate-organ-preservation-devices,
FDA,FDA-2014-D-2245,Policy Clarification for Certain Fluoroscopic Equipment Requirements:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-clarification-certain-fluoroscopic-equipment-requirements,
FDA,FDA-2014-D-1344,Guidance for Industry: Preparation of Food Contact Notifications for Food Contact Substances in Contact with Infant Formula and/or Human Milk,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparation-food-contact-notifications-food-contact-substances-contact-infant,
FDA,FDA-2017-D-4886,Classification and Requirements for Laser Illuminated Projectors (LIPs) (Laser Notice No. 57):  Guidance for Industry and Food and Drug Administration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/classification-and-requirements-laser-illuminated-projectors-lips-laser-notice-no-57,
FDA,FDA-2019-D-0849,Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/attention-deficit-hyperactivity-disorder-developing-stimulant-drugs-treatment-guidance-industry,
FDA,FDA-2016-D-0363,Unique Device Identification: Convenience Kits :  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identification-convenience-kits,
FDA,FDA-2015-D-4048,Characterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/characterization-ultrahigh-molecular-weight-polyethylene-uhmwpe-used-orthopedic-devices,
FDA,2019-08349,Extending Expiration Dates of Doxycycline Tablets and Capsules in Strategic Stockpiles :  Guidance for Government Public Health and Emergency Response Stakeholders,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/extending-expiration-dates-doxycycline-tablets-and-capsules-strategic-stockpiles,
FDA,FDA-2008-N-0424,Compliance Policy for Combination Product Postmarketing Safety Reporting:  Immediately in Effect Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-combination-product-postmarketing-safety-reporting,
FDA,2019-06663,FDAâ€™s Application of Statutory Factors in Determining When a REMS Is Necessary,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fdas-application-statutory-factors-determining-when-rems-necessary,
FDA,FDA-2016-D-2730,REMS: FDAâ€™s Application of Statutory Factors in Determining When a REMS Is Necessary Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-fdas-application-statutory-factors-determining-when-rems-necessary-guidance-industry,
FDA,FDA-2013-D-0169,Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling Good Review Practice,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-information-incorporated-human-prescription-drug-and-biological-products-labeling-good,
FDA,FDA-2019-D-1266,"Guidance for Industry: Enforcement Policy for Entities Growing, Harvesting, Packing, or Holding Hops, Wine Grapes, Pulse Crops, and Almonds",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-enforcement-policy-entities-growing-harvesting-packing-or-holding-hops-wine-grapes,
FDA,FDA-2017-D-6535,Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standards-development-and-use-standards-regulatory-submissions-reviewed-center-biologics-evaluation,
FDA,FDA-2019-D-0481,Rare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-natural-history-studies-drug-development,
FDA,FDA-2018-D-1638,Pediatric HIV Infection: Drug Development for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-hiv-infection-drug-development-treatment,
FDA,FDA-2018-D-1918,Human Immunodeficiency Virus-1 Infection:  Developing Systemic Drug Products for Pre-Exposure Prophylaxis,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-immunodeficiency-virus-1-infection-developing-systemic-drug-products-pre-exposure-prophylaxis,
FDA,FDA-2018-D-1328,Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/severely-debilitating-or-life-threatening-hematologic-disorders-nonclinical-development,
FDA,FDA-2012-D-1145,Medical Devices Containing Materials Derived from Animal Sources (Except for In Vitro Diagnostic Devices):  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-devices-containing-materials-derived-animal-sources-except-in-vitro-diagnostic-devices,
FDA,FDA-2013-D-1574,Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products,
FDA,FDA-2018-D-1540,"Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-bulk-drug-substances-nominated-use-compounding-under-section-503b-federal-food-drug-and,
FDA,FDA-2018-D-1067,Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-inclusion-adolescent-patients-adult-oncology-clinical-trials,
FDA,FDA-2000-D-0075,Guidance for Industry: Voluntary Labeling Indicating Whether Foods Have or Have Not Been Derived from Genetically Engineered Plants,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-voluntary-labeling-indicating-whether-foods-have-or-have-not-been-derived,
FDA,FDA-2015-D-4272,Draft Guidance for Industry: Voluntary Labeling Indicating Whether Food Has or Has Not Been Derived From Genetically Engineered Atlantic Salmon,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-voluntary-labeling-indicating-whether-food-has-or-has-not-been-derived,
FDA,FDA-2013-D-1543,Nonproprietary Naming of Biological Products: Update Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonproprietary-naming-biological-products-update-guidance-industry,
FDA,FDA-2018-D-1398,Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-mitigation-strategies-protect-food-against-intentional-adulteration,
FDA,,Release of ORA Laboratory Analytical Results to the Responsible Party:  Guidance for Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/release-ora-laboratory-analytical-results-responsible-party,
FDA,,CPG Sec. 683.100  Action Levels for Aflatoxins in Animal Feeds,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-683100-action-levels-aflatoxins-animal-feeds,
FDA,,CPG Sec. 666.100  Alternate Feeding of Different Medicated Feeds,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-666100-alternate-feeding-different-medicated-feeds,
FDA,,CPG Sec. 665.300 Use of Type A Medicated Article Proprietary Names in the Names of Medicated Feeds,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-665300-use-type-medicated-article-proprietary-names-names-medicated-feeds,
FDA,,CPG Sec. 653.100  Animal Grooming Aids,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-653100-animal-grooming-aids,
FDA,,CPG Sec. 635.100  Large Volume Parenterals (LVPs) for Animal Use,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-635100-large-volume-parenterals-lvps-animal-use,
FDA,FDA-2019-D-1163,CPG Sec. 608.200  Prescription Use of Certain Injectable Animal Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-608200-prescription-use-certain-injectable-animal-drugs,
FDA,FDA-2018-D-3244,Enforcement Policy for Certain Marketed Tobacco Products: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-certain-marketed-tobacco-products,
FDA,FDA-1998-D-0095,Providing Lot Release Protocol Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-lot-release-protocol-submissions-center-biologics-evaluation-and-research-cber-electronic,
FDA,FDA-2014-D-1939,Use of Investigational Tobacco Products: Draft Guidance for Industry and Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-investigational-tobacco-products,
FDA,FDA-2017-D-6154,Expedited Programs for Regenerative Medicine Therapies for Serious Conditions:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-regenerative-medicine-therapies-serious-conditions,
FDA,FDA-2017-D-6159,Evaluation of Devices Used with Regenerative Medicine Advanced Therapies:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-devices-used-regenerative-medicine-advanced-therapies,
FDA,FDA-2016-D-3548,"Public Warning-Notification of Recalls Under 21 CFR Part 7, Subpart C :  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/public-warning-notification-recalls-under-21-cfr-part-7-subpart-c,
FDA,FDA-2014-D-0967,Intent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/intent-exempt-certain-unclassified-medical-devices-premarket-notification-requirements,
FDA,FDA-2018-D-1334,Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/opioid-use-disorder-developing-depot-buprenorphine-products-treatment,
FDA,FDA-2017-D-6702,The Least Burdensome Provisions: Concept and Principles:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/least-burdensome-provisions-concept-and-principles,
FDA,FDA-2014-D-0250,Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-human-prescription-drug-and-biological-products-approved-under-accelerated-approval,
FDA,FDA-2009-D-0539,Survey Methodologies to Assess REMS Goals That Relate to Knowledge,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/survey-methodologies-assess-rems-goals-relate-knowledge,
FDA,FDA-2018-D-4628,REMS Assessment: Planning and Reporting,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-assessment-planning-and-reporting,
FDA,FDA-2018-D-4629,Immunogenicity Testing of Therapeutic Protein Products â€”Developing and Validating Assays for Anti-Drug Antibody Detection,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug,
FDA,FDA-2016-D-2561,Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/coordinated-development-antimicrobial-drugs-and-antimicrobial-susceptibility-test-devices,
FDA,FDA-2018-D-4455,Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-and-submitting-proposed-draft-guidance-relating-patient-experience-data,
FDA,FDA-2016-D-4308,Labeling of Red Blood Cell Units with Historical Antigen Typing Results:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-red-blood-cell-units-historical-antigen-typing-results,
FDA,FDA-2005-D-0225,Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics,
FDA,FDA-2015-N-3454,Manufacturing Site Change Supplements: Content and Submission:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-site-change-supplements-content-and-submission,
FDA,FDA-2018-D-3984,Data Integrity and Compliance With Drug CGMP: Questions and Answers:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers,
FDA,FDA-2015-D-4750,Interpretation of the â€œDeemed to be a Licenseâ€ Provision of the Biologics Price Competition and Innovation Act of 2009 :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interpretation-deemed-be-license-provision-biologics-price-competition-and-innovation-act-2009,
FDA,FDA-2018-D-4267,Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biomarker-qualification-evidentiary-framework,
FDA,FDA-2018-D-3632,Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/noncirrhotic-nonalcoholic-steatohepatitis-liver-fibrosis-developing-drugs-treatment,
FDA,FDA-2006-N-0183,"Guidance for Industry: Establishing and Maintaining a List of U.S. Milk and Milk Product, Seafood, Infant Formula, and Formula for Young Children Manufacturers/Processors with Interest in Exporting to China",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-establishing-and-maintaining-list-us-milk-and-milk-product-seafood-infant-formula,
FDA,FDA-2016-D-4484,Guidance for Industry and FDA: Establishing and Maintaining a List of U.S. Dairy Product Manufacturers/Processors with Interest in Exporting to Chile,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-establishing-and-maintaining-list-us-dairy-product-manufacturersprocessors,
FDA,FDA-2016-D-4461,CVM GFI #243 (VICH GL56) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Study Design Recommendations for Residue Studies in Honey for Establishing Maximum Residue Limits and Withdrawal Periods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-243-vich-gl56-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,
FDA,FDA-2018-D-3860,Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/meta-analyses-randomized-controlled-clinical-trials-evaluate-safety-human-drugs-or-biological,
FDA,FDA-2018-D-3710,Hypertension: Developing Fixed-Dose Combination Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypertension-developing-fixed-dose-combination-drugs-treatment,
FDA,FDA-2015-D-0138,Guidance for Industry and FDA Staff: Questions and Answers Regarding Mandatory Food Recalls,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-staff-questions-and-answers-regarding-mandatory-food-recalls,
FDA,FDA-2015-D-2306,Testicular Toxicity: Evaluation During Drug Development,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testicular-toxicity-evaluation-during-drug-development,
FDA,FDA-2018-D-3583,"Draft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-standards-growing-harvesting-packing-and-holding-produce-human-consumption,
FDA,FDA-2018-D-3631,Draft Guidance for Industry: Guide to Minimize Food Safety Hazards of Fresh-cut Produce,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-guide-minimize-food-safety-hazards-fresh-cut-produce,
FDA,FDA-2017-D-6617,Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings : Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-early-drug-development-and-role-pre-ind-meetings,
FDA,FDA-2018-D-3268,Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-targeted-therapies-low-frequency-molecular-subsets-disease,
FDA,FDA-2018-D-3551,"Impact of Certain Provisions of the Revised Common Rule on FDA-Regulated Clinical Investigations:  Guidance for Sponsors, Investigators, and Institutional Review Boards",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/impact-certain-provisions-revised-common-rule-fda-regulated-clinical-investigations,
FDA,FDA-2018-D-1175,"Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/selection-appropriate-package-type-terms-and-recommendations-labeling-injectable-medical-products,
FDA,FDA-2015-D-3438,Atopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/atopic-dermatitis-timing-pediatric-studies-during-development-systemic-drugs,
FDA,FDA-2018-D-3275,Contents of a Complete Submission for Threshold Analyses and Human Factors Submissions to Drug and Biologic Applications,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contents-complete-submission-threshold-analyses-and-human-factors-submissions-drug-and-biologic,
FDA,,Compliance Policy Guides Index,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-guides-index,
FDA,FDA-2016-D-4317,Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies and Federal Facilities Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-and-repackaging-radiopharmaceuticals-state-licensed-nuclear-pharmacies-and-federal,
FDA,FDA-2016-D-4318,Compounding and Repackaging of Radiopharmaceuticals By Outsourcing Facilities Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-and-repackaging-radiopharmaceuticals-outsourcing-facilities-guidance-industry,
FDA,FDA-2014-D-0900,Good Review Management Principles and Practices for New Drug Applications and Biologics License Applications: Draft Guidance for Industry and Review Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-review-management-principles-and-practices-new-drug-applications-and-biologics-license,
FDA,FDA-2018-D-3103,Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-factors-consider-when-determining-substantial-equivalence-premarket-notifications-510k,
FDA,,Product Identifier Requirements Under the Drug Supply Chain Security Act â€“ Compliance Policy Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-identifier-requirements-under-drug-supply-chain-security-act-compliance-policy-guidance,
FDA,FDA-2015-D-2167,Heparin-Containing Medical Devices and Combination Products: Recommendations for Labeling and Safety Testing:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/heparin-containing-medical-devices-and-combination-products-recommendations-labeling-and-safety,
FDA,,Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/grandfathering-policy-packages-and-homogenous-cases-product-without-product-identifier,
FDA,FDA-2011-D-0733,GuÃ­a para la industria: EvaluaciÃ³n de la inocuidad de los cultivos alimentarios para el consumo humano afectados por las inundaciones,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guia-para-la-industria-evaluacion-de-la-inocuidad-de-los-cultivos-alimentarios-para-el-consumo,
FDA,FDA-2016-D-1164,Guidance for Industry: Determination of Status as a Qualified Facility,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-determination-status-qualified-facility,
FDA,FDA-2014-D-0456,Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices,
FDA,FDA-2018-D-3151,Postapproval Changes to Drug Substances Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-changes-drug-substances-guidance-industry,
FDA,FDA-2011-D-0376,Draft Guidance for Industry: Policy Regarding Quantitative Labeling of Dietary Supplements Containing Live Microbials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-policy-regarding-quantitative-labeling-dietary-supplements-containing-live,
FDA,FDA-2000-D-0277,Nonallergic Rhinitis:  Developing Drug Products for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonallergic-rhinitis-developing-drug-products-treatment,
FDA,FDA-2016-D-0236,Allergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/allergic-rhinitis-developing-drug-products-treatment-guidance-industry,
FDA,FDA-2016-D-3969,Physiologically Based Pharmacokinetic Analyses â€” Format and Content Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry,
FDA,FDA-2018-D-2896,Osteoarthritis: Structural Endpoints for the Development of Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/osteoarthritis-structural-endpoints-development-drugs,
FDA,FDA-2016-D-1490,Quality Attribute Considerations for Chewable Tablets Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-attribute-considerations-chewable-tablets-guidance-industry,
FDA,FDA-2017-D-5297,Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/microdose-radiopharmaceutical-diagnostic-drugs-nonclinical-study-recommendations,
FDA,FDA-2012-D-1002,Guidance for Industry: Questions and Answers Regarding Food Facility Registration (Seventh Edition),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-food-facility-registration-seventh-edition,
FDA,FDA-2012-D-1002,Draft Guidance for Industry: Supplemental Questions and Answers Regarding Food Facility Registration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-supplemental-questions-and-answers-regarding-food-facility-registration,
FDA,FDA-2018-D-2614,Tobacco Retailer Training Programs:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tobacco-retailer-training-programs,
FDA,FDA-2018-D-3047,Submission of Warning Plans for Cigars:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-warning-plans-cigars,
FDA,FDA-2017-D-0121,Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dissolution-testing-and-acceptance-criteria-immediate-release-solid-oral-dosage-form-drug-products,
FDA,FDA-2016-D-2495,Compliance Policy for Required Warning Statements on Small-Packaged Cigars:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-required-warning-statements-small-packaged-cigars,
FDA,FDA-2010-D-0350,Compliance Policy for Certain Labeling and Warning Statement Requirements for Cigars and Pipe Tobacco:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-certain-labeling-and-warning-statement-requirements-cigars-and-pipe-tobacco,
FDA,FDA-2016-D-1692,Elemental Impurities in Drug Products Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/elemental-impurities-drug-products-guidance-industry,
FDA,,Q3C Tables and List Rev. 4,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-tables-and-list-rev-4,
FDA,FDA-2018-D-1873,"Medical Device User Fee Small Business Qualification and Certification:  Guidance for Industry, Food and Drug Administration Staff and Foreign Governments",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-user-fee-small-business-qualification-and-certification,
FDA,FDA-2018-D-2456,"Slowly Progressive, Low-Prevalence Rare Diseases with Substrate Deposition That Results from Single Enzyme Defects: Providing Evidence of Effectiveness for Replacement or Corrective Therapies Guidance for Industry:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/slowly-progressive-low-prevalence-rare-diseases-substrate-deposition-results-single-enzyme-defects,
FDA,FDA-2018-D-2544,Use of Liquids and/or Soft Foods as Vehicles for Drug Administration:  General Considerations for Selection and In Vitro Methods for Product Quality Assessments,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-liquids-andor-soft-foods-vehicles-drug-administration-general-considerations-selection-and-vitro,
FDA,2018-15395,Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-health-record-data-clinical-investigations-guidance-industry,
FDA,FDA-2016-D-1224,E17 General Principles for Planning and Design of Multi-Regional Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e17-general-principles-planning-and-design-multi-regional-clinical-trials,
FDA,,Real World Data / Real World Evidence RWD/RWE,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-real-world-evidence-rwdrwe,
FDA,FDA-2016-D-0643,Labeling for Biosimilar Products Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-biosimilar-products-guidance-industry,
FDA,FDA-2018-D-2281,Innovative Approaches for Nonprescription Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/innovative-approaches-nonprescription-drug-products,
FDA,FDA-2018-D-2515,Hypertension: Conducting Studies of Drugs to Treat Patients on a Background of Multiple Antihypertensive Drugs Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypertension-conducting-studies-drugs-treat-patients-background-multiple-antihypertensive-drugs,
FDA,FDA-2018-D-1895,Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products â€” Content and Format Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/indications-and-usage-section-labeling-human-prescription-drug-and-biological-products-content-and,
FDA,FDA-2012-N-0447,CVM GFI #252 Small Entity Compliance Guide Antimicrobial Animal Drug Sales and Distribution Reporting,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-252-small-entity-compliance-guide-antimicrobial-animal-drug-sales-and-distribution-reporting,
FDA,FDA-2018-D-1919,Major Depressive Disorder:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment,
FDA,FDA-2018-D-1323,Logical Observation Identifiers Names and Codes for In Vitro Diagnostic Tests :  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/logical-observation-identifiers-names-and-codes-in-vitro-diagnostic-tests,
FDA,FDA-2018-D-1861,Guidance for Industry: The Declaration of Certain Isolated or Synthetic Non-Digestible Carbohydrates as Dietary Fiber on Nutrition and Supplement Facts Labels,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-declaration-certain-isolated-or-synthetic-non-digestible-carbohydrates-dietary,
FDA,FDA-2017-D-6982,CVM GFI #246 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply-Chain Program,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-246-hazard-analysis-and-risk-based-preventive-controls-food-animals-supply-chain-program,
FDA,FDA-2018-D-1893,Patient-Focused Drug Development:  Collecting Comprehensive and Representative Input,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-collecting-comprehensive-and-representative-input,
FDA,FDA-2016-D-2285,Medical Product Communications That Are Consistent With the FDA-Required Labeling â€” Questions and Answers :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-product-communications-are-consistent-fda-required-labeling-questions-and-answers,
FDA,FDA-2016-D-1307,"Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities â€“ Questions and Answers:  Guidance for Industry and Review Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-and-device-manufacturer-communications-payors-formulary-committees-and-similar-entities,
FDA,FDA-2018-D-1635,Prescription Drug User Fee Act Waivers for Fixed-Combination Antiretroviral Drugs for the Presidentâ€™s Emergency Plan for AIDS Relief: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-drug-user-fee-act-waivers-fixed-combination-antiretroviral-drugs-presidents-emergency,
FDA,FDA-2012-D-0148,Development of a Shared System REMS Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-shared-system-rems-guidance-industry,
FDA,FDA-2018-D-1041,Complicated Urinary Tract Infections:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-urinary-tract-infections-developing-drugs-treatment,
FDA,FDA-2012-D-1003,Small Entity Compliance Guide: Registration of Food Facilities,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-registration-food-facilities,
FDA,FDA-2016-D-0412,Anthrax: Developing Drugs for Prophylaxis of Inhalational Anthrax Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anthrax-developing-drugs-prophylaxis-inhalational-anthrax-guidance-industry,
FDA,FDA-2002-D-0147,CVM GFI #132 Administrative Applications and the Phased Review Process,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-132-administrative-applications-and-phased-review-process,
FDA,FDA-2005-D-0461,Bioanalytical Method Validation Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry,
FDA,FDA-2013-D-1020,Acne Vulgaris:  Establishing Effectiveness of Drugs Intended for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acne-vulgaris-establishing-effectiveness-drugs-intended-treatment,
FDA,FDA-2018-D-1711,Cytomegalovirus in Transplantation:  Developing Drugs to Treat or Prevent Disease,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cytomegalovirus-transplantation-developing-drugs-treat-or-prevent-disease,
FDA,,Establishing Effectiveness for Drugs Intended to Treat Male Hypogonadotropic Hypogonadism Attributed to Nonstructural Disorders Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-effectiveness-drugs-intended-treat-male-hypogonadotropic-hypogonadism-attributed,
FDA,FDA-2016-D-1605,Institutional Review Board (IRB) Written Procedures:  Guidance for Institutions and IRBs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-board-irb-written-procedures,
FDA,FDA-2018-D-1378,Small Entity Compliance Guide: Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules of the FDA Food Safety Modernization Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-extension-and-clarification-compliance-dates-certain-provisions-four,
FDA,,"Facility Definition Under Section 503B of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/facility-definition-under-section-503b-federal-food-drug-and-cosmetic-act,
FDA,FDA-2016-D-2513,S3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies: Focus on Microsampling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s3a-guidance-note-guidance-toxicokinetics-assessment-systemic-exposure-toxicity-studies-focus,
FDA,FDA-2012-D-0973,Guidance for Industry: Menu Labeling Supplemental Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-menu-labeling-supplemental-guidance,
FDA,FDA-2011-F-0172,Complicated Intra-Abdominal Infections: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-intra-abdominal-infections-developing-drugs-treatment,
FDA,FDA-2011-D-0586,Clinical Trial Imaging Endpoint Process Standards Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-imaging-endpoint-process-standards-guidance-industry,
FDA,FDA-2018-D-1176,Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Questions and Answers Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-questions-and-answers,
FDA,FDA-2018-D-1098,Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products--Quality Considerations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/metered-dose-inhaler-mdi-and-dry-powder-inhaler-dpi-drug-products-quality-considerations,
FDA,FDA–2018–D–1189,Special Protocol Assessment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/special-protocol-assessment-guidance-industry,
FDA,FDA-2016-D-1174,Guidance for Industry: Highly Concentrated Caffeine in Dietary Supplements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-highly-concentrated-caffeine-dietary-supplements,
FDA,FDA-2016-D-1270,Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics :  Guidance for Stakeholders and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-public-human-genetic-variant-databases-support-clinical-validity-genetic-and-genomic-based-vitro,
FDA,FDA-2016-D-1233,"Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) - Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases:  Guidance for Stakeholders and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-development-and-analytical-validation-next-generation-sequencing-ngs-based,
FDA,FDA-2016-D-3848,E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e11r1-addendum-clinical-investigation-medicinal-products-pediatric-population,
FDA,FDA-2018-D-1201,Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pregnant-women-scientific-and-ethical-considerations-inclusion-clinical-trials,
FDA,FDA-2016-D-2817,"Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/liposome-drug-products-chemistry-manufacturing-and-controls-human-pharmacokinetics-and,
FDA,FDA-2017-D-6821,Questions and Answers on Current Good Manufacturing Practices for Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-current-good-manufacturing-practices-drugs,
FDA,FDA-2017-D-6821,Chronic Obstructive Pulmonary Disease: Use of the St. Georgeâ€™s Respiratory Questionnaire as a PRO Assessment Tool Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-obstructive-pulmonary-disease-use-st-georges-respiratory-questionnaire-pro-assessment-tool,
FDA,FDA-2018-D-0721,Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to the Importation of Live Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-application-foreign-supplier-verification-program-regulation-importation-live,
FDA,FDA-2016-D-1255,Standardization of Data and Documentation Practices for Product Tracing Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standardization-data-and-documentation-practices-product-tracing-guidance-industry,
FDA,FDA-2006-P-0207,"Guidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion; Dual-Column Labeling; Updating, Modifying, and Establishing Certain Reference Amounts Customarily Consumed; Serving Size for Breath Mints",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-serving-sizes-foods-can-reasonably-be-consumed-one-eating-occasion-dual-column,
FDA,FDA-2016-D-4098,Guidance for Industry: Scientific Evaluation of the Evidence on the Beneficial Physiological Effects of Isolated or Synthetic Non-Digestible Carbohydrates Submitted as a Citizen Petition (21 CFR 10.30),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-scientific-evaluation-evidence-beneficial-physiological-effects-isolated-or,
FDA,FDA-2016-D-3401,Guidance for Industry: Reference Amounts Customarily Consumed (List of Products for Each Product Category),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-reference-amounts-customarily-consumed-list-products-each-product-category,
FDA,FDA-2004-N-0258,Guidance for Industry: Proper Labeling of Honey and Honey Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-proper-labeling-honey-and-honey-products,
FDA,FDA-2018-D-0688,E18 Genomic Sampling and Management of Genomic Data Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e18-genomic-sampling-and-management-genomic-data-guidance-industry,
FDA,FDA-2018-D-0719,E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r2-good-clinical-practice-integrated-addendum-ich-e6r1,
FDA,FDA-2011-D-0436,Q11 Development and Manufacture of Drug Substances--Questions and Answers (Chemical Entities and Biotechnological/Biological Entities),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q11-development-and-manufacture-drug-substances-questions-and-answers-chemical-entities-and,
FDA,FDA-2013-N-0080,Acceptance of Clinical Data to Support Medical Device Applications and Submissions: Frequently Asked Questions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptance-clinical-data-support-medical-device-applications-and-submissions-frequently-asked,
FDA,FDA-2015-D-1884,Standardized Format for Electronic Submission of NDA and BLA Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for CDER Submissions Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standardized-format-electronic-submission-nda-and-bla-content-planning-bioresearch-monitoring-bimo,
FDA,FDA-2014-D-1540,Migraine: Developing Drugs for Acute Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/migraine-developing-drugs-acute-treatment,
FDA,FDA-2018-D-0481,Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-treatment-guidance,
FDA,FDA-2011-D-0800,Regulatory Classification of Pharmaceutical Co-Crystals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-classification-pharmaceutical-co-crystals,
FDA,FDA-2017-D-0040,How to Prepare a Pre-Request for Designation (Pre-RFD):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-prepare-pre-request-designation-pre-rfd,
FDA,FDA-2009-D-0408,"Microbiological Data for Systemic Antibacterial Drug Products â€” Development, Analysis, and Presentation",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/microbiological-data-systemic-antibacterial-drug-products-development-analysis-and-presentation,
FDA,,Payment and Reimbursement to Research Subjects:  Guidance for Institutional Review Boards and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/payment-and-reimbursement-research-subjects,
FDA,FDA-2017-D-6592,Small Entity Compliance Guide: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-foreign-supplier-verification-programs-importers-food-humans-and,
FDA,FDA-2011-N-0143,Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to Importers of Grain Raw Agricultural Commodities,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-application-foreign-supplier-verification-program-regulation-importers-grain-raw,
FDA,FDA-2017-D-0397,Draft Guidance for Industry: Considerations for Determining Whether a Measure Provides the Same Level of Public Health Protection as the Corresponding Requirement in 21 CFR part 112 or the Preventive Controls Requirements in part 117 or 507,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-considerations-determining-whether-measure-provides-same-level-public-health,
FDA,FDA-2016-D-1309,Product Title and Initial U.S. Approval in the Highlights of Prescribing Information for Human Prescription Drug and Biological Products â€” Content and Format Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-title-and-initial-us-approval-highlights-prescribing-information-human-prescription-drug-and,
FDA,FDA-2016-D-1267,Material Threat Medical Countermeasure Priority Review Vouchers  - Draft Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/material-threat-medical-countermeasure-priority-review-vouchers-draft-guidance-industry,
FDA,FDA-2017-D-6969,"Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounded-drug-products-are-essentially-copies-approved-drug-products-under-section-503b-federal,
FDA,FDA-2017-D-6880,"Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounded-drug-products-are-essentially-copies-commercially-available-drug-product-under-section,
FDA,,"Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mixing-diluting-or-repackaging-biological-products-outside-scope-approved-biologics-license,
FDA,FDA-2017-N-6908,"Guidance for Industry: Policy Regarding Certain Entities Subject to the Current Good Manufacturing Practice and Preventive Controls, Produce Safety, and/or Foreign Supplier Verification Programs",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-policy-regarding-certain-entities-subject-current-good-manufacturing-practice-and,
FDA,FDA-2017-D-1846,Labeling for Combined Hormonal Contraceptives Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-combined-hormonal-contraceptives-guidance-industry,
FDA,FDA-2017-D-6564,Best Practices for Communication Between IND Sponsors and FDA During Drug Development,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-communication-between-ind-sponsors-and-fda-during-drug-development,
FDA,FDA-2005-D-0140,"Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nucleic-acid-testing-nat-human-immunodeficiency-virus-type-1-hiv-1-and-hepatitis-c-virus-hcv-testing,
FDA,FDA-2015-D-0025,Medical Device Accessories - Describing Accessories and Classification Pathways:   Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-accessories-describing-accessories-and-classification-pathways,
FDA,FDA-2017-D-6380.,Clarification of Orphan Designation of Drugs and  Biologics for Pediatric Subpopulations of Common Diseases:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-orphan-designation-drugs-and-biologics-pediatric-subpopulations-common-diseases,
FDA,FDA-2017-N-6356,"Investigational IVDs Used in Clinical Investigations of Therapeutic Products: Draft Guidance for Industry, Food and Drug Administration Staff, Sponsors, and Institutional Review Boards",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-ivds-used-clinical-investigations-therapeutic-products,
FDA,FDA-2017-N-5925,Systemic Antibacterial and Antifungal Drugs:  Susceptibility Test Interpretive Criteria Labeling for NDAs and ANDAs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/systemic-antibacterial-and-antifungal-drugs-susceptibility-test-interpretive-criteria-labeling-ndas,
FDA,FDA-2017-D-6554,Refuse to File: NDA and BLA Submissions to CDER Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/refuse-file-nda-and-bla-submissions-cder-guidance-industry,
FDA,FDA-1999-D-4079,"Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling-Final",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-name-placement-size-and-prominence-advertising-and-promotional-labeling-final,
FDA,FDA-2017-D-6352,Gluten in Drug Products and Associated Labeling Recommendations; Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/gluten-drug-products-and-associated-labeling-recommendations-draft-guidance-industry,
FDA,FDA-2016-D-2483,Software as a Medical Device (SAMD): Clinical Evaluation:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/software-medical-device-samd-clinical-evaluation,
FDA,FDA-2017-N-6476,Pediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-rare-diseases-collaborative-approach-drug-development-using-gaucher-disease-model-draft,
FDA,FDA-2009-D-0137,Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-serological-tests-reduce-risk-transmission-trypanosoma-cruzi-infection-blood-and-blood,
FDA,FDA-2016-D-1210,Technical Considerations for Additive Manufactured Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-additive-manufactured-medical-devices,
FDA,FDA-2016-D-1159,"FDA Categorization of Investigational Device Exemption (IDE) Devices to Assist the Centers for Medicare and Medicaid Services (CMS) with Coverage Decisions:  Guidance for Sponsors, Clinical Investigators, Industry, Institutional Review Boards, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-categorization-investigational-device-exemption-ide-devices-assist-centers-medicare-and-medicaid,
FDA,FDA-2012-D-0384,Pediatric Information for X-ray Imaging Device Premarket Notifications:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-information-x-ray-imaging-device-premarket-notifications,
FDA,FDA-2013-N-0013,Small Entity Compliance Guide: Sanitary Transportation of Human and Animal Food - What You Need to Know About the FDA Regulation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-sanitary-transportation-human-and-animal-food-what-you-need-know-about,
FDA,FDA-2016-D-0785,General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-evaluating-abuse-deterrence-generic-solid-oral-opioid-drug-products-guidance,
FDA,FDA-2015-D-2245,Unique Device Identification: Direct Marking of Devices :  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identification-direct-marking-devices,
FDA,FDA-2014-D-1584,Same Surgical Procedure Exception under 21 CFR 1271.15(b):Â Questions and Answers Regarding the Scope of the Exception,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/same-surgical-procedure-exception-under-21-cfr-127115b-questions-and-answers-regarding-scope,
FDA,,Guidance for Industry: Use of the Terms â€œBrown King Crabâ€ and â€œGolden King Crabâ€ in the Labeling of Human Food Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-use-terms-brown-king-crab-and-golden-king-crab-labeling-human-food-products,
FDA,FDA-2017-D-6231,Use of a Drug Master File for Shared System REMS Submissions Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-drug-master-file-shared-system-rems-submissions-guidance-industry,
FDA,,Recurrent Herpes Labialis:  Developing Drugs for Treatment and Prevention,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recurrent-herpes-labialis-developing-drugs-treatment-and-prevention,
FDA,FDA-2016-D-1504,Evaluating Drug Effects on the Ability to Operate a Motor Vehicle,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluating-drug-effects-ability-operate-motor-vehicle,
FDA,FDA-2013-D-1170,Recommended Statement for Over-the-Counter Aspirin-Containing Drug Products Labeled With Cardiovascular Related Imagery Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-statement-over-counter-aspirin-containing-drug-products-labeled-cardiovascular-related,
FDA,FDA-2012-D-0529,Chronic Hepatitis C Virus Infection:  Developing Direct-Acting Antiviral Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-hepatitis-c-virus-infection-developing-direct-acting-antiviral-drugs-treatment-guidance,
FDA,FDA-2017-D-5996,Guidance for Industry: Supply-Chain Program Requirements and Co-Manufacturer Supplier Approval and Verification for Human Food and Animal Food,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-supply-chain-program-requirements-and-co-manufacturer-supplier-approval-and,
FDA,FDA-2017-D-3101,ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence) Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-pre-submission-facility-information-related-prioritized-generic-drug-applications-pre,
FDA,FDA-2016-D-4484,Recommendations for the Submission of LOINCÂ® Codes in Regulatory Applications to the U.S. Food and Drug Administration:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-submission-loincr-codes-regulatory-applications-us-food-and-drug-administration,
FDA,FDA-2017-D-6982,"Guidance for Industry: Regulatory Framework for Substances Intended for Use in Human Food or Animal Food on the Basis of the Generally Recognized as Safe (GRAS) Provision of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-regulatory-framework-substances-intended-use-human-food-or-animal-food-basis,
FDA,FDA-2012-D-0880,Product Labeling for Certain Ultrasonic Surgical Aspirator Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-labeling-certain-ultrasonic-surgical-aspirator-devices,
FDA,FDA-2016-D-1264,Manufacturers Sharing Patient-Specific Information from Medical Devices with Patients Upon Request:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturers-sharing-patient-specific-information-medical-devices-patients-upon-request,
FDA,FDA-2016-D-3275,Assessing User Fees Under the Generic Drug User Fee Amendments of 2017 Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-generic-drug-user-fee-amendments-2017-guidance-industry,
FDA,FDA-2017-D-5912,Pediatric Gastroesophageal Reflux Disease: Developing Drugs for Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-gastroesophageal-reflux-disease-developing-drugs-treatment-guidance-industry,
FDA,FDA-2011-D-0453,Deciding When to Submit a 510(k) for a Software Change to an Existing Device:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-software-change-existing-device,
FDA,FDA-2016-D-2021,Deciding When to Submit a 510(k) for a Change to an Existing Device:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-change-existing-device,
FDA,FDA-2016-D-1229,Draft Guidance for Industry: Application of the â€œSolely Engagedâ€ Exemptions in Parts 117 and 507,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-application-solely-engaged-exemptions-parts-117-and-507,
FDA,FDA-2017-D-6133,CVM GFI #235 Current Good Manufacturing Practice Requirements for Food for Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-235-current-good-manufacturing-practice-requirements-food-animals,
FDA,,Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/respiratory-syncytial-virus-infection-developing-antiviral-drugs-prophylaxis-and-treatment-guidance,
FDA,None found,Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/completeness-assessments-type-ii-api-dmfs-under-gdufa-guidance-industry,
FDA,FDA-2016-D-4482,CVM GFI #236 Clarification of FDA and EPA Jurisdiction Over Mosquito-Related Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-236-clarification-fda-and-epa-jurisdiction-over-mosquito-related-products,
FDA,FDA-2015-D-0268,"Waiver of IRB Requirements for Drug and Biological Product Studies:  Guidance For Sponsors, Clinical Investigators, and IRBs",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/waiver-irb-requirements-drug-and-biological-product-studies,
FDA,FDA-2017-D-5139,M4 Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-organization-common-technical-document-registration-pharmaceuticals-human-use-guidance-industry,
FDA,FDA-2017-D-5846,Individual Patient Expanded Access Applications: Form FDA 3926,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/individual-patient-expanded-access-applications-form-fda-3926,
FDA,,ANDA Submissions - Refuse-to-Receive Standards: Questions and Answers Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-refuse-receive-standards-questions-and-answers-guidance-industry,
FDA,FDA-2008-D-0228,Administrative Procedures for CLIA Categorization:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/administrative-procedures-clia-categorization,
FDA,FDA-2015-D-4644,Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/advancement-emerging-technology-applications-pharmaceutical-innovation-and-modernization-guidance,
FDA,FDA-2011-D-0429,Minutes of Institutional Review Board (IRB) Meetings:  Guidance for Institutions and IRBs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/minutes-institutional-review-board-irb-meetings,
FDA,FDA-2015-D-3638,Classification of Products as Drugs and Devices and Additional Product Classification Issues:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/classification-products-drugs-and-devices-and-additional-product-classification-issues,
FDA,FDA-2008-D-0081,Q4B Annex 2: Test for Extractable Volume of Parenteral Preparations General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-2-test-extractable-volume-parenteral-preparations-general-chapter,
FDA,FDA-2009-D-0386,Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Human Papillomaviruses:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-performance-characteristics-in-vitro-diagnostic-devices-detection-or-detection-and-0,
FDA,FDA-2016-D-0734,"Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-and-reporting-age-race-and-ethnicity-specific-data-medical-device-clinical-studies,
FDA,FDA-2015-D-4386,"Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deviation-reporting-human-cells-tissues-and-cellular-and-tissue-based-products-regulated-solely,
FDA,FDA-2015-D-4852,Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-considerations-and-pre-market-submission-recommendations-interoperable-medical-devices,
FDA,FDA-2017-D-5152,Requalification of Donors Previously Deferred for a History of Viral Hepatitis after the 11th Birthday:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requalification-donors-previously-deferred-history-viral-hepatitis-after-11th-birthday,
FDA,FDA-2015-D-0838,Procedures for Meetings of the Medical Devices Advisory Committee:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-meetings-medical-devices-advisory-committee,
FDA,FDA-2016-D-2153,Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices :   Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices,
FDA,FDA-2013-N-1425,Small Entity Compliance Guide: Mitigation Strategies to Protect Food Against Intentional Adulteration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-mitigation-strategies-protect-food-against-intentional-adulteration,
FDA,FDA-2015-D-1804,CVM GFI #237 Oncology Drugs for Companion Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-237-oncology-drugs-companion-animals,
FDA,FDA-2016-D-1248,CVM GFI #232 (VICH GL54) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish an Acute Reference Dose (ARfD),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-232-vich-gl54-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach,
FDA,,Identifying Trading Partners Under the Drug Supply Chain Security Act Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/identifying-trading-partners-under-drug-supply-chain-security-act-guidance-industry,
FDA,FDA-2017-D-4713,Guidance for Industry: Ultrafiltered Milk in the Production of Standardized Cheeses and Related Cheese Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-ultrafiltered-milk-production-standardized-cheeses-and-related-cheese-products,
FDA,FDA-2013-D-0744,Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases,
FDA,FDA-2013-N-0013,Guidance for Industry: Clarification on Food Establishment Waiver from Requirements of the Sanitary Transportation of Human and Animal Food Rule,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-clarification-food-establishment-waiver-requirements-sanitary-transportation-human,
FDA,FDA-2017-D-3906,Consumer Antiseptic Wash Final Rule Questions and Answers:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/consumer-antiseptic-wash-final-rule-questions-and-answers,
FDA,FDA-2010-N-0327 (Cumene) FDA-2015-D-3474 (Triethylamine/Methylisobutylketone)  4 Guidances listed under this Document:Triethylamine/Methylisobutylketone - pdf on web Tetrahydrofuran (THF) - pdf ON web; Docket #2001B-0431 N-Methylpyrrolidone (NMP) - pdf ON,PDEs for Triethylamine and for Methylisobutylketone,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pdes-triethylamine-and-methylisobutylketone,
FDA,,ICH Q3C Maintenance Procedures for the Guidance for Industry Q3C Impurities: Residual Solvents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ich-q3c-maintenance-procedures-guidance-industry-q3c-impurities-residual-solvents,
FDA,FDA-2015-D-3235,Q3C Maintenance Procedures,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-maintenance-procedures,
FDA,,M4E(R2):  The CTD â€“ Efficacy,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4er2-ctd-efficacy,
FDA,FDA-2003-D-0431,Current Good Manufacturing Practice for Medical Gases: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-medical-gases,
FDA,FDA-2004-D-0241,E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R3) Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-1,
FDA,,"Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions:  Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/form-fda-3674-certifications-accompany-drug-biological-product-and-device-applicationssubmissions,
FDA,FDA-2011-N-0143,Guidance for Industry: Recognition of Acceptable Unique Facility Identifier (UFI) for the Foreign Supplier Verification Programs Regulation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recognition-acceptable-unique-facility-identifier-ufi-foreign-supplier,
FDA,FDA-2010-D-0026,Assessment of Abuse Potential of Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-abuse-potential-drugs,
FDA,FDA-2016-D-4412,Draft Guidance for Industry: Control of Listeria monocytogenes in Ready-To-Eat Foods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-control-listeria-monocytogenes-ready-eat-foods,
FDA,FDA-2008-D-0096,Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/comparative-analyses-and-related-comparative-use-human-factors-studies-drug-device-combination,
FDA,,2016 Medical Gas Container-Closure Rule Questions and Answers Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/2016-medical-gas-container-closure-rule-questions-and-answers-guidance-industry,
FDA,FDA-2014-D-1524,Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/repackaging-certain-human-drug-products-pharmacies-and-outsourcing-facilities,
FDA,FDA-2016-D-1025,"Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions:  Guidance for Investigational Device Exemption Sponsors, Sponsor-Investigators and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/factors-consider-when-making-benefit-risk-determinations-medical-device-investigational-device,
FDA,FDA-2015-D-1777,Emergency Use Authorization of Medical Products and Related Authorities:  Guidance for Industry and Other Stakeholders,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities,
FDA,FDA-2013-D-1543,Nonproprietary Naming of Biological Products Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonproprietary-naming-biological-products-guidance-industry,
FDA,FDA-2016-D-4645,Guidance for Industry 180-Day Exclusivity: Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-180-day-exclusivity-questions-and-answers,
FDA,FDA-2014-D-1862,Recommended Warning for Over-the-Counter Acetaminophen-Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-warning-over-counter-acetaminophen-containing-drug-products-and-labeling-statements,
FDA,FDA-2015-D-0198,Current Good Manufacturing Practice Requirements for Combination Products:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-requirements-combination-products,
FDA,FDA-2016-D-4646,"Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-assessment-blood-donor-eligibility-donor-deferral-and-blood-product-management,
FDA,FDA-2014-D-2175,Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers: Questions and Answers Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/annual-reporting-prescription-drug-wholesale-distributors-and-third-party-logistics-providers,
FDA,FDA-2013-N-1428,"Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act.â€",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-drug-product-reporting-human-drug-compounding-outsourcing-facilities-under-section-503b,
FDA,FDA-2000-D-0103,"Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-requirement-under-section-503a-federal-food-drug-and-cosmetic-act-guidance-industry,
FDA,FDA-2014-D-0234,Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference  Product,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-data-support-demonstration-biosimilarity-reference-product,
FDA,FDA-2016-D-0269,Botanical Drug Development: Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/botanical-drug-development-guidance-industry,
FDA,FDA-2013-D-1120,Postmarket Management of Cybersecurity in Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices,
FDA,FDA-2015-D-5105,ANDA Submissions -- Refuse-to-Receive Standards Rev.2,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-refuse-receive-standards-rev2,
FDA,FDA-2016-D-1495,"Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/factors-consider-regarding-benefit-risk-medical-device-product-availability-compliance-and,
FDA,FDA-2014-D-2275,Draft Guidance for Industry: Lead in Cosmetic Lip Products and Externally Applied Cosmetics: Recommended Maximum Level,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-lead-cosmetic-lip-products-and-externally-applied-cosmetics-recommended,
FDA,FDA-2016-D-0620,"CVM GFI #234 Question-Based Review for the Chemistry, Manufacturing, and Controls Technical Section of Animal Drug Applications",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-234-question-based-review-chemistry-manufacturing-and-controls-technical-section-animal-drug,
FDA,FDA-2014-D-1352,Gifts to FDA: Evaluation and Acceptance:  Guidance for the Public and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/gifts-fda-evaluation-and-acceptance,
FDA,FDA-2012-D-1083,CVM GFI #224 (VICH GL52) Bioequivalence: Blood Level Bioequivalence Study,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-224-vich-gl52-bioequivalence-blood-level-bioequivalence-study,
FDA,FDA-2015-D-4361,Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Responses to Frequently Asked Questions (*Revised):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/civil-money-penalties-and-no-tobacco-sale-orders-tobacco-retailers-responses-frequently-asked,
FDA,FDA-2015-D-0390,"Use of Electronic Informed Consent in Clinical Investigations â€“ Questions and Answers:  Guidance for Institutional Review Boards, Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-informed-consent-clinical-investigations-questions-and-answers,
FDA,FDA-2015-D-4803,"Public Notification of Emerging Postmarket Medical Device Signals (""Emerging Signals""):  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/public-notification-emerging-postmarket-medical-device-signals-emerging-signals,
FDA,FDA-2000-D-0129,"Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/source-animal-product-preclinical-and-clinical-issues-concerning-use-xenotransplantation-products,
FDA,FDA-2009-D-0095,Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products â€” Content and Format,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-labeling-human-prescription-drug-and-biological-products-content-and-format,
FDA,,CPG Sec 615.115 Extralabel Use of Medicated Feeds for Minor Species,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-615115-extralabel-use-medicated-feeds-minor-species,
FDA,FDA-2013-D-0349,Providing Postmarket Periodic Safety Reports in the ICH E2C(R2) Format (Periodic Benefit-Risk Evaluation Report),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-postmarket-periodic-safety-reports-ich-e2cr2-format-periodic-benefit-risk-evaluation,
FDA,FDA-2014-D-2153,Mitigating the Risk of Cross-Contamination from Valves and Accessories Used for Irrigation Through Flexible Gastrointestinal Endoscopes:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/mitigating-risk-cross-contamination-valves-and-accessories-used-irrigation-through-flexible,
FDA,FDA-2015-D-2537,Submission of Quality Metrics Data Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-quality-metrics-data-guidance-industry,
FDA,FDA-2015-D-4033,Nonprescription Sunscreen Drug Products â€“ Format and Content of Data Submissions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonprescription-sunscreen-drug-products-format-and-content-data-submissions,
FDA,FDA-2013-D-0558,Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry,
FDA,FDA-2015-D-4021,Safety Testing of Drug Metabolites,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-drug-metabolites,
FDA,FDA-2008-D-0065,Nonprescription Sunscreen Drug Products â€“ Safety and Effectiveness Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonprescription-sunscreen-drug-products-safety-and-effectiveness-data,
FDA,FDA-2012-D-0880,Generic Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/generic-drug-user-fee-amendments-2012-questions-and-answers-related-user-fee-assessments,
FDA,FDA-2010-D-0075,Non-Inferiority Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-inferiority-clinical-trials,
FDA,FDA-2013-D-0743,Medical Device Reporting for Manufacturers :  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-reporting-manufacturers,
FDA,FDA-2016-D-0539,Clinical Considerations for Investigational Device Exemptions (IDEs) for Neurological Devices Targeting Disease Progression and Clinical Outcomes:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-considerations-investigational-device-exemptions-ides-neurological-devices-targeting,
FDA,FDA-2011-N-0922,"Revised Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products Who Have Received Human-Derived Clotting Factor Concentrates:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-determining-eligibility-donors-human-cells-tissues-and-cellular-and-tissue,
FDA,FDA-2013-D-1622,Guidance for Industry: Submitting Forms for Food Canning Establishment Registration and Food Process Filing to FDA in Electronic or Paper Format,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-submitting-forms-food-canning-establishment-registration-and-food-process-filing,
FDA,FDA-2016-D-3750,"CVM GFI #241 Small Entity Compliance Guide â€“ What You Need to Know About the FDA Regulation: Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals (21 CFR Part 507)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-241-small-entity-compliance-guide-what-you-need-know-about-fda-regulation-current-good,
FDA,FDA-2011-N-0920,"Small Entity Compliance Guide: What You Need to Know About Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-what-you-need-know-about-current-good-manufacturing-practice-hazard,
FDA,FDA-2016-D-0435,Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-permanent-hysteroscopically-placed-tubal-implants-intended-sterilization,
FDA,FDA-2016-D-2841,"Draft Guidance for Industry: Describing a Hazard That Needs Control in Documents Accompanying the Food, as Required by Four Rules Implementing FSMA",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-describing-hazard-needs-control-documents-accompanying-food-required-four,
FDA,FDA-2016-D-3561,Collection of Race and Ethnicity Data in Clinical Trials:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-race-and-ethnicity-data-clinical-trials,
FDA,FDA-2016-D-2817,"Low Sexual Interest, Desire, and/or Arousal in Women: Developing Drugs for Treatment Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/low-sexual-interest-desire-andor-arousal-women-developing-drugs-treatment-guidance-industry,
FDA,,CPG Sec. 101.100 FDA Considerations for Recommending Charges for Causing the Introduction of Violative Products into Interstate Commerce,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-101100-fda-considerations-recommending-charges-causing-introduction-violative-products,
FDA,FDA-2015-D-3990,Sunscreen Innovation Act: Withdrawal of a 586A Request or Pending Request Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sunscreen-innovation-act-withdrawal-586a-request-or-pending-request-guidance-industry,
FDA,FDA-2015-D-4012,Sunscreen Innovation Act:  Section 586C(c) Advisory Committee Process,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sunscreen-innovation-act-section-586cc-advisory-committee-process,
FDA,FDA-2008-D-0530,Tropical Disease Priority Review Vouchers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tropical-disease-priority-review-vouchers,
FDA,,Head Lice Infestation: Developing Drugs for Topical Treatment Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/head-lice-infestation-developing-drugs-topical-treatment-guidance-industry,
FDA,FDA-2020-D-1908,Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-guidance-industry,
FDA,FDA-1995-D-0288,Guidance for Industry:  Frequently Asked Questions About GRAS for Substances Intended for Use in Human or Animal Food,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-frequently-asked-questions-about-gras-substances-intended-use-human-or-animal-food,
FDA,FDA-2016-D-2335,Guidance for Industry: Use of the Term â€œHealthyâ€ in the Labeling of Human Food Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-use-term-healthy-labeling-human-food-products,
FDA,FDA-2012-D-0881,"Self-Identification of Generic Drug Facilities, Sites, and Organizations; Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/self-identification-generic-drug-facilities-sites-and-organizations-guidance-industry,
FDA,FDA-2010-N-0155,CVM GFI #233 Veterinary Feed Directive Common Format Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-233-veterinary-feed-directive-common-format-questions-and-answers,
FDA,FDA-2013-D-1530,Reporting of Computational Modeling Studies in Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-computational-modeling-studies-medical-device-submissions,
FDA,FDA-2015-D-2843,Recommendations for Microbial Vectors Used for Gene Therapy:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-microbial-vectors-used-gene-therapy,
FDA,FDA-2015-D-3399,Qualification of Biomarker Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-biomarker-total-kidney-volume-studies-treatment-autosomal-dominant-polycystic-kidney,
FDA,FDA-2014-D-1292,ANDA Submissions â€” Refuse to Receive for Lack of Justification of Impurity Limits:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-refuse-receive-lack-justification-impurity-limits,
FDA,FDA-2015-D-2244,Qualification of Biomarker Plasma Fibrinogen in Studies Examining Exacerbations and/or All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-biomarker-plasma-fibrinogen-studies-examining-exacerbations-andor-all-cause-mortality,
FDA,FDA-2016-D-2241,Draft Guidance for Industry: Substantiation for Structure/Function Claims Made in Infant Formula Labels and Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-substantiation-structurefunction-claims-made-infant-formula-labels-and,
FDA,FDA-2013-D-1143,"Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-nucleic-acid-tests-reduce-risk-transmission-west-nile-virus-living-donors-human-cells-tissues,
FDA,,"â€œHarmful and Potentially Harmful Constituentsâ€ in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/harmful-and-potentially-harmful-constituents-tobacco-products-used-section-904e-federal-food-drug,
FDA,FDA-2012-D-0585,Guidance for the Submission of 510(k)s for Solid State X-ray Imaging Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-submission-510ks-solid-state-x-ray-imaging-devices,
FDA,FDA-2010-D-0281,Guidance for Industry: Necessity of the Use of Food Product Categories in Food Facility Registrations and Updates to Food Product Categories (2016 Edition),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-necessity-use-food-product-categories-food-facility-registrations-and-updates-food,
FDA,FDA-1997-N-0389,CPG Sec. 150.200 Compliance Review of Private Laboratory Analytical Packages (PLAPs),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-150200-compliance-review-private-laboratory-analytical-packages-plaps,
FDA,FDA-2016-D-1220,"Draft Guidance for Industry: Classification of Activities as Harvesting, Packing, Holding, or Manufacturing/Processing for Farms and Facilities",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-classification-activities-harvesting-packing-holding-or,
FDA,FDA-2016-D-2373,CVM GFI #239 Human Food By-Products For Use As Animal Food,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-239-human-food-products-use-animal-food,
FDA,FDA-2015-D-1580,"Patient Preference Information - Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-preference-information-voluntary-submission-review-premarket-approval-applications,
FDA,FDA-2011-F-0171,Small Entity Compliance Guide: Calorie Labeling of Articles of Food in Vending Machines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-calorie-labeling-articles-food-vending-machines,
FDA,FDA-2011-F-0171,Draft Guidance for Industry: Calorie Labeling of Articles of Food in Vending Machines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-calorie-labeling-articles-food-vending-machines,
FDA,FDA-2014-D-0218,Premarket Notification (510(k)) Submissions for Bipolar Electrosurgical Vessel Sealers for General Surgery:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-510k-submissions-bipolar-electrosurgical-vessel-sealers-general-surgery,
FDA,FDA-2016-D-2071,"Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-nucleic-acid-tests-reduce-risk-transmission-hepatitis-b-virus-donors-human-cells-tissues-and,
FDA,FDA-2015-D-5073,Determining Donor Eligibility for Autologous Donors of Blood and Blood Components Intended Solely for Autologous Use - Compliance Policy:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-donor-eligibility-autologous-donors-blood-and-blood-components-intended-solely,
FDA,FDA-2015-D-1439,Adaptive Designs for Medical Device Clinical Studies:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-designs-medical-device-clinical-studies,
FDA,FDA-2012-D-0315,E2C(R2) Periodic Benefit-Risk Evaluation Report â€“ Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2cr2-periodic-benefit-risk-evaluation-report-questions-and-answers,
FDA,FDA-2012-D-0315,E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2cr2-periodic-benefit-risk-evaluation-report-pbrer,
FDA,FDA-2016-D-1703,Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/principles-codevelopment-in-vitro-companion-diagnostic-device-therapeutic-product,
FDA,FDA-2016-D-1673,Updating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/updating-anda-labeling-after-marketing-application-reference-listed-drug-has-been-withdrawn-guidance,
FDA,FDA-2015-D-1839,Guidance for Industry: FDA's Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fdas-policy-declaring-small-amounts-nutrients-and-dietary-ingredients-nutrition,
FDA,FDA-2010-D-0500,"Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-clinical-trials-live-biotherapeutic-products-chemistry-manufacturing-and-control-information,
FDA,FDA-2016-D-1399,"Procedures for Evaluating Appearance Issues and Granting Authorizations for Participation in FDA Advisory Committees: Draft Guidance for the Public, FDA Advisory Committee Members, and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-evaluating-appearance-issues-and-granting-authorizations-participation-fda-advisory,
FDA,FDA-2015-D-1376,Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/leveraging-existing-clinical-data-extrapolation-pediatric-uses-medical-devices,
FDA,FDA-2015-N-4563,"CVM GFI #238 Modified Release Veterinary Parenteral Dosage Forms: Development, Evaluation, and Establishment of Specifications",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-238-modified-release-veterinary-parenteral-dosage-forms-development-evaluation-and,
FDA,FDA-2015-D-3517,"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503b-federal-food-drug-and,
FDA,FDA-2015-D-3539,"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and,
FDA,FDA-2013-D-0446,Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expanded-access-investigational-drugs-treatment-use-questions-and-answers,
FDA,FDA-2009-D-0430,Guidance for Industry: Ingredients Declared as Evaporated Cane Juice,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-ingredients-declared-evaporated-cane-juice,
FDA,FDA-2011-D-0872,Considerations for Use of Histopathology and Its Associated Methodologies to Support Biomarker Qualification Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-histopathology-and-its-associated-methodologies-support-biomarker-qualification,
FDA,FDA-2014-D-0917,Tobacco Product Master Files:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tobacco-product-master-files,
FDA,FDA-2015-D-2325,Requirements for the Submission of Data Needed to Calculate User Fees for Domestic Manufacturers and Importers of Tobacco Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requirements-submission-data-needed-calculate-user-fees-domestic-manufacturers-and-importers-tobacco,
FDA,FDA-2011-F-0172,Guidance for Industry: A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part II,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-labeling-guide-restaurants-and-retail-establishments-selling-away-home-foods-part-0,
FDA,FDA-2014-D-1842,"CPG Sec 540.275 Crabmeat â€“ Fresh and Frozen â€“ Adulteration with Filth, Involving the Presence of Escherichia coli",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540275-crabmeat-fresh-and-frozen-adulteration-filth-involving-presence-escherichia-coli,
FDA,FDA-2015-D-3056,Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices :  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-performance-assessment-digital-pathology-whole-slide-imaging-devices,
FDA,FDA-2015-D-0230,CVM GFI #231 Distributor Labeling for New Animal Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-231-distributor-labeling-new-animal-drugs,
FDA,FDA-2014-D-2065,Radiation Biodosimetry Medical Countermeasure Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/radiation-biodosimetry-medical-countermeasure-devices,
FDA,FDA-2014-D-0044,Guidance for Industry: Exempt Infant Formula Production,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-exempt-infant-formula-production,
FDA,FDA-2012-D-1005,Safety Considerations for Product Design to Minimize Medication Errors Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-product-design-minimize-medication-errors-guidance-industry,
FDA,FDA-2008-D-0592,Contents of a Complete Submission for the Evaluation of Proprietary Names,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contents-complete-submission-evaluation-proprietary-names,
FDA,FDA-2016-D-0938,"CVM GFI #156 Comparability Protocols - Chemistry, Manufacturing, and Controls Information for New Animal Drugs",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-156-comparability-protocols-chemistry-manufacturing-and-controls-information-new-animal,
FDA,FDA-2012-D-0755,"CPG Sec. 690.150 Labeling and Marketing of Dog and Cat Food Diets Intended to Diagnose, Cure, Mitigate, Treat, or Prevent Diseases",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-690150-labeling-and-marketing-dog-and-cat-food-diets-intended-diagnose-cure-mitigate-treat,
FDA,FDA-2015-D-2104,Assessment of Radiofrequency-Induced Heating in the Magnetic Resonance (MR) Environment for Multi-Configuration Passive Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-radiofrequency-induced-heating-magnetic-resonance-mr-environment-multi-configuration,
FDA,FDA-2003-D-0432,CVM GFI #158 Use of Material from Deer and Elk in Animal Feed,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-158-use-material-deer-and-elk-animal-feed,
FDA,FDA-2013-D-0715,Guidance for Industry: Acrylamide in Foods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-acrylamide-foods,
FDA,FDA-2014-D-1180,CVM GFI #203 Ensuring Safety of Animal Feed Maintained and Fed On-Farm,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-203-ensuring-safety-animal-feed-maintained-and-fed-farm,
FDA,FDA-2015-D-0309,"Investigating and Reporting Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Regulated Solely under Section 361 of the Public Health Service Act and 21 CFR Part 1271:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigating-and-reporting-adverse-reactions-related-human-cells-tissues-and-cellular-and-tissue,
FDA,FDA-2014-D-1849,Medical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-devices-and-clinical-trial-design-treatment-or-improvement-appearance-fungally-infected,
FDA,,"Environmental Assessment: Questions and Answers Regarding Drugs With Estrogenic, Androgenic, or Thyroid Activity",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/environmental-assessment-questions-and-answers-regarding-drugs-estrogenic-androgenic-or-thyroid,
FDA,,"Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported Outcome Instrument for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluating-respiratory-symptoms-chronic-obstructive-pulmonary-disease-patient-reported-outcome,
FDA,FDA-2016-D-0631,"Requirements for Transactions with First Responders under Section 582 of the Federal Food, Drug, and Cosmetic Actâ€” Compliance Policy Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requirements-transactions-first-responders-under-section-582-federal-food-drug-and-cosmetic-act,
FDA,FDA-2016-N-0585,"Small Entity Compliance Guide: Alpha-Linolenic Acid, Eicosapentaenoic Acid, and Docosahexaenoic Acid Omega-3 Fatty Acids Nutrient Content Claims",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-alpha-linolenic-acid-eicosapentaenoic-acid-and-docosahexaenoic-acid,
FDA,FDA-2012-D-0096,Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-extent-safety-data-collection-needed-late-stage-premarket-and-postapproval-clinical,
FDA,,Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-related-considerations-low-molecular-weight-heparin-guidance-industry,
FDA,FDA-2010-D-0395,Recommendations for Premarket Notifications for Lamotrigine and Zonisamide Assays:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-premarket-notifications-lamotrigine-and-zonisamide-assays,
FDA,FDA-2011-D-0469,List of Highest Priority Devices for Human Factors Review: Draft Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/list-highest-priority-devices-human-factors-review,
FDA,FDA-2015-D-4599,Applying Human Factors and Usability Engineering to Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices,
FDA,FDA-2015-D-0839,Implanted Blood Access Devices for Hemodialysis:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implanted-blood-access-devices-hemodialysis,
FDA,FDA-2013-D-0749,CVM GFI #226 Target Animal Safety Data Presentation and Statistical Analysis,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-226-target-animal-safety-data-presentation-and-statistical-analysis,
FDA,FDA-2015-D-0288,Premarket Studies of Implantable Minimally Invasive Glaucoma Surgical (MIGS) Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-studies-implantable-minimally-invasive-glaucoma-surgical-migs-devices,
FDA,FDA-2015-D-2261,Premarket Notification Requirements Concerning Gowns Intended for Use in Health Care Settings:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-requirements-concerning-gowns-intended-use-health-care-settings,
FDA,FDA-2012-D-0419,CVM GFI #204 Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for use in Companion Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-204-active-controls-studies-demonstrate-effectiveness-new-animal-drug-use-companion-animals,
FDA,FDA-2012-D-1197,Certification Process of Designated Medical Gases,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/certification-process-designated-medical-gases,
FDA,FDA-2012-D-0529,"Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use â€”:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/organ-specific-warnings-internal-analgesic-antipyretic-and-antirheumatic-drug-products-over-counter-0,
FDA,FDA-2013-D-1630,Qualification of Biomarker â€” Galactomannan in studies of treatments of invasive,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-biomarker-galactomannan-studies-treatments-invasive,
FDA,,Guidance for Industry: Questions and Answers on FDAâ€™s Fortification Policy,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-fdas-fortification-policy,
FDA,FDA-2015-D-2270,Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-immunodeficiency-virus-1-infection-developing-antiretroviral-drugs-treatment,
FDA,,DSCSA Implementation: Product Tracing Requirements for Dispensers â€” Compliance Policy (Revised) Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dscsa-implementation-product-tracing-requirements-dispensers-compliance-policy-revised-guidance,
FDA,FDA-2008-D-0142,Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-evaluation-reformulated-drug-products-and-products-intended-administration,
FDA,FDA-2013-N-1282,National Environmental Policy Act; Environmental Assessments for Tobacco Products; Categorical Exclusions â€“ Small Entity Compliance Guide:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/national-environmental-policy-act-environmental-assessments-tobacco-products-categorical-exclusions,
FDA,FDA-2015-D-0235,CVM GFI #229 Evaluating the Effectiveness of New Animal Drugs for the Reduction of Pathogenic Shiga Toxin-Producing E. coli in Cattle,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-229-evaluating-effectiveness-new-animal-drugs-reduction-pathogenic-shiga-toxin-producing-e,
FDA,FDA-2014-D-2138,Integrated Summary of Effectiveness,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/integrated-summary-effectiveness,
FDA,FDA-2008-D-0449,"Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adverse-event-reporting-outsourcing-facilities-under-section-503b-federal-food-drug-and-cosmetic-act,
FDA,FDA-2015-D-3378,Acceptability of Draft Labeling to Support Abbreviated New Drug Application Approval; Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptability-draft-labeling-support-abbreviated-new-drug-application-approval-guidance-industry,
FDA,FDA-2009-D-0007,Product Development Under the Animal Rule,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-development-under-animal-rule,
FDA,FDA-2015-D-2994,CPG Sec 100.101 Crotalaria spp. Seeds in Grains,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100101-crotalaria-spp-seeds-grains,
FDA,FDA-2013-D-1600,Enforcement Policy for Certain (Provisional) Tobacco Products that FDA Finds Not Substantially Equivalent:  Guidance for Industry and Tobacco Retailers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-certain-provisional-tobacco-products-fda-finds-not-substantially-equivalent,
FDA,,"Use of Donor Screening Tests to Test Donors of Human Cells, Tissues and Cellular and Tissue-Based Products for Infection with Treponema pallidum (Syphilis):  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-donor-screening-tests-test-donors-human-cells-tissues-and-cellular-and-tissue-based-products,
FDA,FDA-2013-D-1213,Nonclinical Evaluation of Endocrine-Related Drug Toxicity,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-evaluation-endocrine-related-drug-toxicity,
FDA,FDA-2014-D-1177,Guidance for Industry: Colored Sea Salt,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-colored-sea-salt,
FDA,,CVM GFI #225 (VICH GL53) Electronic Exchange of Documents: File Format Recommendations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-225-vich-gl53-electronic-exchange-documents-file-format-recommendations,
FDA,FDA-2014-D-0852,Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-and-analysis-shedding-studies-virus-or-bacteria-based-gene-therapy-and-oncolytic-products,
FDA,FDA-2014-D-0640,Uncomplicated Gonorrhea: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/uncomplicated-gonorrhea-developing-drugs-treatment,
FDA,FDA-2014-D-0903,Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/select-updates-non-clinical-engineering-tests-and-recommended-labeling-intravascular-stents-and,
FDA,FDA-2013-D-0920,Providing Submissions in Electronic Format â€” Postmarketing Safety Reports for Vaccines:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-submissions-electronic-format-postmarketing-safety-reports-vaccines,
FDA,FDA-2014-D-0332,Endotoxin Testing Recommendations for Single-Use Intraocular Ophthalmic Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/endotoxin-testing-recommendations-single-use-intraocular-ophthalmic-devices,
FDA,,"Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-entities-considering-whether-register-outsourcing-facilities-under-section-503b-federal,
FDA,FDA-2004-D-0500,Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Prescription Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/brief-summary-and-adequate-directions-use-disclosing-risk-information-consumer-directed-print,
FDA,FDA-2013-D-1009,Over-the-Counter Pediatric Oral Liquid Drug Products Containing Acetaminophen,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/over-counter-pediatric-oral-liquid-drug-products-containing-acetaminophen,
FDA,FDA-2014-D-1473,CVM GFI #220 Use of Nanomaterials in Food for Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-220-use-nanomaterials-food-animals,
FDA,FDA-2009-D-0309,Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen (HLA) Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-premarket-notification-510k-submissions-nucleic-acid-based-human-leukocyte-antigen,
FDA,FDA-2013-D-1358,CVM GFI #198 (VICH GL45) Bracketing and Matrixing Designs For Stability Testing of New Veterinary Drug Substances and Medicinal Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-198-vich-gl45-bracketing-and-matrixing-designs-stability-testing-new-veterinary-drug,
FDA,FDA-2015-N-0007,Analytical Procedures and Methods Validation for Drugs and Biologics,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/analytical-procedures-and-methods-validation-drugs-and-biologics,
FDA,FDA-2014-D-0313,"Meetings with the Office of Orphan Products Development:  Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/meetings-office-orphan-products-development,
FDA,FDA-2011-D-0398,"Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-final-rule-prevention-salmonella-enteritidis-shell,
FDA,FDA-2013-D-0576,Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-early-phase-clinical-trials-cellular-and-gene-therapy-products,
FDA,FDA-2014-D-0248,Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/allowable-excess-volume-and-labeled-vial-fill-size-injectable-drug-and-biological-products,
FDA,FDA-2014-D-0052,Guidance for Industry: Food Allergen Labeling Exemption Petitions and Notifications,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-allergen-labeling-exemption-petitions-and-notifications,
FDA,FDA-2013-D-1566,Naming of Drug Products Containing Salt Drug Substances,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/naming-drug-products-containing-salt-drug-substances,
FDA,FDA-2014-D-1242,Content and Format for Abbreviated 510(k)s for Early Growth Response 1 (EGR1) Gene Fluorescence In-Situ Hybridization (FISH) Test System for Specimen Characterization Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-abbreviated-510ks-early-growth-response-1-egr1-gene-fluorescence-situ,
FDA,FDA-2014-D-0634,CVM GFI #221 Recommendations for Preparation and Submission of Animal Food Additive Petitions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-221-recommendations-preparation-and-submission-animal-food-additive-petitions,
FDA,FDA-2013-D-0928,CVM GFI #218 Cell-Based Products for Animal Use,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-218-cell-based-products-animal-use,
FDA,,"Pregnancy, Lactation, and Reproductive Potential:  Labeling for Human Prescription Drug and Biological Products â€” Content and Format Guidance for Industry  (Small Entity Compliance Guide)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pregnancy-lactation-and-reproductive-potential-labeling-human-prescription-drug-and-biological-0,
FDA,FDA-2015-D-1484,Investigational New Drug Applications Prepared and Submitted by Sponsor-Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-applications-prepared-and-submitted-sponsor-investigators,
FDA,FDA-2011-D-0602,Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-considerations-demonstrating-biosimilarity-therapeutic-protein-product-reference-product,
FDA,FDA-2011-D-0605,Scientific Considerations in Demonstrating Biosimilarity to a Reference Product,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product,
FDA,FDA-2011-D-0432,Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-non-small-cell-lung-cancer-drugs-and-biologics,
FDA,FDA-2014-D-0090,Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/balancing-premarket-and-postmarket-data-collection-devices-subject-premarket-approval,
FDA,FDA-2010-D-0566,CVM GFI #211 Residual Solvents in Animal Drug Products Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-211-residual-solvents-animal-drug-products-questions-and-answers,
FDA,FDA-2013-D-0045,Abuse-Deterrent Opioids-Evaluation and Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/abuse-deterrent-opioids-evaluation-and-labeling,
FDA,,Critical Path Innovation Meetings,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/critical-path-innovation-meetings,
FDA,FDA-2014-D-1288,Electronic Submission of Lot Distribution Reports:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-lot-distribution-reports,
FDA,FDA-2011-D-0293,Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling :  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reprocessing-medical-devices-health-care-settings-validation-methods-and-labeling,
FDA,FDA-2011-F-0172,Small Entity Compliance Guide: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-nutrition-labeling-standard-menu-items-restaurants-and-similar-retail,
FDA,FDA-2010-D-0166,CVM GFI #208 (VICH GL49) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-208-vich-gl49-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,
FDA,FDA-2010-D-0165,CVM GFI #207 (VICH GL48) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs In Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-207-vich-gl48-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,
FDA,FDA-2014-D-0663,"Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-need-and-content-environmental-assessments-gene-therapies-vectored-vaccines-and-related,
FDA,FDA-2015-D-0152,Alcoholism:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alcoholism-developing-drugs-treatment,
FDA,FDA-2012-D-0630,Safety Considerations to Mitigate the Risks of Misconnections with Small-bore Connectors Intended for Enteral Applications:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-mitigate-risks-misconnections-small-bore-connectors-intended-enteral,
FDA,FDA-2013-D-0068,S10 Photosafety Evaluation of Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s10-photosafety-evaluation-pharmaceuticals,
FDA,FDA-2014-D-2254,DSCSA Implementation: Product Tracing Requirements â€” Compliance Policy,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dscsa-implementation-product-tracing-requirements-compliance-policy,
FDA,FDA-2012-D-1092,Minimizing Risk for Children's Toy Laser Products:   Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/minimizing-risk-childrens-toy-laser-products,
FDA,FDA-2014-D-1953,"Providing Regulatory Submissions in Electronic Format â€” Submissions Under Section 745A(a) of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-submissions-under-section-745aa-federal-food-drug,
FDA,FDA-2014-D-1842,"CPG Sec 540.275 (Draft) Crabmeat - Fresh and Frozen - Adulteration with Filth, Involving the Presence of Escherichia coli",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540275-draft-crabmeat-fresh-and-frozen-adulteration-filth-involving-presence-escherichia,
FDA,FDA-2013-D-1067,Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products â€” Content and Format,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-counseling-information-section-labeling-human-prescription-drug-and-biological-products,
FDA,FDA-2014-D-2083,DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dscsa-implementation-annual-reporting-prescription-drug-wholesale-distributors-and-third-party,
FDA,FDA-2013-D-0295,SUPAC: Manufacturing Equipment Addendum,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-manufacturing-equipment-addendum,
FDA,FDA-2010-D-0194,Recommendations for Labeling Medical Products to Inform Users that the Product or Product Container is not Made with Natural Rubber Latex:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-labeling-medical-products-inform-users-product-or-product-container-not-made-natural,
FDA,FDA-2013-D-0168,Infusion Pumps Total Product Life Cycle:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/infusion-pumps-total-product-life-cycle,
FDA,,CPG Sec 540.700 Labeling of Processed and Blended Seafood Products Made Primarily with Fish Protein,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540700-labeling-processed-and-blended-seafood-products-made-primarily-fish-protein,
FDA,FDA-1999-D-3528,Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture:  Final Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-application-biological-products-human-blood-and-blood-components-intended,
FDA,FDA-2013-N-1429,"Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/registration-human-drug-compounding-outsourcing-facilities-under-section-503b-federal-food-drug-and,
FDA,FDA-2012-D-1161,Design Considerations for Devices Intended for Home Use:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-considerations-devices-intended-home-use,
FDA,FDA-2012-D-1120,Vaginal Microbicides:Development for the Prevention of HIV Infection PDF,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vaginal-microbicidesdevelopment-prevention-hiv-infection-pdf,
FDA,FDA-2013-D-0258,Molecular Diagnostic Instruments with Combined Functions:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/molecular-diagnostic-instruments-combined-functions,
FDA,FDA-2013-D-0984,Specification of the Unique Facility Identifier (UFI) System for Drug Establishment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/specification-unique-facility-identifier-ufi-system-drug-establishment,
FDA,FDA-2013-D-1675,New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/new-chemical-entity-exclusivity-determinations-certain-fixed-combination-drug-products,
FDA,FDA-2013-D-0114,Distinguishing Medical Device Recalls from Medical Device Enhancements:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distinguishing-medical-device-recalls-medical-device-enhancements,
FDA,FDA-2002-D-0268,CVM GFI #143 (VICH GL30) Pharmacovigilance of Veterinary Medicinal Products: Controlled List of Terms,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-143-vich-gl30-pharmacovigilance-veterinary-medicinal-products-controlled-list-terms,
FDA,FDA-2014-D-1352,CVM GFI #224 (Supplement to VICH GL52) Supplemental Examples For Illustrating Statistical Concepts Described in the VICH In Vivo Bioequivalence Guidance GL52,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-224-supplement-vich-gl52-supplemental-examples-illustrating-statistical-concepts-described,
FDA,FDA-2013-D-1601,Custom Device Exemption:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/custom-device-exemption,
FDA,FDA-2012-D-1057,Highly Multiplexed Microbiological/Medical Countermeasure In Vitro Nucleic Acid Based Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/highly-multiplexed-microbiologicalmedical-countermeasure-in-vitro-nucleic-acid-based-diagnostic-devices,
FDA,FDA-2011-D-0817,Evaluation of Sex-Specific Data in Medical Device Clinical Studies - Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-sex-specific-data-medical-device-clinical-studies-guidance-industry-and-food-and-drug,
FDA,FDA-2020-D-0957,"Unique Device Identifier System: Frequently Asked Questions, Vol. 1 :  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identifier-system-frequently-asked-questions-vol-1,
FDA,FDA-2011-D-0790,"FDA Decisions for Investigational Device Exemption Clinical Investigations:  Guidance for Sponsors, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-decisions-investigational-device-exemption-clinical-investigations,
FDA,FDA-2013-D-0092,Immunogenicity Assessment for Therapeutic Protein Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-assessment-therapeutic-protein-products,
FDA,FDA-2011-D-0790,Unique Device Identification System: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/unique-device-identification-system-small-entity-compliance-guide,
FDA,FDA-2014-D-0968,Upper Facial Lines:  Developing Botulinum Toxin Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/upper-facial-lines-developing-botulinum-toxin-drug-products,
FDA,FDA-2011-D-0215,In Vitro Companion Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-companion-diagnostic-devices,
FDA,FDA-2013-D-1165,Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reference-product-exclusivity-biological-products-filed-under-section-351a-phs-act,
FDA,FDA-2010-D-0432,CVM GFI #201 SECG for The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-201-secg-index-legally-marketed-unapproved-new-animal-drugs-minor-species,
FDA,FDA-2010-D-0435,CVM GFI #200 SECG for Designation of New Animal Drugs for Minor Uses or Minor Species,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-200-secg-designation-new-animal-drugs-minor-uses-or-minor-species,
FDA,FDA-2011-D-0652,The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k,
FDA,FDA-2014-D-0829,Reporting Drug Sample Information Under Section 6004 of the Affordable Care Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-drug-sample-information-under-section-6004-affordable-care-act,
FDA,FDA-2011-D-0587,Neglected Tropical Diseases of the Developing World: Developing Drugs for Treatment or Prevention,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/neglected-tropical-diseases-developing-world-developing-drugs-treatment-or-prevention,
FDA,FDA-2013-D-1444,"Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacy-compounding-human-drug-products-under-section-503a-federal-food-drug-and-cosmetic-act,
FDA,FDA-2011-D-0490,"Guidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that Are Color Additives",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-assessing-effects-significant-manufacturing-process-changes-including-emerging,
FDA,FDA-2013-D-0636,Global Unique Device Identification Database (GUDID):  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/global-unique-device-identification-database-gudid,
FDA,FDA-2005-N-0404,Small Entity Compliance Guide: Gluten-Free Labeling of Foods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-gluten-free-labeling-foods,
FDA,FDA-2011-D-0489,Guidance for Industry: Safety of Nanomaterials in Cosmetic Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-safety-nanomaterials-cosmetic-products,
FDA,FDA-2010-D-0530,Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considering-whether-fda-regulated-product-involves-application-nanotechnology,
FDA,FDA-2020-D-0957,Criteria for Significant Risk Investigations of Magnetic Resonance Diagnostic Devices - Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/criteria-significant-risk-investigations-magnetic-resonance-diagnostic-devices-guidance-industry-and,
FDA,FDA-2014-D-0397,Internet/Social Media Platforms with Character Space Limitationsâ€” Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/internetsocial-media-platforms-character-space-limitations-presenting-risk-and-benefit-information,
FDA,FDA-2014-D-0397,Internet/Social Media Platforms with Character Space Limitationsâ€” Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/internetsocial-media-platforms-character-space-limitations-presenting-risk-and-benefit-information-0,
FDA,FDA-2014-D-0397,Drug Master Files: Guidelines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-master-files-guidelines,
FDA,FDA-2009-D-0011,Q4B Annex 6: Uniformity of Dosage Units General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-6-uniformity-dosage-units-general-chapter,
FDA,FDA-2014-D-0758,Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Productsâ€”Recommended Practices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distributing-scientific-and-medical-publications-risk-information-approved-prescription-drugs-and,
FDA,FDA-2014-D-0033,"Guidance for Industry: Demonstration of the Quality Factor Requirements Under 21 CFR 106.96(i) for ""Eligible"" Infant Formulas",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-demonstration-quality-factor-requirements-under-21-cfr-10696i-eligible-infant,
FDA,FDA-2013-D-0126,CPG Sec 100.250 Food Facility Registration (Human and Animal Food),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100250-food-facility-registration-human-and-animal-food,
FDA,FDA-2013-D-0575,Expedited Programs for Serious Conditions | Drugs and Biologics,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics,
FDA,FDA-2003-D-0307,CVM GFI #79 Dispute Resolution Procedures for Science-Based Decisions on Products Regulated by CVM,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-79-dispute-resolution-procedures-science-based-decisions-products-regulated-cvm,
FDA,FDA-2011-D-0835,"Considerations When Transferring Clinical Investigation Oversight to Another IRB:  Guidance for IRBs, Clinical Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-when-transferring-clinical-investigation-oversight-another-irb,
FDA,FDA-2014-D-0547,"ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-stability-testing-drug-substances-and-products-questions-and-answers,
FDA,FDA-2012-D-0288,CVM GFI #219 (VICH GL51) Statistical Evaluation of Stability Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-219-vich-gl51-statistical-evaluation-stability-data,
FDA,FDA-2010-D-0589,Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia-developing-drugs,
FDA,FDA-2013-D-0117,Providing Information about Pediatric Uses of Medical Devices:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-information-about-pediatric-uses-medical-devices,
FDA,FDA-2011-D-0674,Types of Communication During the Review of Medical Device Submissions:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/types-communication-during-review-medical-device-submissions,
FDA,FDA-2013-N-1421,Small Entity Compliance Guide: What You Need to Know About Establishment and Maintenance of Records,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-what-you-need-know-about-establishment-and-maintenance-records,
FDA,FDA-2013-D-0147,"Guidance for Industry: FDA Records Access Authority Under Sections 414 and 704 of the Federal Food, Drug, & Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fda-records-access-authority-under-sections-414-and-704-federal-food-drug-cosmetic,
FDA,,Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interpreting-sameness-monoclonal-antibody-products-under-orphan-drug-regulations,
FDA,FDA-1999-D-0178,"CPG Sec 550.050 Canned Ackee, Frozen Ackee, and Other Ackee Products- Hypoglycin A Toxin",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550050-canned-ackee-frozen-ackee-and-other-ackee-products-hypoglycin-toxin,
FDA,FDA-2014-D-0261,"The Meaning of ""Spouse"" and ""Family"" in FDA's Regulations after the Supreme Court's Ruling in United States v. Windsor: Questions and Answers:  Guidance for Industry, Consumers, and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/meaning-spouse-and-family-fdas-regulations-after-supreme-courts-ruling-united-states-v-windsor,
FDA,FDA-2020-D-0957,Medical Device Tracking :  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-tracking,
FDA,FDA-2003-D-0367,Premarket Assessment of Pediatric Medical Devices:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-assessment-pediatric-medical-devices,
FDA,FDA-2014-D-0204,Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs â€” General Considerations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-and-bioequivalence-studies-submitted-ndas-or-inds-general-considerations,
FDA,FDA-2014-D-0264,Chronic Fatigue Syndrome/Myalgic Encephalomyelitis:  Developing Drug Products for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-fatigue-syndromemyalgic-encephalomyelitis-developing-drug-products-treatment,
FDA,FDA-2010-D-0283,CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cmc-postapproval-manufacturing-changes-be-documented-annual-reports,
FDA,FDA-2006-D-0157,"IND Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-applications-minimally-manipulated-unrelated-allogeneic-placentalumbilical-cord-blood-intended,
FDA,FDA-2009-D-0490,"BLA for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bla-minimally-manipulated-unrelated-allogeneic-placentalumbilical-cord-blood-intended-hematopoietic,
FDA,FDA-2014-D-0180,"Public Availability of Advisory Committee Members' Financial Interest Information and Waivers:  Guidance for the Public, FDA Advisory Committee Members, and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/public-availability-advisory-committee-members-financial-interest-information-and-waivers,
FDA,,Antiviral Product Development â€” Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV-1 Resistance Data: Attachment to the Guidance: Draft Draft Guidance: This draft guidance updates the final guidance posted 6/2/06,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-4,
FDA,,The Electronic Transmission of Individual Case Safety Reports Implementation Guide â€” Data Elements and Message Specification,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-transmission-individual-case-safety-reports-implementation-guide-data-elements-and,
FDA,FDA-2008-N-0393,"Questions and Answers about eMDR - Electronic Medical Device Reporting - Guidance for Industry, User Facilities and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-about-emdr-electronic-medical-device-reporting-guidance-industry-user,
FDA,FDA-2007-D-0077,Providing Regulatory Submissions in Electronic Format--Receipt Date:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-receipt-date,
FDA,FDA-2009-D-0542,Guidance for Industry: Distinguishing Liquid Dietary Supplements from Beverages,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-distinguishing-liquid-dietary-supplements-beverages,
FDA,FDA-2009-D-0542,"Guidance for Industry: Considerations Regarding Substances Added to Foods, Including Beverages and Dietary Supplements",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-considerations-regarding-substances-added-foods-including-beverages-and-dietary,
FDA,FDA-2013-N-1430,Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fulfilling-regulatory-requirements-postmarketing-submissions-interactive-promotional-media,
FDA,FDA-2009-D-0136,Community-Acquired Bacterial Pneumonia:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/community-acquired-bacterial-pneumonia-developing-drugs-treatment,
FDA,FDA-2013-D-1630,Attachement - Qualification Process for Drug Development Tools: Qualification of Exacerbations of Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute Bacterial Exacerbation of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/attachement-qualification-process-drug-development-tools-qualification-exacerbations-chronic,
FDA,FDA-2010-D-0319,Dear Health Care Provider Letters: Improving Communication of Important Safety Information,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dear-health-care-provider-letters-improving-communication-important-safety-information,
FDA,,Guidance for Industry: Dear Manufacturer Letter Regarding Changes to FDA's Administration of Process Filings (Forms FDA 2541a and FDA 2541c) for Acidified Foods and Low-Acid Canned Foods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-dear-manufacturer-letter-regarding-changes-fdas-administration-process-filings,
FDA,FDA-2011-D-0889,CVM GFI #213 New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-213-new-animal-drugs-and-new-animal-drug-combination-products-administered-or-medicated-feed,
FDA,FDA-2010-D-0094,FDA's Strategy on Antimicrobial Resistance - Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fdas-strategy-antimicrobial-resistance-questions-and-answers,
FDA,,"CPG Sec. 460.200 Pharmacy Compounding (Withdrawn December 4, 2013)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460200-pharmacy-compounding-withdrawn-december-4-2013,
FDA,FDA-2011-D-0305,Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-in-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only,
FDA,FDA-2011-D-0567,"Design Considerations for Pivotal Clinical Investigations for Medical Devices:  Guidance for Industry, Clinical Investigators, Institutional Review Boards and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-considerations-pivotal-clinical-investigations-medical-devices,
FDA,FDA-2012-D-1038,Preclinical Assessment of Investigational Cellular and Gene Therapy Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preclinical-assessment-investigational-cellular-and-gene-therapy-products,
FDA,FDA-2013-D-1181,Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions: Annex 14: Bacterial Endotoxins Test General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-annex-14-bacterial-endotoxins,
FDA,FDA-2010-D-0343,Acute Bacterial Skin and Skin Structure Infections:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-bacterial-skin-and-skin-structure-infections-developing-drugs-treatment,
FDA,FDA-2011-D-0787,"Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies:  Guidance for Industry and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-device-exemptions-ides-early-feasibility-medical-device-clinical-studies-including,
FDA,FDA-2013-D-1088,CVM GFI #223 Small Entity Compliance Guide Declaring Color Additives in Animal Foods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-223-small-entity-compliance-guide-declaring-color-additives-animal-foods,
FDA,FDA-2010-D-0643,Electronic Source Data in Clinical Investigations:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-source-data-clinical-investigations,
FDA,FDA-2010-D-0503,"Investigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND:  Guidance for Clinical Investigators, Sponsors, and IRBs",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-applications-inds-determining-whether-human-research-studies-can-be,
FDA,FDA-2007-D-0372,Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-adverse-event-reporting-and-recordkeeping-dietary,
FDA,FDA-2012-D-0847,"IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed:  Guidance for IRBs, Clinical Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irb-responsibilities-reviewing-qualifications-investigators-adequacy-research-sites-and,
FDA,FDA-2010-D-0277,Compliance with Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-regulations-restricting-sale-and-distribution-cigarettes-and-smokeless-tobacco-protect,
FDA,FDA-2006-D-0300,Radio Frequency Wireless Technology in Medical Devices - Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/radio-frequency-wireless-technology-medical-devices-guidance-industry-and-fda-staff,
FDA,FDA-2011-D-0597,Oversight of Clinical Investigations â€” A Risk-Based Approach to Monitoring:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oversight-clinical-investigations-risk-based-approach-monitoring,
FDA,FDA-2011-D-0164,"Safety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-labeling-changes-implementation-section-505o4-federal-food-drug-and-cosmetic-act,
FDA,FDA-2013-D-0755,Providing Submissions in Electronic Format â€“ Postmarket Non-Expedited ICSRs Technical Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-submissions-electronic-format-postmarket-non-expedited-icsrs-technical-questions-and,
FDA,FDA-2010-D-0378,CPG Sec  690.800 Compliance Policy Guide Salmonella in Food for Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-690800-compliance-policy-guide-salmonella-food-animals,
FDA,FDA-2012-D-0083,Heparin for Drug and Medical Device Use:  Monitoring Crude Heparin for Quality:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/heparin-drug-and-medical-device-use-monitoring-crude-heparin-quality,
FDA,FDA-2012-D-0938,ANDAs: Stability Testing of Drug Substances and Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-stability-testing-drug-substances-and-products,
FDA,FDA-2010-D-0616,Codevelopment of Two or More New Investigational Drugs for Use in Combination,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/codevelopment-two-or-more-new-investigational-drugs-use-combination,
FDA,FDA-2009-D-0179,"Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products:  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-pen-jet-and-related-injectors-intended-use-drugs-and-biological-products,
FDA,,Draft Guidance for Industry: Cosmetic Good Manufacturing Practices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-cosmetic-good-manufacturing-practices,
FDA,FDA-2013-D-0571,Rheumatoid Arthritis: Developing Drug Products for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rheumatoid-arthritis-developing-drug-products-treatment,
FDA,,Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Annex 13: Bulk Density and Tapped Density of Powders General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-annex-13-bulk-density-and-tapped,
FDA,,Annex 13 Bulk Density and Tapped Density of Powders General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/annex-13-bulk-density-and-tapped-density-powders-general-chapter,
FDA,,"The Open Public Hearing at FDA Advisory Committee Meetings:  Guidance for the Public, FDA Advisory Committee Members, and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/open-public-hearing-fda-advisory-committee-meetings,
FDA,FDA-2011-D-0057,Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic,
FDA,FDA-2008-D-0642,Assay Migration Studies for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assay-migration-studies-in-vitro-diagnostic-devices,
FDA,FDA-2011-D-0104,Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-penicillin-beta-lactam-drugs-cgmp-framework-preventing-cross-contamination,
FDA,FDA-2011-D-0620,Self-Selection Studies for Nonprescription Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/self-selection-studies-nonprescription-drug-products,
FDA,FDA-2011-D-0916,Medical Device Classification Product Codes - Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-classification-product-codes-guidance-industry-and-food-and-drug-administration-staff,
FDA,FDA-2007-D-0069,"Exception from Informed Consent Requirements for Emergency Research:  Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exception-informed-consent-requirements-emergency-research,
FDA,FDA-2006-D-0464,Blood Establishment Computer System Validation in the User's Facility:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/blood-establishment-computer-system-validation-users-facility,
FDA,FDA-2013-D-0362,Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4: Draft Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/glass-syringes-delivering-drug-and-biological-products-technical-information-supplement,
FDA,FDA-2008-D-0095,Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia burgdorferi - Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-performance-characteristics-in-vitro-diagnostic-devices-detection-antibodies-borrelia,
FDA,FDA-2008-D-0470,"Tablet Scoring:Nomenclature, Labeling, and Data for Evaluation",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tablet-scoringnomenclature-labeling-and-data-evaluation,
FDA,FDA-2011-D-0595,M3(R2)Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals: Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m3r2nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization,
FDA,FDA-2011-D-0643,Small Entity Compliance Guide: What You Need To Know About Administrative Detention of Foods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-what-you-need-know-about-administrative-detention-foods,
FDA,FDA-2009-D-0010,Investigational Device Exemption (IDE) Guidance for Retinal Prostheses:  Guidance for Industry and FDA  Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-device-exemption-ide-guidance-retinal-prostheses,
FDA,FDA-2007-D-0205,Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pulse-oximeters-premarket-notification-submissions-510ks-guidance-industry-and-food-and-drug,
FDA,FDA-2005-D-0153,Labeling for Human Prescription Drug and Biological Products - Implementing the PLR Content and Format Requirements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-human-prescription-drug-and-biological-products-implementing-plr-content-and-format,
FDA,FDA-2005-D-0282,Antiviral Product Development â€” Conducting and Submitting Virology Studies to the Agency Guidance for Submitting HCV Resistance Data -Attachment to Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-3,
FDA,FDA-2009-D-0395,Clinical Study Designs for Surgical Ablation Devices for Treatment of Atrial Fibrillation - Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-study-designs-surgical-ablation-devices-treatment-atrial-fibrillation-guidance-industry-and,
FDA,FDA-2020-D-0957,CPG Sec. 390.225 Early Defects or Noncompliance - 21 CFR 1004.6,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390225-early-defects-or-noncompliance-21-cfr-10046,
FDA,FDA-1999-D-0742,"Financial Disclosure by Clinical Investigators:  Guidance for Clinical Investigators, Industry,and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/financial-disclosure-clinical-investigators,
FDA,,E3 Structure and Content of Clinical Study Reports - Questions and Answers (R1),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e3-structure-and-content-clinical-study-reports-questions-and-answers-r1,
FDA,FDA-2011-D-0082,Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacogenomics-premarket-evaluation-early-phase-clinical-studies-and-recommendations,
FDA,FDA-2012-D-1240,"Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA: Draft Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submissions-postapproval-modifications-combination-product-approved-under-bla-nda-or-pma,
FDA,,Guidance for Industry: Food Labeling Guide,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-labeling-guide,
FDA,FDA-2010-D-0482,Safety Reporting Requirements for INDs and BA/BE Studies:  Guidance for Industry and Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-reporting-requirements-inds-and-babe-studies,
FDA,FDA-2010-D-0482,Safety Reporting Requirements for INDs (Investigational New Drug Applications) and BA/BE (Bioavailability/Bioequivalence) Studies:  Guidance for Industry and Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-reporting-requirements-inds-investigational-new-drug-applications-and-babe,
FDA,,Limiting the Use of Certain Phthalates as Excipients in CDER-Regulated Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/limiting-use-certain-phthalates-excipients-cder-regulated-products,
FDA,FDA-2012-D-1135,Labeling and Effectiveness Testing: Sunscreen Drug Products for Over-The-Counter Human Use â€” Small Entity Compliance Guide:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-and-effectiveness-testing-sunscreen-drug-products-over-counter-human-use-small-entity,
FDA,,Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-applications-positron-emission-tomography-pet-drugs,
FDA,FDA-2012-D-0081,FDA Oversight of PET Drug Products -- Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-oversight-pet-drug-products-questions-and-answers,
FDA,FDA-2011-D-0784,Q11 Development and Manufacture of Drug Substances,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q11-development-and-manufacture-drug-substances,
FDA,,CVM GFI #217 Evaluating the Effectiveness of Anticoccidial Drugs in Food-Producing Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-217-evaluating-effectiveness-anticoccidial-drugs-food-producing-animals,
FDA,,"Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, And Antiasthmatic Drug Products for Over-the-Counter Human Use (Small Entity Compliance Guide):  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-bronchodilators-cold-cough-allergy-bronchodilator-and-antiasthmatic-drug-products-over,
FDA,FDA-2011-D-0464,The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-investigational-device-exemption-ide-and-premarket-approval-pma-applications-artificial,
FDA,FDA-2020-D-0957,CPG Sec. 420.500 *Interference with Compendial Tests* (revised 11/14/2012),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420500-interference-compendial-tests-revised-11142012,
FDA,,"CPG Sec 550.050 (Draft) Canned Ackee, Frozen Ackee, and Other Ackee Products â€“ Hypoglycin A Toxin",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550050-draft-canned-ackee-frozen-ackee-and-other-ackee-products-hypoglycin-toxin,
FDA,,Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect - 21 CFR 1003.11,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-guide-sec-390200-determination-secretary-product-fails-comply-or-has-defect-21-cfr,
FDA,,E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs  - Questions and Answers (R1),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic,
FDA,,Acute Bacterial Sinusitis â€” Developing Antimicrobial Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-bacterial-sinusitis-developing-antimicrobial-drugs-treatment,
FDA,,Guidance for Industry Acute Bacterial Sinusitis: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-acute-bacterial-sinusitis-developing-drugs-treatment,
FDA,FDA-2008-D-0419,"Use of Nucleic Acid Tests on Pooled and Individual Samples From Donors of Whole Blood and Blood Components, Including Source Plasma, to Reduce the Risk of Transmission of Hepatitis B Virus:  Final Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-nucleic-acid-tests-pooled-and-individual-samples-donors-whole-blood-and-blood-components,
FDA,FDA-2011-D-0799,Acute Bacterial Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-bacterial-exacerbations-chronic-bronchitis-patients-chronic-obstructive-pulmonary-disease-0,
FDA,,Guidance for Industry: Acute Bacterial Otitis Media: Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-acute-bacterial-otitis-media-developing-drugs-treatment,
FDA,FDA-2008-D-0419,Acute Bacterial Exacerbations of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease:  Acute Bacterial Exacerbations of Chronic Bronchitis in Patients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-bacterial-exacerbations-chronic-bronchitis-patients-chronic-obstructive-pulmonary-disease,
FDA,FDA-2001-D-0254,Pre-Storage Leukocyte Reduction of Whole Blood and Blood Components Intended for Transfusion:  Final Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pre-storage-leukocyte-reduction-whole-blood-and-blood-components-intended-transfusion,
FDA,,"Q8, Q9, & Q10 Questions and Answers -- Appendix:  Q&As from Training Sessions (Q8, Q9, & Q10 Points to Consider)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q8-q9-q10-questions-and-answers-appendix-qas-training-sessions-q8-q9-q10-points-consider,
FDA,,Guidance for Industry:  Suicidal Ideation and Behavior:  Prospective Assessment of Occurrence in Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-suicidal-ideation-and-behavior-prospective-assessment-occurrence-clinical-trials,
FDA,,CPG Sec. 490.200 Parametric Release of Parenteral Drug Products Terminally Sterilized by Moist Heat,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-490200-parametric-release-parenteral-drug-products-terminally-sterilized-moist-heat,
FDA,,Pyrogen and Endotoxins Testing: Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers,
FDA,,Guidance for Industry:  Pyrogen and Endotoxins Testing: Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-pyrogen-and-endotoxins-testing-questions-and-answers,
FDA,FDA-2012-D-0544,"""Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications""",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toll-free-number-labeling-and-related-requirements-over-counter-and-prescription-drugs-marketed,
FDA,FDA-2010-D-0146,Irritable Bowel Syndrome -- Clinical Evaluation of Products for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irritable-bowel-syndrome-clinical-evaluation-products-treatment,
FDA,FDA-2008-D-0178,S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s2r1-genotoxicity-testing-and-data-interpretation-pharmaceuticals-intended-human-use,
FDA,FDA-2009-D-0573,S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6r1-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals,
FDA,FDA-2011-D-0021,Size of Beads in Drug Products Labeled for Sprinkle Rev.1:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/size-beads-drug-products-labeled-sprinkle-rev1,
FDA,FDA-2012-D-0316,Small Entity Compliance Guide: Establishing an Allowable Level for di (2-ethylhexyl)phthalate in Bottled Water,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-establishing-allowable-level-di-2-ethylhexylphthalate-bottled-water,
FDA,FDA-2010-D-0094,CVM GFI #209 The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-209-judicious-use-medically-important-antimicrobial-drugs-food-producing-animals,
FDA,FDA-2011-D-0691,Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/media-fills-validation-aseptic-preparations-positron-emission-tomography,
FDA,FDA-2012-D-0071,"Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-harmful-and-potentially-harmful-constituents-tobacco-products-and-tobacco-smoke-under,
FDA,FDA-2012-D-0049,Modified Risk Tobacco Product Applications: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/modified-risk-tobacco-product-applications,
FDA,FDA-2011-D-0112,Guidance for Industry: Testing for Salmonella Species in Human Foods and Direct-Human-Contact Animal Foods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-testing-salmonella-species-human-foods-and-direct-human-contact-animal-foods,
FDA,FDA-2011-D-0091,"CVM GFI #216 Chemistry, Manufacturing, and Controls (CMC) Information - Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-216-chemistry-manufacturing-and-controls-cmc-information-fermentation-derived-intermediates,
FDA,FDA-2009-D-0528,FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND: Frequently Asked Questions:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-acceptance-foreign-clinical-studies-not-conducted-under-ind-frequently-asked-questions,
FDA,,E7 Studies in Support of Special Populations; Geriatrics; Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e7-studies-support-special-populations-geriatrics-questions-and-answers,
FDA,FDA-2009-D-0605,"IRB Continuing Review After Clinical Investigation Approval:  Guidance for IRBs, Clinical Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irb-continuing-review-after-clinical-investigation-approval,
FDA,,"Questions and Answers on Informed Consent Elements, 21 CFR Â§ 50.25(c):  Guidance for Sponsors, Investigators, and Institutional Review Boards",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-informed-consent-elements-21-cfr-ss-5025c,
FDA,,"Guidance for Industry: Questions and Answers Regarding Establishment and Maintenance of Records By Persons Who Manufacture, Process, Pack, Transport, Distribute, Receive, Hold, or Import Food (Edition 5)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-establishment-and-maintenance-records-persons-who,
FDA,FDA-2011-D-0598,"CPG Sec. 400.210, Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400210-radiofrequency-identification-feasibility-studies-and-pilot-programs-drugs,
FDA,FDA-2011-D-0868,Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/responding-unsolicited-requests-label-information-about-prescription-drugs-and-medical-devices,
FDA,FDA-2010-D-0313,"Guidance for Industry: Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-prevention-salmonella-enteritidis-shell-eggs-during-production-storage-and,
FDA,FDA-2011-D-0855,Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preparation-ides-and-inds-products-intended-repair-or-replace-knee-cartilage,
FDA,FDA–2008–D–0659,"Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-tissue-practice-cgtp-and-additional-requirements-manufacturers-human-cells-tissues-and,
FDA,FDA-2007-D-0020,General Principles for the Development of Vaccines to Protect Against Global Infectious Diseases:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-development-vaccines-protect-against-global-infectious-diseases,
FDA,,Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-evaluation-late-radiation-toxicity-therapeutic-radiopharmaceuticals,
FDA,,Medication Guides â€” Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medication-guides-distribution-requirements-and-inclusion-risk-evaluation-and-mitigation-strategies,
FDA,,"Q8, Q9, and Q10 Questions and Answers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q8-q9-and-q10-questions-and-answers,
FDA,FDA-2008-D-0263,Requalification Method for Reentry of Donors Who Test Hepatitis B Surface Antigen (HBsAg) Positive Following a Recent Vaccination against Hepatitis B Virus Infection:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requalification-method-reentry-donors-who-test-hepatitis-b-surface-antigen-hbsag-positive-following,
FDA,,"Guidance for Industry: Letter to Firms that Grow, Harvest, Sort, Pack, Process, or Ship Fresh Cantaloupe",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-letter-firms-grow-harvest-sort-pack-process-or-ship-fresh-cantaloupe,
FDA,FDA-2011-D-0733,Guidance for Industry: Evaluating the Safety of Flood-affected Food Crops for Human Consumption,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-evaluating-safety-flood-affected-food-crops-human-consumption,
FDA,FDA-2011-D-0694,"Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products â€” Content and Format",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/warnings-and-precautions-contraindications-and-boxed-warning-sections-labeling-human-prescription,
FDA,FDA-2009-D-0212,Incorporation of  Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/incorporation-physical-chemical-identifiers-solid-oral-dosage-form-drug-products-anticounterfeiting,
FDA,FDA-2011-D-0721,Guidance for Industry: Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-implementation-fee-provisions-section-107-fda-food-safety-modernization-act,
FDA,FDA-2009-D-0427,Clinical Considerations for Therapeutic Cancer Vaccines:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-considerations-therapeutic-cancer-vaccines,
FDA,FDA-2011-D-0023,Time and Extent Applications for Nonprescription Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/time-and-extent-applications-nonprescription-drug-products,
FDA,FDA-2004-D-0438,CVM GFI #215 Target Animal Safety & Effectiveness Protocol Development & Submission,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-215-target-animal-safety-effectiveness-protocol-development-submission,
FDA,FDA-2011-D-0212,Applications for Premarket Review of New Tobacco Products: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-premarket-review-new-tobacco-products,
FDA,FDA-2011-D-0108,"User Fee Waivers, Reductions, and Refunds for Drug and Biological Products",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fee-waivers-reductions-and-refunds-drug-and-biological-products,
FDA,FDA-1999-N-0082,Reproductive and Developmental Toxicities -- Integrating Study Results to Assess Concerns,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reproductive-and-developmental-toxicities-integrating-study-results-assess-concerns,
FDA,FDA-2010-D-8228,CVM GFI #206 (VICH GL47) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Comparative Metabolism Studies in Laboratory Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-206-vich-gl47-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,
FDA,FDA-2010-D-8229,CVM GFI #205 (VICH GL46) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals:  Metabolism Study to Determine the Quantity and Identify the Nature of Residues (MRK),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-205-vich-gl46-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food,
FDA,FDA-2011-D-0480,Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-warning-plans-cigarettes-and-smokeless-tobacco-products,
FDA,FDA-2000-D-1542,"PET Drug Applications - Content and Format for NDAs and ANDAs:  Attachment I: Sample formats for chemistry, manufacturing, and controls (CMC) sections_2011",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pet-drug-applications-content-and-format-ndas-and-andas-attachment-i-sample-formats-chemistry,
FDA,FDA-2009-D-0271,PET Drug Applications - Content and Format for NDAs and ANDAs_2011,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pet-drug-applications-content-and-format-ndas-and-andas_2011,
FDA,,Guidance for Industry:  Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Pistachio-Derived Product as an Ingredient,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-measures-address-risk-contamination-salmonella-species-food-containing-pistachio,
FDA,FDA-2008-D-0386,E2F Development Safety Update Report,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2f-development-safety-update-report,
FDA,HHS-OPHS-2011-0014,Exculpatory Language in Informed Consent,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exculpatory-language-informed-consent,
FDA,FDA-2010-D-0246,Residual Drug in Transdermal and Related Drug Delivery Systems:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/residual-drug-transdermal-and-related-drug-delivery-systems,
FDA,FDA-2011-N-0179,Guidance for Industry: What You Need to Know About Prior Notice of Imported Food Shipments,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-what-you-need-know-about-prior-notice-imported-food-shipments,
FDA,FDA-2009-D-0324,"E16 Biomarkers Related to Drug or Biotechnology Product Development:  Context, Structure, and Format of Qualification Submissions",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e16-biomarkers-related-drug-or-biotechnology-product-development-context-structure-and-format,
FDA,FDA-2011-D-0541,PET Drugs--Current Good Manufacturing Practice (CGMP); Small Entity Compliance Guide,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pet-drugs-current-good-manufacturing-practice-cgmp-small-entity-compliance-guide,
FDA,FDA-2011-D-0579,Availability of FDAâ€™s eSubmitter Program for Regulatory Submissions from Licensed Blood Establishments:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/availability-fdas-esubmitter-program-regulatory-submissions-licensed-blood-establishments,
FDA,FDA-2008-D-0095,Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Influenza Viruses - Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishing-performance-characteristics-in-vitro-diagnostic-devices-detection-or-detection-and,
FDA,FDA-2009-D-0012,Q4B Annex 7 (R2): Dissolution Test General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-7-r2-dissolution-test-general-chapter,
FDA,FDA-2011-D-0404,Topical Acne Drug Products for Over-the-Counter Human Use--Revision of Labeling and Classification of Benzoyl Peroxide as Safe and Effective:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/topical-acne-drug-products-over-counter-human-use-revision-labeling-and-classification-benzoyl,
FDA,FDA-1998-N-1016,"Donors of Blood and Blood Components: Notification of Donor Deferral, Small Entity Compliance Guide:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/donors-blood-and-blood-components-notification-donor-deferral-small-entity-compliance-guide,
FDA,FDA-2009-D-0126,Submission of Summary Bioequivalence Data for Abbreviated New Drug Applications,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-summary-bioequivalence-data-abbreviated-new-drug-applications,
FDA,FDA-2009-D-0322,Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dosage-delivery-devices-orally-ingested-otc-liquid-drug-products,
FDA,FDA-2011-D-0214,How to Write a Request for Designation (RFD):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-write-request-designation-rfd,
FDA,FDA-2009-D-0044,Influenza: Developing Drugs for Treatment and/or Prophylaxis,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/influenza-developing-drugs-treatment-andor-prophylaxis,
FDA,FDA-2009-D-0283,"Postmarketing Studies and  Clinical Trialsâ€”Implementation  of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-studies-and-clinical-trials-implementation-section-505o3-federal-food-drug-and,
FDA,FDA-2007-D-0019,"""Computer Crossmatch"" (Computerized Analysis of the Compatibility between the Donor's Cell Type and the Recipient's Serum or Plasma Type); :  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-crossmatch-computerized-analysis-compatibility-between-donors-cell-type-and-recipients,
FDA,FDA-2020-D-1917,Guidance for Industry: Questions and Answers About the Food Additive or Color Additive Petition Process,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-about-food-additive-or-color-additive-petition-process,
FDA,FDA-2008-D-0150,Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/planning-effects-high-absenteeism-ensure-availability-medically-necessary-drug-products-0,
FDA,FDA-2009-D-0568,Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypertension-indication-drug-labeling-cardiovascular-outcome-claims,
FDA,,Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/planning-effects-high-absenteeism-ensure-availability-medically-necessary-drug-products,
FDA,FDA-2008-D-0457,Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence - Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-investigations-devices-indicated-treatment-urinary-incontinence-guidance-industry-and-fda,
FDA,,"Guidance for Industry: Letter to Firms that Grow, Harvest, Sort, Pack, or Ship Fresh Cilantro",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-letter-firms-grow-harvest-sort-pack-or-ship-fresh-cilantro,
FDA,FDA-2020-D-0957,CPG Sec. 335.700 Surgeons' Gloves and Patient Examination Gloves; Defects - Criteria for Direct Reference Seizure,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-335700-surgeons-gloves-and-patient-examination-gloves-defects-criteria-direct-reference,
FDA,FDA-2000-D-1542,Sample formats for Form FDA 356h_2011,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sample-formats-form-fda-356h_2011,
FDA,FDA-2008-D-0559,Process Validation: General Principles and Practices:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-validation-general-principles-and-practices,
FDA,FDA-2008-D-0520,Potency Tests for Cellular and Gene Therapy Products:  Final Guidance for Industry:,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-tests-cellular-and-gene-therapy-products,
FDA,FDA-2009-D-0466,CPG Sec 527.300 Microbial Contaminants & Alkaline Phosphatase Activity,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527300-microbial-contaminants-alkaline-phosphatase-activity,
FDA,FDA-2010-D-0605,"Small Entity Compliance Guide: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-current-good-manufacturing-practice-manufacturing-packaging-labeling,
FDA,,"â€œLookbackâ€ for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test Results Indicating Infection with HCV:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/lookback-hepatitis-c-virus-hcv-product-quarantine-consignee-notification-further-testing-product,
FDA,,CPG Sec 527.300 Dairy Products - Microbial Contaminants & Alkaline Phosphatase Activity,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527300-dairy-products-microbial-contaminants-alkaline-phosphatase-activity,
FDA,FDA-1999-D-0002,CPG Sec 510.800 Beverages-Serving Size Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510800-beverages-serving-size-labeling,
FDA,FDA-2007-D-0150,Antibacterial Drug Products: Use of Noninferiority Studies to Support Approval,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antibacterial-drug-products-use-noninferiority-studies-support-approval,
FDA,FDA-2010-D-0584,ANDAs: Impurities in Drug Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-impurities-drug-products,
FDA,FDA-2010-D-0590,Blood Lancet Labeling - Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/blood-lancet-labeling-guidance-industry-and-food-and-drug-administration-staff,
FDA,FDA-2010-D-0571,"Guidance for Industry: Safety of Imported Traditional Pottery Intended for Use with Food and the Use of the Term ""Lead Free"" in the Labeling of Pottery/Proper Identification of Ornamental and Decorative Ceramicware",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-safety-imported-traditional-pottery-intended-use-food-and-use-term-lead-free,
FDA,FDA-2009-D-0533,"Recommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-blood-establishments-training-back-personnel-assessment-blood-donor-suitability-and,
FDA,FDA-2009-D-0132,Cellular Therapy for Cardiac Disease:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cellular-therapy-cardiac-disease,
FDA,FDA-2020-D-1918,Guidance for Industry: Food Additive Petition Expedited Review,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-additive-petition-expedited-review,
FDA,FDA-2020-D-0957,Addition of URLs to Electronic Product Labeling:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/addition-urls-electronic-product-labeling,
FDA,FDA-2009-D-0342,Q4B Annex 10: Polyacrylamide Gel Electrophoresis General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-10-polyacrylamide-gel-electrophoresis-general-chapter,
FDA,FDA-2009-D-0579,Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 11: Capillary Electrophoresis General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-annex-11-capillary,
FDA,FDA-2009-D-0579,Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 12: Analytical Sieving General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-annex-12-analytical-sieving,
FDA,FDA-2007-D-0367,Impact-Resistant Lenses: Questions and Answers:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/impact-resistant-lenses-questions-and-answers,
FDA,,"Organ-Specific Warnings:  Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use â€” Small Entity Compliance Guide",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/organ-specific-warnings-internal-analgesic-antipyretic-and-antirheumatic-drug-products-over-counter,
FDA,FDA-2020-D-0957,Contact Lens Care Products Labeling:  Guidance for Industry and Food and Drug Administration Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contact-lens-care-products-labeling,
FDA,FDA-2003-D-0243,"CVM GFI #169 Drug Substance Chemistry, Manufacturing, and Controls Information",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-169-drug-substance-chemistry-manufacturing-and-controls-information,
FDA,FDA-2009-D-0181,Label Comprehension Studies for Nonprescription Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/label-comprehension-studies-nonprescription-drug-products,
FDA,FDA-2009-D-0125,Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/radioactive-drug-research-committee-human-research-without-investigational-new-drug-application,
FDA,,Guidance for Industry and FDA: Advisory Levels for Deoxynivalenol (DON) in Finished Wheat Products for Human Consumption and Grains and Grain By-Products used for Animal Feed,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-advisory-levels-deoxynivalenol-don-finished-wheat-products-human,
FDA,,Guidance for Industry: Recommendations for Submission of Chemical and Technological Data for Food Additive Petitions and GRAS Notices for Enzyme Preparations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-submission-chemical-and-technological-data-food-additive-petitions,
FDA,FDA-2007-D-0076,In Vitro Diagnostic (IVD) Device Studies - Frequently Asked Questions:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-diagnostic-ivd-device-studies-frequently-asked-questions,
FDA,FDA-2010-D-0249,Systemic Lupus Erythematosus --Developing Medical Products for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/systemic-lupus-erythematosus-developing-medical-products-treatment,
FDA,FDA-2007-D-0433,"Use of â€œLight,â€ â€œMild,â€ â€œLow,â€ or Similar Descriptors in the Label, Labeling, or Advertising of Tobacco Products:  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-light-mild-low-or-similar-descriptors-label-labeling-or-advertising-tobacco-products,
FDA,FDA-2010-D-0282,Individual Product Bioequivalence Recommendations for Specific Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/individual-product-bioequivalence-recommendations-specific-products,
FDA,FDA-2008-D-0406,"Frequently Asked Questions â€“ Statement of Investigator (Form FDA 1572):  Guidance for Sponsors, Clinical Investigators, and IRBs",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-statement-investigator-form-fda-1572,
FDA,,"FDA Inspections of Clinical Investigators:  Guidance For IRBs, Clinical Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-inspections-clinical-investigators,
FDA,FDA-2009-D-0260,Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007 (Edition 2),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-questions-and-answers-regarding-reportable-food-registry-established-food,
FDA,FDA-2009-D-0260,"OrientaciÃ³n preliminar de la industria: Preguntas y respuestas sobre el Registro de productos sanitarios en productos agroalimentarios, segÃºn establecido por la Ley de Enmiendas a la AlimentaciÃ³n y Medicamentos (FDA), 2007 (EdiciÃ³n 2)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orientacion-preliminar-de-la-industria-preguntas-y-respuestas-sobre-el-registro-de-productos,
FDA,FDA-2009-D-0260,Guide pour lâ€™industrie: Questions et rÃ©ponses concernant le Registre de denrÃ©es alimentaires Ã  signaler Reportable Food Registry (RFR) tel quâ€™Ã©tabli par le Food and Drug Administration Amendments Act de 2007 (FDAAA) (2Ã¨me Ã©dition),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guide-pour-lindustrie-questions-et-reponses-concernant-le-registre-de-denrees-alimentaires-signaler,
FDA,FDA-2009-D-0260,Chinese Translation of Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry Edition 2 (å…³äºŽç¾Žå›½é£Ÿå“è¯å“ç®¡ç†å±€2007å¹´ä¿®æ­£æ³•æ¡ˆè§„å®šçš„åº”é€šæŠ¥é£Ÿå“æ³¨å†Œçš„é—®ç­” 2010å¹´5æœˆ),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chinese-translation-draft-guidance-industry-questions-and-answers-regarding-reportable-food-registry,
FDA,FDA-2010-D-0236,Guidance for Industry: Use of Water by Food Manufacturers in Areas Subject to a Boil-Water Advisory,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-use-water-food-manufacturers-areas-subject-boil-water-advisory,
FDA,FDA-2010-D-0189,Enforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-concerning-certain-regulations-restricting-sale-and-distribution-cigarettes-and,
FDA,FDA-2008-D-0263,Requalification Method for Reentry of Blood Donors Deferred Because of Reactive Test Results for Antibody to Hepatitis B Core Antigen (Anti-HBc):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requalification-method-reentry-blood-donors-deferred-because-reactive-test-results-antibody,
FDA,FDA-2020-D-1920,Guidance for Industry: Sanitary Transportation of Food,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-sanitary-transportation-food,
FDA,FDA-2020-D-0957,Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems - Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-clinical-engineering-tests-and-recommended-labeling-intravascular-stents-and-associated-delivery,
FDA,FDA-2010-D-0183,"Small Entity Compliance Guide: Prevention of Salmonella Enteritidis in Shell Eggs During Production, Transportation, and Storage",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-prevention-salmonella-enteritidis-shell-eggs-during-production,
FDA,FDA-2009-D-0343,Q4B Annex 9: Tablet Friability General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-9-tablet-friability-general-chapter,
FDA,FDA-2010-D-0141,Small Entity Compliance Guide: Bottled Water and Total Coliform and E. coli,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-bottled-water-and-total-coliform-and-e-coli,
FDA,FDA-2009-D-0260,OrientaciÃ³n preliminar para la industria: PresentaciÃ³n de Informe para mÃºltiples instalaciones al Portal electrÃ³nico de incidentes,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orientacion-preliminar-para-la-industria-presentacion-de-informe-para-multiples-instalaciones-al,
FDA,FDA-2009-D-0260,Guidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal as Established by the Food and Drug Administration Amendments Act of 2007,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-submitting-report-multiple-facilities-reportable-food-electronic-portal,
FDA,FDA-2009-D-0260,French Translation of Guidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal (Soumission dâ€™un rapport concernant plusieurs usines auprÃ¨s du portail Ã©lectronique dâ€™enregistrement des denrÃ©es alimentaires),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/french-translation-guidance-industry-submitting-report-multiple-facilities-reportable-food,
FDA,FDA-2008-D-0623,CVM GFI #192 Anesthetics for Companion Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-192-anesthetics-companion-animals,
FDA,,CPG Sec 540.375 Canned Salmon - Adulteration Involving Decomposition (Withdrawn 3/22/2010),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540375-canned-salmon-adulteration-involving-decomposition-withdrawn-3222010,
FDA,FDA-2009-D-0006,S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s9-nonclinical-evaluation-anticancer-pharmaceuticals-questions-and-answers,
FDA,FDA-2009-D-0006,S9 Nonclinical Evaluation for Anticancer Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s9-nonclinical-evaluation-anticancer-pharmaceuticals,
FDA,,Draft Guidance for Industry: Providing Regulatory Submissions in Electronic or Paper Format to the Office of Food Additive Safety,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-providing-regulatory-submissions-electronic-or-paper-format-office-food,
FDA,FDA-2009-D-0260,Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standards-securing-drug-supply-chain-standardized-numerical-identification-prescription-drug,
FDA,,Chinese Translation of Guidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal (è¡Œä¸šæŒ‡å—ï¼šå‘ç¾Žå›½é£Ÿè§„å®šçš„åº”é€šæŠ¥é£Ÿå“é—¨æˆ·ç½‘æäº¤å¤šä¸ªæœºæž„çš„æŠ¥å‘Š),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chinese-translation-guidance-industry-submitting-report-multiple-facilities-reportable-food,
FDA,FDA-2008-D-0391,Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-documentation-applications-parametric-release-human-and-veterinary-drug-products,
FDA,FDA-2006-D-0410,Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials (PDF Version),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-use-bayesian-statistics-medical-device-clinical-trials-pdf-version,
FDA,,Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-use-bayesian-statistics-medical-device-clinical-trials,
FDA,FDA-2006-D-0223,Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/characterization-and-qualification-cell-substrates-and-other-biological-materials-used-production,
FDA,FDA-2007-D-0420,The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 â€“ Current Good Manufacturing Practice (CGMP):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-mechanical-calibration-dissolution-apparatus-1-and-2-current-good-manufacturing-practice-cgmp,
FDA,FDA-2008-D-0470,M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m3r2-nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization,
FDA,FDA-2008-D-0525,New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/new-contrast-imaging-indication-considerations-devices-and-approved-drug-and-biological-products,
FDA,FDA-2008-D-0399,Q4B Annex 5: Disintegration Test General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-5-disintegration-test-general-chapter,
FDA,FDA-2009-N-0449,General Questions and Answers on the Ban of Cigarettes that Contain Certain Characterizing Flavors (Edition 2):  Guidance to Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-questions-and-answers-ban-cigarettes-contain-certain-characterizing-flavors-edition-2,
FDA,FDA-2009-D-0013,Q4B Annex 8: Sterility Test General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-8-sterility-test-general-chapter,
FDA,FDA-2009-D-0573,S6(R1) Addendum: Preclinical Safety Evaluation of Biotechnology:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6r1-addendum-preclinical-safety-evaluation-biotechnology,
FDA,,S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6-r1-addendum-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals,
FDA,FDA-1998-D-0025,PET Drug Products - Current Good Manufacturing Practice (CGMP),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pet-drug-products-current-good-manufacturing-practice-cgmp,
FDA,FDA-2006-D-0362,Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims,
FDA,FDA-2008-D-0413,Residual Solvents in Drug Products Marketed in the United States:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/residual-solvents-drug-products-marketed-united-states,
FDA,FDA-2005-D-0154,Q8(R2) Pharmaceutical Development,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q8r2-pharmaceutical-development,
FDA,FDA-2008-D-0263,Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Whole Blood and Blood Components Intended for Transfusion:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-nucleic-acid-tests-reduce-risk-transmission-west-nile-virus-donors-whole-blood-and-blood,
FDA,FDA-2009-D-0355,SPL Standard for Content of Labeling Technical Qs & As,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/spl-standard-content-labeling-technical-qs,
FDA,,"Investigator Responsibilities â€” Protecting the Rights, Safety, and Welfare of Study Subjects:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigator-responsibilities-protecting-rights-safety-and-welfare-study-subjects,
FDA,FDA-2020-D-1921,Guidance for Industry: Letter Regarding Point of Purchase Food Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-letter-regarding-point-purchase-food-labeling,
FDA,FDA-2007-D-0302,Labeling for Human Prescription Drug and Biological Products â€” Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-human-prescription-drug-and-biological-products-determining-established-pharmacologic-class,
FDA,FDA-2009-D-0447,Helicobacter pylori-Associated Duodenal Ulcer Disease in Adults:  Developing Drugs for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/helicobacter-pylori-associated-duodenal-ulcer-disease-adults-developing-drugs-treatment,
FDA,FDA-2009-D-0470,"The Scope of the Prohibition Against Marketing a Tobacco Product in Combination with Another Article or Product Regulated under the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Manufacturers, Retailers, Importers and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scope-prohibition-against-marketing-tobacco-product-combination-another-article-or-product-regulated,
FDA,FDA-2008-D-0514,End-of-Phase 2A Meetings,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/end-phase-2a-meetings,
FDA,FDA-2009-D-0260,"Preguntas y respuestas sobre el Registro de incidentes sanitarios en productos agroalimentarios, segÃºn lo establecido por la Ley de Enmiendas de la AdministraciÃ³n de Medicamentos y Alimentos de 2007",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preguntas-y-respuestas-sobre-el-registro-de-incidentes-sanitarios-en-productos-agroalimentarios,
FDA,FDA-2009-D-0260,Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Adminstration Amendments Act of 2007 - Appendix,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-reportable-food-registry-established-food-and-drug-0,
FDA,FDA-2009-D-0260,Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-reportable-food-registry-established-food-and-drug,
FDA,FDA-2009-D-0260,French Translation of Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry (Questions et RÃ©ponses relatives au Registre des aliments Ã  signaler),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/french-translation-guidance-industry-questions-and-answers-regarding-reportable-food-registry,
FDA,FDA-2009-D-0260,Chinese Translation of the Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry (å…³äºŽç¾Žå›½é£Ÿå“è¯å“ç®¡ç†å±€2007å¹´ä¿®æ­£æ³•æ¡ˆè§„å®šçš„åº”é€šæŠ¥é£Ÿå“æ³¨å†Œçš„é—®ç­”),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chinese-translation-guidance-industry-questions-and-answers-regarding-reportable-food-registry,
FDA,FDA-2007-D-0209,Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act:  Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-nonprescription-human-drug-products-marketed-without-approved-application-required-dietary,
FDA,FDA-2007-D-0429,Guidance for Industry: Questions and Answers Regarding the Labeling of Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-labeling-dietary-supplements-required-dietary,
FDA,FDA-2008-D-0293,Considerations for Allogeneic Pancreatic Islet Cell Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-allogeneic-pancreatic-islet-cell-products,
FDA,FDA-2009-D-0354,Pharmaceutical Components at Risk for Melamine Contamination:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmaceutical-components-risk-melamine-contamination,
FDA,FDA-2008-D-0128,Drug-Induced Liver Injury: Premarketing Clinical Evaluation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation,
FDA,FDA-2008-D-0379,Nucleic Acid Testing  to Reduce the Possible Risk of Parvovirus B19 Transmission by Plasma-Derived Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nucleic-acid-testing-reduce-possible-risk-parvovirus-b19-transmission-plasma-derived-products,
FDA,FDA-1998-D-0021,ANDAs: Impurities in Drug Substances:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-impurities-drug-substances,
FDA,FDA-2007-D-0434,Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-adverse-event-reporting-nonprescription-human-drug-products-marketed-without-approved,
FDA,,CVM GFI #70 Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-70-small-entities-compliance-guide-feeders-ruminant-animals-without-farm-feed-mixing,
FDA,FDA-2009-D-0312,Frequently Asked Questions - IRB Registration:  Guidance for Institutional Review Boards (IRBs),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-irb-registration,
FDA,,"Guidance for Industry: Color Additive Petitions - FDA Recommendations for Submission of Chemical and Technological Data on Color Additives for Food, Drugs, Cosmetics, or Medical Devices",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-color-additive-petitions-fda-recommendations-submission-chemical-and-technological,
FDA,FDA-2009-D-0217,Medication Guides â€” Adding a Toll-Free Number for Reporting Adverse Events,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medication-guides-adding-toll-free-number-reporting-adverse-events,
FDA,FDA-2009-D-0224,Small Entity Compliance Guide: Bottled Water and Residual Disinfectants and Disinfection Byproducts,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-bottled-water-and-residual-disinfectants-and-disinfection-byproducts,
FDA,FDA-2005-N-0464,Providing Regulatory Submissions in Electronic Format â€“ Drug Establishment Registration and Drug Listing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-drug-establishment-registration-and-drug-listing,
FDA,FDA-2008-D-0253,Presenting Risk Information in Prescription Drug and Medical Device Promotion,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/presenting-risk-information-prescription-drug-and-medical-device-promotion,
FDA,FDA-2009-D-0209,"Small Entity Compliance Guide: Health Claims on Calcium and Osteoporosis; and Calcium, Vitamin D, and Osteoporosis",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-health-claims-calcium-and-osteoporosis-and-calcium-vitamin-d-and,
FDA,FDA-2004-D-0122,Labeling OTC Human Drug Products; Small Entity Compliance Guide:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-otc-human-drug-products-small-entity-compliance-guide,
FDA,FDA-2007-D-0487,CVM GFI #195 Small Entities Compliance Guide For Renderersâ€”Substances Prohibited From Use In Animal Food Or Feed,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-195-small-entities-compliance-guide-renderers-substances-prohibited-use-animal-food-or-feed,
FDA,FDA-2008-D-0597,CPG Sec 110.310 Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-110310-prior-notice-imported-food-under-public-health-security-and-bioterrorism-preparedness,
FDA,FDA-2017-D-6821,Small Entity Compliance Guide: Declaration by Name on the Label of All Foods and Cosmetic Products that Contain Cochineal Extract and Carmine,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-declaration-name-label-all-foods-and-cosmetic-products-contain,
FDA,FDA-2009-D-0198,Questions and Answers on Current Good Manufacturing Practice Questions and Answers on Current Good Manufacturing Practice Requirements | General Provisions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-current-good-manufacturing-practice-questions-and-answers-current-good,
FDA,FDA-2009-D-0196,Small Entity Compliance Guide: Bottled Water and Uranium,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-bottled-water-and-uranium,
FDA,FDA-2009-D-0195,Small Entity Compliance Guide: Bottled Water and Arsenic,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-bottled-water-and-arsenic,
FDA,FDA-2007-D-0430,CVM GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-185-vich-gl43-target-animal-safety-veterinary-pharmaceutical-products,
FDA,FDA-2007-D-0031,Integrated Summaries of Effectiveness and Safety: Location Within the Common Technical Document,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/integrated-summaries-effectiveness-and-safety-location-within-common-technical-document,
FDA,FDA-2007-D-0370,Q4B Annex 4C: Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-4c-microbiological-examination-non-sterile-products-acceptance-criteria-pharmaceutical,
FDA,FDA-2008-D-0396,Q4B Annex 4B: Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-4b-microbiological-examination-non-sterile-products-tests-specified-micro-organisms,
FDA,FDA-2008-D-0398,Q4B Annex 4A: Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-4a-microbiological-examination-non-sterile-products-microbial-enumeration-tests-general,
FDA,FDA-2008-D-0400,Q10 Pharmaceutical Quality System,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q10-pharmaceutical-quality-system,
FDA,FDA-2020-D-1922,Guidance for Industry: Recommendations for Submission of Chemical and Technological Data for Direct Food Additive Petitions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-submission-chemical-and-technological-data-direct-food-additive,
FDA,FDA-2002-D-0186,CVM GFI #149 (VICH GL33) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Testing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-149-vich-gl33-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach,
FDA,FDA-2009-D-0060,Guidance for Industry: Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Peanut-Derived Product as an Ingredient,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-measures-address-risk-contamination-salmonella-species-food-containing-peanut,
FDA,FDA-2020-D-1923,Guidance for Industry: 1991 Letter to Seafood Manufacturers Regarding the Fraudulent Practice of Including Glaze (ice) as Part of the Weight of Frozen Seafood,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-1991-letter-seafood-manufacturers-regarding-fraudulent-practice-including-glaze,
FDA,FDA-2004-D-0043,Guidance for Industry: Referral Program from the Food and Drug Administration to the National Oceanic and Atmospheric Administration Seafood Inspection Program for the Certification of Fish and Fishery Products for Export to the European Union and the European Free Trade Association,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-referral-program-food-and-drug-administration-national-oceanic-and-atmospheric,
FDA,None found,Animal Models â€” Essential Elements to Address Efficacy Under the Animal Rule_09,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/animal-models-essential-elements-address-efficacy-under-animal-rule_09,
FDA,FDA-2007-D-0371,Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-evidence-based-review-system-scientific-evaluation-health-claims,
FDA,FDA-2007-D-0202,"Adverse Event Reporting to IRBs â€” Improving Human Subject Protection:  Guidance for Clinical Investigators, Sponsors, and IRBs",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adverse-event-reporting-irbs-improving-human-subject-protection,
FDA,FDA-2007-D-0306,Q4B Annex 3: Test for Particulate Contamination: Subvisible Particles General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-3-test-particulate-contamination-subvisible-particles-general-chapter,
FDA,FDA-2004-D-0303,Labeling OTC Human Drug Products -- Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-otc-human-drug-products-questions-and-answers,
FDA,FDA-2004-D-0437,"Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-substantiation-dietary-supplement-claims-made-under-section-403r-6-federal-food,
FDA,,CPG Sec 540.370 Fish and Fishery Products - Decomposition,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540370-fish-and-fishery-products-decomposition,
FDA,FDA-2020-D-0957,Radiation Safety Considerations for X-Ray Equipment Designed for Hand-Held Use,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/radiation-safety-considerations-x-ray-equipment-designed-hand-held-use,
FDA,FDA-2007-D-0365,Orally Disintegrating Tablets:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orally-disintegrating-tablets,
FDA,FDA-2007-D-0025,Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/modifications-devices-subject-premarket-approval-pma-pma-supplement-decision-making-process,
FDA,FDA-2020-D-1385,CVM GFI #5 Drug Stability Guidelines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-5-drug-stability-guidelines,
FDA,FDA-2020-D-1924,Guidance for Industry: Dear Manufacturer Letter Regarding Front-of-Package Symbols,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-dear-manufacturer-letter-regarding-front-package-symbols,
FDA,FDA-1999-D-0128,Cooperative Manufacturing Arrangements for Licensed Biologics:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cooperative-manufacturing-arrangements-licensed-biologics,
FDA,FDA-2008-N-0281,PDUFA Pilot Project: Proprietary Name Review - Concept Paper,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pdufa-pilot-project-proprietary-name-review-concept-paper,
FDA,FDA-2008-D-0576,"Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials:  Guidance for Sponsors, Clinical Investigators, and IRBs",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-retention-when-subjects-withdraw-fda-regulated-clinical-trials,
FDA,,S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s1cr2-dose-selection-carcinogenicity-studies-pharmaceuticals,
FDA,None found,Animal Models â€” Essential Elements to Address Efficacy Under the Animal Rule - Concept Paper,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/animal-models-essential-elements-address-efficacy-under-animal-rule-concept-paper,
FDA,FDA-2020-D-0957,Clinical Study Designs for Catheter Ablation Devices for Treatment of Atrial Flutter:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-study-designs-catheter-ablation-devices-treatment-atrial-flutter,
FDA,,Voting Procedures for Advisory Committee Meetings:  Guidance for FDA Advisory Committee Members and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/voting-procedures-advisory-committee-meetings,
FDA,,Preparation and Public Availability  of Information Given to Advisory Committee Members:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preparation-and-public-availability-information-given-advisory-committee-members,
FDA,,Small Entity Compliance Guide: Nutrient Content Claims Definition for â€œHigh Potencyâ€ and Definition for â€œAntioxidantâ€ for Use in Nutrient Content Claims for Dietary Supplements and Conventional Foods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-nutrient-content-claims-definition-high-potency-and-definition,
FDA,FDA-1995-N-0400,CPG Sec 540.575 Fish - Fresh and Frozen - Adulteration Involving Decomposition (Withdrawn 7/18/2008),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540575-fish-fresh-and-frozen-adulteration-involving-decomposition-withdrawn-7182008,
FDA,FDA-1995-N-0054,Small Entity Compliance Guide: Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-final-rule-declaring-dietary-supplements-containing-ephedrine,
FDA,FDA-2008-N-0361,Small Entity Compliance Guide: Standard of Identity for White Chocolate,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-standard-identity-white-chocolate,
FDA,FDA-2005-D-0157,Current Good Manufacturing Practice for Phase 1 Investigational Drugs:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-phase-1-investigational-drugs,
FDA,FDA-2020-D-0957,Surveillance and Detention Without Physical Examination of Surgeons' and/or Patient Examination Gloves:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surveillance-and-detention-without-physical-examination-surgeons-andor-patient-examination-gloves,
FDA,FDA-2000-D-0137,Surveillance and Detention Without Physical Examination of Condoms:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surveillance-and-detention-without-physical-examination-condoms,
FDA,FDA-2000-D-0186,Intravascular Administration Sets Premarket Notification Submissions [510(k)]:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/intravascular-administration-sets-premarket-notification-submissions-510k,
FDA,,Q3A(R) Impurities in New Drug Substances,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3ar-impurities-new-drug-substances,
FDA,,"CPG Sec 560.700 - Processing of Imported Frozen Products of Multiple Sizes (e.g., Shrimp, Prawns, Etc.) (Withdrawn 6/6/2008)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560700-processing-imported-frozen-products-multiple-sizes-eg-shrimp-prawns-etc-withdrawn,
FDA,FDA-2007-D-0364,Indexing Structured Product Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/indexing-structured-product-labeling,
FDA,FDA-2005-D-0208,"Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-efficacy-and-pharmacokinetic-studies-support-marketing-immune-globulin-intravenous-human,
FDA,FDA-2020-D-0957,Hemodialysis Blood Tubing Sets - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hemodialysis-blood-tubing-sets-premarket-notification-510k-submissions,
FDA,FDA-2007-D-0070,"Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered from Donors Who Were Tested for Communicable Diseases Using Pooled Specimens or Diagnostic Tests:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/certain-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-recovered-donors-who-were,
FDA,FDA-2020-D-0957,Investigational Device Exemptions (IDEs) for Devices Indicated for Nocturnal Home Hemodialysis:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-device-exemptions-ides-devices-indicated-nocturnal-home-hemodialysis,
FDA,FDA-2020-D-0957,Preparation and Review of Investigational Device Exemption Applications (IDEs) for Total Artificial Discs:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preparation-and-review-investigational-device-exemption-applications-ides-total-artificial-discs,
FDA,FDA-2008-D-0199,E15 Pharmacogenomics Definitions and Sample Coding,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e15-pharmacogenomics-definitions-and-sample-coding,
FDA,FDA-2008-D-0206,"Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs):  Guidance for FDA Reviewers and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-review-chemistry-manufacturing-and-control-cmc-information-human-somatic-cell-therapy,
FDA,,Guidance for Industry: A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part I,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-labeling-guide-restaurants-and-retail-establishments-selling-away-home-foods-part,
FDA,,"CPG Sec 500.500 Guidance Levels for 3-MCPD (3-chloro-1,2-propanediol) in Acid-Hydrolyzed Protein and Asian-Style Sauces",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500500-guidance-levels-3-mcpd-3-chloro-12-propanediol-acid-hydrolyzed-protein-and-asian,
FDA,FDA-2008-D-0108,Guidance for Industry: Guide to Minimize Microbial Food Safety Hazards of Fresh-cut Fruits and Vegetables,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-guide-minimize-microbial-food-safety-hazards-fresh-cut-fruits-and-vegetables,
FDA,FDA-2008-D-0060,Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-and-closure-system-integrity-testing-lieu-sterility-testing-component-stability-protocol,
FDA,FDA-2008-D-0083,Q4B Annex I: Residue on Ignition/Sulphated Ash General Chapter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-annex-i-residue-ignitionsulphated-ash-general-chapter,
FDA,FDA-2008-D-0081,Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-international-conference-harmonisation,
FDA,FDA-2020-D-0957,Coronary and Carotid Embolic Protection Devices - Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/coronary-and-carotid-embolic-protection-devices-premarket-notification-510k-submissions,
FDA,,CPG Sec 555.320 Listeria monocytogenes,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555320-listeria-monocytogenes,
FDA,FDA-2020-D-0957,Medical Glove Guidance Manual:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-glove-guidance-manual,
FDA,FDA-2008-N-0033,CVM GFI #179 Use of Animal Clones and Clone Progeny for Human Food and Animal Feed,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-179-use-animal-clones-and-clone-progeny-human-food-and-animal-feed,
FDA,FDA-2020-D-0957,The Review and Inspection of Premarket Approval Application Manufacturing Information and Operations:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-and-inspection-premarket-approval-application-manufacturing-information-and-operations,
FDA,,CPG Sec 575.100 Draft Revision - Pesticide Chemical Residues in Food - Enforcement Criteria,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-575100-draft-revision-pesticide-chemical-residues-food-enforcement-criteria,
FDA,FDA-2020-D-1925,Guidance for Industry: Preparation of Premarket Submissions for Food Contact Substances (Chemistry Recommendations),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparation-premarket-submissions-food-contact-substances-chemistry,
FDA,FDA-2005-D-0013,Collection of Platelets by Automated Methods:  Guidance for Industry and FDA Review Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-platelets-automated-methods,
FDA,FDA-1999-D-0064,CVM GFI #92 (VICH GL10(R)) Impurities In New Veterinary Drug Substances,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-92-vich-gl10r-impurities-new-veterinary-drug-substances,
FDA,FDA-2006-D-0299,CVM GFI #93 (VICH GL11(R)) Impurities in New Veterinary Medicinal Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-93-vich-gl11r-impurities-new-veterinary-medicinal-products,
FDA,FDA-1999-D-0048,CVM GFI #73 (VICH GL3(R)) Stability Testing of New Veterinary Drug Substances and Medicinal Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-73-vich-gl3r-stability-testing-new-veterinary-drug-substances-and-medicinal-products,
FDA,FDA-2002-D-0175,"Adequate and Appropriate Donor Screening Tests for Hepatitis B; Hepatitis B Surface Antigen (HBsAg) Assays Used to Test Donors of Whole Blood and Blood Components, Including Source Plasma and Source Leukocytes:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adequate-and-appropriate-donor-screening-tests-hepatitis-b-hepatitis-b-surface-antigen-hbsag-assays,
FDA,FDA-2005-D-0211,Considerations for Plasmid DNA Vaccines for Infectious Disease Indications:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-plasmid-dna-vaccines-infectious-disease-indications,
FDA,FDA-2004-D-0242,Role of HIV Drug Resistance Testing in Antiretroviral Drug Development,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/role-hiv-drug-resistance-testing-antiretroviral-drug-development,
FDA,FDA-2020-D-0957,Inspection and Field Testing of Radiation-Emitting Electronic Products: Attachment C: Specific Instructions for Sunlamp Product Inspections and Tests,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inspection-and-field-testing-radiation-emitting-electronic-products-attachment-c-specific,
FDA,FDA-2020-D-0957,Inspection and Field Testing of Radiation-Emitting Electronic Products: Attachment A,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inspection-and-field-testing-radiation-emitting-electronic-products-attachment,
FDA,FDA-2020-D-0957,Biological Indicator (BI) Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biological-indicator-bi-premarket-notification-510k-submissions,
FDA,FDA-2020-D-1926,"Guidance for Industry: Food Security Preventive Measures Guidance for Dairy Farms, Bulk Milk Transporters, Bulk Milk Transfer Stations and Fluid Milk Processors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-security-preventive-measures-guidance-dairy-farms-bulk-milk-transporters-bulk,
FDA,FDA-2020-D-1927,Guidance for Industry: Food Security Preventive Measures Guidance for  Retail Food Stores and Food Service Establishments,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-security-preventive-measures-guidance-retail-food-stores-and-food-service,
FDA,FDA-2020-D-1928,Guidance for Industry: Food Security Preventive Measures for Importers and Filers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-security-preventive-measures-importers-and-filers,
FDA,FDA-2006-D-0479,CVM GFI #178 Recommended Design and Evaluation of Effectiveness Studies for Swine Respiratory Disease Claims,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-178-recommended-design-and-evaluation-effectiveness-studies-swine-respiratory-disease-claims,
FDA,FDA-2020-D-1929,"Guidance for Industry: Food Security Preventive Measures Guidance for Food Producers, Processors, and Transporters",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-food-security-preventive-measures-guidance-food-producers-processors-and,
FDA,FDA-2005-D-0272,Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical,
FDA,FDA-2020-D-0957,Procedures for Renewal and Amendment of Certain Laser Light Show Variances (Laser Notice 55),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-renewal-and-amendment-certain-laser-light-show-variances-laser-notice-55,
FDA,FDA-2020-D-0957,Compliance Guide for Cabinet X-Ray Systems,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-guide-cabinet-x-ray-systems,
FDA,FDA-2020-D-0957,Non-clinical Information for Femoral Stem Prostheses:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-clinical-information-femoral-stem-prostheses,
FDA,FDA-2006-D-0357,Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/commercially-distributed-analyte-specific-reagents-asrs-frequently-asked-questions,
FDA,FDA-2020-D-1930,Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-dear-manufacturer-letter-regarding-sugar-free-claims,
FDA,FDA-2003-N-0096,Manufacturing Biological Intermediates and Biological Drug Substances Using Spore-Forming Microorganisms:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-biological-intermediates-and-biological-drug-substances-using-spore-forming,
FDA,FDA-2007-D-0136,Pharmacogenomic Data Submissions â€” Companion Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenomic-data-submissions-companion-guidance,
FDA,FDA-2004-D-0225,"Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/eligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-products,
FDA,FDA-2020-D-0957,Writing Dear Doctor Letters for Recalls of Implantable Cardioverter Defibrillators (ICDs):  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/writing-dear-doctor-letters-recalls-implantable-cardioverter-defibrillators-icds,
FDA,FDA-2004-D-0182,"ANDAs:Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andaspharmaceutical-solid-polymorphism-chemistry-manufacturing-and-controls-information,
FDA,,Guidance for Industry and Other Stakeholders: Redbook 2000 :  Toxicological Principles for the Safety Assessment of Food Ingredients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-other-stakeholders-redbook-2000,
FDA,,Redbook 2000: IV.C.8. In-Utero Exposure Phase for Addition to Carcinogenicity Studies or Chronic Toxicity Studies with Rodents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc8-utero-exposure-phase-addition-carcinogenicity-studies-or-chronic-toxicity-studies,
FDA,,Redbook 2000: IV.C.7. Combined Chronic Toxicity/Carcinogenicity Studies with Rodents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc7-combined-chronic-toxicitycarcinogenicity-studies-rodents,
FDA,,Redbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc5a-chronic-toxicity-studies-rodents,
FDA,,Redbook 2000: IV.C.1. Short-Term Tests for Genetic Toxicity,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc1-short-term-tests-genetic-toxicity,
FDA,,Redbook 2000: III Recommended Toxicity Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-iii-recommended-toxicity-studies,
FDA,,Redbook 2000: I Introduction,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-i-introduction,
FDA,FDA-2020-D-1407,"Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/devices-used-process-human-cells-tissues-and-cellular-and-tissue-based-products-hctps,
FDA,FDA-2020-D-0957,Laser Products - Conformance with IEC 60825-1 and IEC 60601-2-22; (Laser Notice No. 50),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laser-products-conformance-iec-60825-1-and-iec-60601-2-22-laser-notice-no-50,
FDA,FDA-2003-D-0376,Bundling Multiple Devices or Multiple Indications in a Single Submission:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bundling-multiple-devices-or-multiple-indications-single-submission,
FDA,FDA-2020-D-0957,Pre-Clinical and Clinical Studies for Neurothrombectomy Devices:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pre-clinical-and-clinical-studies-neurothrombectomy-devices,
FDA,FDA-2007-D-0030,Guidance for Industry: Refrigerated Carrot Juice and Other Refrigerated Low-Acid Juices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-refrigerated-carrot-juice-and-other-refrigerated-low-acid-juices,
FDA,,Redbook 2000: IV.B.4. Statistical Considerations in Toxicity Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivb4-statistical-considerations-toxicity-studies,
FDA,,Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent-recommendations-source-plasma-donors-participating-plasmapheresis-and-immunization,
FDA,FDA-2006-D-0350,CPG Sec. 130.300  FDA Access to Results of Quality Assurance Program Audits and Inspections,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-130300-fda-access-results-quality-assurance-program-audits-and-inspections,
FDA,FDA-2006-D-0351,Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-data-needed-support-licensure-seasonal-inactivated-influenza-vaccines,
FDA,FDA-2006-D-0222,Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-data-needed-support-licensure-pandemic-influenza-vaccines,
FDA,FDA-1999-D-0011,"CVM GFI #83 Chemistry, Manufacturing and Controls Changes to Approved NADA/ANADA",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-83-chemistry-manufacturing-and-controls-changes-approved-nadaanada,
FDA,FDA-2006-D-0231,CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-137-analytical-methods-description-type-c-medicated-feeds,
FDA,,Small Business Nutrition Labeling Exemption Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-business-nutrition-labeling-exemption-guidance,
FDA,FDA-2020-D-0957,Dental Handpieces - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-handpieces-premarket-notification-510k-submissions,
FDA,FDA-2006-D-0230,CVM GFI #136 Protocols for the Conduct of Method Transfer Studies for Type C Medicated Feed Assay Methods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-136-protocols-conduct-method-transfer-studies-type-c-medicated-feed-assay-methods,
FDA,FDA-2020-D-1442,CVM GFI #150 Concerns Related to the use of Clove Oil as an Anesthetic for Fish,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-150-concerns-related-use-clove-oil-anesthetic-fish,
FDA,FDA-2020-D-0957,Approval of Alternate Means of Labeling for Laser Products (Laser Notice 53),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/approval-alternate-means-labeling-laser-products-laser-notice-53,
FDA,FDA-2020-D-0957,Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests - Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-guidance-reporting-results-studies-evaluating-diagnostic-tests-guidance-industry-and-fda,
FDA,FDA-2006-D-0361,CVM GFI #183 Animal Drug User Fees: Fees Exceed Costs Waiver/Reduction,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-183-animal-drug-user-fees-fees-exceed-costs-waiverreduction,
FDA,FDA-2001-D-0137,Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orally-inhaled-and-intranasal-corticosteroids-evaluation-effects-growth-children,
FDA,FDA-2006-D-0102,Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complementary-and-alternative-medicine-products-and-their-regulation-food-and-drug-administration,
FDA,,"Guidance for Industry and FDA: Letter to Industry, State and Local Food Regulators and Inspectors Regarding  Web-based ALERT Training",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-letter-industry-state-and-local-food-regulators-and-inspectors-regarding,
FDA,FDA-2007-D-0435,Developing Products for Weight Management Revision 1,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-products-weight-management-revision-1,
FDA,FDA-2005-D-0083,User Fee Waivers for FDC and Co-Packaged HIV Drugs for PEPFAR,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-fee-waivers-fdc-and-co-packaged-hiv-drugs-pepfar,
FDA,,"CPG Sec 540.600 Fish, Shellfish, Crustaceans and other Aquatic Animals - Fresh, Frozen or Processed - Methyl Mercury",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540600-fish-shellfish-crustaceans-and-other-aquatic-animals-fresh-frozen-or-processed-methyl,
FDA,FDA-1998-N-0050,Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Food Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-dear-manufacturer-letter-regarding-food-labeling,
FDA,,"Process for Handling Referrals to FDA Under 21 CFR 50.54 - Additional Safeguards for Children in Clinical Investigations:  Guidance for Clinical Investigators, Institutional Review Boards and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-handling-referrals-fda-under-21-cfr-5054-additional-safeguards-children-clinical,
FDA,FDA-2005-D-0084,Guidance for Industry: Lead in Candy Likely To Be Consumed Frequently by Small Children:  Recommended Maximum Level and Enforcement Policy,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-lead-candy-likely-be-consumed-frequently-small-children,
FDA,FDA-2020-D-0957,"Decorative, Non-corrective Contact Lenses:  Guidance for Industry, FDA Staff, Eye Care Professionals, and Consumers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/decorative-non-corrective-contact-lenses,
FDA,FDA-1992-N-0056,Prescription Drug Marketing Act (PDMA) Requirements- Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-drug-marketing-act-pdma-requirements-questions-and-answers,
FDA,FDA-1994-D-0317,CVM GFI #35 Bioequivalence Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-35-bioequivalence-guidance,
FDA,FDA-2001-D-0008,Biological Product Deviation Reporting for Licensed Manufacturers of Biological Products Other than Blood and Blood Components,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biological-product-deviation-reporting-licensed-manufacturers-biological-products-other-blood-and,
FDA,FDA-2020-D-0957,Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations,
FDA,FDA-2004-D-0300,CPG Sec. 100.550 Status and Responsibilities of Contract Sterilizers Engaged in the Sterilization of Drugs and Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100550-status-and-responsibilities-contract-sterilizers-engaged-sterilization-drugs-and,
FDA,FDA-2006-D-0038,"Public Availability of Labeling Changes in ""Changes Being Effected"" Supplements",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/public-availability-labeling-changes-changes-being-effected-supplements,
FDA,FDA-2020-D-0957,Keratome and Replacement Keratome Blades Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/keratome-and-replacement-keratome-blades-premarket-notification-510k-submissions,
FDA,,Compliance with 21 CFR Part 1271.150(c)(1) â€“ Manufacturing Arrangements:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-21-cfr-part-1271150c1-manufacturing-arrangements,
FDA,FDA-2020-D-1455,Early Development Considerations for Innovative Combination Products:  Guidance for Industry  and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-development-considerations-innovative-combination-products,
FDA,FDA-2005-D-0014,Implementing a Collection Program for Source Plasma Containing Disease-Associated and Other Immunoglobulin (IgG) Antibodies:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implementing-collection-program-source-plasma-containing-disease-associated-and-other-immunoglobulin,
FDA,FDA-1996-D-0048 (Revision 1),Q3B(R) Impurities in New Drug Products (Revision 3),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3br-impurities-new-drug-products-revision-3,
FDA,,Guidance for Industry: Estimating Dietary Intake of Substances in Food,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-estimating-dietary-intake-substances-food,
FDA,FDA-2001-D-0101,CVM GFI #160 (VICH GL37) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (Chronic) Toxicity Testing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-160-vich-gl37-studies-evaluate-safety-residues-veterinary-drugs-human-food-repeat-dose,
FDA,FDA-2002-D-0091,CVM GFI #148 (VICH GL32) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Developmental Toxicity Testing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-148-vich-gl32-studies-evaluate-safety-residues-veterinary-drugs-human-food-developmental,
FDA,FDA-2002-D-0090,CVM GFI #147 (VICH GL31) Studies to Evaluate the Safety of Residues of  Veterinary Drugs in Human Food: Repeat-Dose (90 Day) Toxicity Testing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-147-vich-gl31-studies-evaluate-safety-residues-veterinary-drugs-human-food-repeat-dose-90,
FDA,FDA-2003-D-0372,CVM GFI #141 (VICH GL28) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Carcinogenicity Testing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-141-vich-gl28-studies-evaluate-safety-residues-veterinary-drugs-human-food-carcinogenicity,
FDA,FDA-2005-D-0397,Useful Written Consumer Medication Information (CMI),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/useful-written-consumer-medication-information-cmi,
FDA,,CPG Sec. 608.100  Human-Labeled Drugs Distributed and Used in Animal  Medicine (Withdrawn 7/7/2006),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-608100-human-labeled-drugs-distributed-and-used-animal-medicine-withdrawn-772006,
FDA,,CPG Sec. 616.100  Streptomycin Residues in Cattle Tissues (Withdrawn 7/7/2006),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-616100-streptomycin-residues-cattle-tissues-withdrawn-772006,
FDA,FDA-2004-D-0044,Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-early-food-safety-evaluation-new-non-pesticidal-proteins-produced,
FDA,FDA-2005-D-0336,CVM GFI #177 (VICH GL40) Test Procedures/Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-177-vich-gl40-test-proceduresacceptance-criteria-new-biotechnologicalbiological-veterinary,
FDA,FDA-2005-D-0028,CVM GFI #176 (VICH GL39) Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-176-vich-gl39-specifications-test-procedures-and-acceptance-criteria-new-veterinary-drug,
FDA,FDA-2005-D-0282,Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency,
FDA,FDA-2005-D-0282,Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-cutaneous-ulcer-and-burn-wounds-developing-products-treatment,
FDA,,Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting,
FDA,FDA-2005-D-0183,Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HBV Resistance Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-2,
FDA,None found,Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency:  Guidance for Submitting HCV Resistance Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-1,
FDA,FDA-2000-D-0037,Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency : Guidance for Submitting Influenza Resistance Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-0,
FDA,FDA-2020-D-1936,Guidance for Industry: Summary Table of Recommended Toxicological Testing for Additives Used in Food,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-summary-table-recommended-toxicological-testing-additives-used-food,
FDA,FDA-2021-D-0610,"CVM GFI #126 BACPAC I-Intermediates in Drug Substance Synthesis Bulk Actives Postapproval Changes: Chemistry, Manufacturing, and Controls Documentation",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-126-bacpac-i-intermediates-drug-substance-synthesis-bulk-actives-postapproval-changes,
FDA,,Guidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN - Attachment 2,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparing-claim-categorical-exclusion-or-environmental-assessment-submission-cfsan-0,
FDA,,Guidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN - Attachment 1,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparing-claim-categorical-exclusion-or-environmental-assessment-submission-cfsan-1,
FDA,,Guidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparing-claim-categorical-exclusion-or-environmental-assessment-submission-cfsan,
FDA,FDA-2003-D-0087,Guidance for Industry: Appendix E of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN (40 CFR 1508.27),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-appendix-e-preparing-claim-categorical-exclusion-or-environmental-assessment,
FDA,,Guidance for Industry: Appendix D of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-appendix-d-preparing-claim-categorical-exclusion-or-environmental-assessment,
FDA,,Guidance for Industry: Appendix C of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-appendix-c-preparing-claim-categorical-exclusion-or-environmental-assessment,
FDA,,Guidance for Industry: FDA's Implementation of Qualified Health Claims,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fdas-implementation-qualified-health-claims,
FDA,,Guidance for Industry: Preparing a Color Additive Petition for Submission to the Center for Food Safety and Applied Nutrition for Color Additives Used in or on Contact Lenses,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-preparing-color-additive-petition-submission-center-food-safety-and-applied,
FDA,,Guidance for Industry: Appendix B for Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-appendix-b-preparing-claim-categorical-exclusion-or-environmental-assessment,
FDA,,Guidance for Industry: Appendix A of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-appendix-preparing-claim-categorical-exclusion-or-environmental-assessment,
FDA,FDA-2000-D-0136,CVM GFI #117 (VICH GL24) Management of Adverse Event Reports (AER's),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-117-vich-gl24-management-adverse-event-reports-aers,
FDA,FDA-2005-D-0156,"Compliance with Section 301 of the Medical Device User Fee and Modernization Act of 2002, as amended â€“ Prominent and Conspicuous Mark of Manufacturers on Single-Use Devices:  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-section-301-medical-device-user-fee-and-modernization-act-2002-amended-prominent-and,
FDA,FDA-2006-D-0095,"Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable :  Guidance for Sponsors, Institutional Review Boards, and Food and Drug Administration Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-informed-consent-in-vitro-diagnostic-device-studies-using-leftover-human-specimens-are-not,
FDA,FDA-2005-D-0398,S8 Immunotoxicity Studies for Human Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s8-immunotoxicity-studies-human-pharmaceuticals,
FDA,,Redbook 2000: IV.C.1.c Mouse Lymphoma Thymidine Kinase Gene Mutation Assay,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc1c-mouse-lymphoma-thymidine-kinase-gene-mutation-assay,
FDA,FDA-2001-D-0219,Establishment and Operation of Clinical Trial Data Monitoring Committees:  Guidance for Clinical Trial Sponsors,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishment-and-operation-clinical-trial-data-monitoring-committees,
FDA,FDA-2020-D-0957,Tonometers - Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tonometers-premarket-notification-510k-submissions,
FDA,FDA-2020-D-0957,Dental Curing Lights - Premarket Notification [510(k)]:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-curing-lights-premarket-notification-510k,
FDA,FDA-2005-D-0443,Using a Centralized IRB Review Process in Multicenter Clinical Trials:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-centralized-irb-review-process-multicenter-clinical-trials,
FDA,2005D-0004,Nonclinical Safety Evaluation of Drug or Biologic Combinations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-evaluation-drug-or-biologic-combinations,
FDA,FDA-2002-D-0092,Prescription Drug Marketing Act â€” Donation of Prescription Drug Samples to Free Clinics,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-drug-marketing-act-donation-prescription-drug-samples-free-clinics,
FDA,FDA-2004-D-0499,Hospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hospital-bed-system-dimensional-and-assessment-guidance-reduce-entrapment,
FDA,FDA-2005-D-0025,Internal Radioactive Contamination â€”Development of Decorporation Agents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/internal-radioactive-contamination-development-decorporation-agents,
FDA,FDA-2020-D-1937,Guidance for Industry: Frequently Asked Questions about FDA's Regulation of Infant Formula,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-frequently-asked-questions-about-fdas-regulation-infant-formula,
FDA,,Using Electronic Means to Distribute Certain Product Information:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-electronic-means-distribute-certain-product-information,
FDA,FDA-2006-D-0298,Draft Guidance for Industry and FDA Staff: Whole Grain Label Statements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-and-fda-staff-whole-grain-label-statements,
FDA,FDA-1999-N-0098,Reports on the Status of Postmarketing Study Commitments â€” Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reports-status-postmarketing-study-commitments-implementation-section-130-food-and-drug,
FDA,2003D-0001,Nonclinical Safety Evaluation of Pediatric Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-evaluation-pediatric-drug-products,
FDA,FDA-2006-D-0232,Pharmacogenetic Tests and Genetic Tests for Heritable Markers:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenetic-tests-and-genetic-tests-heritable-markers,
FDA,FDA-2006-D-0159,Providing Regulatory Submissions in Electronic Format Orphan-Drug and Humanitarian Use Device Designation Requests and Related Submissions: Draft Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-orphan-drug-and-humanitarian-use-device,
FDA,FDA-2000-D-0029,Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-developmental-toxicity-studies-preventive-and-therapeutic-vaccines-infectious-disease,
FDA,FDA-2005-D-0153,Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products â€” Content and Format:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-studies-section-labeling-human-prescription-drug-and-biological-products-content-and-format,
FDA,FDA-2000-D-0074,Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products â€” Content and Format,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adverse-reactions-section-labeling-human-prescription-drug-and-biological-products-content-and,
FDA,,"Exploratory IND Studies:  Guidance for Industry, Investigators, and Reviewers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exploratory-ind-studies,
FDA,FDA-2003-D-0369,Formal Dispute Resolution:  Scientific and Technical Issues Related to Pharmaceutical CGMP,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-dispute-resolution-scientific-and-technical-issues-related-pharmaceutical-cgmp,
FDA,FDA-2004-D-0273,CVM GFI #166 (VICH GL38) Environmental Impact Assessments (EIA's) for Veterinary Medicinal Products (VMPâ€™s) - Phase II,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-166-vich-gl38-environmental-impact-assessments-eias-veterinary-medicinal-products-vmps-phase,
FDA,FDA-2004-D-0372,Exemption from Reporting and Recordkeeping Requirements for Low Power Laser Products (Laser Notice 54):  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exemption-reporting-and-recordkeeping-requirements-low-power-laser-products-laser-notice-54,
FDA,FDA-2020-D-0957,CVM GFI #123 Development of Data Supporting Approval of NSAIDS for Use in Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-123-development-data-supporting-approval-nsaids-use-animals,
FDA,FDA-2004-D-0374,Recommended Approaches to Integration of Genetic Toxicology Study Results,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-approaches-integration-genetic-toxicology-study-results,
FDA,,"Significant Risk and Nonsignificant Risk Medical Device Studies:  Guidance For IRBs, Clinical Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/significant-risk-and-nonsignificant-risk-medical-device-studies,
FDA,,Redbook 2000: IV.C.6. Carcinogenicity Studies with Rodents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc6-carcinogenicity-studies-rodents,
FDA,FDA-2006-D-0031,"Frequently Asked Questions About Medical Devices:  Guidance For IRBs, Clinical Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-about-medical-devices,
FDA,FDA-2006-D-0031,"FDA Institutional Review Board Inspections:  Guidance For IRBs, Clinical Investigators, and Sponsors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-institutional-review-board-inspections,
FDA,,"Guidance for Industry and FDA Staff: Guidance for Records Access Authority Provided in Title III, Subtitle A, of the Public Health Security and Bioterrorism Preparedness and Response Act of 2002",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-staff-guidance-records-access-authority-provided-title-iii-subtitle-public,
FDA,,CPG Sec 590.500 Packaging Technologies and Tamper-Resistant Packaging Requirements for Cosmetic Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-590500-packaging-technologies-and-tamper-resistant-packaging-requirements-cosmetic-products,
FDA,,"CPG Sec 590.400 Natural Bristle Brushes (i.e., Hair Brushes, Shaving Brushes) - Nit Contamination",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-590400-natural-bristle-brushes-ie-hair-brushes-shaving-brushes-nit-contamination,
FDA,,CPG Sec 590.300 Direct Reference Authority for Pseudomonas Contamination of Cosmetics Used in the Eye Area,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-590300-direct-reference-authority-pseudomonas-contamination-cosmetics-used-eye-area,
FDA,,CPG Sec 587.300 Color Additives,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-587300-color-additives,
FDA,,CPG Sec 587.100 Label Declaration of Certification-Exempt Color Additives,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-587100-label-declaration-certification-exempt-color-additives,
FDA,,CPG Sec 585.825 Sweet Potatoes - Dyeing of Yellow and Red Varieties,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585825-sweet-potatoes-dyeing-yellow-and-red-varieties,
FDA,,"CPG Sec 585.775 Spinach, Canned or Frozen - Adulteration Involving Insects, Decomposition",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585775-spinach-canned-or-frozen-adulteration-involving-insects-decomposition,
FDA,,"CPG Sec 585.575 Peas and Beans; Dried - Adulteration Involving Storage, Insect Damage, Rocks",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585575-peas-and-beans-dried-adulteration-involving-storage-insect-damage-rocks,
FDA,,CPG Sec 585.475 Canned Green Beans and Canned Wax Beans - Misbranding Involving Food Standards,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585475-canned-green-beans-and-canned-wax-beans-misbranding-involving-food-standards,
FDA,,CPG Sec 585.400 Cowpeas (Black-Eyed Peas); Canned (Succulent Peas) - Adulteration by Insects,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585400-cowpeas-black-eyed-peas-canned-succulent-peas-adulteration-insects,
FDA,,"CPG Sec 585.300 Corn, Sweet; Canned - Adulteration by Corn Ear Worms, Corn Borers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585300-corn-sweet-canned-adulteration-corn-ear-worms-corn-borers,
FDA,,"CPG Sec 585.275 Brussels Sprouts, Frozen - Adulteration by Insects",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585275-brussels-sprouts-frozen-adulteration-insects,
FDA,,"CPG Sec 585.200 Beets, Canned - Adulteration with Rot",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585200-beets-canned-adulteration-rot,
FDA,,CPG Sec 580.100 Food Storage and Warehousing-Adulteration-Filth (Domestic and Import),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-580100-food-storage-and-warehousing-adulteration-filth-domestic-and-import,
FDA,,CPG Sec 570.700 Mixed Nuts - Misbranding Involving Food Standards,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570700-mixed-nuts-misbranding-involving-food-standards,
FDA,,"CPG Sec 570.450 Tree Nuts - Adulteration with Filth, Involving the Presence of the Organism Escherichia coli",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570450-tree-nuts-adulteration-filth-involving-presence-organism-escherichia-coli,
FDA,,"CPG Sec 570.425 Tree Nuts - Adulteration Involving Rejects (Insect Infestation, Moldy, Rancid, Otherwise Decomposed, Blanks, and Shriveled)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570425-tree-nuts-adulteration-involving-rejects-insect-infestation-moldy-rancid-otherwise,
FDA,,"CPG Sec 570.350 Peanuts, Shelled and Unshelled - Adulteration with Filth and Reject Nuts",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570350-peanuts-shelled-and-unshelled-adulteration-filth-and-reject-nuts,
FDA,FDA-2004-G-0002,CPG Sec 570.300 Peanut Butter - Adulteration with Filth; Grit,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570300-peanut-butter-adulteration-filth-grit,
FDA,,CPG Sec 565.100 FDA Jurisdiction Over Meat and Poultry Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-565100-fda-jurisdiction-over-meat-and-poultry-products,
FDA,,CPG Sec 562.550 Safety and Labeling of Waxed (Coated) Fruits and Vegetables,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562550-safety-and-labeling-waxed-coated-fruits-and-vegetables,
FDA,,CPG Sec 562.300 Foods - Net Weight,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562300-foods-net-weight,
FDA,,CPG Sec 562.200 Foods - FPLA Compliance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562200-foods-fpla-compliance,
FDA,,"CPG Sec 560.600 Clams, Mussels, Oysters; Fresh or Frozen - Adulteration by Bacteriological Contamination",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560600-clams-mussels-oysters-fresh-or-frozen-adulteration-bacteriological-contamination,
FDA,,CPG Sec 560.200 Country of Origin Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560200-country-origin-labeling,
FDA,,CPG Sec 555.880 Guidance Levels for Radionuclides in Domestic and Imported Foods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555880-guidance-levels-radionuclides-domestic-and-imported-foods,
FDA,,CPG Sec 555.250 Statement of Policy for Labeling and Preventing Cross-contact of Common Food Allergens,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555250-statement-policy-labeling-and-preventing-cross-contact-common-food-allergens,
FDA,,"CPG Sec 550.850 Strawberries; Frozen, Whole, or Sliced - Adulteration with Sand, Mold",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550850-strawberries-frozen-whole-or-sliced-adulteration-sand-mold,
FDA,,CPG Sec 550.800 Standardized Canned Fruit - Misbranding Involving Improper Declaration of Packing Medium,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550800-standardized-canned-fruit-misbranding-involving-improper-declaration-packing-medium,
FDA,,"CPG Sec 550.750 Raisins - Adulteration Involving Mold, Sand, Grit, & Insects",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550750-raisins-adulteration-involving-mold-sand-grit-insects,
FDA,,"CPG Sec 550.700 Dried Prunes, Dehydrated Low Moisture Prunes, and Pitted Prunes - Adulteration Involving Insects; Decomposition; Dirt; Pits; and Pit Fragments",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550700-dried-prunes-dehydrated-low-moisture-prunes-and-pitted-prunes-adulteration-involving,
FDA,,"CPG Sec 550.690 Plums, Canned - Adulteration with Rot",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550690-plums-canned-adulteration-rot,
FDA,,"CPG Sec 550.685 Pineapple, Canned; Imported and Domestic - Misbranding Involving Food Standards",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550685-pineapple-canned-imported-and-domestic-misbranding-involving-food-standards,
FDA,,"CPG Sec 550.655 Peaches, Canned - Misbranding Involving Food Standards",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550655-peaches-canned-misbranding-involving-food-standards,
FDA,,CPG Sec 550.600 Olives - Adulteration Involving Pits; Rot; Insect Infestation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550600-olives-adulteration-involving-pits-rot-insect-infestation,
FDA,,"CPG Sec 550.500 Lingon Berries, Canned - Adulteration by Insects",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550500-lingon-berries-canned-adulteration-insects,
FDA,,"CPG Sec 550.350 Figs; Fig Paste - Adulteration Involving Insect Infestation; Mold, Dirt",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550350-figs-fig-paste-adulteration-involving-insect-infestation-mold-dirt,
FDA,,"CPG Sec 550.300 Dates and Date Material; Imported and Domestic - Adulteration Involving Mold, Insect Excreta, Sour, Dirty, Worthless and Pits",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550300-dates-and-date-material-imported-and-domestic-adulteration-involving-mold-insect,
FDA,,"CPG Sec 550.230 Cherries, Canned - Misbranding Involving Food Standards",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550230-cherries-canned-misbranding-involving-food-standards,
FDA,,"CPG Sec 550.225 Cherries Brined, Fresh, Canned and Frozen - Adulteration Involving Rot and Insect",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550225-cherries-brined-fresh-canned-and-frozen-adulteration-involving-rot-and-insect,
FDA,,"CPG Sec 550.200 Drupelet Berries (Blackberries, Raspberries, Etc.) - Common or Usual Names of Varieties; Canned and Frozen - Adulteration with Rot and Insects",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550200-drupelet-berries-blackberries-raspberries-etc-common-or-usual-names-varieties-canned,
FDA,,"CPG Sec 550.155 Apricot, Peach and Pear Nectars and Purees - Adulteration with Mold",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550155-apricot-peach-and-pear-nectars-and-purees-adulteration-mold,
FDA,,CPG Sec 550.150 Apricots - Canned - Adulteration with Insects,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550150-apricots-canned-adulteration-insects,
FDA,,"CPG Sec 550.100 Apple Butter - Adulteration with Mold; Rodent Filth, Insect",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550100-apple-butter-adulteration-mold-rodent-filth-insect,
FDA,,CPG Sec 545.600 Cinnamon-Flavored Toothpicks,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545600-cinnamon-flavored-toothpicks,
FDA,,CPG Sec 545.500 Silver-Plated Hollowware - Lead Contamination,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545500-silver-plated-hollowware-lead-contamination,
FDA,,CPG Sec 545.450 Pottery (Ceramics); Import and Domestic - Lead Contamination,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545450-pottery-ceramics-import-and-domestic-lead-contamination,
FDA,,CPG Sec 545.400 Pottery (Ceramics); Import and Domestic - Cadmium Contamination,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545400-pottery-ceramics-import-and-domestic-cadmium-contamination,
FDA,,"CPG Sec 545.300 Foods, Rail Car Sanitation - Adulteration",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545300-foods-rail-car-sanitation-adulteration,
FDA,,"CPG Sec 540.650 Uneviscerated Fish Products that are Salt-cured, Dried, or Smoked (Revised)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540650-uneviscerated-fish-products-are-salt-cured-dried-or-smoked-revised,
FDA,,"CPG Sec 540.590 Fish - Fresh and Frozen, as Listed - Adulteration by Parasites",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540590-fish-fresh-and-frozen-listed-adulteration-parasites,
FDA,,"CPG Sec 540.500 Tuna, Sable, Salmon, Shad-Smoked Cured, Adulteration Involving Food Additives, Sodium Nitrite",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540500-tuna-sable-salmon-shad-smoked-cured-adulteration-involving-food-additives-sodium,
FDA,,CPG Sec 540.420 Raw Breaded Shrimp - Microbiological Criteria for Evaluating Compliance with Current Good Manufacturing Practice Regulations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540420-raw-breaded-shrimp-microbiological-criteria-evaluating-compliance-current-good,
FDA,,CPG Sec 537.100 Eggs and Egg Products - Frozen - Adulteration Involving Decomposition,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-537100-eggs-and-egg-products-frozen-adulteration-involving-decomposition,
FDA,,CPG Sec 535.100 Oleomargarine - Misbranding Due to Insufficient Fat,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-535100-oleomargarine-misbranding-due-insufficient-fat,
FDA,,CPG Sec 527.225 Cheese - Misbranding Due to Moisture and Fat,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527225-cheese-misbranding-due-moisture-and-fat,
FDA,,CPG Sec 527.100 Butter - Adulteration Involving Insufficient Fat Content,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527100-butter-adulteration-involving-insufficient-fat-content,
FDA,,"CPG Sec 525.950 Whole Plant (Unprocessed) Sage, and Ground Sage - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525950-whole-plant-unprocessed-sage-and-ground-sage-adulteration-insect-and-rodent-filth,
FDA,,"CPG Sec 525.925 Whole Plant (Unprocessed) Thyme, Unground (Processed) Thyme & Ground Thyme - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525925-whole-plant-unprocessed-thyme-unground-processed-thyme-ground-thyme-adulteration,
FDA,,"CPG Sec 525.900 Whole Plant (Unprocessed) Marjoram, Unground (Processed) Marjoram & Ground Marjoram - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525900-whole-plant-unprocessed-marjoram-unground-processed-marjoram-ground-marjoram,
FDA,,"CPG Sec 525.850 Whole Plant (Unprocessed) Oregano, Crushed Oregano & Ground Oregano - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525850-whole-plant-unprocessed-oregano-crushed-oregano-ground-oregano-adulteration-insect,
FDA,,CPG Sec 525.700 Sesame Seeds - Adulteration with Insect Filth; Decomposition; Mammalian Excreta; Foreign Matter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525700-sesame-seeds-adulteration-insect-filth-decomposition-mammalian-excreta-foreign-matter,
FDA,,CPG Sec 525.625 Whole and Ground Pepper - Adulteration with Insect & Rodent Filth; Mold; Mammalian Excreta; Foreign Matter,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525625-whole-and-ground-pepper-adulteration-insect-rodent-filth-mold-mammalian-excreta,
FDA,,CPG Sec 525.600 Whole and Ground Nutmeg - Adulteration with Insect Filth; Mold; Rodent Filth,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525600-whole-and-ground-nutmeg-adulteration-insect-filth-mold-rodent-filth,
FDA,,CPG Sec 525.550 Mace - Adulteration with Insect Filth; Mold; Foreign Matter; Mammalian Excreta,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525550-mace-adulteration-insect-filth-mold-foreign-matter-mammalian-excreta,
FDA,,"CPG Sec 525.500 Leafy Spices, Other than Bay Leaves - Whole Oregano Leaves, Whole Marjoram, Whole Sage Leaves and Whole Thyme Leaves - Adulteration with Insect Filth; Mold; Mammalian Excreta",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525500-leafy-spices-other-bay-leaves-whole-oregano-leaves-whole-marjoram-whole-sage-leaves,
FDA,,CPG Sec 525.375 Whole Ginger - Adulteration with Insect Filth; Mold; Mammalian Excreta,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525375-whole-ginger-adulteration-insect-filth-mold-mammalian-excreta,
FDA,,CPG Sec 525.350 Fennel Seed - Adulteration by Mammalian Excreta; Insects,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525350-fennel-seed-adulteration-mammalian-excreta-insects,
FDA,,CPG Sec 525.330 Curry Powder - Adulteration by Insect and Rodent Filth,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525330-curry-powder-adulteration-insect-and-rodent-filth,
FDA,,CPG Sec 525.325 Cumin Seed - Adulteration with Sand and Grit,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525325-cumin-seed-adulteration-sand-and-grit,
FDA,,CPG Sec 525.300 Condimental Seeds Other than Fennel Seeds and Sesame Seeds - Adulteration by Mammalian Excreta,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525300-condimental-seeds-other-fennel-seeds-and-sesame-seeds-adulteration-mammalian-excreta,
FDA,,CPG Sec 525.250 Cloves - Adulteration with Stems,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525250-cloves-adulteration-stems,
FDA,,"CPG Sec 525.200 Capsicum Pods, Ground Capsicums Excluding Paprika, Ground Paprika - Adulteration with Insect and Rodent Filth, Mold, Mammalian Excreta",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525200-capsicum-pods-ground-capsicums-excluding-paprika-ground-paprika-adulteration-insect,
FDA,,CPG Sec 525.150 Bay (Laurel) Leaves - Adulteration by Insect Filth; Mold; Mammalian Excreta,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525150-bay-laurel-leaves-adulteration-insect-filth-mold-mammalian-excreta,
FDA,,"CPG Sec 515.775 Cocoa Powder, Press Cake - Adulteration with Insect and Rodent Filth",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515775-cocoa-powder-press-cake-adulteration-insect-and-rodent-filth,
FDA,,"CPG Sec 515.750 Cocoa Beans - Adulteration by Mold, Insect Infestation, and Mammalian Excreta",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515750-cocoa-beans-adulteration-mold-insect-infestation-and-mammalian-excreta,
FDA,,CPG Sec 510.600 Dimethylnitrosamine in Malt Beverages,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510600-dimethylnitrosamine-malt-beverages,
FDA,,CPG Sec 510.500 Green Coffee Beans - Adulteration with Insects; Mold,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510500-green-coffee-beans-adulteration-insects-mold,
FDA,,CPG Sec 510.400 Dealcoholized Wine and Malt Beverages - Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510400-dealcoholized-wine-and-malt-beverages-labeling,
FDA,,"CPG Sec 510.150 Apple Juice, Apple Juice Concentrates, and Apple Juice Products - Adulteration with Patulin",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510150-apple-juice-apple-juice-concentrates-and-apple-juice-products-adulteration-patulin,
FDA,,"CPG Sec 505.100 Bakery Products, Candy - ""Catch-All"" or ""Shotgun"" Ingredients Declaration",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505100-bakery-products-candy-catch-all-or-shotgun-ingredients-declaration,
FDA,,CPG Sec 500.450 Volatile N-Nitrosamines in Rubber Baby Bottle Nipples,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500450-volatile-n-nitrosamines-rubber-baby-bottle-nipples,
FDA,,CPG Sec 500.425 Use of Color Additives in Paper and Paperboard Intended for Use with Food,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500425-use-color-additives-paper-and-paperboard-intended-use-food,
FDA,,"CPG Sec 500.200 Food Additives -""GRAS""",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500200-food-additives-gras,
FDA,,CPG Sec. 160.100 Regulatory Actions and Small Business,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-160100-regulatory-actions-and-small-business,
FDA,,CPG Sec 585.750 Sauerkraut - Definition; Adulteration by Thrips,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585750-sauerkraut-definition-adulteration-thrips,
FDA,,"CPG Sec 585.500 Mushrooms, Canned or Dried (Freeze-Dried or Dehydrated) - Adulteration Involving Maggots, Mites, Decomposition",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585500-mushrooms-canned-or-dried-freeze-dried-or-dehydrated-adulteration-involving-maggots,
FDA,,"CPG Sec 585.325 Corn on the Cob, Canned - Quantity of Contents Declaration",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585325-corn-cob-canned-quantity-contents-declaration,
FDA,,CPG Sec 578.500 Dimethylnitrosamine (DMNA) in Barley Malt,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578500-dimethylnitrosamine-dmna-barley-malt,
FDA,,"CPG Sec 550.650 Peaches, Canned, Frozen - Adulteration Due to Insects and Mold",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550650-peaches-canned-frozen-adulteration-due-insects-and-mold,
FDA,,CPG Sec 550.605 Olives Stuffed with Minced Pimentos - Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550605-olives-stuffed-minced-pimentos-labeling,
FDA,,"CPG Sec 550.475 Jellies, Nonstandardized",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550475-jellies-nonstandardized,
FDA,,"CPG Sec 540.410 Shrimp - Frozen, Raw, Breaded or Lightly Breaded, Misbranding Involving Non-Compliance with Standards",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540410-shrimp-frozen-raw-breaded-or-lightly-breaded-misbranding-involving-non-compliance,
FDA,,"CPG Sec 540.250 Clams, Mussels, Oysters, Fresh, Frozen or Canned - Paralytic Shellfish Poison",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540250-clams-mussels-oysters-fresh-frozen-or-canned-paralytic-shellfish-poison,
FDA,,"CPG Sec 540.200 Chubs, Hot Process Smoked with Added Nitrite - Adulteration Involving Food Additives, Sodium Nitrite",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540200-chubs-hot-process-smoked-added-nitrite-adulteration-involving-food-additives-sodium,
FDA,,CPG Sec 530.500 Wheat Germ Containing Non-Wheat Germ Tissue,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-530500-wheat-germ-containing-non-wheat-germ-tissue,
FDA,,"CPG Sec 527.400 Whole Milk, Lowfat Milk, Skim Milk - Aflatoxin M1",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527400-whole-milk-lowfat-milk-skim-milk-aflatoxin-m1,
FDA,,CPG Sec 527.350 Eggnog; Egg Nog Flavored Milk - Common or Usual Names,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527350-eggnog-egg-nog-flavored-milk-common-or-usual-names,
FDA,,CPG Sec 527.250 Cheese & Cheese Products - Misbranding Involving Net Contents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527250-cheese-cheese-products-misbranding-involving-net-contents,
FDA,,CPG Sec 525.800 Tomato Sauce or Tomato Hot Sauce Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525800-tomato-sauce-or-tomato-hot-sauce-labeling,
FDA,,CPG Sec 525.575 Prepared Mustard - Composition,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525575-prepared-mustard-composition,
FDA,,CPG Sec 525.100 Whole & Ground Allspice - Adulteration by Mold; Insect & Rodent Filth,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525100-whole-ground-allspice-adulteration-mold-insect-rodent-filth,
FDA,,CPG Sec 520.300 Acidified Low-Acid Canned Foods - Adulteration Due to High pH,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-520300-acidified-low-acid-canned-foods-adulteration-due-high-ph,
FDA,,CPG Sec 585.900 Tomato Products - Adulteration with Mold,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585900-tomato-products-adulteration-mold,
FDA,,CPG Sec 585.890 Tomato Products - Adulteration with Drosophila Fly Eggs and Maggots,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585890-tomato-products-adulteration-drosophila-fly-eggs-and-maggots,
FDA,,CPG Sec 585.875 Tomatoes - Canned - Misbranding Involving Food Standards (Peel),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585875-tomatoes-canned-misbranding-involving-food-standards-peel,
FDA,FDA-2004-D-0370,CVM GFI #135 Validation of Analytical Procedures for Type C Medicated Feeds,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-135-validation-analytical-procedures-type-c-medicated-feeds,
FDA,FDA-2020-D-0957,Applicability of the Performance Standard for High-Intensity Mercury Vapor Discharge Lamps (21 CFR 1040.30),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applicability-performance-standard-high-intensity-mercury-vapor-discharge-lamps-21-cfr-104030,
FDA,FDA-2005-D-0337,"Guidance for Industry: Notice to Growers, Food Manufacturers, Food Warehouse Managers, and Transporters of Food Products on Decontamination of Transport Vehicles",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-notice-growers-food-manufacturers-food-warehouse-managers-and-transporters-food,
FDA,FDA-2020-D-0957,Dental Composite Resin Devices - Premarket Notification [510(k)] Submissions -  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dental-composite-resin-devices-premarket-notification-510k-submissions-guidance-industry-and-fda,
FDA,FDA-2004-D-0366,S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s7b-nonclinical-evaluation-potential-delayed-ventricular-repolarization-qt-interval-prolongation,
FDA,FDA-2004-D-0241,E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-0,
FDA,FDA-2020-D-1938,"Review Criteria for Assessment of C-Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Assays:  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-criteria-assessment-c-reactive-protein-crp-high-sensitivity-c-reactive-protein-hscrp-and,
FDA,FDA-2020-D-0957,Letter to State Regulatory Agencies and Firms That Produce Treated (but not Pasteurized) and Untreated Juice and Cider,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/letter-state-regulatory-agencies-and-firms-produce-treated-not-pasteurized-and-untreated-juice-and,
FDA,,How to Comply with the Pediatric Research Equity Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-comply-pediatric-research-equity-act,
FDA,FDA-2005-D-0459,M5International Conference on Harmonisation; Draft Guidance on M5 Data Elements and Standards for Drug Dictionaries,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m5international-conference-harmonisation-draft-guidance-m5-data-elements-and-standards-drug,
FDA,FDA-2020-D-0957,Medical Devices with Sharps Injury Prevention Features -  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-devices-sharps-injury-prevention-features-guidance-industry-and-fda-staff,
FDA,,Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers,
FDA,FDA-2020-D-0957,Menstrual Tampons and Pads: Information for Premarket Notification Submissions (510(k)s) -  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/menstrual-tampons-and-pads-information-premarket-notification-submissions-510ks-guidance-industry,
FDA,,Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5e-comparability-biotechnologicalbiological-products-subject-changes-their-manufacturing-process,
FDA,FDA-2004-D-0440,Nonclinical Pharmacology/Toxicology Development of Topical Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases (STD) and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-pharmacologytoxicology-development-topical-drugs-intended-prevent-transmission-sexually,
FDA,FDA-2005-D-0139,Assessing Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-donor-suitability-and-blood-and-blood-product-safety-cases-known-or-suspected-west-nile,
FDA,FDA-2020-D-0957,Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-studies-safety-evaluation-pharmaceutical-excipients,
FDA,FDA-2002-D-0188,CPG Sec. 315.100 Illegal Interstate Commercial Shipment of Dentures (CPG retitled and revised 5/19/2005),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-315100-illegal-interstate-commercial-shipment-dentures-cpg-retitled-and-revised-5192005,
FDA,FDA-2003-D-0430,"Guidance for Industry: Channels of Trade Policy for Commodities With Residues of Pesticide Chemicals, for Which Tolerances Have Been Revoked, Suspended, or Modified by the Environmental Protection Agency Pursuant to Dietary Risk Considerations",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-channels-trade-policy-commodities-residues-pesticide-chemicals-which-tolerances,
FDA,,CPG Sec 560.400 Imported Milk and Cream - Federal Import Milk Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560400-imported-milk-and-cream-federal-import-milk-act,
FDA,,"CPG Sec 555.425  Foods, Adulteration Involving hard or Sharp Foreign Objects",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555425-foods-adulteration-involving-hard-or-sharp-foreign-objects,
FDA,,"CPG Sec 525.225 - Whole Cassia or Whole Cinnamon, Ground Cinnamon - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525225-whole-cassia-or-whole-cinnamon-ground-cinnamon-adulteration-insect-and-rodent-filth,
FDA,,Evaluating the Risks of Drug Exposure in Human Pregnancies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluating-risks-drug-exposure-human-pregnancies,
FDA,,CPG Sec. 100.700  GWQAP Pre-Award Evaluation - Inadequate Information to Evaluate Prospective Supplier,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100700-gwqap-pre-award-evaluation-inadequate-information-evaluate-prospective-supplier,
FDA,,Providing Regulatory Submissions in Electronic Format â€” Content of Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-content-labeling,
FDA,FDA-2020-D-1941,Guidance for Industry: Templates for Reporting Toxicology Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-templates-reporting-toxicology-data,
FDA,,Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-review-staff-and-industry-good-review-management-principles-and-practices-pdufa-products,
FDA,FDA-2020-D-1944,Guidance for Industry: Submitting Requests under 21 CFR 170.39 Threshold of Regulation for Substances Used in Food-Contact Articles,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-submitting-requests-under-21-cfr-17039-threshold-regulation-substances-used-food,
FDA,FDA-2013-N-0730,Guidance for Industry: Pre-Petition Consultations for Food Additives and Color Additives,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-pre-petition-consultations-food-additives-and-color-additives,
FDA,FDA-2004-D-0245,E2E Pharmacovigilance Planning,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2e-pharmacovigilance-planning,
FDA,,CPG Sec. 390.300 Assessment of Civil Penalties Against Manufacturers and Importers of Electronic Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390300-assessment-civil-penalties-against-manufacturers-and-importers-electronic-products,
FDA,FDA-2004-D-0544,Guidance for Industry: Dietary Supplement Labeling Guide,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-dietary-supplement-labeling-guide,
FDA,FDA-2004-D-0441,Premarketing Risk Assessment:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarketing-risk-assessment,
FDA,FDA-2004-D-0121,Development and Use of Risk Minimization Action Plans:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-use-risk-minimization-action-plans,
FDA,FDA-2004-D-0041,Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment,
FDA,FDA-1996-D-0168,E2B(M) Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2bm-questions-and-answers,
FDA,FDA-2020-D-0957,"Pharmacogenomic Data Submissions; Examples of Voluntary Submissions or Submissions Required Under 21 CFR 312, 314, or 601",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenomic-data-submissions-examples-voluntary-submissions-or-submissions-required-under-21-cfr,
FDA,,Pharmacogenomic Data Submissions:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenomic-data-submissions,
FDA,FDA-2003-D-0031,CPG Sec. 390.400 Examples of Electronic Products Subject to the Reporting Requirements Under 21 CFR 1000.15(a),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390400-examples-electronic-products-subject-reporting-requirements-under-21-cfr-100015a,
FDA,,"CPG Sec. 398.700 Reloaders of X-ray Tube Housing Assemblies; Applicability of Medical Device Establishment Registration, Device Listing and Biennial Inspection",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398700-reloaders-x-ray-tube-housing-assemblies-applicability-medical-device-establishment,
FDA,FDA-2020-D-0957,CPG Sec. 398.325 Regulatory Actions Against Assemblers Noncompliant Diagnostic X-Ray Equipment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398325-regulatory-actions-against-assemblers-noncompliant-diagnostic-x-ray-equipment,
FDA,,CPG Sec. 398.100 Definition of General Purpose Radiographic X-Ray System - 21 CFR 1020.30(b),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398100-definition-general-purpose-radiographic-x-ray-system-21-cfr-102030b,
FDA,,CPG Sec. 396.300 Defective Suntanning Booths and Bed,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-396300-defective-suntanning-booths-and-bed,
FDA,FDA-2005-D-0029,CPG Sec. 310.210 Blood Pressure Measurement Devices (Sphygmomanometers) - Accuracy,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-310210-blood-pressure-measurement-devices-sphygmomanometers-accuracy,
FDA,FDA-2020-D-0957,"Information for Healthcare Organizations about FDA's ""Guidance for Industry: Cybersecurity for Networked Medical Devices Containing Off-The-Shelf (OTS) Software""",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/information-healthcare-organizations-about-fdas-guidance-industry-cybersecurity-networked-medical,
FDA,FDA-2004-D-0181,CVM GFI #173 Appendix for the Animal Drug Sponsor Fees Under ADUFA,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-173-appendix-animal-drug-sponsor-fees-under-adufa,
FDA,FDA-2004-D-0181,CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-173-animal-drug-sponsor-fees-under-animal-drug-user-fee-act-adufa,
FDA,,Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/gingivitis-development-and-evaluation-drugs-treatment-or-prevention,
FDA,FDA-2020-D-0957,Cybersecurity for Networked Medical Devices Containing Off-the-Shelf (OTS) Software:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-networked-medical-devices-containing-shelf-ots-software,
FDA,FDA-2000-P-0063,Guidance for Industry: Labeling for Cosmetics Containing Alpha Hydroxy Acids,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-labeling-cosmetics-containing-alpha-hydroxy-acids,
FDA,FDA-2001-D-0134,Submitting Separate Marketing Applications and Clinical Data for Purposes of Assessing User Fees:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-separate-marketing-applications-and-clinical-data-purposes-assessing-user-fees,
FDA,,M4:  The CTD -- General Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-ctd-general-questions-and-answers,
FDA,FDA-2020-D-0957,M4: The CTD -- Efficacy Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-ctd-efficacy-questions-and-answers,
FDA,,Clinical Data Presentations for Orthopedic Device Applications -  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-data-presentations-orthopedic-device-applications-guidance-industry-and-fda-staff,
FDA,FDA-2004-D-0179,Changes to an Approved NDA or ANDA; Specifications â€“ Use of Enforcement Discretion for Compendial Changes:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-nda-or-anda-specifications-use-enforcement-discretion-compendial-changes,
FDA,FDA-2002-D-0148,CVM GFI #122 Manufacture and Labeling of Raw Meat Foods for Companion and Captive Noncompanion Carnivores and Omnivores,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-122-manufacture-and-labeling-raw-meat-foods-companion-and-captive-noncompanion-carnivores,
FDA,,CPG Sec. 130.400  Use of Microfiche and/or Microfilm for Method of Records Retention,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-130400-use-microfiche-andor-microfilm-method-records-retention,
FDA,FDA-2004-D-0459,"Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-obtaining-labeling-claim-communicable-disease-donor-screening-tests-using-cadaveric,
FDA,FDA-2005-D-0273,"Pharmacokinetics in Pregnancy â€” Study Design, Data Analysis, and Impact on Dosing and Labeling",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-pregnancy-study-design-data-analysis-and-impact-dosing-and-labeling,
FDA,FDA-2020-D-0957,Clinical Trial Considerations: Vertebral Augmentation Devices to Treat Spinal Insufficiency Fractures -  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-considerations-vertebral-augmentation-devices-treat-spinal-insufficiency-fractures,
FDA,FDA-2001-D-0095,Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately Reduce the Risk of Transmission of  of HIV-1 and HCV:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-nucleic-acid-tests-pooled-and-individual-samples-donors-whole-blood-and-blood-components-0,
FDA,FDA-2003-D-0032,Sterile Drug Products Produced by Aseptic Processing â€” Current Good Manufacturing Practice:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice,
FDA,FDA-2003-D-0145,"PAT â€” A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pat-framework-innovative-pharmaceutical-development-manufacturing-and-quality-assurance,
FDA,FDA-2004-D-0531,Guidance for Industry: Recommendations to Processors of Apple Juice or Cider on the Use of Ozone for Pathogen Reduction Purposes,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-processors-apple-juice-or-cider-use-ozone-pathogen-reduction,
FDA,FDA-2004-D-0286,"FDA Review of Vaccine Labeling Requirements for Warnings, Use Instructions, and Precautionary Information:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-review-vaccine-labeling-requirements-warnings-use-instructions-and-precautionary-information,
FDA,,Class II Special Controls Guidance Document: Serological Assays for the Detection of Beta-Glucan (PDF version),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/class-ii-special-controls-guidance-document-serological-assays-detection-beta-glucan-pdf-version,
FDA,FDA-2002-D-0053,The Use of Clinical Holds Following Clinical Investigator Misconduct:  Guidance for Industry and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-clinical-holds-following-clinical-investigator-misconduct,
FDA,FDA-2003-D-0288,Independent Consultants for Biotechnology Clinical Trial Protocols:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/independent-consultants-biotechnology-clinical-trial-protocols,
FDA,None found,Calcium DTPA and Zinc DTPA Drug Products-Submitting a New Drug Application,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/calcium-dtpa-and-zinc-dtpa-drug-products-submitting-new-drug-application,
FDA,FDA-1998-D-0035,"Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis, and Interpretation of Clinical Studies",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-medical-imaging-drug-and-biological-products-part-3-design-analysis-and-interpretation,
FDA,FDA-1998-D-0035,Developing Medical Imaging Drug and Biological Products Part 2: Clinical Indications,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-medical-imaging-drug-and-biological-products-part-2-clinical-indications,
FDA,FDA-1998-D-0035,Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-medical-imaging-drug-and-biological-products-part-1-conducting-safety-assessments,
FDA,,CPG Sec. 690.300  Canned Pet Food (Withdrawn 4/30/2019),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-690300-canned-pet-food-withdrawn-4302019,
FDA,FDA-2002-D-0261,M4: The CTD -- Quality Questions and Answers /Location Issues,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-ctd-quality-questions-and-answers-location-issues,
FDA,FDA-2002-D-0180,Q1E Evaluation of Stability Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1e-evaluation-stability-data,
FDA,FDA-2003-D-0309,"Medical Device User Fee and Modernization Act of 2002, Validation Data in Premarket Notification Submissions (510(k)s) for Reprocessed Single-Use Medical Devices:  Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-user-fee-and-modernization-act-2002-validation-data-premarket-notification,
FDA,,Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System (PDF version),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/class-ii-special-controls-guidance-document-immunomagnetic-circulating-cancer-cell-selection-and,
FDA,FDA-2004-D-0502,Submission and Resolution of Formal Disputes Regarding the Timeliness of Premarket Review of a Combination Product:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-and-resolution-formal-disputes-regarding-timeliness-premarket-review-combination-product,
FDA,FDA-2020-D-0957,Guidance for Industry and FDA Staff: Spinal System 510(k)s,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-staff-spinal-system-510ks,
FDA,FDA-2003-D-0152,CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-144-vich-gl27-pre-approval-information-registration-new-veterinary-medicinal-products-food,
FDA,,"Redbook 2000: VII Glossary, Acronyms and Definitions",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-vii-glossary-acronyms-and-definitions,
FDA,FDA-1999-D-0049,Changes to an Approved NDA or ANDA:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-nda-or-anda,
FDA,,CPG Sec. 490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-490100-process-validation-requirements-drug-products-and-active-pharmaceutical-ingredients-0,
FDA,,CPG Sec.  490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-490100-process-validation-requirements-drug-products-and-active-pharmaceutical-ingredients,
FDA,FDA-2003-D-0029,Potassium Iodide Tablets - Shelf Life Extension,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potassium-iodide-tablets-shelf-life-extension,
FDA,FDA-2003-D-0305,Surgical Masks - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/surgical-masks-premarket-notification-510k-submissions,
FDA,FDA-2002-D-0298,"Guidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance, First Edition",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-juice-hazard-analysis-critical-control-point-hazards-and-controls-guidance-first,
FDA,FDA-2020-D-0957,Guidance for Industry and FDA Staff: Vocal Fold Medialization Devices - Premarket Notification [510(k)] Submissions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-staff-vocal-fold-medialization-devices-premarket-notification-510k,
FDA,,IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-exemptions-studies-lawfully-marketed-drug-or-biological-products-treatment-cancer,
FDA,FDA-2020-D-0957,Premarket Notification [510(k)] Submissions for Chemical Indicators - Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-510k-submissions-chemical-indicators-guidance-industry-and-fda-staff,
FDA,FDA-2002-D-0222,Q1A(R2) Stability Testing of New Drug Substances and Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products,
FDA,FDA-2020-D-0957,Premarket Approval Application Modular Review:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-approval-application-modular-review,
FDA,,Redbook 2000: IV.C.5.b. One-Year Toxicity Studies with Non-Rodents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc5b-one-year-toxicity-studies-non-rodents,
FDA,,Redbook 2000: IV.C.4.b. Subchronic Toxicity Studies with Non-Rodents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc4b-subchronic-toxicity-studies-non-rodents,
FDA,,Redbook 2000: IV.C.4.a. Subchronic Toxicity Studies with Rodents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc4a-subchronic-toxicity-studies-rodents,
FDA,,Redbook 2000: IV.C.3.b. Short-Term Toxicity Studies with Non-Rodents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc3b-short-term-toxicity-studies-non-rodents,
FDA,,Redbook 2000: IV.C.3.a. Short-Term Toxicity Studies with Rodents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc3a-short-term-toxicity-studies-rodents,
FDA,,Redbook 2000: IV.C.1.b. In vitro Mammalian Chromosomal Aberration Test,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc1b-in-vitro-mammalian-chromosomal-aberration-test,
FDA,,Redbook 2000: IV.B.2 Guidelines for Reporting the Results of Toxicity Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivb2-guidelines-reporting-results-toxicity-studies,
FDA,,Redbook 2000: IV.B.1. General Guidelines for Designing and Conducting Toxicity Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivb1-general-guidelines-designing-and-conducting-toxicity-studies,
FDA,,Redbook 2000: IV. A. Introduction to Guidelines for Toxicity Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-iv-introduction-guidelines-toxicity-studies,
FDA,FDA-1997-D-0056,Small Entity Compliance Guide: Label Warning Statements for Iron-Containing Supplements and Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-label-warning-statements-iron-containing-supplements-and-drugs,
FDA,FDA-2003-D-0371,E2D Postapproval Safety Data Management: Definitions and Standards for Expedited Reporting,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2d-postapproval-safety-data-management-definitions-and-standards-expedited-reporting,
FDA,FDA-2003-D-0143,"Part 11, Electronic Records; Electronic Signatures - Scope and Application:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application,
FDA,FDA-2020-D-0957,Information Disclosure by Manufacturers to Assemblers for Diagnostic X-ray Systems - Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/information-disclosure-manufacturers-assemblers-diagnostic-x-ray-systems-guidance-industry-and-fda,
FDA,FDA-2020-D-1951,Guidance for Industry: Questions and Answers on Juice HACCP Regulation (2003),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-juice-haccp-regulation-2003,
FDA,FDA-2003-D-0035,"Small Entity Compliance Guide: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-trans-fatty-acids-nutrition-labeling-nutrient-content-claims-and,
FDA,FDA-2003-D-0037,IRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irb-review-stand-alone-hipaa-authorizations-under-fda-regulations,
FDA,FDA-2020-D-0957,"Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors - Three Additional Questions:  Guidance for Industry, FDA Staff, Third-Party and Hospital Reprocessors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-about-reprocessing-and-reuse-single-use-devices-third-party-and-hospital-0,
FDA,FDA-2003-N-0103,Guidance for Industry: Interim Procedures for Qualified Health Claims in the Labeling of Conventional Human Food and Human Dietary Supplements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-interim-procedures-qualified-health-claims-labeling-conventional-human-food-and,
FDA,FDA-2002-D-0524,Streamlining the Donor Interview Process: Recommendations for Self-Administered Questionnaires:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/streamlining-donor-interview-process-recommendations-self-administered-questionnaires,
FDA,2003D-0325,180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/180-day-exclusivity-when-multiple-andas-are-submitted-same-day,
FDA,FDA-2002-D-0227,Guidance for Industry: Standardized Training Curriculum for Application of HACCP Principles to Juice Processing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-standardized-training-curriculum-application-haccp-principles-juice-processing,
FDA,FDA-2003-D-0090,"Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate â€” Labeling Enforcement Policy",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-containing-ensulizole-hypromellose-meradimate-octinoxate-and-octisalate-labeling,
FDA,FDA-2003-D-0147,Pediatric Expertise for Advisory Panels - Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-expertise-advisory-panels-guidance-industry-and-fda-staff,
FDA,FDA-1999-D-0063,"Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and,
FDA,FDA-1999-D-0030,"INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inds-phase-2-and-phase-3-studies-chemistry-manufacturing-and-controls-information,
FDA,FDA-2002-D-0177,"Exposure-Response Relationships â€” Study Design, Data Analysis, and Regulatory Applications",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exposure-response-relationships-study-design-data-analysis-and-regulatory-applications,
FDA,FDA-2001-D-0102,CVM GFI #118 Mass Spectrometry for Confirmation of Identity of Animal Drug Residues,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-118-mass-spectrometry-confirmation-identity-animal-drug-residues,
FDA,FDA-2002-P-0302,Guidance for Industry: Bulk Transport of Juice Concentrates and Certain Shelf-Stable Juices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-bulk-transport-juice-concentrates-and-certain-shelf-stable-juices,
FDA,,Guidance for Industry: Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-recommendations-assessment-donor-suitability-and-blood-product-safety-cases,
FDA,,"Statistical Information from the June 1999 Draft Guidance and Statistical Information for In Vitro Bioequivalence Data Posted on August 18, 1999",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-information-june-1999-draft-guidance-and-statistical-information-in-vitro-bioequivalence,
FDA,FDA-2003-D-0283,Small Entity Compliance Guide: Juice HACCP,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-juice-haccp,
FDA,FDA-1999-D-0050,Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-and-bioequivalence-studies-nasal-aerosols-and-nasal-sprays-local-action,
FDA,FDA-2020-D-0957,User Labeling for Devices that Contain Natural Rubber (21 CFR 801.437); Small Entity Compliance Guide - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-labeling-devices-contain-natural-rubber-21-cfr-801437-small-entity-compliance-guide-guidance,
FDA,FDA-2003-D-0285,Integration of Dose-Counting Mechanisms into MDI Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/integration-dose-counting-mechanisms-mdi-drug-products,
FDA,,Prussian Blue Drug Products â€” Submitting a New Drug Application,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prussian-blue-drug-products-submitting-new-drug-application,
FDA,FDA-2003-D-0727,M4: The CTD -- Safety Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-ctd-safety-questions-and-answers,
FDA,FDA-2020-D-0957,Quality System Information for Certain Premarket Application Reviews :  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-system-information-certain-premarket-application-reviews,
FDA,,Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms â€” Recommendations for Clinical Evaluation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estrogen-and-estrogenprogestin-drug-products-treat-vasomotor-symptoms-and-vulvar-and-vaginal-atrophy,
FDA,FDA-2001-D-0164,Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1d-bracketing-and-matrixing-designs-stability-testing-new-drug-substances-and-products,
FDA,FDA-2002-D-0013,Recommendations for Deferral of Donors and Quarantine and Retrieval of Blood and Blood Products in Recent Recipients of Smallpox Vaccine (Vaccinia Virus) and Certain Contacts of Smallpox Vaccine Recipients:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-deferral-donors-and-quarantine-and-retrieval-blood-and-blood-products-recent,
FDA,None found,(Potassium Iodide) KI in Radiation Emergencies-Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potassium-iodide-ki-radiation-emergencies-questions-and-answers,
FDA,FDA-2002-D-0174,"Guidance for Industry: Implementation of Section 403(t) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 343(t)) Regarding the Use of the Term ""Catfish""",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-implementation-section-403t-federal-food-drug-and-cosmetic-act-21-usc-343t,
FDA,FDA-2020-D-0957,Determination of Intended Use for 510(k) Devices - Guidance for CDRH Staff (Update to K98-1),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determination-intended-use-510k-devices-guidance-cdrh-staff-update-k98-1,
FDA,FDA-2001-D-0040,Food-Effect Bioavailability and Fed Bioequivalence Studies:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/food-effect-bioavailability-and-fed-bioequivalence-studies,
FDA,FDA-1994-D-0007,CVM GFI #80 Evaluation the Utility of Anti-Salmonella Chemical Food Additives,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-80-evaluation-utility-anti-salmonella-chemical-food-additives,
FDA,,"CPG Sec 555.600 Filth from Insects, Rodents, and Other Pests in Foods",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555600-filth-insects-rodents-and-other-pests-foods,
FDA,FDA-2020-D-0957,"Needlesticks -  Medical Device Reporting Guidance for User Facilities, Manufacturers, and Importers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/needlesticks-medical-device-reporting-guidance-user-facilities-manufacturers-and-importers,
FDA,FDA-2002-D309,Draft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been Reconditioned,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-regulatory-procedures-manual-chapter-9-subchapter-recommending-customs,
FDA,FDA-1999-N-1881,CVM GFI #82 Development of Supplemental Applications for Approved New Animal Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-82-development-supplemental-applications-approved-new-animal-drugs,
FDA,,Guidance for Small Businesses: Submission of Comments for CFSAN Rulemaking,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-small-businesses-submission-comments-cfsan-rulemaking,
FDA,FDA-2001-D-0135,Labeling OTC Human Drug Products Updating Labeling in RLDs and ANDAs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-otc-human-drug-products-updating-labeling-rlds-and-andas,
FDA,FDA-2002-D-0189,Guidance for Industry: Exemptions from the Warning Label Requirement for Juice,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-exemptions-warning-label-requirement-juice,
FDA,FDA-2001-D-0138,Guidance for Industry:  Implementation of Section 10809 of the Farm Security and Investment Act of 2002 Regarding the Petition Process to Request Approval of Labeling for Foods that Have Been Treated with Irradiation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-implementation-section-10809-farm-security-and-investment-act-2002-regarding,
FDA,FDA-2001-D-0011,CVM GFI #119 How CVM Intends to Handle Deficient Submissions Filed During the Investigation of a New Animal Drug,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-119-how-cvm-intends-handle-deficient-submissions-filed-during-investigation-new-animal-drug,
FDA,FDA-2020-D-0957,Guidance on the Department of Defense Exemption from the FDA Performance Standard for Laser Products:  Guidance for Industry and FDA,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-department-defense-exemption-fda-performance-standard-laser-products,
FDA,FDA-1999-D-0060,"Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nasal-spray-and-inhalation-solution-suspension-and-spray-drug-products-chemistry-manufacturing-and,
FDA,FDA-2020-D-0957,Guidance for Resorbable Adhesion Barrier Devices for Use in Abdominal and/or Pelvic Surgery - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-resorbable-adhesion-barrier-devices-use-abdominal-andor-pelvic-surgery-guidance-industry,
FDA,FDA-2001-D-0094,Guidance for Industry: Channels of Trade Policy for Commodities with Vinclozolin Residues,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-channels-trade-policy-commodities-vinclozolin-residues,
FDA,FDA-2000-D-1405,Carcinogenicity Study Protocol Submissions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/carcinogenicity-study-protocol-submissions,
FDA,None found,Container Closure Systems for Packaging Human Drugs and Biologics -- Questions and Answers:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-packaging-human-drugs-and-biologics-questions-and-answers,
FDA,FDA-1996-D-0168,E2BM Data Elements for Transmission Of Individual Case Safety Reports,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2bm-data-elements-transmission-individual-case-safety-reports,
FDA,FDA-2002-D-0181,Validation of Procedures for Processing of Human Tissues Intended for Transplantation:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/validation-procedures-processing-human-tissues-intended-transplantation,
FDA,,Guidance for Industry: Providing Regulatory Submissions to CBER in Electronic Format -- Investigational New Drug Applications (INDs) (PDF),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-providing-regulatory-submissions-cber-electronic-format-investigational-new-drug,
FDA,FDA-1997-D-0029,General Principles of Software Validation:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation,
FDA,FDA-1998-N-0071,Small Entity Compliance Guide on Structure/Function Claims,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-structurefunction-claims,
FDA,FDA-2020-D-0957,Sterilized Convenience Kits for Clinical and Surgical Use:  Final Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterilized-convenience-kits-clinical-and-surgical-use,
FDA,FDA-2000-D-1403,Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potassium-iodide-thyroid-blocking-agent-radiation-emergencies,
FDA,FDA-2001-D-0398,CVM GFI #142 (VICH GL29) Pharmacovigilance of Veterinary Medicinal Products: Management of Periodic Summary Update Reports (PSUs),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-142-vich-gl29-pharmacovigilance-veterinary-medicinal-products-management-periodic-summary,
FDA,FDA-1999-D-1301,Information Request and Discipline Review Letters Under the Prescription Drug User Fee Act:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/information-request-and-discipline-review-letters-under-prescription-drug-user-fee-act,
FDA,,Guidance for Industry: Fumonisin Levels in Human Foods and Animal Feeds,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-fumonisin-levels-human-foods-and-animal-feeds,
FDA,,Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation â€” Small Entity Compliance Guide:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterility-requirement-aqueous-based-drug-products-oral-inhalation-small-entity-compliance-guide,
FDA,FDA-2001-D-0488,Recommendations for Assessment of Donor Suitability and Blood and Blood Product Safety in Cases of Possible Exposure to Anthrax:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-assessment-donor-suitability-and-blood-and-blood-product-safety-cases-possible,
FDA,FDA-2000-D-0100,Cancer Drug and Biological Products - Clinical Data in Marketing Applications,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-drug-and-biological-products-clinical-data-marketing-applications,
FDA,,Redbook 2000: VI.B Epidemiology,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-vib-epidemiology,
FDA,FDA-2001-D-0061,Submitting Marketing Applications According to the ICH/CTD Format: General Considerations 2001,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-marketing-applications-according-ichctd-format-general-considerations-2001,
FDA,,Submitting Marketing Applications According to the ICH/CTD Format: General Considerations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-marketing-applications-according-ichctd-format-general-considerations,
FDA,,Guidance for Industry: Questions and Answers on Juice HACCP Regulation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-juice-haccp-regulation,
FDA,,Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7a-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients,
FDA,,M4S: The CTD -- Safety Appendices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4s-ctd-safety-appendices,
FDA,,M4S: The CTD -- Safety,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4s-ctd-safety,
FDA,,M4: The CTD -- Quality,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4-ctd-quality,
FDA,FDA-2020-D-0957,Labeling Recommendations for Single-Use Devices Reprocessed by Third Parties and Hospitals:  Final Guidance for Industry and FDA,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-recommendations-single-use-devices-reprocessed-third-parties-and-hospitals,
FDA,FDA-2007-D-0251,Premarket Notification Submissions for Transfer Sets (Excluding Sterile Connecting Devices):  Guidance for FDA Reviewers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-submissions-transfer-sets-excluding-sterile-connecting-devices,
FDA,FDA-2022-D-0484,Premarket Notification Submissions for Blood and Plasma Warmers:  Guidance for FDA Reviewers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-submissions-blood-and-plasma-warmers,
FDA,FDA-2022-D-0485,Premarket Notification Submissions for Empty Containers for the Collection and Processing of Blood and Blood Components:  Guidance for FDA Reviewers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-submissions-empty-containers-collection-and-processing-blood-and-blood,
FDA,,S7A Safety Pharmacology Studies for Human Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s7a-safety-pharmacology-studies-human-pharmaceuticals,
FDA,FDA-2000-D-0274,"Levothyroxine Sodium Products Enforcement of August 14, 2001 Compliance Date and Submission of New Applications",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/levothyroxine-sodium-products-enforcement-august-14-2001-compliance-date-and-submission-new,
FDA,FDA-1999-D-0743,Revised Recommendations Regarding Invalidation of Test Results of Licensed and 510(k) Cleared Bloodborne Pathogen Assays Used to Test Donors:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-regarding-invalidation-test-results-licensed-and-510k-cleared-bloodborne,
FDA,FDA-2021-D-0619,CVM GFI #56 Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-56-protocol-development-guideline-clinical-effectiveness-and-target-animal-safety-trials,
FDA,FDA-2021-D-0611,CVM GFI #104 Content and Format of Effectiveness and Target Animal Safety Technical Sections and Final Study Reports For Submission,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-104-content-and-format-effectiveness-and-target-animal-safety-technical-sections-and-final,
FDA,FDA-2020-D-0957,Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors:  Final Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-about-reprocessing-and-reuse-single-use-devices-third-party-and-hospital,
FDA,FDA-2000-D-0278,"Small Entity Compliance Guide: Serving Sizes Reference Amount for Baking Powder, Baking Soda, and Pectin",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-serving-sizes-reference-amount-baking-powder-baking-soda-and-pectin,
FDA,FDA-2020-D-1954,Small Entity Compliance Guide: Safe Handling Statements on Labeling of Shell Eggs and the Refrigeration of Shell Eggs Held for Retail Distribution,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-safe-handling-statements-labeling-shell-eggs-and-refrigeration-shell,
FDA,FDA-2020-D-1955,Guidance for Industry: Refusal of Inspection or Access to HACCP Records Pertaining to the Safe and Sanitary Processing of Fish and Fishery Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-refusal-inspection-or-access-haccp-records-pertaining-safe-and-sanitary-processing,
FDA,FDA-2020-D-0957,Information for Keratome Manufacturers Regarding LASIK - Final Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/information-keratome-manufacturers-regarding-lasik-final-guidance-industry,
FDA,FDA-2020-D-0957,Changes or Modifications During the Conduct of a Clinical Investigation; Final Guidance for Industry and CDRH Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-or-modifications-during-conduct-clinical-investigation-final-guidance-industry-and-cdrh,
FDA,FDA-2020-D-0957,"Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; (Laser Notice 51)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/responsibilities-laser-light-show-projector-manufacturers-dealers-and-distributors-laser-notice-51,
FDA,FDA-1999-D-1874,E10 Choice of Control Group and Related Issues in Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e10-choice-control-group-and-related-issues-clinical-trials,
FDA,FDA-1999-D-0754,CVM GFI #85 (VICH GL9) Good Clinical Practice,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-85-vich-gl9-good-clinical-practice,
FDA,FDA-2001-D-0043,"Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-aspects-design-analysis-and-interpretation-chronic-rodent-carcinogenicity-studies,
FDA,,"IND Meetings for Human Drugs and Biologics Chemistry, Manufacturing, and Controls Information:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-meetings-human-drugs-and-biologics-chemistry-manufacturing-and-controls-information,
FDA,FDA-2000-D-0067,Guidance on Medical Device Patient Labeling:  Final Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-medical-device-patient-labeling,
FDA,,"Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities - FDA Public Health Advisory:  Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-hospitals-nursing-homes-and-other-health-care-facilities-fda-public-health-advisory,
FDA,FDA-2021-D-0612,CVM GFI #99 (VICH GL17) Testing of New Biotechnological/Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-99-vich-gl17-testing-new-biotechnologicalbiological-products,
FDA,FDA-2001-D-0506,Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines: Draft Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-safety-reporting-human-drug-and-biological-products-including-vaccines,
FDA,FDA-1999-D-0010,Levothyroxine Sodium Tablets - In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/levothyroxine-sodium-tablets-in-vivo-pharmacokinetic-and-bioavailability-studies-and-in-vitro-dissolution,
FDA,FDA-1999-D-3541,CVM GFI #89 (VICH GL6) EIAs for Veterinary Medicinal Products  - Phase I,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-89-vich-gl6-eias-veterinary-medicinal-products-phase-i,
FDA,,Monoclonal Antibodies Used as Reagents in Drug Manufacturing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/monoclonal-antibodies-used-reagents-drug-manufacturing,
FDA,FDA-2020-D-0957,Early Collaboration Meetings Under the FDA Modernization Act (FDAMA); Final Guidance for Industry and for CDRH Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-collaboration-meetings-under-fda-modernization-act-fdama-final-guidance-industry-and-cdrh,
FDA,FDA-1998-D-0851,Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods - Technical Correction February 2001:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-collecting-red-blood-cells-automated-apheresis-methods-technical-correction-february,
FDA,None found,Clinical Development and Labeling of Anti-Infective Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-development-and-labeling-anti-infective-drug-products,
FDA,01D-0027,Statistical Approaches to Establishing Bioequivalence,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence,
FDA,FDA-1996-M-0140,PHS Guideline on Infectious Disease Issues in Xenotransplantation:  PHS Guideline,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/phs-guideline-infectious-disease-issues-xenotransplantation,
FDA,FDA-2020-D-0957,"Content of Investigational Device Exemptions for Solutions for Hypothermic Flushing, Transport and Storage of Organs for Transplantation - Guidance for Industry and FDA Reviewers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-investigational-device-exemptions-solutions-hypothermic-flushing-transport-and-storage,
FDA,FDA-1999-D-0049,Changes to an Approved NDA or ANDA: Questions and Answers:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-nda-or-anda-questions-and-answers,
FDA,FDA-1997-D-0005,Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products:  Chemical Substances,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products,
FDA,FDA-1999-D-1300,Labeling OTC Human Drug Products Using a Column Format,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-otc-human-drug-products-using-column-format,
FDA,FDA-2000-D-0942,E11 Clinical Investigation of Medicinal Products in the Pediatric Population,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e11-clinical-investigation-medicinal-products-pediatric-population,
FDA,None found,Alternate Source of the Active Pharmaceutical Ingredient in Pending ANDAs:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alternate-source-active-pharmaceutical-ingredient-pending-andas,
FDA,FDA-2000-D-0028,Guidance for Industry: Channels of Trade Policy for Commodities with Methyl Parathion Residues,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-channels-trade-policy-commodities-methyl-parathion-residues,
FDA,FDA-2022-D-0486,Use of Sterile Connecting Devices in Blood Bank Practices:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-sterile-connecting-devices-blood-bank-practices,
FDA,FDA-2020-D-0957,Guidance Document for Dura Substitute Devices - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-dura-substitute-devices-guidance-industry,
FDA,FDA-1998-D-0279,Submitting and Reviewing Complete Responses to Clinical Holds (Revised),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-and-reviewing-complete-responses-clinical-holds-revised,
FDA,None found,"Content and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products.  Questions and Answers:  Guidance for Industry Q&A",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-inds-phase-1-studies-drugs-including-well-characterized-therapeutic-biotechnology,
FDA,,"CPG Sec. 230.110-  Registration of Blood Banks, Other Firms Collecting, Manufacturing, Preparing or Processing Human Blood or Blood Products",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-230110-registration-blood-banks-other-firms-collecting-manufacturing-preparing-or-processing,
FDA,FDA-2020-D-0957,Labeling for Electronic Anti-Theft Systems:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-electronic-anti-theft-systems,
FDA,FDA-2000-D-0785,E12A Principles for Clinical Evaluation of New Antihypertensive Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e12a-principles-clinical-evaluation-new-antihypertensive-drugs,
FDA,FDA-2020-D-0957,Guidance on Section 216 of the Food and Drug Administration Modernization Act of 1997 - Guidance for Industry and for FDA Reviewers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-section-216-food-and-drug-administration-modernization-act-1997-guidance-industry-and-fda,
FDA,,Guidance for the Submission of Premarket Notifications for Photon-Emitting Brachytherapy Sources - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-submission-premarket-notifications-photon-emitting-brachytherapy-sources-guidance-industry,
FDA,FDA-2020-D-0957,CPG Sec 515.700 Chocolate & Chocolate Liquor - Adulteration with Insect and Rodent Filth,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515700-chocolate-chocolate-liquor-adulteration-insect-and-rodent-filth,
FDA,,Guidance for Industry: Action Levels for Poisonous or Deleterious Substances in Human Food and Animal Feed,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-action-levels-poisonous-or-deleterious-substances-human-food-and-animal-feed,
FDA,,CPG Sec. 270.100 Final Container Labels - Allergenic Extracts Containing Glycerin; Reporting Changes,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-270100-final-container-labels-allergenic-extracts-containing-glycerin-reporting-changes,
FDA,FDA-2020-D-1956,CPG Sec. 220.100 - IS Shipment Biologicals for Medical Emergency,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-220100-shipment-biologicals-medical-emergency,
FDA,FDA-2020-D-0957,Guidance for Over-the-Counter (OTC) Human Chorionic Gonadotropin (hCG) 510(k)s - Guidance for Industry and FDA Reviewers/Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-over-counter-otc-human-chorionic-gonadotropin-hcg-510ks-guidance-industry-and-fda,
FDA,FDA-2020-D-0957,1-Consolidated Annual Report for a Device product line (1-CARD) - Guidance for Industry and CDRH Reviewers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/1-consolidated-annual-report-device-product-line-1-card-guidance-industry-and-cdrh-reviewers,
FDA,,Redbook 2000: IV.C.9.b. Guidelines for Developmental Toxicity Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc9b-guidelines-developmental-toxicity-studies,
FDA,,Redbook 2000: IV.C.9.a.Guidelines for Reproduction Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc9aguidelines-reproduction-studies,
FDA,,Redbook 2000: IV.C.10. Neurotoxicity Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc10-neurotoxicity-studies,
FDA,,Redbook 2000: IV.C.1.d. Mammalian Erythrocyte Micronucleus Test,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc1d-mammalian-erythrocyte-micronucleus-test,
FDA,,Redbook 2000: IV.C.1.a. Bacterial Reverse Mutation Test,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc1a-bacterial-reverse-mutation-test,
FDA,,Redbook 2000: IV.B.3. Pathology Considerations in Toxicity Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivb3-pathology-considerations-toxicity-studies,
FDA,,CPG Sec. 100.950  International Partnership Agreements for Compliance Activities,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100950-international-partnership-agreements-compliance-activities,
FDA,FDA-1999-D-2441,CVM GFI #98  Dioxin In Anti-Caking Agents In Animal Feed And Feed Ingredients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-98-dioxin-anti-caking-agents-animal-feed-and-feed-ingredients,
FDA,FDA-2020-D-0957,Guidance for Premarket Submissions of Orthokeratology Rigid Gas Permeable Contact Lenses - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-premarket-submissions-orthokeratology-rigid-gas-permeable-contact-lenses-guidance-industry,
FDA,FDA-2000-D-0783,Street Drug Alternatives,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/street-drug-alternatives,
FDA,,"CPG Sec. 215.100 IND Filings; Completion of Applicable Portions Prior to Final Action on License Applications or License Supplements, Deleted 03/28/2000, Outdated and Obsolete",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-215100-ind-filings-completion-applicable-portions-prior-final-action-license-applications-or,
FDA,,"Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/court-decisions-anda-approvals-and-180-day-exclusivity-under-hatch-waxman-amendments-federal-food,
FDA,FDA-2020-D-0957,"Guidance for Manufacturers Seeking Marketing Clearance of Ear, Nose, and Throat Endoscope Sheaths Used as Protective Barriers: Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-manufacturers-seeking-marketing-clearance-ear-nose-and-throat-endoscope-sheaths-used,
FDA,,"CPG Sec. 252.110 Volume Limits for Automated Collection of Source Plasma (Obsolete, Withdrawn on 11/28/2017)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-252110-volume-limits-automated-collection-source-plasma-obsolete-withdrawn-11282017,
FDA,FDA-2021-D-0613,CVM GFI #91 (VICH GL8) Stability Testing for Medicated Premixes,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-91-vich-gl8-stability-testing-medicated-premixes,
FDA,FDA-2020-D-0957,NDAs: Impurities in Drug Substances,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ndas-impurities-drug-substances,
FDA,FDA-1998-D-0277,Guidance for Industry on the Testing of Metallic Plasma Sprayed Coatings on Orthopedic Implants to Support Reconsideration of Postmarket Surveillance Requirements - Guidance for Industry and for FDA Reviewers/Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-testing-metallic-plasma-sprayed-coatings-orthopedic-implants-support,
FDA,FDA-1999-D-4090,"Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer and Nitrogen Dioxide Analyzer:  Guidance for Industry and for FDA Reviewers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-premarket-notification-submissions-nitric-oxide-delivery-apparatus-nitric-oxide,
FDA,FDA-2020-D-0957,Guidance for the Content of Premarket Notifications for Penile Rigidity Implants - Guidance for Industry and for FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-penile-rigidity-implants-guidance-industry-and-fda-staff,
FDA,FDA-2020-D-0957,Guidance Document for the Preparation of IDEs for Spinal Systems - Guidance for Industry and/or FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-preparation-ides-spinal-systems-guidance-industry-andor-fda-staff,
FDA,FDA-2020-D-0957,Content and Format of Premarket Notification [510(k)] Submissions for Liquid Chemical Sterilants/High Level Disinfectants - Guidance for Industry and FDA Reviewers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-premarket-notification-510k-submissions-liquid-chemical-sterilantshigh-level,
FDA,,"Disclosure of Materials Provided to Advisory Committees in Connection with Open Advisory Committee Meetings Convened by the Center for Drug Evaluation and Research Beginning on January 1, 2000",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/disclosure-materials-provided-advisory-committees-connection-open-advisory-committee-meetings,
FDA,FDA-1999-D-0738,Applications Covered by Section 505(b)(2),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-covered-section-505b2,
FDA,FDA-1999-D-3543,Guidance for Industry: Seafood HACCP Transition Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-seafood-haccp-transition-guidance,
FDA,FDA-1999-D-1314,Drug Master Files for Bulk Antibiotic Drug Substances:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-master-files-bulk-antibiotic-drug-substances,
FDA,FDA-2020-D-0957,Guidance for Cardiovascular Intravascular Filter 510(k) Submissions - Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-cardiovascular-intravascular-filter-510k-submissions-guidance-industry-and-fda-staff,
FDA,FDA-1998-D-0850,Providing Regulatory Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format - Biologics Marketing Applications:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-center-biologics-evaluation-and-research-cber-electronic-format,
FDA,FDA-1998-D-0141,Submission of Abbreviated Reports and Synopses in Support of Marketing Applications.,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-abbreviated-reports-and-synopses-support-marketing-applications,
FDA,FDA -2006-D-0299,CVM GFI #75 (VICH GL5) Stability Testing-Photostability Testing of New Veterinary Drug Substances and Medicinal Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-75-vich-gl5-stability-testing-photostability-testing-new-veterinary-drug-substances-and,
FDA,FDA-1998-D-1165,CVM GFI #74 (VICH GL4 ) Stability Testing of New Veterinary Dosage Forms,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-74-vich-gl4-stability-testing-new-veterinary-dosage-forms,
FDA,,Possible Dioxin/PCB Contamination of Drug and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/possible-dioxinpcb-contamination-drug-and-biological-products,
FDA,FDA-1998-D-0003,Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6b-specifications-test-procedures-and-acceptance-criteria-biotechnologicalbiological-products,
FDA,FDA-1997-D-0048,Consumer-Directed Broadcast Advertisements:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/consumer-directed-broadcast-advertisements,
FDA,,CPG Sec. 230.140 Evaluation and Processing Post Donation Information Reports is obsolete and was withdrawn on 7/16/2018.,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-230140-evaluation-and-processing-post-donation-information-reports-obsolete-and-was,
FDA,FDA-1997-D-0145,Container Closure Systems for Packaging Human Drugs and Biologics:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-packaging-human-drugs-and-biologics,
FDA,FDA-1999-D-1298,Guidance for Industry: Antimicrobial Food Additives,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-antimicrobial-food-additives,
FDA,FDA-1997-D-0153,S4A Duration of Chronic Toxicity Testing in Animals (Rodent and Nonrodent Toxicity Testing),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s4a-duration-chronic-toxicity-testing-animals-rodent-and-nonrodent-toxicity-testing,
FDA,FDA-2020-D-0957,"Guidance Document for Powered Muscle Stimulator 510(k)s - Guidance for Industry, FDA Reviewers/Staff and Compliance",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-powered-muscle-stimulator-510ks-guidance-industry-fda-reviewersstaff-and,
FDA,,Fees-Exceed-the-Costs Waivers Under the Prescription Drug User Fee Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fees-exceed-costs-waivers-under-prescription-drug-user-fee-act,
FDA,FDA-1997-D-0186,Efficacy Studies to Support Marketing of Fibrin Sealant Products Manufactured for Commercial Use:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/efficacy-studies-support-marketing-fibrin-sealant-products-manufactured-commercial-use,
FDA,FDA-1998-D-0995,"For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and For the Completion of the Form FDA 356h:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-chemistry-manufacturing-and-controls-and-establishment-description-information-human,
FDA,FDA-2020-D-0957,Recommended Clinical Study Design for Ventricular Tachycardia Ablation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-clinical-study-design-ventricular-tachycardia-ablation,
FDA,FDA-2020-D-0957,Immunotoxicity Testing Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunotoxicity-testing-guidance,
FDA,,"CPG Sec. 210.100 Deleted 4/26/99,  Outdated and Obsolete",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-210100-deleted-42699-outdated-and-obsolete,
FDA,FDA-1998-D-1277,"On the Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for an Allergenic Extract or Allergen Patch Test:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-chemistry-manufacturing-and-controls-information-and-establishment-description,
FDA,FDA-2020-D-0957,Preparing Notices of Availability of Investigational Medical Devices and for Recruiting Study Subjects:  Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preparing-notices-availability-investigational-medical-devices-and-recruiting-study-subjects,
FDA,FDA-1998-D-0689,"Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Biological In Vitro Diagnostic Product:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-chemistry-manufacturing-and-controls-information-and-establishment-description-0,
FDA,FDA-2020-D-0957,Guidance on 510(k) Submissions for Keratoprostheses - Guidance for Industry and for FDA Reviewers/Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-510k-submissions-keratoprostheses-guidance-industry-and-fda-reviewersstaff,
FDA,FDA-2020-D-0957,Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh - Guidance for Industry and/or for FDA Reviewers/Staff and/or Compliance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-preparation-premarket-notification-application-surgical-mesh-guidance-industry-andor-fda,
FDA,FDA-2020-D-0957,Guidance for Dermabrasion Devices - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-dermabrasion-devices-guidance-industry,
FDA,FDA-1996-D-0004,"For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Plasma-Derived Biological Products, Animal Plasma or Serum-Derived Products:  Guidance for Industry:",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-chemistry-manufacturing-and-controls-and-establishment-description-information-human-0,
FDA,FDA-1998-D-0405,"Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-development-programs-drugs-devices-and-biological-products-treatment-rheumatoid-arthritis,
FDA,,Providing Regulatory Submissions in Electronic Format; General Considerations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-general-considerations,
FDA,FDA-2020-D-0957,Premarket Notification [510(k)] Submissions for Testing for Skin Sensitization To Chemicals In Natural Rubber Products - Guidance for Industry and FDA Reviewers/Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-notification-510k-submissions-testing-skin-sensitization-chemicals-natural-rubber-products,
FDA,FDA-1998-D-0854,"Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-chemistry-manufacturing-and-controls-information-and-establishment-description-1,
FDA,FDA-2020-D-1959,"Small Entity Compliance Guide: Statement of Identity, Nutrition Labeling and Ingredient Labeling of Dietary Supplements",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-statement-identity-nutrition-labeling-and-ingredient-labeling-dietary,
FDA,FDA-2020-D-1960,Guidance for Industry: Questions and Answers on HACCP Regulation for Fish and Fishery Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-haccp-regulation-fish-and-fishery-products,
FDA,,"CPG Sec. 205.100 Deleted 12/21/98, Obsolete",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-205100-deleted-122198-obsolete,
FDA,FDA-2020-D-0957,Guidance for the Submission of Premarket Notifications for Emission Computed Tomography Devices and Accessories (SPECT and PET) and Nuclear Tomography Systems :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-submission-premarket-notifications-emission-computed-tomography-devices-and-accessories,
FDA,,Variations in Drug Products that May Be Included in a Single ANDA,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/variations-drug-products-may-be-included-single-anda,
FDA,FDA-2021-D-0385,FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-approval-new-cancer-treatment-uses-marketed-drug-and-biological-products,
FDA,FDA-2020-D-0957,Guidance for the Submission of Premarket Notifications For Radionuclide Dose Calibrators - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-submission-premarket-notifications-radionuclide-dose-calibrators-guidance-industry,
FDA,FDA-2020-D-0957,Non-Automated Sphygmomanometer (Blood Pressure Cuff) Guidance - Version 1 - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-automated-sphygmomanometer-blood-pressure-cuff-guidance-version-1-guidance-industry,
FDA,FDA-2020-D-0957,Aqueous Shunts - 510(k) Submissions - Guidance for Industry and for FDA Reviewers/Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/aqueous-shunts-510k-submissions-guidance-industry-and-fda-reviewersstaff,
FDA,,CPG Sec. 675.400 Rendered Animal Feed Ingredients (Withdrawn 4/30/2019),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-675400-rendered-animal-feed-ingredients-withdrawn-4302019,
FDA,FDA-1997-N-0257,Protection of Human Subjects: Categories of Research That May Be Reviewed by the Institutional Review Board (IRB) Through an Expedited Review Procedure:  Guidance for Institutional Review Boards and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/protection-human-subjects-categories-research-may-be-reviewed-institutional-review-board-irb-through,
FDA,FDA-2020-D-0957,FDA Animal Products Database Data Entry Form,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-animal-products-database-data-entry-form,
FDA,FDA-2020-D-0957,Diagnostic ECG Guidance (Including Non-Alarming ST Segment Measurement) - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diagnostic-ecg-guidance-including-non-alarming-st-segment-measurement-guidance-industry,
FDA,FDA-2020-D-0957,Cardiac Monitor Guidance (including Cardiotachometer and Rate Alarm) - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cardiac-monitor-guidance-including-cardiotachometer-and-rate-alarm-guidance-industry,
FDA,FDA-2020-D-0957,General/Specific Intended Use - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/generalspecific-intended-use-guidance-industry,
FDA,FDA-1997-N-0152,Guidance for Industry: Guide to Minimize Microbial Food Safety Hazards for Fresh Fruits and Vegetables,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-guide-minimize-microbial-food-safety-hazards-fresh-fruits-and-vegetables,
FDA,FDA-2020-D-0957,Noise Claims in Hearing Aid Labeling - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/noise-claims-hearing-aid-labeling-guidance-industry,
FDA,FDA-2020-D-0957,Guidance Document For Nonprescription Sunglasses - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-nonprescription-sunglasses-guidance-industry,
FDA,FDA-1998-D-0556,Submitting Debarment Certification Statements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-debarment-certification-statements,
FDA,,Implementation of Section 120 of the Food and Drug Administration Modernization Act of 1997-Advisory Committees,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implementation-section-120-food-and-drug-administration-modernization-act-1997-advisory-committees,
FDA,FDA-2020-D-0957,Guidance Document for Powered Suction Pump 510(k)s - Guidance for Industry and FDA Reviewers/Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-powered-suction-pump-510ks-guidance-industry-and-fda-reviewersstaff,
FDA,,CPG Sec. 615.100  Extralabel Use of New Animal Drugs in Food Producing Animals - Revoked on 09/24/1998 (63 FR 51074),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-615100-extralabel-use-new-animal-drugs-food-producing-animals-revoked-09241998-63-fr-51074,
FDA,FDA-1997-D-0098,Q5D Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products; Availability,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5d-quality-biotechnologicalbiological-products-derivation-and-characterization-cell-substrates-used,
FDA,FDA-1997-D-0508,E9 Statistical Principles for Clinical Trials,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e9-statistical-principles-clinical-trials,
FDA,FDA-2022-D-0487,How to Complete the Vaccine Adverse Event Reporting System Form (VAERS-1):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-complete-vaccine-adverse-event-reporting-system-form-vaers-1,
FDA,FDA-2017-P-5124,"OTC Denture Cushions, Pads, Reliners, Repair Kits, and Partially Fabricated Denture Kits - Guidance for Industry and FDA Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/otc-denture-cushions-pads-reliners-repair-kits-and-partially-fabricated-denture-kits-guidance,
FDA,FDA-2020-D-0957,Accidental Radioactive Contamination of Human Food and Animal Feeds:  Recommendations for State and Local Agencies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/accidental-radioactive-contamination-human-food-and-animal-feeds,
FDA,FDA-2020-D-0957,Revised Procedures for Adding Lens Finishing Laboratories to Approved Premarket Approval Applications for Class III Rigid Gas Permeable Contact Lenses for Extended Wear - Guidance for Industry and FDA Staff,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-procedures-adding-lens-finishing-laboratories-approved-premarket-approval-applications-class,
FDA,FDA-1998-D-0278,Environmental Assessment of Human Drug and Biologics Applications:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/environmental-assessment-human-drug-and-biologics-applications,
FDA,FDA-2020-D-0957,Latex Condoms for Men - Information for 510(k) Premarket Notifications: Use of Consensus Standards for Abbreviated Submissions:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/latex-condoms-men-information-510k-premarket-notifications-use-consensus-standards-abbreviated,
FDA,FDA-2020-D-0957,Uniform Contraceptive Labeling - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/uniform-contraceptive-labeling-guidance-industry,
FDA,,Women and Minorities Guidance Requirements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/women-and-minorities-guidance-requirements,
FDA,FDA-2020-D-0957,Slit Lamp Guidance - Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/slit-lamp-guidance-guidance-industry,
FDA,,CVM GFI #76 Questions and Answers BSE Feed Regulations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-76-questions-and-answers-bse-feed-regulations,
FDA,FDA-1998-D-0864,"Repeal of Section 507 of the Federal Food, Drug and Cosmetic Act _1",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/repeal-section-507-federal-food-drug-and-cosmetic-act-_1,
FDA,FDA-1998-D-0102,Guidance for Industry: Notification of a Health Claim or Nutrient Content Claim Based on an Authoritative Statement of a Scientific Body,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-notification-health-claim-or-nutrient-content-claim-based-authoritative-statement,
FDA,FDA-1997-D-0360,E5 Ethnic Factors in the Acceptability of Foreign Clinical Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e5-ethnic-factors-acceptability-foreign-clinical-data,
FDA,FDA-2020-D-0957,Guidance Document For Washers And Washer-Disinfectors Intended For Processing Reusable Medical Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-washers-and-washer-disinfectors-intended-processing-reusable-medical-devices,
FDA,FDA-1998-D-101c,"180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/180-day-generic-drug-exclusivity-under-hatch-waxman-amendments-federal-food-drug-and-cosmetic-act,
FDA,FDA-2020-D-0957,"Supplements to Approved Applications for Class III Medical Devices: Use of Published Literature, Use of Previously Submitted Materials, and Priority Review :  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supplements-approved-applications-class-iii-medical-devices-use-published-literature-use-previously,
FDA,FDA-1997-D-0027,Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products.,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-clinical-evidence-effectiveness-human-drug-and-biological-products,
FDA,,"Standards for the Prompt Review of Efficacy Supplements, Including Priority Efficacy Supplements :  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/standards-prompt-review-efficacy-supplements-including-priority-efficacy-supplements,
FDA,98-0276,CVM GFI #72 GMP'S For Medicated Feed Manufacturers Not Required to Register and be Licensed with FDA,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-72-gmps-medicated-feed-manufacturers-not-required-register-and-be-licensed-fda,
FDA,FDA-1998-D-1157,PAC-ATLS: Postapproval Changes - Analytical Testing Laboratory Sites:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pac-atls-postapproval-changes-analytical-testing-laboratory-sites,
FDA,FDA-2020-D-0957,Guidance For The Content Of Premarket Notifications For Esophageal And Tracheal Prostheses - Guidance For Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-esophageal-and-tracheal-prostheses-guidance-industry,
FDA,FDA-1998-D-1007,National Uniformity for Nonpresciption Drugs - Ingredient Listing for OTC Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/national-uniformity-nonpresciption-drugs-ingredient-listing-otc-drugs,
FDA,None found,Q3C: Appendix 6,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-appendix-6,
FDA,,Q3C: Appendix 5,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-appendix-5,
FDA,,Q3C: Appendix 4,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-appendix-4,
FDA,,Third of a series of letters regarding the implementation of the Act,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/third-series-letters-regarding-implementation-act,
FDA,,"Supplement to 10/11/1984 letter about policies, procedures and implementation of the Act (Q&A format)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supplement-10111984-letter-about-policies-procedures-and-implementation-act-qa-format,
FDA,,Reference Guide for the Nonclinical Toxicity Studies of Antivial Drugs Indicated for the Treatment of N/A Non-Life Threatening Disease Evaluation of Drug Toxicity Prior to Phase I Clinical Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reference-guide-nonclinical-toxicity-studies-antivial-drugs-indicated-treatment-na-non-life,
FDA,,Psychoactive Drugs in Infants and Children--Clinical Evaluation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychoactive-drugs-infants-and-children-clinical-evaluation,
FDA,,Oncologic Drugs Advisory Committee Discussion on FDA Requirements or Approval of New Drugs for Treatment of Colon and Rectal Cancer,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oncologic-drugs-advisory-committee-discussion-fda-requirements-or-approval-new-drugs-treatment-colon,
FDA,,Local Anesthetics--Clinical Evaluation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/local-anesthetics-clinical-evaluation,
FDA,,Guidance for the Development of Vaginal Contraceptive Drugs (NDA),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-development-vaginal-contraceptive-drugs-nda,
FDA,,Good Laboratory Practice Regulations Questions and Answers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-laboratory-practice-regulations-questions-and-answers,
FDA,FDA-2011-D-0595,FDA Requirements for Approval of Drugs to Treat Non-Small Cell Lung Cancer,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-requirements-approval-drugs-treat-non-small-cell-lung-cancer,
FDA,FDA-2020-D-1961,Guidance for Industry: Guide for Developing and Using Data Bases for Nutrition Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-guide-developing-and-using-data-bases-nutrition-labeling,
FDA,FDA-2009-D-0132-0016,Guidance for Human Somatic Cell Therapy and Gene Therapy:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-human-somatic-cell-therapy-and-gene-therapy,
FDA,FDA-1996-D-0010,S1B Testing for Carcinogenicity of Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s1b-testing-carcinogenicity-pharmaceuticals,
FDA,FDA-2020-D-0957,"Procedures for Class II Device Exemptions from Premarket Notification, Guidance for Industry and CDRH Staff",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-class-ii-device-exemptions-premarket-notification-guidance-industry-and-cdrh-staff,
FDA,FDA-2017-N-1129,Guidance on PMA Interactive Procedures for Day-100 Meetings and Subsequent Deficiencies - for Use by CDRH and Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-pma-interactive-procedures-day-100-meetings-and-subsequent-deficiencies-use-cdrh-and,
FDA,,CVM GFI #69  Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-69-small-entities-compliance-guide-feeders-ruminant-animals-farm-feed-mixing-operations,
FDA,,"CVM GFI #68  Small Entities Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-68-small-entities-compliance-guide-protein-blenders-feed-manufacturers-and-distributors,
FDA,,CVM GFI #67 Small Entities Compliance Guide for Renderers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-67-small-entities-compliance-guide-renderers,
FDA,,Use of Investigational Products When Subjects Enter a Second Institution:  Guidance for Institutional Review Boards and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-investigational-products-when-subjects-enter-second-institution,
FDA,,Sponsor - Investigator - IRB Interrelationship:  Guidance for Institutional Review Boards and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sponsor-investigator-irb-interrelationship,
FDA,,Screening Tests Prior to Study Enrollment:  Guidance for Institutional Review Boards and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/screening-tests-prior-study-enrollment,
FDA,,Recruiting Study Subjects:  Guidance for Institutional Review Boards and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recruiting-study-subjects,
FDA,,Non-local IRB Review :  Guidance for Institutional Review Boards and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-local-irb-review,
FDA,,Institutional Review Boards Frequently Asked Questions:  Guidance for Institutional Review Boards and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-boards-frequently-asked-questions,
FDA,,Evaluation of Gender Differences in Clinical Investigations:  Guidance for Institutional Review Boards and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-gender-differences-clinical-investigations,
FDA,,Emergency Use of an Investigational Drug or Biologic:  Guidance for Institutional Review Boards and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-investigational-drug-or-biologic,
FDA,,Cooperative Research:  Guidance for Institutional Review Boards and Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cooperative-research,
FDA,FDA-1997-D-0381,Q3C Impurities: Residual Solvents_2011,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-impurities-residual-solvents_2011,
FDA,92N-0434,Industry-Supported Scientific and Educational Activites,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/industry-supported-scientific-and-educational-activites,
FDA,FDA-1997-D-0199,S2B Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s2b-genotoxicity-standard-battery-genotoxicity-testing-pharmaceuticals,
FDA,,Direct Final Rule Procedures:  Guidance for FDA and Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/direct-final-rule-procedures,
FDA,FDA-1997-D-0265,S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals,
FDA,FDA-1992-N-0007,Industry Supported Scientific and Educational Activities:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/industry-supported-scientific-and-educational-activities,
FDA,FDA-1997-D-0507,"SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-mr-modified-release-solid-oral-dosage-forms-scale-and-postapproval-changes-chemistry,
FDA,,Guidance for Industry: Consultation Procedures under FDA's 1992 Statement of Policy for Foods Derived from New Plant Varieties,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-consultation-procedures-under-fdas-1992-statement-policy-foods-derived-new-plant,
FDA,,"Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-in-vivo-correlations,
FDA,FDA-1997-D-0445,Postmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-adverse-experience-reporting-human-drug-and-licensed-biological-products-clarification,
FDA,FDA-1997-D-0187,Dissolution Testing of Immediate Release Solid Oral Dosage Forms,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dissolution-testing-immediate-release-solid-oral-dosage-forms,
FDA,FDA-1997-D-0489,Expiration Dating and Stability Testing of Solid Oral Dosage Form Drugs Containing Iron:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expiration-dating-and-stability-testing-solid-oral-dosage-form-drugs-containing-iron,
FDA,FDA-1995-D-0101,Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-application-specified-biotechnology-and-specified-synthetic-biological-products,
FDA,FDA-2020-D-0957,Kit Certification for 510(k)s,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/kit-certification-510ks,
FDA,FDA-2020-D-0957,Q2B Validation of Analytical Procedures: Methodology,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2b-validation-analytical-procedures-methodology,
FDA,FDA-1996-D-0169,Convenience Kits Interim Regulatory Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/convenience-kits-interim-regulatory-guidance,
FDA,FDA-2013-S-0610,Q1C Stability Testing for New Dosage Forms,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1c-stability-testing-new-dosage-forms,
FDA,FDA-1997-D-0380,"SUPAC-SS: Nonsterile Semisolid Dosage Forms; Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-ss-nonsterile-semisolid-dosage-forms-scale-and-post-approval-changes-chemistry-manufacturing,
FDA,FDA-1997-N-0454,"Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-evaluation-combination-vaccines-preventable-diseases-production-testing-and,
FDA,FDA-2020-D-0957,Design Control Guidance For Medical Device Manufacturers:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-control-guidance-medical-device-manufacturers,
FDA,FDA-2020-D-0957,Non-Invasive Blood Pressure (NIBP) Monitor Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-invasive-blood-pressure-nibp-monitor-guidance,
FDA,FDA-1994-D-0318,Proposed Approach to Regulation of Cellular and Tissue-Based Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/proposed-approach-regulation-cellular-and-tissue-based-products,
FDA,FDA-1997-N-0207,Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/points-consider-manufacture-and-testing-monoclonal-antibody-products-human-use,
FDA,FDA-1996-D-0012,Guidance on Labeling of Foods That Need Refrigeration by Consumers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-labeling-foods-need-refrigeration-consumers,
FDA,FDA-2020-D-0957,Reviewers Guidance Checklist For Orthopedic External Fixation Devices Version #5,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reviewers-guidance-checklist-orthopedic-external-fixation-devices-version-5,
FDA,FDA-2020-D-0957,510(K) Information Needed for Hydroxyapatite Coated Orthopedic Implants,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-information-needed-hydroxyapatite-coated-orthopedic-implants,
FDA,,SUPAC-IR Questions and Answers about SUPAC-IR Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-ir-questions-and-answers-about-supac-ir-guidance,
FDA,FDA-2020-D-0957,Third Party Review Guidance for Phacofragmentation System Device Premarket Notification (510(k)),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/third-party-review-guidance-phacofragmentation-system-device-premarket-notification-510k,
FDA,FDA-2020-D-0957,Third Party Review Guidance For Vitreous Aspiration and Cutting Device Premarket Notification (510(k)),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/third-party-review-guidance-vitreous-aspiration-and-cutting-device-premarket-notification-510k,
FDA,,General Considerations for the Clinical Evaluation of Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-considerations-clinical-evaluation-drugs,
FDA,,"CPG Sec 540.400 Shrimp - Fresh or Frozen, Raw, Headless, Peeled or Breaded (Revoked 12/24/96)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540400-shrimp-fresh-or-frozen-raw-headless-peeled-or-breaded-revoked-122496,
FDA,,Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 :  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996,
FDA,FDA-2020-D-0957,Prospective Manufacturers of Barrier Devices Used During Oral Sex for STD Protection,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prospective-manufacturers-barrier-devices-used-during-oral-sex-std-protection,
FDA,FDA-2020-D-0957,Checklist of Information Usually Submitted in an Investigational Device Exemptions (IDE) Application for Refractive Surgery Lasers [excimer],Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/checklist-information-usually-submitted-investigational-device-exemptions-ide-application-refractive,
FDA,FDA-2020-D-0957,Identification Labels for Certain Class I Laser Products (Laser Notice 48),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/identification-labels-certain-class-i-laser-products-laser-notice-48,
FDA,FDA-2020-D-0957,Emitted Laser Beam as Emission Indicator for Class II and Class IIIa Laser Products (Laser Notice 49),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emitted-laser-beam-emission-indicator-class-ii-and-class-iiia-laser-products-laser-notice-49,
FDA,FDA-1992-N-0026,Single Dose Acute Toxicity Testing for Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/single-dose-acute-toxicity-testing-pharmaceuticals,
FDA,,CPG Sec 540.350 Common or Usual Names for Crustaceans (Revoked 8/23/96),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540350-common-or-usual-names-crustaceans-revoked-82396,
FDA,,CPG Sec 540.300 Crabmeat - Product Name (Revoked 8/23/96),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540300-crabmeat-product-name-revoked-82396,
FDA,,CPG Sec 540.100 Capelin - Prohibited from Being Labeled as Smelt (Revoked 8/23/96),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540100-capelin-prohibited-being-labeled-smelt-revoked-82396,
FDA,,CPG Sec 110.900 Imported Products - Lack of English Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-110900-imported-products-lack-english-labeling,
FDA,FDA-2020-D-0957,Variance from Manufacturer Report Number Format - No. 5,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/variance-manufacturer-report-number-format-no-5,
FDA,,"Guidance for Industry for the Submission of Chemistry, Manufacturing, and Controls Information for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibody Product for In Vivo Use",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-submission-chemistry-manufacturing-and-controls-information-therapeutic,
FDA,,CPG Sec. 690.600  Rodent Contaminated Pet Foods - *Direct Reference  Seizure Authority* (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-690600-rodent-contaminated-pet-foods-direct-reference-seizure-authority-withdrawn-2202020,
FDA,,CPG Sec. 654.300  Chloramphenicol as an Unapproved New Animal Drug - Direct Reference Seizure Authority (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-654300-chloramphenicol-unapproved-new-animal-drug-direct-reference-seizure-authority,
FDA,,CPG Sec 585.675 Popcorn - Adulteration with Rodent Filth and Field Corn,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585675-popcorn-adulteration-rodent-filth-and-field-corn,
FDA,,CPG Sec 527.200 Cheese & Cheese Products - Adulteration with Filth,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527200-cheese-cheese-products-adulteration-filth,
FDA,,CPG Sec 515.200 Malt Extract; Malt Syrup; Malted Cereal Syrup; Liquid Malt; Dried Malt,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515200-malt-extract-malt-syrup-malted-cereal-syrup-liquid-malt-dried-malt,
FDA,,CPG Sec 510.700 Fortification of Standardized Juices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510700-fortification-standardized-juices,
FDA,,CPG Sec 510.450 Labeling - Diluted Wines and Cider with Less Than 7% Alcohol,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510450-labeling-diluted-wines-and-cider-less-7-alcohol,
FDA,,CPG Sec 505.500 Macaroni and Noodle Products - Adulteration Involving Insect Fragments and Rodent Hairs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505500-macaroni-and-noodle-products-adulteration-involving-insect-fragments-and-rodent-hairs,
FDA,,"CPG Sec 505.400 Chow Mein Noodles, Chinese Noodles and Other Oriental Noodles (Labeling)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505400-chow-mein-noodles-chinese-noodles-and-other-oriental-noodles-labeling,
FDA,,"CPG Sec 500.300 ""Approved by FDA"" - Use of Phrase Objectionable in Marketing or Labeling of a Food Additive",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500300-approved-fda-use-phrase-objectionable-marketing-or-labeling-food-additive,
FDA,FDA-1996-D-0071,CPG Sec 500.250 Food Additives - Labeling Directions Necessary for Safe Use:  CPG Sec 500.250 Food Additives,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500250-food-additives-labeling-directions-necessary-safe-use,
FDA,,CPG Sec. 160.750  Drug and Device Products (Including Biologics and Animal Drugs) Found in Violation of GMPRs - Reconditioning,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-160750-drug-and-device-products-including-biologics-and-animal-drugs-found-violation-gmprs,
FDA,,CPG Sec. 160.500  Answering Inquiries on Status of Criminal Referrals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-160500-answering-inquiries-status-criminal-referrals,
FDA,,CPG Sec 527.600 Use of DDVP (dichlorvos) Strips in Milkhouses and Milkrooms,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527600-use-ddvp-dichlorvos-strips-milkhouses-and-milkrooms,
FDA,,CPG Sec 527.500 Malted Milk,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527500-malted-milk,
FDA,FDA-2022-D-0497,"Recommendations for the Quarantine and Disposition of Units from Prior Collections from Donors with Repeatedly Reactive Screening Tests for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human T-Lymphotropic Virus Type I (HTLV-I)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-quarantine-and-disposition-units-prior-collections-donors-repeatedly-reactive,
FDA,FDA-2020-D-0957,Variance from Manufacturer Report Number Format [MDR letter],Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/variance-manufacturer-report-number-format-mdr-letter,
FDA,FDA-1995-D-0201,Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5c-quality-biotechnological-products-stability-testing-biotechnologicalbiological-products,
FDA,FDA-1993-D-0183,E4 Dose-Response Information to Support Drug Registration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e4-dose-response-information-support-drug-registration,
FDA,,E3 Structure and Content of Clinical Study Reports,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e3-structure-and-content-clinical-study-reports,
FDA,FDA-2020-D-0957,Effective Visual Control of Laser Projections (Laser Notice 47),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/effective-visual-control-laser-projections-laser-notice-47,
FDA,FDA-2020-D-0957,Suggested Format For IDE Progress Report,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/suggested-format-ide-progress-report,
FDA,FDA-2022-D-0498,"Additional Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV):  Memorandum to Registered Blood and Plasma Establishments",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/additional-recommendations-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes,
FDA,FDA-1994-D-0134,S2A Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s2a-specific-aspects-regulatory-genotoxicity-tests-pharmaceuticals,
FDA,FDA-1993-D-0285,CVM GFI #49 Target Animal Safety And Drug Effectiveness Studies for Anti-Microbial Bovine Mastitis Products (Lactating and Non-Lactating Cow Products),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-49-target-animal-safety-and-drug-effectiveness-studies-anti-microbial-bovine-mastitis,
FDA,FDA-2020-D-0957,Medical Device Reporting for User Facilities,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-reporting-user-facilities,
FDA,,"Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstration-comparability-human-biological-products-including-therapeutic-biotechnology-derived,
FDA,FDA-2022-D-0499,Additional Recommendations for Donor Screening With a Licensed Test for HIV-1 Antigen:  Memorandum to Registered Blood and Plasma Establishments,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/additional-recommendations-donor-screening-licensed-test-hiv-1-antigen,
FDA,FDA-2020-D-0957,Thermal Endometrial Ablation Devices (Submission Guidance for an IDE),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/thermal-endometrial-ablation-devices-submission-guidance-ide,
FDA,FDA-2020-D-0957,Q1B Photostability Testing of New Drug Substances and Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1b-photostability-testing-new-drug-substances-and-products,
FDA,,Hysteroscopes and Gynecology Laparoscopes - Submission Guidance for a 510(k),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hysteroscopes-and-gynecology-laparoscopes-submission-guidance-510k,
FDA,FDA-1996-D-0010,S1A The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s1a-need-long-term-rodent-carcinogenicity-studies-pharmaceuticals,
FDA,FDA-1995-D-0245,Q5B Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5b-quality-biotechnological-products-analysis-expression-construct-cells-used-production-r-dna,
FDA,FDA-2020-D-0957,All Holders of Approved Variances For Laser Light Shows and Displays (Laser Notice 46),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/all-holders-approved-variances-laser-light-shows-and-displays-laser-notice-46,
FDA,FDA-2022-D-0500,Donor Deferral Due to Red Blood Cell Loss During Collection of Source Plasma by Automated Plasmapheresis,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/donor-deferral-due-red-blood-cell-loss-during-collection-source-plasma-automated-plasmapheresis,
FDA,,"SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-ir-immediate-release-solid-oral-dosage-forms-scale-and-post-approval-changes-chemistry,
FDA,FDA-1995-D-0251,"Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-format-investigational-new-drug-applications-inds-phase-1-studies-drugs-including-well,
FDA,FDA-2020-D-0957,Addendum to: Guidance on Premarket Notification [510(k)] Submissions for Sterilizers Intended for Use in Health Care Facilities,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/addendum-guidance-premarket-notification-510k-submissions-sterilizers-intended-use-health-care,
FDA,FDA-2020-D-0957,User Instruction for Medical Products (Laser Notice 44),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-instruction-medical-products-laser-notice-44,
FDA,FDA-2022-D-0501,Recommendations for Donor Screening with a Licensed Test for HIV-1 Antigen:  Memorandum to All Registered Blood Establishments,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-donor-screening-licensed-test-hiv-1-antigen,
FDA,FDA-2020-D-0957,Hysteroscopic and Laparoscopic Insufflators: Submission Guidance for a 510(k),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hysteroscopic-and-laparoscopic-insufflators-submission-guidance-510k,
FDA,FDA-2020-D-0957,"Guidance Document for the Preparation of Premarket Notification [510(k)] Applications for Mechanical and Powered Wheelchairs, and Motorized Three-Wheeled Vehicles",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-preparation-premarket-notification-510k-applications-mechanical-and-powered,
FDA,FDA-2020-D-0957,Guidance Document for the Preparation of Premarket Notification [510(k)] Applications for Heating and Cooling Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-preparation-premarket-notification-510k-applications-heating-and-cooling-devices,
FDA,FDA-2020-D-0957,Guidance Document for the Preparation of Premarket Notification [510(K)] Applications for Exercise Equipment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-preparation-premarket-notification-510k-applications-exercise-equipment,
FDA,FDA-1995-D-0149,FDA Guidance Document Concerning Use of Pilot Manufacturing Facilities for the Development and Manufacture of Biological Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-document-concerning-use-pilot-manufacturing-facilities-development-and-manufacture,
FDA,FDA-2020-D-0957,Testing Guidance for Male Condoms Made From New Material (Non-Latex),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-guidance-male-condoms-made-new-material-non-latex,
FDA,FDA-2020-D-2006,"Guidance for Industry: Letter to Manufacturers, Importers, and Distributors of Imported Candy and Candy Wrappers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-letter-manufacturers-importers-and-distributors-imported-candy-and-candy-wrappers,
FDA,,CPG Sec 100.900  International Memoranda of Understanding,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100900-international-memoranda-understanding,
FDA,FDA-2021-D-0384,Topical Dermatologic Corticosteroids: in Vivo Bioequivalence,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/topical-dermatologic-corticosteroids-in-vivo-bioequivalence,
FDA,FDA-2020-D-0957,Guidance on the Content and Organization of a Premarket Notification for a Medical Laser,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-and-organization-premarket-notification-medical-laser,
FDA,FDA-2020-D-0957,"Guidance Document for Testing Non-Articulating, 'Mechanically Locked', Modular Implant Components",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-testing-non-articulating-mechanically-locked-modular-implant-components,
FDA,FDA-2013-S-0611,Revised Recommendations for Red Blood Cell Immunization Programs for Source Plasma Donors:  Memorandum to Licensed Establishments,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-red-blood-cell-immunization-programs-source-plasma-donors,
FDA,,S3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s3b-pharmacokinetics-guidance-repeated-dose-tissue-distribution-studies,
FDA,FDA-2012-E-0163,S3A Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s3a-toxicokinetics-assessment-systemic-exposure-toxicity-studies,
FDA,,Q2A Text on Validation of Analytical Procedures,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2a-text-validation-analytical-procedures,
FDA,,E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2a-clinical-safety-data-management-definitions-and-standards-expedited-reporting,
FDA,,E1A The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e1a-extent-population-exposure-assess-clinical-safety-drugs-intended-long-term-treatment-non-life,
FDA,,CPG Sec. 625.500  Failure to Register *and/or Drug List* (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-625500-failure-register-andor-drug-list-withdrawn-2202020,
FDA,,CPG Sec. 625.300  Unapproved New Animal Drugs - Follow-up Action to Approved Warning Letter - Direct Reference Seizure Authority (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-625300-unapproved-new-animal-drugs-follow-action-approved-warning-letter-direct-reference,
FDA,,CPG Sec. 608.500  Illegal Sales of Veterinary Prescription Drugs Direct Reference Authority for *Warning* Letter Issuance (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-608500-illegal-sales-veterinary-prescription-drugs-direct-reference-authority-warning-letter,
FDA,,CPG Sec. 480.300 Lack of Expiration Date of Stability Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-480300-lack-expiration-date-stability-data-0,
FDA,FDA-2020-D-0957,CPG Sec. 480.300 Lack of Expiration Date of Stability Data,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-480300-lack-expiration-date-stability-data,
FDA,FDA-2020-D-0957,CPG Sec. 457.100 Pangamic Acid and Pangamic Acid Products Unsafe for Food and Drug Use,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-457100-pangamic-acid-and-pangamic-acid-products-unsafe-food-and-drug-use,
FDA,FDA-2020-D-0957,CPG Sec. 456.100 Non-Rx Drugs Anti-Obesity Preparations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-456100-non-rx-drugs-anti-obesity-preparations,
FDA,FDA-2020-D-0957,CPG Sec. 450.300 OTC Drugs - General Provisions and Administrative Procedures for Marketing Combination Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450300-otc-drugs-general-provisions-and-administrative-procedures-marketing-combination,
FDA,FDA-2020-D-0957,CPG Sec. 450.200 Drugs - General Provisions and Administrative Procedures for Recognition as Safe and Effective,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450200-drugs-general-provisions-and-administrative-procedures-recognition-safe-and-effective,
FDA,FDA-2020-D-0957,CPG Sec. 448.100 Reconditioning of New Drugs Which Do Not Have Approved NDAs/ANDAs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-448100-reconditioning-new-drugs-which-do-not-have-approved-ndasandas,
FDA,None found,CPG Sec. 430.400 Urinary Preparations - Misbranding - Lack of Rx Legend and Claims,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-430400-urinary-preparations-misbranding-lack-rx-legend-and-claims,
FDA,None found,CPG Sec. 400.500 Identical or Similar Product Names,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400500-identical-or-similar-product-names,
FDA,None found,CPG Sec. 400.200 Consistent Application of CGMP Determinations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400200-consistent-application-cgmp-determinations,
FDA,,"CPG Sec. 400.100 Drugs, Human - Failure to Register",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400100-drugs-human-failure-register,
FDA,None found,CPG Sec. 398.350 Regulatory Actions Against Assemblers of X-ray Equipment that Fail to File Reports of Assembly,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398350-regulatory-actions-against-assemblers-x-ray-equipment-fail-file-reports-assembly,
FDA,None found,"CPG Sec. 393.200 Laser(s) as Medical Devices for Facelift, Wrinkle Removal, Acupuncture, Auricular Stimulation, etc. (CPG 7133.21)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-393200-lasers-medical-devices-facelift-wrinkle-removal-acupuncture-auricular-stimulation-etc,
FDA,,CPG Sec. 391.200 Warning Statement in Advertisements for High-Intensity Mercury Vapor Discharge Lamps that are not Self-Extinguishing (21 CFR 1040.30(e)(3)*),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-391200-warning-statement-advertisements-high-intensity-mercury-vapor-discharge-lamps-are-not,
FDA,,CPG Sec. 390.425 Records and Reports; Applicability - 21 CFR 1002.1,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390425-records-and-reports-applicability-21-cfr-10021,
FDA,,CPG Sec. 370.100 Cytotoxic Testing for Allergic Diseases,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-370100-cytotoxic-testing-allergic-diseases,
FDA,,CPG Sec. 355.300 Ion Generating Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-355300-ion-generating-devices,
FDA,,CPG Sec. 355.200 Electrical Muscle Stimulators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-355200-electrical-muscle-stimulators,
FDA,,CPG Sec. 345.300 Menstrual Sponges,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-345300-menstrual-sponges,
FDA,,CPG Sec. 345.100 Condoms; Defects - Criteria for Direct Reference Seizure,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-345100-condoms-defects-criteria-direct-reference-seizure,
FDA,,CPG Sec. 300.400 Contamination of Devices Labeled as Sterile,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-300400-contamination-devices-labeled-sterile,
FDA,,CPG Sec. 250.500-  Plasma Brokers - Registration and Compliance with Good Manufacturing Practices is obsolete and was withdrawn on 7/16/2018.,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-250500-plasma-brokers-registration-and-compliance-good-manufacturing-practices-obsolete-and,
FDA,,CPG Sec. 231.130-  Storage of *Platelets* [ ] for up to five (5) Days is obsolete and was withdrawn on 7/16/2018.,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-231130-storage-platelets-five-5-days-obsolete-and-was-withdrawn-7162018,
FDA,,CPG Sec. 231.120-  Time Period for Separation of Platelets from Platelet-Rich Plasma When Preparing *Platelets* and Fresh Frozen Plasma* is obsolete and was withdrawn on 7/16/2018.,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-231120-time-period-separation-platelets-platelet-rich-plasma-when-preparing-platelets-and,
FDA,,"CPG Sec. 231.100-  *Platelets, Pooled* is obsolete and was withdrawn on 7/16/2018.",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-231100-platelets-pooled-obsolete-and-was-withdrawn-7162018,
FDA,,"CPG Sec 587.200 Uncertified or Delisted Colors in Foods for Export -  (e.g., FD&C Red #2)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-587200-uncertified-or-delisted-colors-foods-export-eg-fdc-red-2,
FDA,,"CPG Sec 585.225 Black-Eyed Peas (Cow Peas, Field Peas); Dried-Adulteration with Lygus Bug Damage",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585225-black-eyed-peas-cow-peas-field-peas-dried-adulteration-lygus-bug-damage,
FDA,,CPG Sec 575.100 Pesticide Residues in Food and Feed - Enforcement Criteria,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-575100-pesticide-residues-food-and-feed-enforcement-criteria,
FDA,,"CPG Sec 555.300 Foods, Except Dairy Products - Adulteration with Salmonella",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555300-foods-except-dairy-products-adulteration-salmonella,
FDA,,"CPG Sec 550.680 Pineapple, Canned; Pineapple Juice - Adulteration with Mold",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550680-pineapple-canned-pineapple-juice-adulteration-mold,
FDA,,"CPG Sec 550.590 Cloudberries (Multer Berries), Canned - Adulteration by Insects",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550590-cloudberries-multer-berries-canned-adulteration-insects,
FDA,FDA-2020-D-0957,"CPG Sec 550.450 Jam, Black Currant - Adulteration with Mold",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550450-jam-black-currant-adulteration-mold,
FDA,FDA-2020-D-0957,CPG Sec 550.270 Currants - Adulteration Involving Wormy Fruits,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550270-currants-adulteration-involving-wormy-fruits,
FDA,FDA-2020-D-0957,CPG Sec 550.260 Cranberry Sauce - Adulteration with Mold,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550260-cranberry-sauce-adulteration-mold,
FDA,,"CPG Sec 550.250 Citrus Fruit Juices, Canned - Adulteration with Fly Filth and Mold",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550250-citrus-fruit-juices-canned-adulteration-fly-filth-and-mold,
FDA,None found,CPG Sec 550.235 Cherry Jam - Adulteration with Mold,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550235-cherry-jam-adulteration-mold,
FDA,None found,"CPG Sec 525.825 Vinegar, Definitions - Adulteration with Vinegar Eels",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525825-vinegar-definitions-adulteration-vinegar-eels,
FDA,,CPG Sec 525.425 Hops - Adulteration Involving Aphid Infestation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525425-hops-adulteration-involving-aphid-infestation,
FDA,,CPG Sec 515.600 Candied Citron - Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515600-candied-citron-labeling,
FDA,FDA-1994-D-0267,CPG Sec 515.400 Raw Sugar,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515400-raw-sugar,
FDA,FDA-1993-D-0128,CPG Sec 515.100 Confectionery - Use of Non-Nutritive Substances as Ingredients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515100-confectionery-use-non-nutritive-substances-ingredients,
FDA,FDA-1994-D-0401,CPG Sec 500.400 Use of Calcium Chloride as a Drying Agent in Such Products as Packaged Potato Chips and Peanuts,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500400-use-calcium-chloride-drying-agent-such-products-packaged-potato-chips-and-peanuts,
FDA,,CPG Sec 120.500 Health Fraud - Factors in Considering Regulatory Action,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-120500-health-fraud-factors-considering-regulatory-action,
FDA,,"CPG 230.130- Adequate Space for Determination of Donor Suitability (Obsolete, Withdrawn on 7/16/2018)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-230130-adequate-space-determination-donor-suitability-obsolete-withdrawn-7162018,
FDA,,CPG Sec.625.400 Reconditioning of New Animal Drugs Seized Under Section 501(a)(5) (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec625400-reconditioning-new-animal-drugs-seized-under-section-501a5-withdrawn-2202020,
FDA,,CPG Sec.140.500 Metric Declarations of Quantity of Contents on Product Labels,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec140500-metric-declarations-quantity-contents-product-labels,
FDA,,CPG Sec. 690.100  Nutritional Supplements for Companion Animals (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-690100-nutritional-supplements-companion-animals-withdrawn-2202020,
FDA,,CPG Sec. 689.100  Direct-Fed Microbial Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-689100-direct-fed-microbial-products,
FDA,,CPG Sec. 687.500  Silage Ingredients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-687500-silage-ingredients,
FDA,,CPG Sec. 685.100  Recycled Animal Waste,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-685100-recycled-animal-waste,
FDA,,"CPG Sec. 680.600  Sequencing as a Means to Prevent Unsafe Drug   Contamination in the Production, Storage, and Distribution of Feeds (Withdrawn 1/30/2023)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-680600-sequencing-means-prevent-unsafe-drug-contamination-production-storage-and,
FDA,,CPG Sec. 680.500  Unsafe Contamination of Animal Feed from Drug Carryover (Withdrawn 1/30/2023),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-680500-unsafe-contamination-animal-feed-drug-carryover-withdrawn-1302023,
FDA,,CPG Sec. 675.300  Moisture Damaged Grain,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-675300-moisture-damaged-grain,
FDA,,CPG Sec. 675.200  Diversion of Adulterated Food to Acceptable Animal Feed Use,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-675200-diversion-adulterated-food-acceptable-animal-feed-use,
FDA,,CPG Sec. 675.100  Diversion of Contaminated Food for Animal Use,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-675100-diversion-contaminated-food-animal-use,
FDA,,CPG Sec. 670.500  Ammoniated Cottonseed Meal - Interpretation of 21 CFR,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-670500-ammoniated-cottonseed-meal-interpretation-21-cfr,
FDA,,CPG Sec. 665.200  Checklist Labeling for Custom Mixed Medicated Feeds (Withdrawn 7/23/2019),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-665200-checklist-labeling-custom-mixed-medicated-feeds-withdrawn-7232019,
FDA,,CPG Sec. 665.100  Common or Usual Names for Animal Feed Ingredients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-665100-common-or-usual-names-animal-feed-ingredients,
FDA,,CPG Sec. 654.200  Teat Dips and Udder Washes for Dairy Cows and Goats,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-654200-teat-dips-and-udder-washes-dairy-cows-and-goats,
FDA,FDA-2020-D-0957,CPG Sec. 654.100  Dimethyl Sulfoxide (DMSO) for Animal Use (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-654100-dimethyl-sulfoxide-dmso-animal-use-withdrawn-2202020,
FDA,FDA-2020-D-0957,CPG Sec. 650.100  Animal Drugs for Euthanasia (Withdrawn 5/23/2024),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-650100-animal-drugs-euthanasia-withdrawn-5232024,
FDA,,CPG Sec. 643.100  Oral Iron Products for Baby Pigs (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-643100-oral-iron-products-baby-pigs-withdrawn-2202020,
FDA,,CPG Sec. 642.100  *Drugs for Odor Control and Conception in Pet Animals*,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-642100-drugs-odor-control-and-conception-pet-animals,
FDA,,CPG Sec. 641.100  *Products for Control of Fleas and Ticks* Containing a Pesticide (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-641100-products-control-fleas-and-ticks-containing-pesticide-withdrawn-2202020,
FDA,FDA-2020-D-0957,CPG Sec. 640.100  Anthelmintics (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-640100-anthelmintics-withdrawn-2202020,
FDA,FDA-2020-D-0957,CPG Sec. 638.100  Process Validation Requirements for Drug Products Subject to Pre-Market Approval,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-638100-process-validation-requirements-drug-products-subject-pre-market-approval,
FDA,FDA-2020-D-0957,CPG Sec. 637.100  Plastic Containers for Injectable Animal Drugs (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-637100-plastic-containers-injectable-animal-drugs-withdrawn-2202020,
FDA,,CPG Sec. 608.300  Lay Use of *Animal Capture and Euthanasia* Drugs (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-608300-lay-use-animal-capture-and-euthanasia-drugs-withdrawn-2202020,
FDA,,CPG Sec. 607.100 -  Adequate Directions for Use (Species Designation) - Animal Drugs and Veterinary Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-607100-adequate-directions-use-species-designation-animal-drugs-and-veterinary-devices,
FDA,,CPG Sec. 480.200 Expiration Dating of Unit Dose Repackaged Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-480200-expiration-dating-unit-dose-repackaged-drugs,
FDA,,CPG Sec. 480.100 Requirements for Expiration Dating and Stability Testing,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-480100-requirements-expiration-dating-and-stability-testing,
FDA,FDA-2021-D-0629,CPG Sec. 398.600 Certification and Identification of X-ray Components - Sections 1010.2 and 1020.30(e),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398600-certification-and-identification-x-ray-components-sections-10102-and-102030e,
FDA,,CPG Sec. 398.375 Obligations of Factory-based Manufacturers and Assemblers of Diagnostic X-ray Equipment Under the Performance Standard for Diagnostic X-ray Equipment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398375-obligations-factory-based-manufacturers-and-assemblers-diagnostic-x-ray-equipment,
FDA,,CPG Sec. 398.300 Registration of Assemblers of  Diagnostic X-Ray Systems as Device Manufacturers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398300-registration-assemblers-diagnostic-x-ray-systems-device-manufacturers,
FDA,,CPG Sec. 398.200 Hazardous Diagnostic X-ray Systems,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398200-hazardous-diagnostic-x-ray-systems,
FDA,,CPG Sec. 396.400 Policy on Warned on Sunlamp Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-396400-policy-warned-sunlamp-products,
FDA,,CPG Sec. 396.200 Exemption for Certain Sunlamp Product Purchaser Records,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-396200-exemption-certain-sunlamp-product-purchaser-records,
FDA,FDA-2021-D-0630,CPG Sec. 396.100 Applicability of the Sunlamp Performance Standard To UVA Tanning Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-396100-applicability-sunlamp-performance-standard-uva-tanning-products,
FDA,,CPG Sec. 394.100 Retention of Microwave Oven Test Records,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-394100-retention-microwave-oven-test-records,
FDA,FDA-2021-D-0631,CPG Sec. 310.100 Pacemaker Reuse,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-310100-pacemaker-reuse,
FDA,,CPG Sec. 300.300 Ineffective Devices - 502(f)(I) Labeling Requirements,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-300300-ineffective-devices-502fi-labeling-requirements,
FDA,FDA-2021-D-0632,"CPG Sec. 256.100 Plasmapheresis - 48-hour Period Between Plasmapheresis Procedures (Obsolete, Withdrawn on 11/28/2017)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-256100-plasmapheresis-48-hour-period-between-plasmapheresis-procedures-obsolete-withdrawn,
FDA,FDA-2021-D-0633,"CPG Sec. 255.100 Quantitative Testing for Serum Proteins in Plasmapheresis Donors (Obsolete, Withdrawn on 11/28/2017)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-255100-quantitative-testing-serum-proteins-plasmapheresis-donors-obsolete-withdrawn-11282017,
FDA,,"CPG Sec. 254.100 Source Plasma - Use of Units from Donors Subsequently Found to be Reactive to a Serologic Test for Syphilis (Obsolete, Withdrawn on 11/28/2017)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-254100-source-plasma-use-units-donors-subsequently-found-be-reactive-serologic-test-syphilis,
FDA,FDA-2021-D-0634,CPG Sec. 253.100- Use of Units of *Plasma and Fresh Frozen Plasma* Which Have Been Thawed,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-253100-use-units-plasma-and-fresh-frozen-plasma-which-have-been-thawed,
FDA,FDA-2021-D-0635,"CPG Sec. 252.100 Source Plasma - Regulatory Action Based on Overbleeding (Obsolete, Withdrawn on 11/28/2017)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-252100-source-plasma-regulatory-action-based-overbleeding-obsolete-withdrawn-11282017,
FDA,FDA-2021-D-0636,"CPG Sec. 250.100 Source Plasma â€“ Guidelines for Informed Consent Forms (Obsolete, Withdrawn on 11/28/2017)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-250100-source-plasma-guidelines-informed-consent-forms-obsolete-withdrawn-11282017,
FDA,FDA-2021-D-0637,CPG Sec. 231.110-  Quality Control Testing of *Platelets* [ ] and Cryoprecipitated Antihemophilic Factor [ ],Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-231110-quality-control-testing-platelets-and-cryoprecipitated-antihemophilic-factor,
FDA,FDA-2021-D-0638,CPG Sec. 150.500 Analytical Methodology Used by FDA - Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-150500-analytical-methodology-used-fda-drugs,
FDA,FDA-2021-D-0639,CPG Sec 578.600 Unapproved Additives for Exported Grains,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578600-unapproved-additives-exported-grains,
FDA,FDA-2021-D-0640,CPG Sec 562.400 Foreign Language Declarations on Food Labels,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562400-foreign-language-declarations-food-labels,
FDA,FDA-2021-D-0641,CPG Sec 555.650 Reconditioning Foods by Diversion for Animal Feed,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555650-reconditioning-foods-diversion-animal-feed,
FDA,FDA-2021-D-0642,CPG Sec 550.400 Grenadine,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550400-grenadine,
FDA,,CPG Sec 525.400 Hollandaise Sauce - Common or Usual Name,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525400-hollandaise-sauce-common-or-usual-name,
FDA,,"CPG Sec 520.100 Canned Foods, Use of the Term ""Solid Pack""",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-520100-canned-foods-use-term-solid-pack,
FDA,,CPG Sec 515.425 Sugar - Water Damaged - Reconditioning,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515425-sugar-water-damaged-reconditioning,
FDA,,CPG Sec 275.100 Immune Milk (Withdrawn 1/30/2020) :  CPG Sec 275.100 Immune Milk,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-275100-immune-milk-withdrawn-1302020,
FDA,FDA-2020-D-0957,Guidance Document For The Preparation of Premarket Notification For Ceramic Ball Hip Systems,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-preparation-premarket-notification-ceramic-ball-hip-systems,
FDA,FDA-2021-D-0617,CVM GFI #57 Preparation and Submission of Veterinary Master Files,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-57-preparation-and-submission-veterinary-master-files,
FDA,FDA-2020-D-0957,Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-documentation-sterilization-process-validation-applications-human-and-veterinary-drug,
FDA,,"Reviewer Guidance, Validation of Chromatographic Methods",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reviewer-guidance-validation-chromatographic-methods,
FDA,,Checklist for Mechanical Lithotripters and Stone Dislodgers used in Gastroenterology and Urology,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/checklist-mechanical-lithotripters-and-stone-dislodgers-used-gastroenterology-and-urology,
FDA,FDA-2020-D-0957,510(k) Checklist for Sterile Lubricating Jelly Used With Transurethral Surgical Instruments,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-checklist-sterile-lubricating-jelly-used-transurethral-surgical-instruments,
FDA,FDA-2020-D-0957,Guidance for the Content of Premarket Notifications for Conventional and Antimicrobial Foley Catheters,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-conventional-and-antimicrobial-foley-catheters,
FDA,,Format and Content for the CMC Section of an Annual Report,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-cmc-section-annual-report,
FDA,FDA-2020-D-0957,Guidance for the Preparation of a Premarket Notification for Extended Laparoscopy Devices (ELD),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-preparation-premarket-notification-extended-laparoscopy-devices-eld,
FDA,,CPG Sec. 634.100  Drugs Packaged for Infusion or Injection of Food-Producing Animals (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-634100-drugs-packaged-infusion-or-injection-food-producing-animals-withdrawn-2202020,
FDA,,E7 Studies in Support of Special Populations: Geriatrics,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e7-studies-support-special-populations-geriatrics,
FDA,FDA-2020-D-0957,Points to Consider for Cervical Cytology Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/points-consider-cervical-cytology-devices,
FDA,FDA-2020-D-0957,Guidance for the Content of Premarket Notifications for Urine Drainage Bags,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-urine-drainage-bags,
FDA,FDA-1994-D-0230,"CVM GFI #55 Supportive Data for Cat Food Labels Bearing ""Reduces Urinary pH Claims:  Protocol Development",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-55-supportive-data-cat-food-labels-bearing-reduces-urinary-ph-claims-protocol-development,
FDA,FDA-2021-D-0618,CVM GFI #53  Evaluation of the Utility of Food Additives in Diet Fed to Aquatic Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-53-evaluation-utility-food-additives-diet-fed-aquatic-animals,
FDA,FDA-2020-D-0957,Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone Or Bone Cement,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-testing-orthopedic-implants-modified-metallic-surfaces-apposing-bone-or-bone,
FDA,FDA-2020-D-0957,"Letter - Manufacturers, Distributors and Importers of Condom Products (included in Condom Packet 398) :  Letter - Manufacturers, Distributors and Importers of Condom Products",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/letter-manufacturers-distributors-and-importers-condom-products-included-condom-packet-398,
FDA,FDA-2020-D-0957,Manufacturers/Assemblers of Diagnostic X-ray Systems: Enforcement Policy for Positive-Beam Limitation (PBL) Requirements in 21 CFR 1020.31(g) :,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturersassemblers-diagnostic-x-ray-systems-enforcement-policy-positive-beam-limitation-pbl,
FDA,FDA-2020-D-0957,Guidance on the Content and Format of Premarket Notification [510(k)] Submissions for Sharps Containers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-and-format-premarket-notification-510k-submissions-sharps-containers,
FDA,FDA-2020-D-1977-0001,"Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reviewer-guidance-nebulizers-metered-dose-inhalers-spacers-and-actuators,
FDA,FDA-2020-D-0957,Guidance for Industry: Guidelines for Determining Metric Equivalents of Household Measures,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-guidelines-determining-metric-equivalents-household-measures,
FDA,FDA-2013-S-0612,"Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes,
FDA,,Guidance on Premarket Notification [510(k)] Submissions for Surgical Gowns and Surgical Drapes,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-premarket-notification-510k-submissions-surgical-gowns-and-surgical-drapes,
FDA,FDA-2020-D-0957,"Guidance on Premarket Notification [510(k)] Submissions for Automated Endoscope Washers, Washer/Disinfectors, and Disinfectors Intended for Use in Health Care Facilities",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-premarket-notification-510k-submissions-automated-endoscope-washers-washerdisinfectors-and,
FDA,FDA-2020-D-0957,1993 Draft Redbook II,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/1993-draft-redbook-ii,
FDA,FDA-2021-D-0620,CVM GFI #45 Guideline for Uniform Labeling of Drugs for Dairy and Beef Cattle,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-45-guideline-uniform-labeling-drugs-dairy-and-beef-cattle,
FDA,FDA-2013-S-0613,Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/study-and-evaluation-gender-differences-clinical-evaluation-drugs,
FDA,FDA-1993-D-0184,Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-regarding-license-amendments-and-procedures-gamma-irradiation-blood-products,
FDA,FDA-2021-D-0643,CPG Sec. 615.200  Proper Drug Use and Residue Avoidance by Non-Veterinarians,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-615200-proper-drug-use-and-residue-avoidance-non-veterinarians,
FDA,FDA-2020-D-0957,Beam Attenuators and Emission Indicators for Class II and IIIa Laser Systems (Laser Notice 43),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/beam-attenuators-and-emission-indicators-class-ii-and-iiia-laser-systems-laser-notice-43,
FDA,FDA-2020-D-0957,"Letter to Industry, Powered Wheelchair Manufacturers from RMJohnson",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/letter-industry-powered-wheelchair-manufacturers-rmjohnson,
FDA,,CPG Sec. 680.100  Tracers in Animal Feed (Withdrawn 10/19/2022),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-680100-tracers-animal-feed-withdrawn-10192022,
FDA,FDA-2020-D-0957,Guidance on the Content of Premarket Notification [510(K)] Submissions for Piston Syringes,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notification-510k-submissions-piston-syringes,
FDA,FDA-2020-D-0957,Guidance on the Content of Premarket Notification [510(K)] Submissions for Hypodermic Single Lumen Needles,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notification-510k-submissions-hypodermic-single-lumen-needles,
FDA,FDA-2020-D-0957,Guidance on Premarket Notification 510(k) for Sterilizers Intended for Use in Health Care Facilities,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-premarket-notification-510k-sterilizers-intended-use-health-care-facilities,
FDA,FDA-2020-D-0957,Guidance on the Content of Premarket Notification [510(K)] Submissions for Clinical Electronic Thermometers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notification-510k-submissions-clinical-electronic-thermometers,
FDA,FDA-2020-D-0957,Guidance for the Content of Premarket Notifications for Ureteral Stents,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-ureteral-stents,
FDA,FDA-2020-D-0957,Guidance for the Content of Premarket Notifications for Biopsy Devices Used in Gastroenterology and Urology,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-content-premarket-notifications-biopsy-devices-used-gastroenterology-and-urology,
FDA,FDA-2013-S-0613,Volume Limits for Automated Collection of Source Plasma,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/volume-limits-automated-collection-source-plasma,
FDA,,Preparation of Investigational New Drug Products (Human and Animal):  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preparation-investigational-new-drug-products-human-and-animal,
FDA,,CPG Sec. 681.100  Order for Post-Approval Record Reviews (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-681100-order-post-approval-record-reviews-withdrawn-2202020,
FDA,,CPG Sec. 625.600  Orders for Post-Approval Record Reviews,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-625600-orders-post-approval-record-reviews,
FDA,,CPG Sec. 470.100 Orders for Post-Approval Record Reviews,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-470100-orders-post-approval-record-reviews,
FDA,FDA-2020-D-0957,Compliance Guide for Laser Products (FDA 86-8260),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-guide-laser-products-fda-86-8260,
FDA,,Statement of Policy - Foods Derived from New Plant Varieties,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statement-policy-foods-derived-new-plant-varieties,
FDA,,CPG Sec. 450.500 Tamper-Resistant Packaging Requirements for Certain Over-the-Counter Human Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450500-tamper-resistant-packaging-requirements-certain-over-counter-human-drug-products,
FDA,FDA-2020-D-0957,Review Criteria For Premarket Approval of In Vitro Diagnostic Devices for Detection of Antibodies to Parvovirus B19,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-criteria-premarket-approval-in-vitro-diagnostic-devices-detection-antibodies-parvovirus-b19,
FDA,,Development of New Stereoisomeric Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-new-stereoisomeric-drugs,
FDA,None found,CPG Sec. 420.100 Adulteration of Drugs Under Section 501(b) and 501(c) of the Act. *Direct Reference Seizure Authority for Adulterated Drugs Under Section 501(b)*,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420100-adulteration-drugs-under-section-501b-and-501c-act-direct-reference-seizure-authority,
FDA,FDA-2013-S-0613,"Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes-0,
FDA,FDA-1985-D-0044,Guideline for Postmarketing Reporting of Adverse Drug Experiences,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guideline-postmarketing-reporting-adverse-drug-experiences,
FDA,FDA-2013-S-0613,FDA Recommendations Concerning Testing for Antibody to Hepatitis B Core Antigen (Anti-HBc),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-recommendations-concerning-testing-antibody-hepatitis-b-core-antigen-anti-hbc,
FDA,,"CPG Sec. 120.100  Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-120100-fraud-untrue-statements-material-facts-bribery-and-illegal-gratuities,
FDA,FDA-2020-D-0957,CPG Sec. 335.800 Clinical Thermometer - Adulteration; Misbranding Defects,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-335800-clinical-thermometer-adulteration-misbranding-defects,
FDA,FDA-2020-D-0957,Shelf Life of Medical Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/shelf-life-medical-devices,
FDA,FDA-2020-D-0957,Device Labeling Guidance #G91-1 (Blue Book Memo),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/device-labeling-guidance-g91-1-blue-book-memo,
FDA,FDA-2020-D-0957,Quality Assurance Guidelines for Hemodialysis Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-assurance-guidelines-hemodialysis-devices,
FDA,None found,CPG Sec. 446.100 Regulatory Action Regarding Approved New Drugs and Antibiotic Drug Products Subjected to Additional Processing or other Manipulations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-446100-regulatory-action-regarding-approved-new-drugs-and-antibiotic-drug-products-subjected,
FDA,,"Continuation of a series of letters communicating interim and informal generic drug policy and guidance. Availability of Policy and Procedure Guides, and further operational changes to the generic drug review program",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/continuation-series-letters-communicating-interim-and-informal-generic-drug-policy-and-guidance,
FDA,,Format and Content of the Microbiology Section of an Application*:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-microbiology-section-application,
FDA,FDA-2020-D-0957,Clarification of Compliance Requirements for Certain Manufacturers Who Incorporate Certified Class I Laser Products into Their Products (Laser Notice 42),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-compliance-requirements-certain-manufacturers-who-incorporate-certified-class-i-laser,
FDA,,Study of Drugs Likely to be used in the Elderly,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/study-drugs-likely-be-used-elderly,
FDA,,Review of FDA's Implementation of the Drug Export Amendments of 1986,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-fdas-implementation-drug-export-amendments-1986,
FDA,,CPG Sec 540.550 Kipper and Kipper Unsplit - Definitions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540550-kipper-and-kipper-unsplit-definitions,
FDA,,CPG Sec 540.450 *Imitation Breaded Shrimp*,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540450-imitation-breaded-shrimp,
FDA,,"CPG Sec 540.390 Canned Shrimp - Labeling, Size Designations and Corresponding Counts",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540390-canned-shrimp-labeling-size-designations-and-corresponding-counts,
FDA,,"CPG Sec 540.150 Caviar, Use of Term - Labeling",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540150-caviar-use-term-labeling,
FDA,,CPG Sec 560.250 Imports - Importer can be Required to Reveal Identity of Ingredients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560250-imports-importer-can-be-required-reveal-identity-ingredients,
FDA,FDA-2020-D-0957,Labeling - Regulatory Requirements for Medical Devices (FDA 89-4203),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-regulatory-requirements-medical-devices-fda-89-4203,
FDA,,CPG Sec 100.200 FDA Jurisdiction Over Products Composed of Interstate Ingredients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100200-fda-jurisdiction-over-products-composed-interstate-ingredients,
FDA,,CPG Sec. 160.400  *Section 305 Meeting* Before Report of Criminal Violation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-160400-section-305-meeting-report-criminal-violation,
FDA,,CPG Sec. 160.300  Requests for Records Under Section 703,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-160300-requests-records-under-section-703,
FDA,,CPG Sec. 140.100  Seizure of Books that Constitute Misleading Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-140100-seizure-books-constitute-misleading-labeling,
FDA,,CPG Sec. 130.200  Inspection of Firms when Legal Action is Pending,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-130200-inspection-firms-when-legal-action-pending,
FDA,,CPG Sec. 110.700  Seizures by the U.S. Customs Service of Prohibited Articles of Foreign Origin Not Intended for Entry into the United States,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-110700-seizures-us-customs-service-prohibited-articles-foreign-origin-not-intended-entry,
FDA,,"CPG Sec. 110.600  FDA Authority Over Products of Foreign Origin Located in Foreign Trade Zones, Bonded Warehouses or on Bonded Carriers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-110600-fda-authority-over-products-foreign-origin-located-foreign-trade-zones-bonded,
FDA,,CPG Sec. 110.200  Export of FDA Regulated Products from U.S. Foreign Trade Zones,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-110200-export-fda-regulated-products-us-foreign-trade-zones,
FDA,,CPG Sec. 100.800  Guaranties Over Printed Signatures,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100800-guaranties-over-printed-signatures,
FDA,,"CPG Sec. 100.500 - Common Carrier as a Relabeler, Repacker, Reprocessor, etc.",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100500-common-carrier-relabeler-repacker-reprocessor-etc,
FDA,,"CPG Sec 100.600 Status of Facial Tissues, Paper Napkins, Paper Towels and Similar Paper Products",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100600-status-facial-tissues-paper-napkins-paper-towels-and-similar-paper-products,
FDA,,CPG Sec. 400.700 Drug Product Entries in Periodic Publications,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400700-drug-product-entries-periodic-publications,
FDA,,CPG Sec. 160.700 Reconditioning of Foods Adulterated Under 402(a)(4),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-160700-reconditioning-foods-adulterated-under-402a4,
FDA,,CPG Sec 560.350 Coffee and Cocoa Bean Sweeps,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560350-coffee-and-cocoa-bean-sweeps,
FDA,,"CPG Sec 560.300 Reconditioning of Imported, Insect Infested, Insect Damaged or Moldy Coffee Beans",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560300-reconditioning-imported-insect-infested-insect-damaged-or-moldy-coffee-beans,
FDA,,CPG Sec 560.100 Importation of Unlabeled Foods - Exemption Under *21 CFR 101.100(d)*,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560100-importation-unlabeled-foods-exemption-under-21-cfr-101100d,
FDA,,Metaproterenol Sulfate and Albuterol Metered Dose Inhalers In Vitro,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/metaproterenol-sulfate-and-albuterol-metered-dose-inhalers-vitro,
FDA,,CPG Sec. 690.500  Uncooked Meat for Animal Food (Withdrawn 4/30/2019),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-690500-uncooked-meat-animal-food-withdrawn-4302019,
FDA,FDA-2018-D-4115,Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 3),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-part-3,
FDA,FDA-2018-D-4115,Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 2),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-part-2,
FDA,FDA-2018-D-4115,Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 1 ),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-part-1,
FDA,,Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (FDA 89-8221),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-fda-89-8221,
FDA,,Guidance for Oxygen Conserving Device 510(k) Review 73 BZD 868.5905 Non-continuous Ventilator Class II,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-oxygen-conserving-device-510k-review-73-bzd-8685905-non-continuous-ventilator-class-ii,
FDA,,CPG Sec 562.800 Vending Machine Food - Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562800-vending-machine-food-labeling,
FDA,,CPG Sec 562.750 Labeling of Food Articles Distributed Solely in Puerto Rico,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562750-labeling-food-articles-distributed-solely-puerto-rico,
FDA,,CPG Sec 562.700 Labeling of Food Bearing Residues of Pesticide Chemicals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562700-labeling-food-bearing-residues-pesticide-chemicals,
FDA,,CPG Sec 562.600 Preservatives; Use in Nonstandardized Foods; Label Declaration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562600-preservatives-use-nonstandardized-foods-label-declaration,
FDA,,CPG Sec 562.100 Acetic Acid - Use in Foods - Labeling of Foods in Which Used,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562100-acetic-acid-use-foods-labeling-foods-which-used,
FDA,,"CPG Sec 555.850 Water Damaged Food Products in Screw-Top, Crimped-Cap and Similar Containers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555850-water-damaged-food-products-screw-top-crimped-cap-and-similar-containers,
FDA,FDA-2020-D-0957,"CPG Sec 555.550 Foods, Standardized; Enriched or Fortified - Adulteration Involving Misbranding - Potency",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555550-foods-standardized-enriched-or-fortified-adulteration-involving-misbranding-potency,
FDA,,"CPG Sec 562.650 ""Processing"" - Use of Term in Section 405 of the FD&C Act",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562650-processing-use-term-section-405-fdc-act,
FDA,,CPG Sec 555.875 Water in Food Products (Ingredient or Adulterant),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555875-water-food-products-ingredient-or-adulterant,
FDA,,"CPG Sec 555.800 Polysorbates 20, 40, 60, 65, 80, 85 - Common or Usual Names",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555800-polysorbates-20-40-60-65-80-85-common-or-usual-names,
FDA,,"CPG Sec 555.750 Seeds for Sprouting Prior to Food Use, i.e., Dried Mung Beans, Alfalfa Seeds, Etc.",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555750-seeds-sprouting-prior-food-use-ie-dried-mung-beans-alfalfa-seeds-etc,
FDA,,CPG Sec 555.100 Alcohol; Use of Synthetic Alcohol in Foods,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555100-alcohol-use-synthetic-alcohol-foods,
FDA,,CPG Sec 570.550 Reconditioning - Tree Nuts Contaminated with E. coli,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570550-reconditioning-tree-nuts-contaminated-e-coli,
FDA,,CPG Sec 585.850 Sweet Potatoes - Sirup Pack,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585850-sweet-potatoes-sirup-pack,
FDA,,CPG Sec 585.800 Squash Seeds - Labeling as Pumpkin Seeds,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585800-squash-seeds-labeling-pumpkin-seeds,
FDA,,"CPG Sec 585.725 ""Pumpkin"" - Labeling Articles Made from Certain Varieties of Squash",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585725-pumpkin-labeling-articles-made-certain-varieties-squash,
FDA,,"CPG Sec 585.710 Potato Chips, Ingredients - Labeling",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585710-potato-chips-ingredients-labeling,
FDA,,CPG Sec 585.700 Potato Chips - Adulteration with Rot,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585700-potato-chips-adulteration-rot,
FDA,,CPG Sec 585.650 Canned Pimentos and Red Sweet Peppers - Seeds Should be Removed,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585650-canned-pimentos-and-red-sweet-peppers-seeds-should-be-removed,
FDA,,CPG Sec 585.625 Canned Peas - Label Designation of Sizes,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585625-canned-peas-label-designation-sizes,
FDA,,"CPG Sec 585.600 Peas and Carrots, Labeling of Canned Mixture",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585600-peas-and-carrots-labeling-canned-mixture,
FDA,,CPG Sec 585.525: Mushroom Mycelium - Fitness for Food; Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585525-mushroom-mycelium-fitness-food-labeling,
FDA,,"CPG Sec 585.450 Greens, Canned - Adulteration by Mildew",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585450-greens-canned-adulteration-mildew,
FDA,,CPG Sec 585.350 Corn Husks (for Tamales) - Adulteration with Filth,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585350-corn-husks-tamales-adulteration-filth,
FDA,,"CPG Sec 585.260 Broccoli, Frozen - Adulteration with Insects",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585260-broccoli-frozen-adulteration-insects,
FDA,,"CPG Sec 585.150 Asparagus, Canned or Frozen - Adulteration with Insect Filth",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585150-asparagus-canned-or-frozen-adulteration-insect-filth,
FDA,,CPG Sec 585.100 Artichoke; Jerusalem Artichoke - Common or Usual Name,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-585100-artichoke-jerusalem-artichoke-common-or-usual-name,
FDA,,"CPG Sec 570.250 Cashews, Insect Infested - Reconditioning",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570250-cashews-insect-infested-reconditioning,
FDA,,CPG Sec 570.100 Jordan Almonds - Common or Usual Name,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-570100-jordan-almonds-common-or-usual-name,
FDA,FDA-2020-D-0957,CPG Sec. 350.100 Packaging Technologies and Tamper-Resistant Packaging Requirements for Contact Lens Solutions and Tablets,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-350100-packaging-technologies-and-tamper-resistant-packaging-requirements-contact-lens,
FDA,,CPG Sec 510.100 Beverage Bases,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510100-beverage-bases,
FDA,,"Seventh of a series of letters about the Act providing guidance on the ""130-day exclusivity"" provision of section 505(j)(4)(B)(iv) of the FD&C",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/seventh-series-letters-about-act-providing-guidance-130-day-exclusivity-provision-section-505j4biv,
FDA,,Format and Content of the Clinical and Statistical Sections of an Application,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-clinical-and-statistical-sections-application,
FDA,,CPG Sec 545.200 Confectionery Decorations (Nutritive and Non-Nutritive),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-545200-confectionery-decorations-nutritive-and-non-nutritive,
FDA,,CPG Sec 578.300 Wheat - Adulteration by Insect and Rodent filth,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578300-wheat-adulteration-insect-and-rodent-filth,
FDA,,CPG Sec 578.200 Corn Meal - Adulteration by Insect and Rodent Filth,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578200-corn-meal-adulteration-insect-and-rodent-filth,
FDA,,"CPG Sec 515.800 Labeling of Products Purporting to be ""Chocolate"" or ""Chocolate Flavored""",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515800-labeling-products-purporting-be-chocolate-or-chocolate-flavored,
FDA,,CPG Sec. 160.200  FDA Use of Income Tax Information from IRS in Compliance Activity,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-160200-fda-use-income-tax-information-irs-compliance-activity,
FDA,,CPG Sec. 150.100  Requests for Portions of Intermediate or End Products Resulting from FDA Sample Analysis,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-150100-requests-portions-intermediate-or-end-products-resulting-fda-sample-analysis,
FDA,,"CPG Sec 505.350 Honey Bread, Honey Buns",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505350-honey-bread-honey-buns,
FDA,,"CPG Sec 505.300 ""Butter-Nut"" Bread",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505300-butter-nut-bread,
FDA,,"CPG Sec 505.200 ""Butter"" Featured in Product Name",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-505200-butter-featured-product-name,
FDA,,Quality Control Guide for Sunlamp Products (FDA 88-8234),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-control-guide-sunlamp-products-fda-88-8234,
FDA,FDA-2020-D-0957,Guide for Establishing and Maintaining a Calibration Constancy Intercomparison System for Microwave Oven Compliance Survey Instruments (FDA 88-8264)] (PDF Only),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guide-establishing-and-maintaining-calibration-constancy-intercomparison-system-microwave-oven,
FDA,,CPG Sec 578.450 Wheat Flour-Adulteration with Insect Fragments and Rodent Hairs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578450-wheat-flour-adulteration-insect-fragments-and-rodent-hairs,
FDA,FDA-2013-S-0613,Recommendations for the Management of Donor and Units that are Initially Reactive for Hepatitis B Surface Antigen (HBsAg),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-management-donor-and-units-are-initially-reactive-hepatitis-b-surface-antigen-hbsag,
FDA,,CPG Sec 565.200 Red Meat Adulterated with PCBs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-565200-red-meat-adulterated-pcbs,
FDA,FDA-2020-D-0957,Class II and IIIA Laser Light Show Projectors and Shows (Laser Notice 40),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/class-ii-and-iiia-laser-light-show-projectors-and-shows-laser-notice-40,
FDA,,CPG Sec. 160.600  Payment of Expert Witnesses,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-160600-payment-expert-witnesses,
FDA,,CPG Sec. 460.600 Content Uniformity Testing of Tablets and Capsules,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460600-content-uniformity-testing-tablets-and-capsules,
FDA,,CPG Sec 567.200 Pork and Beans and Similar Bean Products - Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-567200-pork-and-beans-and-similar-bean-products-labeling,
FDA,FDA-2020-D-0957,CPG Sec. 345.200 Diaphragms - Rx Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-345200-diaphragms-rx-devices,
FDA,FDA-2020-D-0957,CPG Sec. 325.100 Karaya Gum Powder and Related Devices for Use by Ostomates,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-325100-karaya-gum-powder-and-related-devices-use-ostomates,
FDA,FDA-2020-D-0957,CPG Sec. 320.100 Ear Piercing Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-320100-ear-piercing-devices,
FDA,FDA-2020-D-0957,CPG Sec. 300.600 Commercial Distribution with Regard to Premarket Notification (Section 510(k)),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-300600-commercial-distribution-regard-premarket-notification-section-510k,
FDA,FDA-2020-D-0957,CPG Sec. 300.100 Inspection of Manufacturers of Device Components,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-300100-inspection-manufacturers-device-components,
FDA,,"CPG Sec. 425.500 Computerized Drug Processing; Identification of ""Persons"" on Batch Production and Control Records",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-425500-computerized-drug-processing-identification-persons-batch-production-and-control,
FDA,,CPG Sec. 425.400 Computerized Drug Processing; Input/Output Checking,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-425400-computerized-drug-processing-inputoutput-checking,
FDA,,CPG Sec. 425.200 Computerized Drug Processing; Vendor Responsibility,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-425200-computerized-drug-processing-vendor-responsibility,
FDA,,CPG Sec. 425.100 Computerized Drug Processing; CGMP Applicability to Hardware and Software*,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-425100-computerized-drug-processing-cgmp-applicability-hardware-and-software,
FDA,,CPG Sec. 410.100 *Finished Dosage Form Drug Products in Bulk Containers - Applications of Current Good Manufacturing Practice Regulations*,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-410100-finished-dosage-form-drug-products-bulk-containers-applications-current-good,
FDA,,CPG Sec. 100.300  *Non-FDA Regulated Products Involving Communicable Disease Hazards*,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100300-non-fda-regulated-products-involving-communicable-disease-hazards,
FDA,,"CPG Sec. 100.100  Responsibility for Reporting Possible or Potential Violations of Laws Administered by FDA, Regulations Issued by FDA, Other Possible or Potential Hazards to the Public Health",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100100-responsibility-reporting-possible-or-potential-violations-laws-administered-fda,
FDA,,"CPG Sec 567.300 *Bouillon, Bouillon Cubes, Granulated Bouillon*",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-567300-bouillon-bouillon-cubes-granulated-bouillon,
FDA,,"CPG Sec 567.100 Antipasto, Common or Usual Name",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-567100-antipasto-common-or-usual-name,
FDA,,CPG Sec. 100.350  FDA Jurisdiction on Indian Reservations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-100350-fda-jurisdiction-indian-reservations,
FDA,FDA-2020-D-0957,User Instructions - Multi Axis Workstations (Laser Notice 39),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-instructions-multi-axis-workstations-laser-notice-39,
FDA,,Master Files Part III - Guidance on Scientific and Technical Information,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-files-part-iii-guidance-scientific-and-technical-information,
FDA,,CPG Sec. 655.400  The Status of Syringes and Needles for Animal Use (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-655400-status-syringes-and-needles-animal-use-withdrawn-2202020,
FDA,,CPG Sec. 655.300  Barking Dog Collar (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-655300-barking-dog-collar-withdrawn-2202020,
FDA,FDA-2020-D-0957,CPG Sec. 655.100  Devices for Use in Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-655100-devices-use-animals,
FDA,FDA-2020-D-0957,Color Additive Petitions - Medical Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/color-additive-petitions-medical-devices,
FDA,,"CPG Sec. 455.100 Inert Glandular Preparations *(OTC)*, Inadequate Full Disclosure and Claims",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-455100-inert-glandular-preparations-otc-inadequate-full-disclosure-and-claims,
FDA,None found,CPG Sec. 454.100 OTC Ear Drop Preparations,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-454100-otc-ear-drop-preparations,
FDA,None found,CPG Sec. 450.400 Labeling and Distribution of OTC Drugs in Vending Machines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450400-labeling-and-distribution-otc-drugs-vending-machines,
FDA,None found,CPG Sec. 430.300 Labeling Shipping Containers of Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-430300-labeling-shipping-containers-drugs,
FDA,None found,CPG Sec. 400.335 Fructose-Containing Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400335-fructose-containing-drugs,
FDA,,CPG Sec. 460.450 Status of Mail-Order Filling of Prescriptions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460450-status-mail-order-filling-prescriptions,
FDA,,CPG Sec. 425.300 Computerized Drug Processing; Source Code for Process Control Application Programs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-425300-computerized-drug-processing-source-code-process-control-application-programs,
FDA,FDA-2020-D-0957,"All U.S. Condom Manufacturers, Importers and Repackagers",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/all-us-condom-manufacturers-importers-and-repackagers,
FDA,,Summary for New Drug and Antibiotic Applications--Format and Content of the Summary for New Drug and Antibiotic Applications,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/summary-new-drug-and-antibiotic-applications-format-and-content-summary-new-drug-and-antibiotic,
FDA,,GUIDELINE FOR SUBMITTING SUPPORTING DOCUMENTATION IN DRUG APPLICATIONS FOR THE MANUFACTURE OF DRUG PRODUCTS,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guideline-submitting-supporting-documentation-drug-applications-manufacture-drug-products,
FDA,FDA-1985-D-0033,"Formatting, Assembling and Submitting New Drug and Antibiotic Applications*",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formatting-assembling-and-submitting-new-drug-and-antibiotic-applications,
FDA,,Format and Content of the Nonclinical Pharmacology/Toxicology Section of an Application*:  Guidance for Industry,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-nonclinical-pharmacologytoxicology-section-application,
FDA,,Format and Content of the Human Pharmacokinetics and Bioavailability Section of an Application,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-human-pharmacokinetics-and-bioavailability-section-application,
FDA,FDA-2020-D-0957,Policy on Lamp Compatibility (sunlamps),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-lamp-compatibility-sunlamps,
FDA,,CPG Sec 590.600 Wigs Compliance Policy Guide 7128.05,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-590600-wigs-compliance-policy-guide-712805,
FDA,,CPG Sec. 605.100 - Use of Statements Regarding NADA Approval by FDA in  Labeling and Advertising of New Animal Drugs (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-605100-use-statements-regarding-nada-approval-fda-labeling-and-advertising-new-animal-drugs,
FDA,,CPG Sec. 680.200  CGMP Regulations for Medicated Feeds - Daily Inventory Requirements (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-680200-cgmp-regulations-medicated-feeds-daily-inventory-requirements-withdrawn-2202020,
FDA,,CPG Sec. 680.400  Medicated Feeds -- Combined Batches,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-680400-medicated-feeds-combined-batches,
FDA,,CPG Sec. 670.200  Status of Vitamins and Minerals in Type B and C Medicated Feed and in Non-Medicated Feed (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-670200-status-vitamins-and-minerals-type-b-and-c-medicated-feed-and-non-medicated-feed,
FDA,FDA-2021-D-0644,CPG Sec. 670.100  Refusals of Formula Information During Inspection of Feed Mills Manufacturing Feeds Requiring Approved Medicated Feed Applications (Withdrawn 6/30/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-670100-refusals-formula-information-during-inspection-feed-mills-manufacturing-feeds,
FDA,FDA-2020-D-0957,Walk-In Workstations (Laser Notice 37),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/walk-workstations-laser-notice-37,
FDA,FDA-2020-D-0957,Policy On Maximum Timer Interval and Exposure Schedule For Sunlamp Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-maximum-timer-interval-and-exposure-schedule-sunlamp-products,
FDA,FDA-2021-D-0623,CVM GFI #23 Medicated Free Choice Feeds--Manufacturing Control,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-23-medicated-free-choice-feeds-manufacturing-control,
FDA,FDA-2020-D-0957,Policy on Warning Label Required on Sunlamp Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-warning-label-required-sunlamp-products,
FDA,FDA-2020-D-0957,User Instruction Hazard Warnings (Laser Notice 35),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/user-instruction-hazard-warnings-laser-notice-35,
FDA,FDA-2020-D-0957,Medical Laser Delivery System Interlocks (Laser Notice 34),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-laser-delivery-system-interlocks-laser-notice-34,
FDA,FDA-2021-D-0624,CVM GFI #13  Evaluation of Effectiveness of New Animal Drugs for Use in Free-Choice Feeds-Medicated Block,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-13-evaluation-effectiveness-new-animal-drugs-use-free-choice-feeds-medicated-block,
FDA,FDA-2013-S-0613,Plasma Derived from Therapeutic Plasma Exchange,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/plasma-derived-therapeutic-plasma-exchange,
FDA,FDA-2021-D-0625,CVM GFI #38 Guideline for Effectiveness Evaluation of Topical/Otic Animal Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-38-guideline-effectiveness-evaluation-topicalotic-animal-drugs,
FDA,,Nuclear Pharmacy Guideline Criteria for Determining When to Register as a Drug Establishment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nuclear-pharmacy-guideline-criteria-determining-when-register-drug-establishment,
FDA,FDA-1975-N-0008,Enforcement Policy on Marketing OTC Combination Products (CPG 7132b.16).,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-marketing-otc-combination-products-cpg-7132b16,
FDA,FDA-2021-D-0626,CVM GFI #37 Evaluation of Effectiveness of New Animal Drugs for Use in Poultry Feed for Pigmentation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-37-evaluation-effectiveness-new-animal-drugs-use-poultry-feed-pigmentation,
FDA,,CPG Sec 430.100 Unit Dose Labeling for Solid and Liquid Oral Dosage Forms,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-430100-unit-dose-labeling-solid-and-liquid-oral-dosage-forms,
FDA,FDA-2021-D-0627,CVM GFI #24 Drug Combinations for Use in Animals,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-24-drug-combinations-use-animals,
FDA,FDA-2020-D-0957,"CPG Sec. 398.450 Applicability of Positive Beam Limitation (PBL) Requirements When PBL is Provided on ""Other than Stationary General Purpose"" Radiographic System",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398450-applicability-positive-beam-limitation-pbl-requirements-when-pbl-provided-other,
FDA,,CPG Sec. 450.550 Control and Accountability of Labeling Associated with Tamper-Resistant Packaging of Over-the-Counter Drug Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450550-control-and-accountability-labeling-associated-tamper-resistant-packaging-over,
FDA,FDA-2021-D-0645,CPG Sec. 682.200  The Use of Antibiotic Drug Residue By-Products in Animal Feed Feed (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-682200-use-antibiotic-drug-residue-products-animal-feed-feed-withdrawn-2202020,
FDA,FDA-2021-D-0646,"CPG Sec. 615.300  Responsibility for Illegal Drug Residues in Meat, Milk and Eggs",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-615300-responsibility-illegal-drug-residues-meat-milk-and-eggs,
FDA,,Clinical Evaluation of General Anesthetics,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-evaluation-general-anesthetics,
FDA,None found,CPG Sec. 450.100 CGMP Enforcement Policy - OTC vs Rx Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-450100-cgmp-enforcement-policy-otc-vs-rx-drugs,
FDA,,CPG Sec. 688.100  Unapproved Additives for Exported Grains,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-688100-unapproved-additives-exported-grains,
FDA,FDA-2020-D-0957,Procedures for Laboratory Testing of Microwave Ovens,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-laboratory-testing-microwave-ovens,
FDA,FDA-2020-D-0957,Exemption from Reporting and Record keeping Requirements for Certain Sunlamp Product Manufacturers,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exemption-reporting-and-record-keeping-requirements-certain-sunlamp-product-manufacturers,
FDA,,CPG Sec. 430.200 Repacking of Drug Products - Testing/Examination under CGMPs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-430200-repacking-drug-products-testingexamination-under-cgmps,
FDA,FDA-2020-D-0957,Investigational Medical Laser Significant Risk Device (Laser Notice 31),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-medical-laser-significant-risk-device-laser-notice-31,
FDA,,Clinical Evaluation of Antiepileptic Drugs (adults and children),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-evaluation-antiepileptic-drugs-adults-and-children,
FDA,,CPG Sec. 690.400  Water and Gravy in Pet Food (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-690400-water-and-gravy-pet-food-withdrawn-2202020,
FDA,,CPG Sec. 460.300 Return of Unused Prescription Drugs to Pharmacy Stock,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460300-return-unused-prescription-drugs-pharmacy-stock,
FDA,,CPG Sec. 460.100 Hospital Pharmacies - Status as Drug Manufacturer,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460100-hospital-pharmacies-status-drug-manufacturer,
FDA,,CPG Sec. 444.100 Recovery of Investigational New Drugs from Clinical Investigators,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-444100-recovery-investigational-new-drugs-clinical-investigators,
FDA,,CPG Sec. 442.100 New Drugs - Export,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-442100-new-drugs-export,
FDA,,CPG Sec. 420.400 Performance of Tests for Compendial Requirements on Compendial Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420400-performance-tests-compendial-requirements-compendial-products,
FDA,,CPG Sec. 400.900 Class I Recalls of Prescription Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400900-class-i-recalls-prescription-drugs,
FDA,,CPG Sec. 400.800 Collection and Charitable Distribution of Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400800-collection-and-charitable-distribution-drugs,
FDA,,CPG Sec. 400.600 Drugs - Declaration of Quantity of Active Ingredient by Both Metric and Apothecary Systems,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400600-drugs-declaration-quantity-active-ingredient-both-metric-and-apothecary-systems,
FDA,,"CPG Sec. 400.325 Candy ""Pills"" Representation as Drug",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-400325-candy-pills-representation-drug,
FDA,,CPG Sec. 110.100 Certification for Exports (Withdrawn 11/04/2021),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-110100-certification-exports-withdrawn-11042021,
FDA,,CPG Sec 578.400 Treated Grain Seed - Mercury Residue,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578400-treated-grain-seed-mercury-residue,
FDA,,CPG Sec 578.350 Wheat for Human Consumption - Reconditioning,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578350-wheat-human-consumption-reconditioning,
FDA,FDA-1996-D-0405,CPG Sec 578.100 Starches - Common or Usual Names,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-578100-starches-common-or-usual-names,
FDA,None found,"CPG Sec 562.450 Identity of Foods - Use of Terms Such as Fresh, Frozen, Dried, Canned, Etc.",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-562450-identity-foods-use-terms-such-fresh-frozen-dried-canned-etc,
FDA,,"CPG Sec 560.500 Jams, Jellies and Related Products - Imports",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560500-jams-jellies-and-related-products-imports,
FDA,,CPG Sec 560.450 Imported Low-Acid Canned Foods (Manufacturer Not Registered and/or No Scheduled Process Filed),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-560450-imported-low-acid-canned-foods-manufacturer-not-registered-andor-no-scheduled-process,
FDA,None found,CPG Sec 555.500 All Food Sanitation (Including Bacteriological) Inspections - Classification of Establishment,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555500-all-food-sanitation-including-bacteriological-inspections-classification,
FDA,,CPG Sec 555.450 Foods - Adulteration Involving Infestation and 1080 Rodenticide,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555450-foods-adulteration-involving-infestation-and-1080-rodenticide,
FDA,None found,CPG Sec 540.475 Snapper - Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540475-snapper-labeling,
FDA,None found,CPG Sec 525.750 Spices - Definitions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525750-spices-definitions,
FDA,None found,"CPG Sec 515.500 Barley Sugar - Definition, and Barley Sugar Candy",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515500-barley-sugar-definition-and-barley-sugar-candy,
FDA,None found,CPG Sec 515.350 Candy - Mixed with Trinkets and Sold in Vending Machines,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515350-candy-mixed-trinkets-and-sold-vending-machines,
FDA,,CPG Sec 515.300 Honey - Source Declaration,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-515300-honey-source-declaration,
FDA,,"CPG Sec 510.300 Unfermented Beverages - Use of Word ""Champagne""",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510300-unfermented-beverages-use-word-champagne,
FDA,,CPG Sec 510.200 Brandy Containing Methyl Alcohol - Food Additive,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-510200-brandy-containing-methyl-alcohol-food-additive,
FDA,,CPG Sec 500.100 Additives - Labeling with Adequate Directions for Many Uses,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-500100-additives-labeling-adequate-directions-many-uses,
FDA,,CPG Sec 390.100 Definition of â€œCommerceâ€ - 21 CFR 1000.3(d) 2,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390100-definition-commerce-21-cfr-10003d-2,
FDA,,CPG Sec. 690.200  Pet Food Labeling (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-690200-pet-food-labeling-withdrawn-2202020,
FDA,,CPG Sec. 682.100  Use of Drug-Contaminated Products in Animal Feed (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-682100-use-drug-contaminated-products-animal-feed-withdrawn-2202020,
FDA,,CPG Sec. 660.100  Failure to Register (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-660100-failure-register-withdrawn-2202020,
FDA,,CPG Sec. 655.200  Adequate Directions for Use - Animal Drugs & Veterinary Devices (Withdrawn 2/20/2020),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-655200-adequate-directions-use-animal-drugs-veterinary-devices-withdrawn-2202020,
FDA,,CPG Sec. 625.200  Availability of Bulk Chemicals for Animal Drug Use (Withdrawn 4/14/2022),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-625200-availability-bulk-chemicals-animal-drug-use-withdrawn-4142022,
FDA,,CPG Sec. 460.500 Prescription Drugs for Ship's Medicine Chests,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460500-prescription-drugs-ships-medicine-chests,
FDA,,CPG Sec. 460.425 Prescription Status when Telephoned to Recording Machine,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460425-prescription-status-when-telephoned-recording-machine,
FDA,,CPG Sec. 460.400 Computerized Prescription Recordkeeping by Pharmacies,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460400-computerized-prescription-recordkeeping-pharmacies,
FDA,,CPG Sec. 420.300 Changes in Compendial Specifications and NDA Supplements withdrawn on 8/30/12,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420300-changes-compendial-specifications-and-nda-supplements-withdrawn-83012,
FDA,,CPG Sec. 420.200 Compendium Revisions and Deletions,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420200-compendium-revisions-and-deletions,
FDA,,CPG Sec. 398.400 Automatic Adjustment of the X-ray Field Size to the Selected Spot-Film Size - 21 CFR 1020.31(g)(1),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-398400-automatic-adjustment-x-ray-field-size-selected-spot-film-size-21-cfr-102031g1,
FDA,,"CPG Sec. 251.100 Schedule of Physical Examination for Donors Receiving Immunization Injections (Obsolete, Withdrawn on 11/28/2017)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-251100-schedule-physical-examination-donors-receiving-immunization-injections-obsolete,
FDA,,CPG Sec. 130.100  Inspectional Authority; Refusal to Permit Inspection.,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-130100-inspectional-authority-refusal-permit-inspection,
FDA,,CPG Sec. 110.500  Food and Drug Guaranty - Imports,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-110500-food-and-drug-guaranty-imports,
FDA,,CPG Sec 555.200 Adulterated Food Mixed with Good Food,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555200-adulterated-food-mixed-good-food,
FDA,,CPG Sec 550.625 Oranges - Artificial Coloring,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550625-oranges-artificial-coloring,
FDA,,CPG Sec 550.575 Marmalade,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550575-marmalade,
FDA,,CPG Sec 550.550 Maraschino Cherries,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-550550-maraschino-cherries,
FDA,FDA-2021-D-0647,CPG Sec 540.285 Crabmeat Products - Labeling; Crabmeat Products with Added Fish or Other Seafood Ingredients - Labeling,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-540285-crabmeat-products-labeling-crabmeat-products-added-fish-or-other-seafood-ingredients,
FDA,,CPG Sec 527.450 Milk & Milk Products Containing Penicillin,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-527450-milk-milk-products-containing-penicillin,
FDA,,CPG Sec 525.650 Labeling of Seasonings,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525650-labeling-seasonings,
FDA,,CPG Sec 520.200 Canned Foods - Seam Defects,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-520200-canned-foods-seam-defects,
FDA,,CPG 230.120- Human Blood and Blood Products as Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-230120-human-blood-and-blood-products-drugs,
FDA,FDA-2020-D-0957,Alternate Wording For Caution Statement (Laser Notice 30),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alternate-wording-caution-statement-laser-notice-30,
FDA,FDA-2020-D-0957,Quality Control Practices for Compliance with the Federal Mercury Vapor Lamp Performance Standard,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-control-practices-compliance-federal-mercury-vapor-lamp-performance-standard,
FDA,FDA-2020-D-0957,Open Door Operation of Microwave Ovens as a Result of Oven Miswiring,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/open-door-operation-microwave-ovens-result-oven-miswiring,
FDA,FDA-2020-D-0957,"Exemption of Certain Lasers Used By DOE, NOAA and U.S. Dept. of Commerce (Laser Notice 25)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exemption-certain-lasers-used-doe-noaa-and-us-dept-commerce-laser-notice-25,
FDA,FDA-1976-N-0476-0380,"Good Laboratory Practice Regulations Management Briefings, Post Conference Report, Aug 1979:  Guidance for Industry",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-laboratory-practice-regulations-management-briefings-post-conference-report-aug-1979,
FDA,,General Guidelines for OTC Combination Products,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-guidelines-otc-combination-products,
FDA,,Upgrading Category III Antiperspirants to Category I (43 FR 46728-46731),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/upgrading-category-iii-antiperspirants-category-i-43-fr-46728-46731,
FDA,FDA-2020-D-0957,Guidance ('Guidelines') for Evaluation of Hysteroscopic Sterilization Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-guidelines-evaluation-hysteroscopic-sterilization-devices,
FDA,FDA-2020-D-0957,Laser Light Shows Subject to Laser Product Performance Standard (Laser Notice 22),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laser-light-shows-subject-laser-product-performance-standard-laser-notice-22,
FDA,,Hypnotic Drugs--Clinical Evaluation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypnotic-drugs-clinical-evaluation,
FDA,,Antidepressant Drugs--Clinical Evaluation,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antidepressant-drugs-clinical-evaluation,
FDA,FDA-2020-D-0957,Procedures for Field Testing Microwave Ovens,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-field-testing-microwave-ovens,
FDA,FDA-2020-D-0957,Warning Labels For Dye And Multiple Wavelength Lasers (Laser Notice 16),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/warning-labels-dye-and-multiple-wavelength-lasers-laser-notice-16,
FDA,FDA-2020-D-0957,Review Guidelines for Oxygen Generators and Oxygen Equipment for Emergency Use,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-guidelines-oxygen-generators-and-oxygen-equipment-emergency-use,
FDA,FDA-2020-D-0957,Lasers Manufactured and Used In-House (Laser Notice 14),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/lasers-manufactured-and-used-house-laser-notice-14,
FDA,FDA-2020-D-0957,Manufacture and Certification of Laser Kits (Laser Notice 13),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacture-and-certification-laser-kits-laser-notice-13,
FDA,FDA-2020-D-0957,Remote Interlock Connectors (Laser Notice 11),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/remote-interlock-connectors-laser-notice-11,
FDA,FDA-2020-D-0957,Certain Military Lasers Exempt From 21 CFR 1040.10 & .11 (Laser Notice 9),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/certain-military-lasers-exempt-21-cfr-104010-11-laser-notice-9,
FDA,FDA-2020-D-0957,Viewing Optics - Sighting Telescope (Laser Notice 8),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/viewing-optics-sighting-telescope-laser-notice-8,
FDA,FDA-2020-D-0957,Quality Control Practices for Compliance with the Federal Laser Performance Standard,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-control-practices-compliance-federal-laser-performance-standard,
FDA,FDA-2020-D-0957,Laser Energy Source (Laser Notice 2),Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/laser-energy-source-laser-notice-2,
FDA,FDA-2020-D-0957,Guidance for the Submission of Cabinet X-Ray System Reports Pursuant to 21-CFR 1020.40,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-submission-cabinet-x-ray-system-reports-pursuant-21-cfr-102040,
FDA,FDA-2020-D-0957,CPG Sec. 335.300 Hypnotherapy Devices - Self-Hypnotic Tape Recordings,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-335300-hypnotherapy-devices-self-hypnotic-tape-recordings,
FDA,,Sample WHO Certificate for Quality of a Pharmaceutical Product,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sample-who-certificate-quality-pharmaceutical-product,
FDA,,New/Revised/Withdrawn Guidances 2014,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/newrevisedwithdrawn-guidances-2014,
FDA,,NEPA_Final_Guidance,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nepa_final_guidance,
FDA,,GuÃ­a para la Industria:Â  Pruebas de disoluciÃ³n de formas de dosificaciÃ³n oral sÃ³lidas de liberaciÃ³n inmediata.,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guia-para-la-industria-pruebas-de-disolucion-de-formas-de-dosificacion-oral-solidas-de-liberacion,
FDA,,"GuÃ­a para la Industria:Â  Formas de dosificaciÃ³n oral de liberaciÃ³n prolongada: elaboraciÃ³n, evaluaciÃ³n y aplicaciÃ³n de correlaciones in vitro/in vivo",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guia-para-la-industria-formas-de-dosificacion-oral-de-liberacion-prolongada-elaboracion-evaluacion-y,
FDA,,"Formas posolÃ³gicas orales sÃ³lidas de liberaciÃ³n inmediata Cambios de escala y posteriores a la aprobaciÃ³n: documentaciÃ³n quÃ­mica, de fabricaciÃ³n y controles, de pruebas de disoluciÃ³n in vitro y bioequivalencia in vivo.",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formas-posologicas-orales-solidas-de-liberacion-inmediata-cambios-de-escala-y-posteriores-la,
FDA,,Final In Vivo Bioavailability-Bioequivalence Studies- Analytical,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/final-in-vivo-bioavailability-bioequivalence-studies-analytical,
FDA,,CPG Sec. 460.700 Controlled Release Dosage Form Drugs - Rate of Release of Active Ingredients,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-460700-controlled-release-dosage-form-drugs-rate-release-active-ingredients,
FDA,,CPG Sec. 420.500 Interference with Compendial Tests,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-420500-interference-compendial-tests,
FDA,,"CPG Sec. 390.100 Definition of ""Commerce"" - 21 CFR 1000.3(d)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-390100-definition-commerce-21-cfr-10003d,
FDA,,CPG Sec. 300.500 *Reprocessing of Single Use* Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-300500-reprocessing-single-use-devices,
FDA,,"CPG Sec. 257.100 Deferral of Source Plasma Donors Due To Red Cell Loss During Collection of Source Plasma by Automated Plasmapheresis (Obsolete, Withdrawn on 11/28/2017)",Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-257100-deferral-source-plasma-donors-due-red-cell-loss-during-collection-source-plasma,
FDA,,Chapter 48 7348.809A Radioactive Drug Research Committee,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-48-7348809a-radioactive-drug-research-committee,
FDA,,CHAPTER 48 - 7348.809 Bioresearch Monitoring,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-48-7348809-bioresearch-monitoring,
FDA,,Chapter 4 - Human Drugs,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-4-human-drugs,
FDA,,Chapter 3 - Devices,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-3-devices,
FDA,,Chapter 1 - General,Visit the link for more information,https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chapter-1-general,
